ID	GSE	SUBSET	GSM	GPL	SOFT_NUMSPACE	AVAIL	FILE	PATHWAY	CELLS	EFFECT	TREATMENT	TIME	COMMENT
ARR00001	GSE22463	GSE22463k	GSM558029	GPL6244	log	raw	CELS/GSE22463/GSM558029.CEL	H2O2	PBMCs from >50 year old female	control	treated with H2O2	6 h	1 replicate each, time series, 8 older individuals
ARR00002	GSE22463	GSE22463k	GSM558045	GPL6244	log	raw	CELS/GSE22463/GSM558045.CEL	H2O2	PBMCs from >50 year old female	activating	treated with H2O2	6 h	1 replicate each, time series, 8 older individuals
ARR00003	GSE22463	GSE22463a	GSM558027	GPL6244	log	raw	CELS/GSE22463/GSM558027.CEL	H2O2	PBMCs from >50 year old female	control	treated with H2O2	3 h	1 replicate each, time series, 8 older individuals
ARR00004	GSE22463	GSE22463a	GSM558035	GPL6244	log	raw	CELS/GSE22463/GSM558035.CEL	H2O2	PBMCs from >50 year old female	activating	treated with H2O2	3 h	1 replicate each, time series, 8 older individuals
ARR00005	GSE22463	GSE22463e	GSM558031	GPL6244	log	raw	CELS/GSE22463/GSM558031.CEL	H2O2	PBMCs from >50 year old female	control	treated with H2O2	3 h	1 replicate each, time series, 8 older individuals
ARR00006	GSE22463	GSE22463e	GSM558039	GPL6244	log	raw	CELS/GSE22463/GSM558039.CEL	H2O2	PBMCs from >50 year old female	activating	treated with H2O2	3 h	1 replicate each, time series, 8 older individuals
ARR00007	GSE22463	GSE22463i	GSM558027	GPL6244	log	raw	CELS/GSE22463/GSM558027.CEL	H2O2	PBMCs from >50 year old female	control	treated with H2O2	6 h	1 replicate each, time series, 8 older individuals
ARR00008	GSE22463	GSE22463i	GSM558043	GPL6244	log	raw	CELS/GSE22463/GSM558043.CEL	H2O2	PBMCs from >50 year old female	activating	treated with H2O2	6 h	1 replicate each, time series, 8 older individuals
ARR00009	GSE22463	GSE22463o	GSM558033	GPL6244	log	raw	CELS/GSE22463/GSM558033.CEL	H2O2	PBMCs from >50 year old female	control	treated with H2O2	6 h	1 replicate each, time series, 8 older individuals
ARR00010	GSE22463	GSE22463o	GSM558049	GPL6244	log	raw	CELS/GSE22463/GSM558049.CEL	H2O2	PBMCs from >50 year old female	activating	treated with H2O2	6 h	1 replicate each, time series, 8 older individuals
ARR00011	GSE22463	GSE22463h	GSM558034	GPL6244	log	raw	CELS/GSE22463/GSM558034.CEL	H2O2	PBMCs from >50 year old female	control	treated with H2O2	3 h	1 replicate each, time series, 8 older individuals
ARR00012	GSE22463	GSE22463h	GSM558042	GPL6244	log	raw	CELS/GSE22463/GSM558042.CEL	H2O2	PBMCs from >50 year old female	activating	treated with H2O2	3 h	1 replicate each, time series, 8 older individuals
ARR00013	GSE21800	GSE21800a	GSM542925	GPL6244	log	raw	CELS/GSE21800/GSM542925.CEL	H2O2	4 lymphoid cell lines pooled	control	treated with 9 µM H2O2	4 h	1 replicate each, time respective control
ARR00014	GSE21800	GSE21800a	GSM542926	GPL6244	log	raw	CELS/GSE21800/GSM542926.CEL	H2O2	4 lymphoid cell lines pooled	activating	treated with 9 µM H2O2	4 h	1 replicate each, time respective control
ARR00015	GSE22463	GSE22463b	GSM558028	GPL6244	log	raw	CELS/GSE22463/GSM558028.CEL	H2O2	PBMCs from >50 year old female	control	treated with H2O2	3 h	1 replicate each, time series, 8 older individuals
ARR00016	GSE22463	GSE22463b	GSM558036	GPL6244	log	raw	CELS/GSE22463/GSM558036.CEL	H2O2	PBMCs from >50 year old female	activating	treated with H2O2	3 h	1 replicate each, time series, 8 older individuals
ARR00017	GSE22463	GSE22463j	GSM558028	GPL6244	log	raw	CELS/GSE22463/GSM558028.CEL	H2O2	PBMCs from >50 year old female	control	treated with H2O2	6 h	1 replicate each, time series, 8 older individuals
ARR00018	GSE22463	GSE22463j	GSM558044	GPL6244	log	raw	CELS/GSE22463/GSM558044.CEL	H2O2	PBMCs from >50 year old female	activating	treated with H2O2	6 h	1 replicate each, time series, 8 older individuals
ARR00019	GSE5339	GSE5339b	GSM120309	GPL571	log	raw	NA	H2O2	ATCC 16Lu ( human lung fibroblasts)	control	H2O2 treatment	4 h	time series 1, 4, 12, 24 h
ARR00020	GSE5339	GSE5339b	GSM120310	GPL571	log	raw	NA	H2O2	ATCC 16Lu ( human lung fibroblasts)	control	H2O2 treatment	4 h	time series 1, 4, 12, 24 h
ARR00021	GSE5339	GSE5339b	GSM120311	GPL571	log	raw	NA	H2O2	ATCC 16Lu ( human lung fibroblasts)	control	H2O2 treatment	4 h	time series 1, 4, 12, 24 h
ARR00022	GSE5339	GSE5339b	GSM120324	GPL571	log	raw	NA	H2O2	ATCC 16Lu ( human lung fibroblasts)	activating	H2O2 treatment	4 h	time series 1, 4, 12, 24 h
ARR00023	GSE5339	GSE5339b	GSM120325	GPL571	log	raw	NA	H2O2	ATCC 16Lu ( human lung fibroblasts)	activating	H2O2 treatment	4 h	time series 1, 4, 12, 24 h
ARR00024	GSE5339	GSE5339b	GSM120326	GPL571	log	raw	NA	H2O2	ATCC 16Lu ( human lung fibroblasts)	activating	H2O2 treatment	4 h	time series 1, 4, 12, 24 h
ARR00025	GSE22463	GSE22463n	GSM558032	GPL6244	log	raw	CELS/GSE22463/GSM558032.CEL	H2O2	PBMCs from >50 year old female	control	treated with H2O2	6 h	1 replicate each, time series, 8 older individuals
ARR00026	GSE22463	GSE22463n	GSM558048	GPL6244	log	raw	CELS/GSE22463/GSM558048.CEL	H2O2	PBMCs from >50 year old female	activating	treated with H2O2	6 h	1 replicate each, time series, 8 older individuals
ARR00027	GSE22463	GSE22463m	GSM558031	GPL6244	log	raw	CELS/GSE22463/GSM558031.CEL	H2O2	PBMCs from >50 year old female	control	treated with H2O2	6 h	1 replicate each, time series, 8 older individuals
ARR00028	GSE22463	GSE22463m	GSM558047	GPL6244	log	raw	CELS/GSE22463/GSM558047.CEL	H2O2	PBMCs from >50 year old female	activating	treated with H2O2	6 h	1 replicate each, time series, 8 older individuals
ARR00029	GSE22463	GSE22463f	GSM558032	GPL6244	log	raw	CELS/GSE22463/GSM558032.CEL	H2O2	PBMCs from >50 year old female	control	treated with H2O2	3 h	1 replicate each, time series, 8 older individuals
ARR00030	GSE22463	GSE22463f	GSM558040	GPL6244	log	raw	CELS/GSE22463/GSM558040.CEL	H2O2	PBMCs from >50 year old female	activating	treated with H2O2	3 h	1 replicate each, time series, 8 older individuals
ARR00031	GSE22463	GSE22463g	GSM558033	GPL6244	log	raw	CELS/GSE22463/GSM558033.CEL	H2O2	PBMCs from >50 year old female	control	treated with H2O2	3 h	1 replicate each, time series, 8 older individuals
ARR00032	GSE22463	GSE22463g	GSM558041	GPL6244	log	raw	CELS/GSE22463/GSM558041.CEL	H2O2	PBMCs from >50 year old female	activating	treated with H2O2	3 h	1 replicate each, time series, 8 older individuals
ARR00033	GSE22463	GSE22463c	GSM558029	GPL6244	log	raw	CELS/GSE22463/GSM558029.CEL	H2O2	PBMCs from >50 year old female	control	treated with H2O2	3 h	1 replicate each, time series, 8 older individuals
ARR00034	GSE22463	GSE22463c	GSM558037	GPL6244	log	raw	CELS/GSE22463/GSM558037.CEL	H2O2	PBMCs from >50 year old female	activating	treated with H2O2	3 h	1 replicate each, time series, 8 older individuals
ARR00035	GSE21800	GSE21800c	GSM542925	GPL6244	log	raw	CELS/GSE21800/GSM542925.CEL	H2O2	4 lymphoid cell lines pooled	control	treated with 900 µM H2O2	4 h	1 replicate each, time respective control
ARR00036	GSE21800	GSE21800c	GSM542928	GPL6244	log	raw	CELS/GSE21800/GSM542928.CEL	H2O2	4 lymphoid cell lines pooled	activating	treated with 900 µM H2O2	4 h	1 replicate each, time respective control
ARR00037	GSE21800	GSE21800b	GSM542925	GPL6244	log	raw	CELS/GSE21800/GSM542925.CEL	H2O2	4 lymphoid cell lines pooled	control	treated with 90 µM H2O2	4 h	1 replicate each, time respective control
ARR00038	GSE21800	GSE21800b	GSM542927	GPL6244	log	raw	CELS/GSE21800/GSM542927.CEL	H2O2	4 lymphoid cell lines pooled	activating	treated with 90 µM H2O2	4 h	1 replicate each, time respective control
ARR00039	GSE22463	GSE22463d	GSM558030	GPL6244	log	raw	CELS/GSE22463/GSM558030.CEL	H2O2	PBMCs from >50 year old female	control	treated with H2O2	3 h	1 replicate each, time series, 8 older individuals
ARR00040	GSE22463	GSE22463d	GSM558038	GPL6244	log	raw	CELS/GSE22463/GSM558038.CEL	H2O2	PBMCs from >50 year old female	activating	treated with H2O2	3 h	1 replicate each, time series, 8 older individuals
ARR00041	GSE22463	GSE22463p	GSM558034	GPL6244	log	raw	CELS/GSE22463/GSM558034.CEL	H2O2	PBMCs from >50 year old female	control	treated with H2O2	6 h	1 replicate each, time series, 8 older individuals
ARR00042	GSE22463	GSE22463p	GSM558050	GPL6244	log	raw	CELS/GSE22463/GSM558050.CEL	H2O2	PBMCs from >50 year old female	activating	treated with H2O2	6 h	1 replicate each, time series, 8 older individuals
ARR00043	GSE5339	GSE5339a	GSM120303	GPL571	log	raw	NA	H2O2	ATCC 16Lu ( human lung fibroblasts)	control	H2O2 treatment	1 h	time series 1, 4, 12, 24 h
ARR00044	GSE5339	GSE5339a	GSM120304	GPL571	log	raw	NA	H2O2	ATCC 16Lu ( human lung fibroblasts)	control	H2O2 treatment	1 h	time series 1, 4, 12, 24 h
ARR00045	GSE5339	GSE5339a	GSM120305	GPL571	log	raw	NA	H2O2	ATCC 16Lu ( human lung fibroblasts)	control	H2O2 treatment	1 h	time series 1, 4, 12, 24 h
ARR00046	GSE5339	GSE5339a	GSM120318	GPL571	log	raw	NA	H2O2	ATCC 16Lu ( human lung fibroblasts)	activating	H2O2 treatment	1 h	time series 1, 4, 12, 24 h
ARR00047	GSE5339	GSE5339a	GSM120319	GPL571	log	raw	NA	H2O2	ATCC 16Lu ( human lung fibroblasts)	activating	H2O2 treatment	1 h	time series 1, 4, 12, 24 h
ARR00048	GSE5339	GSE5339a	GSM120320	GPL571	log	raw	NA	H2O2	ATCC 16Lu ( human lung fibroblasts)	activating	H2O2 treatment	1 h	time series 1, 4, 12, 24 h
ARR00049	GSE22463	GSE22463l	GSM558030	GPL6244	log	raw	CELS/GSE22463/GSM558030.CEL	H2O2	PBMCs from >50 year old female	control	treated with H2O2	6 h	1 replicate each, time series, 8 older individuals
ARR00050	GSE22463	GSE22463l	GSM558046	GPL6244	log	raw	CELS/GSE22463/GSM558046.CEL	H2O2	PBMCs from >50 year old female	activating	treated with H2O2	6 h	1 replicate each, time series, 8 older individuals
ARR00051	GSE32441	GSE32441b	GSM802713	GPL4133	log	raw	NA	Trail	HT1080 fibrosarcoma cells	control	treated with 50 ng/ml TRAIL	6 h	1 replicate each, control and treated cells were additionally treated with 4 µg/ml trabectedin
ARR00052	GSE32441	GSE32441b	GSM802715	GPL4133	log	raw	NA	Trail	HT1080 fibrosarcoma cells	activating	treated with 50 ng/ml TRAIL	6 h	1 replicate each, control and treated cells were additionally treated with 4 µg/ml trabectedin
ARR00053	GSE8346	GSE8346	GSM206809	GPL571	log	raw	CELS/GSE8346/GSM206809.CEL	Trail	T4-2 breat epithelial cells	control	treated with 1 µg/ml TRAIL	4 h	4 replicates each, contain control vector, 3D culture
ARR00054	GSE8346	GSE8346	GSM206827	GPL571	log	raw	CELS/GSE8346/GSM206827.CEL	Trail	T4-2 breat epithelial cells	control	treated with 1 µg/ml TRAIL	4 h	4 replicates each, contain control vector, 3D culture
ARR00055	GSE8346	GSE8346	GSM206828	GPL571	log	raw	CELS/GSE8346/GSM206828.CEL	Trail	T4-2 breat epithelial cells	control	treated with 1 µg/ml TRAIL	4 h	4 replicates each, contain control vector, 3D culture
ARR00056	GSE8346	GSE8346	GSM206829	GPL571	log	raw	CELS/GSE8346/GSM206829.CEL	Trail	T4-2 breat epithelial cells	control	treated with 1 µg/ml TRAIL	4 h	4 replicates each, contain control vector, 3D culture
ARR00057	GSE8346	GSE8346	GSM206834	GPL571	log	raw	CELS/GSE8346/GSM206834.CEL	Trail	T4-2 breat epithelial cells	activating	treated with 1 µg/ml TRAIL	4 h	4 replicates each, contain control vector, 3D culture
ARR00058	GSE8346	GSE8346	GSM206835	GPL571	log	raw	CELS/GSE8346/GSM206835.CEL	Trail	T4-2 breat epithelial cells	activating	treated with 1 µg/ml TRAIL	4 h	4 replicates each, contain control vector, 3D culture
ARR00059	GSE8346	GSE8346	GSM206836	GPL571	log	raw	CELS/GSE8346/GSM206836.CEL	Trail	T4-2 breat epithelial cells	activating	treated with 1 µg/ml TRAIL	4 h	4 replicates each, contain control vector, 3D culture
ARR00060	GSE8346	GSE8346	GSM206837	GPL571	log	raw	CELS/GSE8346/GSM206837.CEL	Trail	T4-2 breat epithelial cells	activating	treated with 1 µg/ml TRAIL	4 h	4 replicates each, contain control vector, 3D culture
ARR00061	GSE32441	GSE32441c	GSM802721	GPL4133	log	raw	NA	Trail	HT1080 fibrosarcoma cells	control	treated with 50 ng/ml TRAIL	6 h	1 replicate each, control and treated cells were additionally treated with 1.5 µg/ml mafosfamide
ARR00062	GSE32441	GSE32441c	GSM802723	GPL4133	log	raw	NA	Trail	HT1080 fibrosarcoma cells	activating	treated with 50 ng/ml TRAIL	6 h	1 replicate each, control and treated cells were additionally treated with 1.5 µg/ml mafosfamide
ARR00063	GSE32441	GSE32441a	GSM802717	GPL4133	log	raw	NA	Trail	HT1080 fibrosarcoma cells	control	treated with 50 ng/ml TRAIL	6 h	1 replicate each, control and treated cells were additionally treated with 0.25 µg/ml doxorubicin
ARR00064	GSE32441	GSE32441a	GSM802719	GPL4133	log	raw	NA	Trail	HT1080 fibrosarcoma cells	activating	treated with 50 ng/ml TRAIL	6 h	1 replicate each, control and treated cells were additionally treated with 0.25 µg/ml doxorubicin
ARR00065	GSE30240	GSE30240c	GSM748833	GPL570	log	raw	CELS/GSE30240/GSM748833.CEL	p53	HepG2 cells	control	treated with 5 GY X-Ray irradiation	3 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00066	GSE30240	GSE30240c	GSM748834	GPL570	log	raw	CELS/GSE30240/GSM748834.CEL	p53	HepG2 cells	control	treated with 5 GY X-Ray irradiation	3 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00067	GSE30240	GSE30240c	GSM748835	GPL570	log	raw	CELS/GSE30240/GSM748835.CEL	p53	HepG2 cells	control	treated with 5 GY X-Ray irradiation	3 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00068	GSE30240	GSE30240c	GSM748839	GPL570	log	raw	CELS/GSE30240/GSM748839.CEL	p53	HepG2 cells	activating	treated with 5 GY X-Ray irradiation	3 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00069	GSE30240	GSE30240c	GSM748840	GPL570	log	raw	CELS/GSE30240/GSM748840.CEL	p53	HepG2 cells	activating	treated with 5 GY X-Ray irradiation	3 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00070	GSE30240	GSE30240c	GSM748841	GPL570	log	raw	CELS/GSE30240/GSM748841.CEL	p53	HepG2 cells	activating	treated with 5 GY X-Ray irradiation	3 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00071	GSE12666	GSE12666d	GSM318069	GPL571	log	normalized	CELS/GSE12666/GSM318069.CEL	p53	MCF7 cells	control	treated with 10 µM BMH-21, p53 activator	6 h	4 replicates each, lead compounds - mechanism of action unknown
ARR00072	GSE12666	GSE12666d	GSM318070	GPL571	log	normalized	CELS/GSE12666/GSM318070.CEL	p53	MCF7 cells	control	treated with 10 µM BMH-21, p53 activator	6 h	4 replicates each, lead compounds - mechanism of action unknown
ARR00073	GSE12666	GSE12666d	GSM318071	GPL571	log	normalized	CELS/GSE12666/GSM318071.CEL	p53	MCF7 cells	control	treated with 10 µM BMH-21, p53 activator	6 h	4 replicates each, lead compounds - mechanism of action unknown
ARR00074	GSE12666	GSE12666d	GSM318072	GPL571	log	normalized	CELS/GSE12666/GSM318072.CEL	p53	MCF7 cells	control	treated with 10 µM BMH-21, p53 activator	6 h	4 replicates each, lead compounds - mechanism of action unknown
ARR00075	GSE12666	GSE12666d	GSM318057	GPL571	log	normalized	CELS/GSE12666/GSM318057.CEL	p53	MCF7 cells	activating	treated with 10 µM BMH-21, p53 activator	6 h	4 replicates each, lead compounds - mechanism of action unknown
ARR00076	GSE12666	GSE12666d	GSM318058	GPL571	log	normalized	CELS/GSE12666/GSM318058.CEL	p53	MCF7 cells	activating	treated with 10 µM BMH-21, p53 activator	6 h	4 replicates each, lead compounds - mechanism of action unknown
ARR00077	GSE12666	GSE12666d	GSM318059	GPL571	log	normalized	CELS/GSE12666/GSM318059.CEL	p53	MCF7 cells	activating	treated with 10 µM BMH-21, p53 activator	6 h	4 replicates each, lead compounds - mechanism of action unknown
ARR00078	GSE12666	GSE12666d	GSM318060	GPL571	log	normalized	CELS/GSE12666/GSM318060.CEL	p53	MCF7 cells	activating	treated with 10 µM BMH-21, p53 activator	6 h	4 replicates each, lead compounds - mechanism of action unknown
ARR00079	GSE30240	GSE30240j	GSM749874	GPL570	log	raw	CELS/GSE30240/GSM749874.CEL	p53	BJ cells	control	treated with 5 GY X-Ray irradiation	6 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00080	GSE30240	GSE30240j	GSM749875	GPL570	log	raw	CELS/GSE30240/GSM749875.CEL	p53	BJ cells	control	treated with 5 GY X-Ray irradiation	6 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00081	GSE30240	GSE30240j	GSM749876	GPL570	log	raw	CELS/GSE30240/GSM749876.CEL	p53	BJ cells	control	treated with 5 GY X-Ray irradiation	6 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00082	GSE30240	GSE30240j	GSM749883	GPL570	log	raw	CELS/GSE30240/GSM749883.CEL	p53	BJ cells	activating	treated with 5 GY X-Ray irradiation	6 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00083	GSE30240	GSE30240j	GSM749884	GPL570	log	raw	CELS/GSE30240/GSM749884.CEL	p53	BJ cells	activating	treated with 5 GY X-Ray irradiation	6 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00084	GSE30240	GSE30240j	GSM749885	GPL570	log	raw	CELS/GSE30240/GSM749885.CEL	p53	BJ cells	activating	treated with 5 GY X-Ray irradiation	6 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00085	GSE30240	GSE30240h	GSM748866	GPL570	log	raw	CELS/GSE30240/GSM748866.CEL	p53	U2OS cells	control	treated with 5 GY X-Ray irradiation	6 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00086	GSE30240	GSE30240h	GSM748867	GPL570	log	raw	CELS/GSE30240/GSM748867.CEL	p53	U2OS cells	control	treated with 5 GY X-Ray irradiation	6 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00087	GSE30240	GSE30240h	GSM748868	GPL570	log	raw	CELS/GSE30240/GSM748868.CEL	p53	U2OS cells	control	treated with 5 GY X-Ray irradiation	6 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00088	GSE30240	GSE30240h	GSM748872	GPL570	log	raw	CELS/GSE30240/GSM748872.CEL	p53	U2OS cells	activating	treated with 5 GY X-Ray irradiation	6 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00089	GSE30240	GSE30240h	GSM748873	GPL570	log	raw	CELS/GSE30240/GSM748873.CEL	p53	U2OS cells	activating	treated with 5 GY X-Ray irradiation	6 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00090	GSE30240	GSE30240h	GSM748874	GPL570	log	raw	CELS/GSE30240/GSM748874.CEL	p53	U2OS cells	activating	treated with 5 GY X-Ray irradiation	6 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00091	GSE12666	GSE12666f	GSM318069	GPL571	log	normalized	CELS/GSE12666/GSM318069.CEL	p53	MCF7 cells	control	treated with 10 µM BMH-23, p53 activator	6 h	4 replicates each, lead compounds - mechanism of action unknown
ARR00092	GSE12666	GSE12666f	GSM318070	GPL571	log	normalized	CELS/GSE12666/GSM318070.CEL	p53	MCF7 cells	control	treated with 10 µM BMH-23, p53 activator	6 h	4 replicates each, lead compounds - mechanism of action unknown
ARR00093	GSE12666	GSE12666f	GSM318071	GPL571	log	normalized	CELS/GSE12666/GSM318071.CEL	p53	MCF7 cells	control	treated with 10 µM BMH-23, p53 activator	6 h	4 replicates each, lead compounds - mechanism of action unknown
ARR00094	GSE12666	GSE12666f	GSM318072	GPL571	log	normalized	CELS/GSE12666/GSM318072.CEL	p53	MCF7 cells	control	treated with 10 µM BMH-23, p53 activator	6 h	4 replicates each, lead compounds - mechanism of action unknown
ARR00095	GSE12666	GSE12666f	GSM318065	GPL571	log	normalized	CELS/GSE12666/GSM318065.CEL	p53	MCF7 cells	activating	treated with 10 µM BMH-23, p53 activator	6 h	4 replicates each, lead compounds - mechanism of action unknown
ARR00096	GSE12666	GSE12666f	GSM318066	GPL571	log	normalized	CELS/GSE12666/GSM318066.CEL	p53	MCF7 cells	activating	treated with 10 µM BMH-23, p53 activator	6 h	4 replicates each, lead compounds - mechanism of action unknown
ARR00097	GSE12666	GSE12666f	GSM318067	GPL571	log	normalized	CELS/GSE12666/GSM318067.CEL	p53	MCF7 cells	activating	treated with 10 µM BMH-23, p53 activator	6 h	4 replicates each, lead compounds - mechanism of action unknown
ARR00098	GSE12666	GSE12666f	GSM318068	GPL571	log	normalized	CELS/GSE12666/GSM318068.CEL	p53	MCF7 cells	activating	treated with 10 µM BMH-23, p53 activator	6 h	4 replicates each, lead compounds - mechanism of action unknown
ARR00099	GSE30240	GSE30240a	GSM748818	GPL570	log	raw	CELS/GSE30240/GSM748818.CEL	p53	G361 cells	control	treated with 5 GY X-Ray irradiation	3 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00100	GSE30240	GSE30240a	GSM748819	GPL570	log	raw	CELS/GSE30240/GSM748819.CEL	p53	G361 cells	control	treated with 5 GY X-Ray irradiation	3 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00101	GSE30240	GSE30240a	GSM748820	GPL570	log	raw	CELS/GSE30240/GSM748820.CEL	p53	G361 cells	control	treated with 5 GY X-Ray irradiation	3 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00102	GSE30240	GSE30240a	GSM748824	GPL570	log	raw	CELS/GSE30240/GSM748824.CEL	p53	G361 cells	activating	treated with 5 GY X-Ray irradiation	3 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00103	GSE30240	GSE30240a	GSM748825	GPL570	log	raw	CELS/GSE30240/GSM748825.CEL	p53	G361 cells	activating	treated with 5 GY X-Ray irradiation	3 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00104	GSE30240	GSE30240a	GSM748826	GPL570	log	raw	CELS/GSE30240/GSM748826.CEL	p53	G361 cells	activating	treated with 5 GY X-Ray irradiation	3 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00105	GSE30240	GSE30240g	GSM748863	GPL570	log	raw	CELS/GSE30240/GSM748863.CEL	p53	U2OS cells	control	treated with 5 GY X-Ray irradiation	3 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00106	GSE30240	GSE30240g	GSM748864	GPL570	log	raw	CELS/GSE30240/GSM748864.CEL	p53	U2OS cells	control	treated with 5 GY X-Ray irradiation	3 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00107	GSE30240	GSE30240g	GSM748865	GPL570	log	raw	CELS/GSE30240/GSM748865.CEL	p53	U2OS cells	control	treated with 5 GY X-Ray irradiation	3 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00108	GSE30240	GSE30240g	GSM748869	GPL570	log	raw	CELS/GSE30240/GSM748869.CEL	p53	U2OS cells	activating	treated with 5 GY X-Ray irradiation	3 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00109	GSE30240	GSE30240g	GSM748870	GPL570	log	raw	CELS/GSE30240/GSM748870.CEL	p53	U2OS cells	activating	treated with 5 GY X-Ray irradiation	3 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00110	GSE30240	GSE30240g	GSM748871	GPL570	log	raw	CELS/GSE30240/GSM748871.CEL	p53	U2OS cells	activating	treated with 5 GY X-Ray irradiation	3 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00111	GSE13291	GSE13291	GSM335410	GPL571	log	raw	CELS/GSE13291/GSM335410.CEL	p53	MCF7 cells	control	treated with 1 µM RITA, p53 activator	2 h	1 replicate each, RITA inhibits HDM2-p53 interaction
ARR00112	GSE13291	GSE13291	GSM335411	GPL571	log	raw	CELS/GSE13291/GSM335411.CEL	p53	MCF7 cells	activating	treated with 1 µM RITA, p53 activator	2 h	1 replicate each, RITA inhibits HDM2-p53 interaction
ARR00113	GSE23010	GSE23010	GSM567732	GPL6884	log	normalized	NA	p53	U2OS cells	control	treated with 5 GY X-Ray irradiation	4 h	3 replicates each, cells transfected with control sh RNA
ARR00114	GSE23010	GSE23010	GSM567740	GPL6884	log	normalized	NA	p53	U2OS cells	control	treated with 5 GY X-Ray irradiation	4 h	3 replicates each, cells transfected with control sh RNA
ARR00115	GSE23010	GSE23010	GSM567748	GPL6884	log	normalized	NA	p53	U2OS cells	control	treated with 5 GY X-Ray irradiation	4 h	3 replicates each, cells transfected with control sh RNA
ARR00116	GSE23010	GSE23010	GSM567733	GPL6884	log	normalized	NA	p53	U2OS cells	activating	treated with 5 GY X-Ray irradiation	4 h	3 replicates each, cells transfected with control sh RNA
ARR00117	GSE23010	GSE23010	GSM567741	GPL6884	log	normalized	NA	p53	U2OS cells	activating	treated with 5 GY X-Ray irradiation	4 h	3 replicates each, cells transfected with control sh RNA
ARR00118	GSE23010	GSE23010	GSM567749	GPL6884	log	normalized	NA	p53	U2OS cells	activating	treated with 5 GY X-Ray irradiation	4 h	3 replicates each, cells transfected with control sh RNA
ARR00119	GSE12666	GSE12666a	GSM318069	GPL571	log	normalized	CELS/GSE12666/GSM318069.CEL	p53	MCF7 cells	control	treated with 10 µM BMH-7, p53 activator	6 h	4 replicates each, lead compounds - mechanism of action unknown
ARR00120	GSE12666	GSE12666a	GSM318070	GPL571	log	normalized	CELS/GSE12666/GSM318070.CEL	p53	MCF7 cells	control	treated with 10 µM BMH-7, p53 activator	6 h	4 replicates each, lead compounds - mechanism of action unknown
ARR00121	GSE12666	GSE12666a	GSM318071	GPL571	log	normalized	CELS/GSE12666/GSM318071.CEL	p53	MCF7 cells	control	treated with 10 µM BMH-7, p53 activator	6 h	4 replicates each, lead compounds - mechanism of action unknown
ARR00122	GSE12666	GSE12666a	GSM318072	GPL571	log	normalized	CELS/GSE12666/GSM318072.CEL	p53	MCF7 cells	control	treated with 10 µM BMH-7, p53 activator	6 h	4 replicates each, lead compounds - mechanism of action unknown
ARR00123	GSE12666	GSE12666a	GSM318045	GPL571	log	normalized	CELS/GSE12666/GSM318045.CEL	p53	MCF7 cells	activating	treated with 10 µM BMH-7, p53 activator	6 h	4 replicates each, lead compounds - mechanism of action unknown
ARR00124	GSE12666	GSE12666a	GSM318046	GPL571	log	normalized	CELS/GSE12666/GSM318046.CEL	p53	MCF7 cells	activating	treated with 10 µM BMH-7, p53 activator	6 h	4 replicates each, lead compounds - mechanism of action unknown
ARR00125	GSE12666	GSE12666a	GSM318047	GPL571	log	normalized	CELS/GSE12666/GSM318047.CEL	p53	MCF7 cells	activating	treated with 10 µM BMH-7, p53 activator	6 h	4 replicates each, lead compounds - mechanism of action unknown
ARR00126	GSE12666	GSE12666a	GSM318048	GPL571	log	normalized	CELS/GSE12666/GSM318048.CEL	p53	MCF7 cells	activating	treated with 10 µM BMH-7, p53 activator	6 h	4 replicates each, lead compounds - mechanism of action unknown
ARR00127	GSE32441	GSE32441	GSM802712	GPL4133	log	raw	NA	p53	HT1080 fibrosarcoma cells	control	treated with 0.25 µg/ml doxorubicin	6 h	1 replicate each
ARR00128	GSE32441	GSE32441	GSM802717	GPL4133	log	raw	NA	p53	HT1080 fibrosarcoma cells	activating	treated with 0.25 µg/ml doxorubicin	6 h	1 replicate each
ARR00129	GSE8939	GSE8939a	GSM226614	GPL96	log	raw	CELS/GSE8939/GSM226614.CEL	p53	CS-B wt rescued cells	control	treated with 10 J/m2 UVC irradiation	2 h	3 replicates each, 2 arrays per sample
ARR00130	GSE8939	GSE8939a	GSM226615	GPL96	log	raw	CELS/GSE8939/GSM226615.CEL	p53	CS-B wt rescued cells	control	treated with 10 J/m2 UVC irradiation	2 h	3 replicates each, 2 arrays per sample
ARR00131	GSE8939	GSE8939a	GSM226619	GPL96	log	raw	CELS/GSE8939/GSM226619.CEL	p53	CS-B wt rescued cells	control	treated with 10 J/m2 UVC irradiation	2 h	3 replicates each, 2 arrays per sample
ARR00132	GSE8939	GSE8939a	GSM226620	GPL96	log	raw	CELS/GSE8939/GSM226620.CEL	p53	CS-B wt rescued cells	activating	treated with 10 J/m2 UVC irradiation	2 h	3 replicates each, 2 arrays per sample
ARR00133	GSE8939	GSE8939a	GSM226621	GPL96	log	raw	CELS/GSE8939/GSM226621.CEL	p53	CS-B wt rescued cells	activating	treated with 10 J/m2 UVC irradiation	2 h	3 replicates each, 2 arrays per sample
ARR00134	GSE8939	GSE8939a	GSM226622	GPL96	log	raw	CELS/GSE8939/GSM226622.CEL	p53	CS-B wt rescued cells	activating	treated with 10 J/m2 UVC irradiation	2 h	3 replicates each, 2 arrays per sample
ARR00135	GSE30240	GSE30240d	GSM748836	GPL570	log	raw	CELS/GSE30240/GSM748836.CEL	p53	HepG2 cells	control	treated with 5 GY X-Ray irradiation	6 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00136	GSE30240	GSE30240d	GSM748837	GPL570	log	raw	CELS/GSE30240/GSM748837.CEL	p53	HepG2 cells	control	treated with 5 GY X-Ray irradiation	6 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00137	GSE30240	GSE30240d	GSM748838	GPL570	log	raw	CELS/GSE30240/GSM748838.CEL	p53	HepG2 cells	control	treated with 5 GY X-Ray irradiation	6 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00138	GSE30240	GSE30240d	GSM748842	GPL570	log	raw	CELS/GSE30240/GSM748842.CEL	p53	HepG2 cells	activating	treated with 5 GY X-Ray irradiation	6 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00139	GSE30240	GSE30240d	GSM748843	GPL570	log	raw	CELS/GSE30240/GSM748843.CEL	p53	HepG2 cells	activating	treated with 5 GY X-Ray irradiation	6 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00140	GSE30240	GSE30240d	GSM748844	GPL570	log	raw	CELS/GSE30240/GSM748844.CEL	p53	HepG2 cells	activating	treated with 5 GY X-Ray irradiation	6 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00141	GSE30240	GSE30240b	GSM748821	GPL570	log	raw	CELS/GSE30240/GSM748821.CEL	p53	G361 cells	control	treated with 5 GY X-Ray irradiation	6 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00142	GSE30240	GSE30240b	GSM748822	GPL570	log	raw	CELS/GSE30240/GSM748822.CEL	p53	G361 cells	control	treated with 5 GY X-Ray irradiation	6 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00143	GSE30240	GSE30240b	GSM748823	GPL570	log	raw	CELS/GSE30240/GSM748823.CEL	p53	G361 cells	control	treated with 5 GY X-Ray irradiation	6 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00144	GSE30240	GSE30240b	GSM748827	GPL570	log	raw	CELS/GSE30240/GSM748827.CEL	p53	G361 cells	activating	treated with 5 GY X-Ray irradiation	6 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00145	GSE30240	GSE30240b	GSM748828	GPL570	log	raw	CELS/GSE30240/GSM748828.CEL	p53	G361 cells	activating	treated with 5 GY X-Ray irradiation	6 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00146	GSE30240	GSE30240b	GSM748829	GPL570	log	raw	CELS/GSE30240/GSM748829.CEL	p53	G361 cells	activating	treated with 5 GY X-Ray irradiation	6 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00147	GSE30240	GSE30240e	GSM748848	GPL570	log	raw	CELS/GSE30240/GSM748848.CEL	p53	TK6 cells	control	treated with 5 GY X-Ray irradiation	3 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00148	GSE30240	GSE30240e	GSM748849	GPL570	log	raw	CELS/GSE30240/GSM748849.CEL	p53	TK6 cells	control	treated with 5 GY X-Ray irradiation	3 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00149	GSE30240	GSE30240e	GSM748850	GPL570	log	raw	CELS/GSE30240/GSM748850.CEL	p53	TK6 cells	control	treated with 5 GY X-Ray irradiation	3 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00150	GSE30240	GSE30240e	GSM748854	GPL570	log	raw	CELS/GSE30240/GSM748854.CEL	p53	TK6 cells	activating	treated with 5 GY X-Ray irradiation	3 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00151	GSE30240	GSE30240e	GSM748855	GPL570	log	raw	CELS/GSE30240/GSM748855.CEL	p53	TK6 cells	activating	treated with 5 GY X-Ray irradiation	3 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00152	GSE30240	GSE30240e	GSM748856	GPL570	log	raw	CELS/GSE30240/GSM748856.CEL	p53	TK6 cells	activating	treated with 5 GY X-Ray irradiation	3 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00153	GSE12666	GSE12666c	GSM318069	GPL571	log	normalized	CELS/GSE12666/GSM318069.CEL	p53	MCF7 cells	control	treated with 10 µM BMH-15, p53 activator	6 h	4 replicates each, lead compounds - mechanism of action unknown
ARR00154	GSE12666	GSE12666c	GSM318070	GPL571	log	normalized	CELS/GSE12666/GSM318070.CEL	p53	MCF7 cells	control	treated with 10 µM BMH-15, p53 activator	6 h	4 replicates each, lead compounds - mechanism of action unknown
ARR00155	GSE12666	GSE12666c	GSM318071	GPL571	log	normalized	CELS/GSE12666/GSM318071.CEL	p53	MCF7 cells	control	treated with 10 µM BMH-15, p53 activator	6 h	4 replicates each, lead compounds - mechanism of action unknown
ARR00156	GSE12666	GSE12666c	GSM318072	GPL571	log	normalized	CELS/GSE12666/GSM318072.CEL	p53	MCF7 cells	control	treated with 10 µM BMH-15, p53 activator	6 h	4 replicates each, lead compounds - mechanism of action unknown
ARR00157	GSE12666	GSE12666c	GSM318053	GPL571	log	normalized	CELS/GSE12666/GSM318053.CEL	p53	MCF7 cells	activating	treated with 10 µM BMH-15, p53 activator	6 h	4 replicates each, lead compounds - mechanism of action unknown
ARR00158	GSE12666	GSE12666c	GSM318054	GPL571	log	normalized	CELS/GSE12666/GSM318054.CEL	p53	MCF7 cells	activating	treated with 10 µM BMH-15, p53 activator	6 h	4 replicates each, lead compounds - mechanism of action unknown
ARR00159	GSE12666	GSE12666c	GSM318055	GPL571	log	normalized	CELS/GSE12666/GSM318055.CEL	p53	MCF7 cells	activating	treated with 10 µM BMH-15, p53 activator	6 h	4 replicates each, lead compounds - mechanism of action unknown
ARR00160	GSE12666	GSE12666c	GSM318056	GPL571	log	normalized	CELS/GSE12666/GSM318056.CEL	p53	MCF7 cells	activating	treated with 10 µM BMH-15, p53 activator	6 h	4 replicates each, lead compounds - mechanism of action unknown
ARR00161	GSE8939	GSE8939b	GSM226616	GPL97	log	raw	CELS/GSE8939/GSM226616.CEL	p53	CS-B wt rescued cells	control	treated with 10 J/m2 UVC irradiation	2 h	3 replicates each, 2 arrays per sample
ARR00162	GSE8939	GSE8939b	GSM226617	GPL97	log	raw	CELS/GSE8939/GSM226617.CEL	p53	CS-B wt rescued cells	control	treated with 10 J/m2 UVC irradiation	2 h	3 replicates each, 2 arrays per sample
ARR00163	GSE8939	GSE8939b	GSM226618	GPL97	log	raw	CELS/GSE8939/GSM226618.CEL	p53	CS-B wt rescued cells	control	treated with 10 J/m2 UVC irradiation	2 h	3 replicates each, 2 arrays per sample
ARR00164	GSE8939	GSE8939b	GSM226623	GPL97	log	raw	CELS/GSE8939/GSM226623.CEL	p53	CS-B wt rescued cells	activating	treated with 10 J/m2 UVC irradiation	2 h	3 replicates each, 2 arrays per sample
ARR00165	GSE8939	GSE8939b	GSM226624	GPL97	log	raw	CELS/GSE8939/GSM226624.CEL	p53	CS-B wt rescued cells	activating	treated with 10 J/m2 UVC irradiation	2 h	3 replicates each, 2 arrays per sample
ARR00166	GSE8939	GSE8939b	GSM226625	GPL97	log	raw	CELS/GSE8939/GSM226625.CEL	p53	CS-B wt rescued cells	activating	treated with 10 J/m2 UVC irradiation	2 h	3 replicates each, 2 arrays per sample
ARR00167	GSE12666	GSE12666e	GSM318069	GPL571	log	normalized	CELS/GSE12666/GSM318069.CEL	p53	MCF7 cells	control	treated with 10 µM BMH-22, p53 activator	6 h	4 replicates each, lead compounds - mechanism of action unknown
ARR00168	GSE12666	GSE12666e	GSM318070	GPL571	log	normalized	CELS/GSE12666/GSM318070.CEL	p53	MCF7 cells	control	treated with 10 µM BMH-22, p53 activator	6 h	4 replicates each, lead compounds - mechanism of action unknown
ARR00169	GSE12666	GSE12666e	GSM318071	GPL571	log	normalized	CELS/GSE12666/GSM318071.CEL	p53	MCF7 cells	control	treated with 10 µM BMH-22, p53 activator	6 h	4 replicates each, lead compounds - mechanism of action unknown
ARR00170	GSE12666	GSE12666e	GSM318072	GPL571	log	normalized	CELS/GSE12666/GSM318072.CEL	p53	MCF7 cells	control	treated with 10 µM BMH-22, p53 activator	6 h	4 replicates each, lead compounds - mechanism of action unknown
ARR00171	GSE12666	GSE12666e	GSM318061	GPL571	log	normalized	CELS/GSE12666/GSM318061.CEL	p53	MCF7 cells	activating	treated with 10 µM BMH-22, p53 activator	6 h	4 replicates each, lead compounds - mechanism of action unknown
ARR00172	GSE12666	GSE12666e	GSM318062	GPL571	log	normalized	CELS/GSE12666/GSM318062.CEL	p53	MCF7 cells	activating	treated with 10 µM BMH-22, p53 activator	6 h	4 replicates each, lead compounds - mechanism of action unknown
ARR00173	GSE12666	GSE12666e	GSM318063	GPL571	log	normalized	CELS/GSE12666/GSM318063.CEL	p53	MCF7 cells	activating	treated with 10 µM BMH-22, p53 activator	6 h	4 replicates each, lead compounds - mechanism of action unknown
ARR00174	GSE12666	GSE12666e	GSM318064	GPL571	log	normalized	CELS/GSE12666/GSM318064.CEL	p53	MCF7 cells	activating	treated with 10 µM BMH-22, p53 activator	6 h	4 replicates each, lead compounds - mechanism of action unknown
ARR00175	GSE12666	GSE12666b	GSM318069	GPL571	log	normalized	CELS/GSE12666/GSM318069.CEL	p53	MCF7 cells	control	treated with 10 µM BMH-9, p53 activator	6 h	4 replicates each, lead compounds - mechanism of action unknown
ARR00176	GSE12666	GSE12666b	GSM318070	GPL571	log	normalized	CELS/GSE12666/GSM318070.CEL	p53	MCF7 cells	control	treated with 10 µM BMH-9, p53 activator	6 h	4 replicates each, lead compounds - mechanism of action unknown
ARR00177	GSE12666	GSE12666b	GSM318071	GPL571	log	normalized	CELS/GSE12666/GSM318071.CEL	p53	MCF7 cells	control	treated with 10 µM BMH-9, p53 activator	6 h	4 replicates each, lead compounds - mechanism of action unknown
ARR00178	GSE12666	GSE12666b	GSM318072	GPL571	log	normalized	CELS/GSE12666/GSM318072.CEL	p53	MCF7 cells	control	treated with 10 µM BMH-9, p53 activator	6 h	4 replicates each, lead compounds - mechanism of action unknown
ARR00179	GSE12666	GSE12666b	GSM318049	GPL571	log	normalized	CELS/GSE12666/GSM318049.CEL	p53	MCF7 cells	activating	treated with 10 µM BMH-9, p53 activator	6 h	4 replicates each, lead compounds - mechanism of action unknown
ARR00180	GSE12666	GSE12666b	GSM318050	GPL571	log	normalized	CELS/GSE12666/GSM318050.CEL	p53	MCF7 cells	activating	treated with 10 µM BMH-9, p53 activator	6 h	4 replicates each, lead compounds - mechanism of action unknown
ARR00181	GSE12666	GSE12666b	GSM318051	GPL571	log	normalized	CELS/GSE12666/GSM318051.CEL	p53	MCF7 cells	activating	treated with 10 µM BMH-9, p53 activator	6 h	4 replicates each, lead compounds - mechanism of action unknown
ARR00182	GSE12666	GSE12666b	GSM318052	GPL571	log	normalized	CELS/GSE12666/GSM318052.CEL	p53	MCF7 cells	activating	treated with 10 µM BMH-9, p53 activator	6 h	4 replicates each, lead compounds - mechanism of action unknown
ARR00183	GSE30240	GSE30240f	GSM748851	GPL570	log	raw	CELS/GSE30240/GSM748851.CEL	p53	TK6 cells	control	treated with 5 GY X-Ray irradiation	6 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00184	GSE30240	GSE30240f	GSM748852	GPL570	log	raw	CELS/GSE30240/GSM748852.CEL	p53	TK6 cells	control	treated with 5 GY X-Ray irradiation	6 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00185	GSE30240	GSE30240f	GSM748853	GPL570	log	raw	CELS/GSE30240/GSM748853.CEL	p53	TK6 cells	control	treated with 5 GY X-Ray irradiation	6 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00186	GSE30240	GSE30240f	GSM748857	GPL570	log	raw	CELS/GSE30240/GSM748857.CEL	p53	TK6 cells	activating	treated with 5 GY X-Ray irradiation	6 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00187	GSE30240	GSE30240f	GSM748858	GPL570	log	raw	CELS/GSE30240/GSM748858.CEL	p53	TK6 cells	activating	treated with 5 GY X-Ray irradiation	6 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00188	GSE30240	GSE30240f	GSM748859	GPL570	log	raw	CELS/GSE30240/GSM748859.CEL	p53	TK6 cells	activating	treated with 5 GY X-Ray irradiation	6 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00189	GSE2238	GSE2238	GSM40961	GPL96	log	raw	NA	p53	HT1080 fibrosarcoma cells	control	treated with doxorubicin	6 h	1 replicate each
ARR00190	GSE2238	GSE2238	GSM40962	GPL96	log	raw	NA	p53	HT1080 fibrosarcoma cells	activating	treated with doxorubicin	6 h	1 replicate each
ARR00191	GSE30240	GSE30240i	GSM749871	GPL570	log	raw	CELS/GSE30240/GSM749871.CEL	p53	BJ cells	control	treated with 5 GY X-Ray irradiation	3 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00192	GSE30240	GSE30240i	GSM749872	GPL570	log	raw	CELS/GSE30240/GSM749872.CEL	p53	BJ cells	control	treated with 5 GY X-Ray irradiation	3 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00193	GSE30240	GSE30240i	GSM749873	GPL570	log	raw	CELS/GSE30240/GSM749873.CEL	p53	BJ cells	control	treated with 5 GY X-Ray irradiation	3 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00194	GSE30240	GSE30240i	GSM749880	GPL570	log	raw	CELS/GSE30240/GSM749880.CEL	p53	BJ cells	activating	treated with 5 GY X-Ray irradiation	3 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00195	GSE30240	GSE30240i	GSM749881	GPL570	log	raw	CELS/GSE30240/GSM749881.CEL	p53	BJ cells	activating	treated with 5 GY X-Ray irradiation	3 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00196	GSE30240	GSE30240i	GSM749882	GPL570	log	raw	CELS/GSE30240/GSM749882.CEL	p53	BJ cells	activating	treated with 5 GY X-Ray irradiation	3 h	3 replicates each, part of time series, time respective control, 5 different tissues
ARR00197	GSE11228	GSE11228d	GSM283080	GPL2986	log	raw	NA	VEGF	LEC (Human dermal lymphatic endothelial cells)	control	treatment with VEGF-C (500 ng/ml)	4 h	time series (1, 4, 8, 24 h)
ARR00198	GSE11228	GSE11228d	GSM283081	GPL2986	log	raw	NA	VEGF	LEC (Human dermal lymphatic endothelial cells)	control	treatment with VEGF-C (500 ng/ml)	4 h	time series (1, 4, 8, 24 h)
ARR00199	GSE11228	GSE11228d	GSM283082	GPL2986	log	raw	NA	VEGF	LEC (Human dermal lymphatic endothelial cells)	control	treatment with VEGF-C (500 ng/ml)	4 h	time series (1, 4, 8, 24 h)
ARR00200	GSE11228	GSE11228d	GSM283098	GPL2986	log	raw	NA	VEGF	LEC (Human dermal lymphatic endothelial cells)	activating	treatment with VEGF-C (500 ng/ml)	4 h	time series (1, 4, 8, 24 h)
ARR00201	GSE11228	GSE11228d	GSM283099	GPL2986	log	raw	NA	VEGF	LEC (Human dermal lymphatic endothelial cells)	activating	treatment with VEGF-C (500 ng/ml)	4 h	time series (1, 4, 8, 24 h)
ARR00202	GSE11228	GSE11228d	GSM283100	GPL2986	log	raw	NA	VEGF	LEC (Human dermal lymphatic endothelial cells)	activating	treatment with VEGF-C (500 ng/ml)	4 h	time series (1, 4, 8, 24 h)
ARR00203	GSE10778	GSE10778e	GSM272122	GPL97	linear	raw	CELS/GSE10778/GSM272122.CEL	VEGF	HUVEC (human umbilical vein endothelial cells)	control	treatment with 100ng VEGF	1 h	time series (0.5, 1, 2.5, 6 h), 2 Chips HG-U133A and B
ARR00204	GSE10778	GSE10778e	GSM272124	GPL97	linear	raw	CELS/GSE10778/GSM272124.CEL	VEGF	HUVEC (human umbilical vein endothelial cells)	activating	treatment with 100ng VEGF	1 h	time series (0.5, 1, 2.5, 6 h), 2 Chips HG-U133A and B
ARR00205	GSE3891	GSE3891a	GSM88897	GPL96	linear	raw	NA	VEGF	HMVEC (Human microvascular endothelial cells)	control	VEGF treatment	30 min	time series 30 min, 1, 2, 4 h
ARR00206	GSE3891	GSE3891a	GSM88898	GPL96	linear	raw	NA	VEGF	HMVEC (Human microvascular endothelial cells)	activating	VEGF treatment	30 min	time series 30 min, 1, 2, 4 h
ARR00207	GSE15464	GSE15464c	GSM385333	GPL570	log	normalized	CELS/GSE15464/GSM385333.CEL	VEGF	HUVECs	control	treated with 100ng/ml VEGF-A165	150 min	1 replicate, part of time series
ARR00208	GSE15464	GSE15464c	GSM385353	GPL570	log	normalized	CELS/GSE15464/GSM385353.CEL	VEGF	HUVECs	activating	treated with 100ng/ml VEGF-A165	150 min	1 replicate, part of time series
ARR00209	GSE10778	GSE10778cVEGF	GSM272113	GPL96	linear	raw	CELS/GSE10778/GSM272113.CEL	VEGF	HUVEC (human umbilical vein endothelial cells)	control	treatment with 100ng VEGF	2.5 h	time series (0.5, 1, 2.5, 6 h), 2 Chips HG-U133A and B
ARR00210	GSE10778	GSE10778cVEGF	GSM272116	GPL96	linear	raw	CELS/GSE10778/GSM272116.CEL	VEGF	HUVEC (human umbilical vein endothelial cells)	activating	treatment with 100ng VEGF	2.5 h	time series (0.5, 1, 2.5, 6 h), 2 Chips HG-U133A and B
ARR00211	GSE3891	GSE3891e	GSM88907	GPL97	linear	raw	NA	VEGF	HMVEC (Human microvascular endothelial cells)	control	VEGF treatment	30 min	time series 30 min, 1, 2, 4 h
ARR00212	GSE3891	GSE3891e	GSM88908	GPL97	linear	raw	NA	VEGF	HMVEC (Human microvascular endothelial cells)	activating	VEGF treatment	30 min	time series 30 min, 1, 2, 4 h
ARR00213	GSE3891	GSE3891c	GSM88897	GPL96	linear	raw	NA	VEGF	HMVEC (Human microvascular endothelial cells)	control	VEGF treatment	2 h	time series 30 min, 1, 2, 4 h
ARR00214	GSE3891	GSE3891c	GSM88900	GPL96	linear	raw	NA	VEGF	HMVEC (Human microvascular endothelial cells)	activating	VEGF treatment	2 h	time series 30 min, 1, 2, 4 h
ARR00215	GSE15464	GSE15464a	GSM385333	GPL570	log	normalized	CELS/GSE15464/GSM385333.CEL	VEGF	HUVECs	control	treated with 100ng/ml VEGF-A165	30 min	1 replicate, part of time series
ARR00216	GSE15464	GSE15464a	GSM385338	GPL570	log	normalized	CELS/GSE15464/GSM385338.CEL	VEGF	HUVECs	activating	treated with 100ng/ml VEGF-A165	30 min	1 replicate, part of time series
ARR00217	GSE15464	GSE15464b	GSM385333	GPL570	log	normalized	CELS/GSE15464/GSM385333.CEL	VEGF	HUVECs	control	treated with 100ng/ml VEGF-A165	60 min	1 replicate, part of time series
ARR00218	GSE15464	GSE15464b	GSM385350	GPL570	log	normalized	CELS/GSE15464/GSM385350.CEL	VEGF	HUVECs	activating	treated with 100ng/ml VEGF-A165	60 min	1 replicate, part of time series
ARR00219	GSE3891	GSE3891d	GSM88897	GPL96	linear	raw	NA	VEGF	HMVEC (Human microvascular endothelial cells)	control	VEGF treatment	4 h	time series 30 min, 1, 2, 4 h
ARR00220	GSE3891	GSE3891d	GSM88901	GPL96	linear	raw	NA	VEGF	HMVEC (Human microvascular endothelial cells)	activating	VEGF treatment	4 h	time series 30 min, 1, 2, 4 h
ARR00221	GSE837	GSE837a	GSM12900	GPL91	log	raw	NA	VEGF	HUVECs	control	treated with VEGF	4 h	1 replicate, part of 3 different isolates
ARR00222	GSE837	GSE837a	GSM12901	GPL91	log	raw	NA	VEGF	HUVECs	activating	treated with VEGF	4 h	1 replicate, part of 3 different isolates
ARR00223	GSE11228	GSE11228c	GSM283080	GPL2986	log	raw	NA	VEGF	LEC (Human dermal lymphatic endothelial cells)	control	treatment with VEGF-C (500 ng/ml)	1 h	time series (1, 4, 8, 24 h)
ARR00224	GSE11228	GSE11228c	GSM283081	GPL2986	log	raw	NA	VEGF	LEC (Human dermal lymphatic endothelial cells)	control	treatment with VEGF-C (500 ng/ml)	1 h	time series (1, 4, 8, 24 h)
ARR00225	GSE11228	GSE11228c	GSM283082	GPL2986	log	raw	NA	VEGF	LEC (Human dermal lymphatic endothelial cells)	control	treatment with VEGF-C (500 ng/ml)	1 h	time series (1, 4, 8, 24 h)
ARR00226	GSE11228	GSE11228c	GSM283095	GPL2986	log	raw	NA	VEGF	LEC (Human dermal lymphatic endothelial cells)	activating	treatment with VEGF-C (500 ng/ml)	1 h	time series (1, 4, 8, 24 h)
ARR00227	GSE11228	GSE11228c	GSM283096	GPL2986	log	raw	NA	VEGF	LEC (Human dermal lymphatic endothelial cells)	activating	treatment with VEGF-C (500 ng/ml)	1 h	time series (1, 4, 8, 24 h)
ARR00228	GSE11228	GSE11228c	GSM283097	GPL2986	log	raw	NA	VEGF	LEC (Human dermal lymphatic endothelial cells)	activating	treatment with VEGF-C (500 ng/ml)	1 h	time series (1, 4, 8, 24 h)
ARR00229	GSE3891	GSE3891b	GSM88897	GPL96	linear	raw	NA	VEGF	HMVEC (Human microvascular endothelial cells)	control	VEGF treatment	1 h	time series 30 min, 1, 2, 4 h
ARR00230	GSE3891	GSE3891b	GSM88899	GPL96	linear	raw	NA	VEGF	HMVEC (Human microvascular endothelial cells)	activating	VEGF treatment	1 h	time series 30 min, 1, 2, 4 h
ARR00231	GSE11228	GSE11228b	GSM283080	GPL2986	log	raw	NA	VEGF	LEC (Human dermal lymphatic endothelial cells)	control	treatment with VEGF-A165 (20 ng/ml)	4 h	time series (1, 4, 8, 24 h)
ARR00232	GSE11228	GSE11228b	GSM283081	GPL2986	log	raw	NA	VEGF	LEC (Human dermal lymphatic endothelial cells)	control	treatment with VEGF-A165 (20 ng/ml)	4 h	time series (1, 4, 8, 24 h)
ARR00233	GSE11228	GSE11228b	GSM283082	GPL2986	log	raw	NA	VEGF	LEC (Human dermal lymphatic endothelial cells)	control	treatment with VEGF-A165 (20 ng/ml)	4 h	time series (1, 4, 8, 24 h)
ARR00234	GSE11228	GSE11228b	GSM283086	GPL2986	log	raw	NA	VEGF	LEC (Human dermal lymphatic endothelial cells)	activating	treatment with VEGF-A165 (20 ng/ml)	4 h	time series (1, 4, 8, 24 h)
ARR00235	GSE11228	GSE11228b	GSM283087	GPL2986	log	raw	NA	VEGF	LEC (Human dermal lymphatic endothelial cells)	activating	treatment with VEGF-A165 (20 ng/ml)	4 h	time series (1, 4, 8, 24 h)
ARR00236	GSE11228	GSE11228b	GSM283088	GPL2986	log	raw	NA	VEGF	LEC (Human dermal lymphatic endothelial cells)	activating	treatment with VEGF-A165 (20 ng/ml)	4 h	time series (1, 4, 8, 24 h)
ARR00237	GSE17777	GSE17777	GSM443878	GPL570	log	raw	CELS/GSE17777/GSM443878.CEL	VEGF	HMVECs	control	treated with 100pg/ml VEGF	4 h	1 replicate
ARR00238	GSE17777	GSE17777	GSM443879	GPL570	log	raw	CELS/GSE17777/GSM443879.CEL	VEGF	HMVECs	activating	treated with 100pg/ml VEGF	4 h	1 replicate
ARR00239	GSE10778	GSE10778bVEGF	GSM272113	GPL96	linear	raw	CELS/GSE10778/GSM272113.CEL	VEGF	HUVEC (human umbilical vein endothelial cells)	control	treatment with 100ng VEGF	1 h	time series (0.5, 1, 2.5, 6 h), 2 Chips HG-U133A and B
ARR00240	GSE10778	GSE10778bVEGF	GSM272115	GPL96	linear	raw	CELS/GSE10778/GSM272115.CEL	VEGF	HUVEC (human umbilical vein endothelial cells)	activating	treatment with 100ng VEGF	1 h	time series (0.5, 1, 2.5, 6 h), 2 Chips HG-U133A and B
ARR00241	GSE18913	GSE18913a	GSM468603	GPL570	log	raw	CELS/GSE18913/GSM468603.CEL	VEGF	HUVECs	control	treated with VEGF	1 h	3 replicates, part of time series
ARR00242	GSE18913	GSE18913a	GSM468604	GPL570	log	raw	CELS/GSE18913/GSM468604.CEL	VEGF	HUVECs	control	treated with VEGF	1 h	3 replicates, part of time series
ARR00243	GSE18913	GSE18913a	GSM468621	GPL570	log	raw	CELS/GSE18913/GSM468621.CEL	VEGF	HUVECs	control	treated with VEGF	1 h	3 replicates, part of time series
ARR00244	GSE18913	GSE18913a	GSM468609	GPL570	log	raw	CELS/GSE18913/GSM468609.CEL	VEGF	HUVECs	activating	treated with VEGF	1 h	3 replicates, part of time series
ARR00245	GSE18913	GSE18913a	GSM468610	GPL570	log	raw	CELS/GSE18913/GSM468610.CEL	VEGF	HUVECs	activating	treated with VEGF	1 h	3 replicates, part of time series
ARR00246	GSE18913	GSE18913a	GSM468622	GPL570	log	raw	CELS/GSE18913/GSM468622.CEL	VEGF	HUVECs	activating	treated with VEGF	1 h	3 replicates, part of time series
ARR00247	GSE837	GSE837b	GSM12902	GPL91	log	raw	NA	VEGF	HUVECs	control	treated with VEGF	4 h	1 replicate, part of 3 different isolates
ARR00248	GSE837	GSE837b	GSM12903	GPL91	log	raw	NA	VEGF	HUVECs	activating	treated with VEGF	4 h	1 replicate, part of 3 different isolates
ARR00249	GSE10778	GSE10778aVEGF	GSM272113	GPL96	linear	raw	CELS/GSE10778/GSM272113.CEL	VEGF	HUVEC (human umbilical vein endothelial cells)	control	treatment with 100ng VEGF	30 min	time series (0.5, 1, 2.5, 6 h), 2 Chips HG-U133A and B
ARR00250	GSE10778	GSE10778aVEGF	GSM272114	GPL96	linear	raw	CELS/GSE10778/GSM272114.CEL	VEGF	HUVEC (human umbilical vein endothelial cells)	activating	treatment with 100ng VEGF	30 min	time series (0.5, 1, 2.5, 6 h), 2 Chips HG-U133A and B
ARR00251	GSE19335	GSE19335	GSM595674	GPL6947	linear	raw	NA	VEGF	HUVECs	control	treated with 50ng/ml VEGF	30 min	2 replicates
ARR00252	GSE19335	GSE19335	GSM595675	GPL6947	linear	raw	NA	VEGF	HUVECs	control	treated with 50ng/ml VEGF	30 min	2 replicates
ARR00253	GSE19335	GSE19335	GSM595676	GPL6947	linear	raw	NA	VEGF	HUVECs	activating	treated with 50ng/ml VEGF	30 min	2 replicates
ARR00254	GSE19335	GSE19335	GSM595677	GPL6947	linear	raw	NA	VEGF	HUVECs	activating	treated with 50ng/ml VEGF	30 min	2 replicates
ARR00255	GSE837	GSE837c	GSM12904	GPL91	log	raw	NA	VEGF	HUVECs	control	treated with VEGF	4 h	1 replicate, part of 3 different isolates
ARR00256	GSE837	GSE837c	GSM12905	GPL91	log	raw	NA	VEGF	HUVECs	activating	treated with VEGF	4 h	1 replicate, part of 3 different isolates
ARR00257	GSE3891	GSE3891g	GSM88907	GPL97	linear	raw	NA	VEGF	HMVEC (Human microvascular endothelial cells)	control	VEGF treatment	2 h	time series 30 min, 1, 2, 4 h
ARR00258	GSE3891	GSE3891g	GSM88910	GPL97	linear	raw	NA	VEGF	HMVEC (Human microvascular endothelial cells)	activating	VEGF treatment	2 h	time series 30 min, 1, 2, 4 h
ARR00259	GSE11228	GSE11228a	GSM283080	GPL2986	log	raw	NA	VEGF	LEC (Human dermal lymphatic endothelial cells)	control	treatment with VEGF-A165 (20ng/ml)	1 h	time series (1, 4, 8, 24 h)
ARR00260	GSE11228	GSE11228a	GSM283081	GPL2986	log	raw	NA	VEGF	LEC (Human dermal lymphatic endothelial cells)	control	treatment with VEGF-A165 (20ng/ml)	1 h	time series (1, 4, 8, 24 h)
ARR00261	GSE11228	GSE11228a	GSM283082	GPL2986	log	raw	NA	VEGF	LEC (Human dermal lymphatic endothelial cells)	control	treatment with VEGF-A165 (20ng/ml)	1 h	time series (1, 4, 8, 24 h)
ARR00262	GSE11228	GSE11228a	GSM283083	GPL2986	log	raw	NA	VEGF	LEC (Human dermal lymphatic endothelial cells)	activating	treatment with VEGF-A165 (20ng/ml)	1 h	time series (1, 4, 8, 24 h)
ARR00263	GSE11228	GSE11228a	GSM283084	GPL2986	log	raw	NA	VEGF	LEC (Human dermal lymphatic endothelial cells)	activating	treatment with VEGF-A165 (20ng/ml)	1 h	time series (1, 4, 8, 24 h)
ARR00264	GSE11228	GSE11228a	GSM283085	GPL2986	log	raw	NA	VEGF	LEC (Human dermal lymphatic endothelial cells)	activating	treatment with VEGF-A165 (20ng/ml)	1 h	time series (1, 4, 8, 24 h)
ARR00265	GSE3891	GSE3891f	GSM88907	GPL97	linear	raw	NA	VEGF	HMVEC (Human microvascular endothelial cells)	control	VEGF treatment	1 h	time series 30 min, 1, 2, 4 h
ARR00266	GSE3891	GSE3891f	GSM88909	GPL97	linear	raw	NA	VEGF	HMVEC (Human microvascular endothelial cells)	activating	VEGF treatment	1 h	time series 30 min, 1, 2, 4 h
ARR00267	GSE10778	GSE10778f	GSM272122	GPL97	linear	raw	CELS/GSE10778/GSM272122.CEL	VEGF	HUVEC (human umbilical vein endothelial cells)	control	treatment with 100ng VEGF	2.5 h	time series (0.5, 1, 2.5, 6 h), 2 Chips HG-U133A and B
ARR00268	GSE10778	GSE10778f	GSM272125	GPL97	linear	raw	CELS/GSE10778/GSM272125.CEL	VEGF	HUVEC (human umbilical vein endothelial cells)	activating	treatment with 100ng VEGF	2.5 h	time series (0.5, 1, 2.5, 6 h), 2 Chips HG-U133A and B
ARR00269	GSE10778	GSE10778d	GSM272122	GPL97	linear	raw	CELS/GSE10778/GSM272122.CEL	VEGF	HUVEC (human umbilical vein endothelial cells)	control	treatment with 100ng VEGF	30 min	time series (0.5, 1, 2.5, 6 h), 2 Chips HG-U133A and B
ARR00270	GSE10778	GSE10778d	GSM272123	GPL97	linear	raw	CELS/GSE10778/GSM272123.CEL	VEGF	HUVEC (human umbilical vein endothelial cells)	activating	treatment with 100ng VEGF	30 min	time series (0.5, 1, 2.5, 6 h), 2 Chips HG-U133A and B
ARR00271	GSE18913	GSE18913b	GSM468603	GPL570	log	raw	CELS/GSE18913/GSM468603.CEL	VEGF	HUVECs	control	treated with VEGF	4 h	3 replicates, part of time series
ARR00272	GSE18913	GSE18913b	GSM468604	GPL570	log	raw	CELS/GSE18913/GSM468604.CEL	VEGF	HUVECs	control	treated with VEGF	4 h	3 replicates, part of time series
ARR00273	GSE18913	GSE18913b	GSM468621	GPL570	log	raw	CELS/GSE18913/GSM468621.CEL	VEGF	HUVECs	control	treated with VEGF	4 h	3 replicates, part of time series
ARR00274	GSE18913	GSE18913b	GSM468615	GPL570	log	raw	CELS/GSE18913/GSM468615.CEL	VEGF	HUVECs	activating	treated with VEGF	4 h	3 replicates, part of time series
ARR00275	GSE18913	GSE18913b	GSM468616	GPL570	log	raw	CELS/GSE18913/GSM468616.CEL	VEGF	HUVECs	activating	treated with VEGF	4 h	3 replicates, part of time series
ARR00276	GSE18913	GSE18913b	GSM468623	GPL570	log	raw	CELS/GSE18913/GSM468623.CEL	VEGF	HUVECs	activating	treated with VEGF	4 h	3 replicates, part of time series
ARR00277	GSE3891	GSE3891h	GSM88907	GPL97	linear	raw	NA	VEGF	HMVEC (Human microvascular endothelial cells)	control	VEGF treatment	4 h	time series 30 min, 1, 2, 4 h
ARR00278	GSE3891	GSE3891h	GSM88911	GPL97	linear	raw	NA	VEGF	HMVEC (Human microvascular endothelial cells)	activating	VEGF treatment	4 h	time series 30 min, 1, 2, 4 h
ARR00279	GSE36176	GSE36176b	GSM882373	GPL570	log	raw	CELS/GSE36176/GSM882373.CEL	notch	H460 cells	control	treated with 2µM GSI RO4929097	6 h	4 replicates each, different cell lines, GSI= gamma secretase inhibitor
ARR00280	GSE36176	GSE36176b	GSM882374	GPL570	log	raw	CELS/GSE36176/GSM882374.CEL	notch	H460 cells	control	treated with 2µM GSI RO4929097	6 h	4 replicates each, different cell lines, GSI= gamma secretase inhibitor
ARR00281	GSE36176	GSE36176b	GSM882375	GPL570	log	raw	CELS/GSE36176/GSM882375.CEL	notch	H460 cells	control	treated with 2µM GSI RO4929097	6 h	4 replicates each, different cell lines, GSI= gamma secretase inhibitor
ARR00282	GSE36176	GSE36176b	GSM882376	GPL570	log	raw	CELS/GSE36176/GSM882376.CEL	notch	H460 cells	control	treated with 2µM GSI RO4929097	6 h	4 replicates each, different cell lines, GSI= gamma secretase inhibitor
ARR00283	GSE36176	GSE36176b	GSM882377	GPL570	log	raw	CELS/GSE36176/GSM882377.CEL	notch	H460 cells	inhibiting	treated with 2µM GSI RO4929097	6 h	4 replicates each, different cell lines, GSI= gamma secretase inhibitor
ARR00284	GSE36176	GSE36176b	GSM882378	GPL570	log	raw	CELS/GSE36176/GSM882378.CEL	notch	H460 cells	inhibiting	treated with 2µM GSI RO4929097	6 h	4 replicates each, different cell lines, GSI= gamma secretase inhibitor
ARR00285	GSE36176	GSE36176b	GSM882379	GPL570	log	raw	CELS/GSE36176/GSM882379.CEL	notch	H460 cells	inhibiting	treated with 2µM GSI RO4929097	6 h	4 replicates each, different cell lines, GSI= gamma secretase inhibitor
ARR00286	GSE36176	GSE36176b	GSM882380	GPL570	log	raw	CELS/GSE36176/GSM882380.CEL	notch	H460 cells	inhibiting	treated with 2µM GSI RO4929097	6 h	4 replicates each, different cell lines, GSI= gamma secretase inhibitor
ARR00287	GSE36176	GSE36176a	GSM882357	GPL570	log	raw	CELS/GSE36176/GSM882357.CEL	notch	A549 cells	control	treated with 2µM GSI RO4929097	6 h	4 replicates each, different cell lines, GSI= gamma secretase inhibitor
ARR00288	GSE36176	GSE36176a	GSM882358	GPL570	log	raw	CELS/GSE36176/GSM882358.CEL	notch	A549 cells	control	treated with 2µM GSI RO4929097	6 h	4 replicates each, different cell lines, GSI= gamma secretase inhibitor
ARR00289	GSE36176	GSE36176a	GSM882359	GPL570	log	raw	CELS/GSE36176/GSM882359.CEL	notch	A549 cells	control	treated with 2µM GSI RO4929097	6 h	4 replicates each, different cell lines, GSI= gamma secretase inhibitor
ARR00290	GSE36176	GSE36176a	GSM882360	GPL570	log	raw	CELS/GSE36176/GSM882360.CEL	notch	A549 cells	control	treated with 2µM GSI RO4929097	6 h	4 replicates each, different cell lines, GSI= gamma secretase inhibitor
ARR00291	GSE36176	GSE36176a	GSM882361	GPL570	log	raw	CELS/GSE36176/GSM882361.CEL	notch	A549 cells	inhibiting	treated with 2µM GSI RO4929097	6 h	4 replicates each, different cell lines, GSI= gamma secretase inhibitor
ARR00292	GSE36176	GSE36176a	GSM882362	GPL570	log	raw	CELS/GSE36176/GSM882362.CEL	notch	A549 cells	inhibiting	treated with 2µM GSI RO4929097	6 h	4 replicates each, different cell lines, GSI= gamma secretase inhibitor
ARR00293	GSE36176	GSE36176a	GSM882363	GPL570	log	raw	CELS/GSE36176/GSM882363.CEL	notch	A549 cells	inhibiting	treated with 2µM GSI RO4929097	6 h	4 replicates each, different cell lines, GSI= gamma secretase inhibitor
ARR00294	GSE36176	GSE36176a	GSM882364	GPL570	log	raw	CELS/GSE36176/GSM882364.CEL	notch	A549 cells	inhibiting	treated with 2µM GSI RO4929097	6 h	4 replicates each, different cell lines, GSI= gamma secretase inhibitor
ARR00295	GSE29544	GSE29544a	GSM731503	GPL570	log	raw	CELS/GSE29544/GSM731503.CEL	notch	CUTLL1 cells	control	treated with washout of GSI inhibitor	2 h	3 replicates each, treatment after 3 days treatment with GSI, GSI= gamma secretase inhibitor
ARR00296	GSE29544	GSE29544a	GSM731504	GPL570	log	raw	CELS/GSE29544/GSM731504.CEL	notch	CUTLL1 cells	control	treated with washout of GSI inhibitor	2 h	3 replicates each, treatment after 3 days treatment with GSI, GSI= gamma secretase inhibitor
ARR00297	GSE29544	GSE29544a	GSM731505	GPL570	log	raw	CELS/GSE29544/GSM731505.CEL	notch	CUTLL1 cells	control	treated with washout of GSI inhibitor	2 h	3 replicates each, treatment after 3 days treatment with GSI, GSI= gamma secretase inhibitor
ARR00298	GSE29544	GSE29544a	GSM731506	GPL570	log	raw	CELS/GSE29544/GSM731506.CEL	notch	CUTLL1 cells	activating	treated with washout of GSI inhibitor	2 h	3 replicates each, treatment after 3 days treatment with GSI, GSI= gamma secretase inhibitor
ARR00299	GSE29544	GSE29544a	GSM731507	GPL570	log	raw	CELS/GSE29544/GSM731507.CEL	notch	CUTLL1 cells	activating	treated with washout of GSI inhibitor	2 h	3 replicates each, treatment after 3 days treatment with GSI, GSI= gamma secretase inhibitor
ARR00300	GSE29544	GSE29544a	GSM731508	GPL570	log	raw	CELS/GSE29544/GSM731508.CEL	notch	CUTLL1 cells	activating	treated with washout of GSI inhibitor	2 h	3 replicates each, treatment after 3 days treatment with GSI, GSI= gamma secretase inhibitor
ARR00301	GSE12355	GSE12355	GSM310330	GPL570	log	raw	CELS/GSE12355/GSM310330.CEL	notch	EREB2-5 B cell line	control	transfected with Notch1 intracellular domain	8 h	3 replicates each
ARR00302	GSE12355	GSE12355	GSM310331	GPL570	log	raw	CELS/GSE12355/GSM310331.CEL	notch	EREB2-5 B cell line	control	transfected with Notch1 intracellular domain	8 h	3 replicates each
ARR00303	GSE12355	GSE12355	GSM310332	GPL570	log	raw	CELS/GSE12355/GSM310332.CEL	notch	EREB2-5 B cell line	control	transfected with Notch1 intracellular domain	8 h	3 replicates each
ARR00304	GSE12355	GSE12355	GSM310333	GPL570	log	raw	CELS/GSE12355/GSM310333.CEL	notch	EREB2-5 B cell line	activating	transfected with Notch1 intracellular domain	8 h	3 replicates each
ARR00305	GSE12355	GSE12355	GSM310334	GPL570	log	raw	CELS/GSE12355/GSM310334.CEL	notch	EREB2-5 B cell line	activating	transfected with Notch1 intracellular domain	8 h	3 replicates each
ARR00306	GSE12355	GSE12355	GSM310335	GPL570	log	raw	CELS/GSE12355/GSM310335.CEL	notch	EREB2-5 B cell line	activating	transfected with Notch1 intracellular domain	8 h	3 replicates each
ARR00307	GSE29544	GSE29544b	GSM731503	GPL570	log	raw	CELS/GSE29544/GSM731503.CEL	notch	CUTLL1 cells	control	treated with washout of GSI inhibitor	4 h	3 replicates each, treatment after 3 days treatment with GSI, GSI= gamma secretase inhibitor
ARR00308	GSE29544	GSE29544b	GSM731504	GPL570	log	raw	CELS/GSE29544/GSM731504.CEL	notch	CUTLL1 cells	control	treated with washout of GSI inhibitor	4 h	3 replicates each, treatment after 3 days treatment with GSI, GSI= gamma secretase inhibitor
ARR00309	GSE29544	GSE29544b	GSM731505	GPL570	log	raw	CELS/GSE29544/GSM731505.CEL	notch	CUTLL1 cells	control	treated with washout of GSI inhibitor	4 h	3 replicates each, treatment after 3 days treatment with GSI, GSI= gamma secretase inhibitor
ARR00310	GSE29544	GSE29544b	GSM731513	GPL570	log	raw	CELS/GSE29544/GSM731513.CEL	notch	CUTLL1 cells	activating	treated with washout of GSI inhibitor	4 h	3 replicates each, treatment after 3 days treatment with GSI, GSI= gamma secretase inhibitor
ARR00311	GSE29544	GSE29544b	GSM731514	GPL570	log	raw	CELS/GSE29544/GSM731514.CEL	notch	CUTLL1 cells	activating	treated with washout of GSI inhibitor	4 h	3 replicates each, treatment after 3 days treatment with GSI, GSI= gamma secretase inhibitor
ARR00312	GSE29544	GSE29544b	GSM731512	GPL570	log	raw	CELS/GSE29544/GSM731512.CEL	notch	CUTLL1 cells	activating	treated with washout of GSI inhibitor	4 h	3 replicates each, treatment after 3 days treatment with GSI, GSI= gamma secretase inhibitor
ARR00313	GSE14107	GSE14107a	GSM354009	GPL571	linear	raw	CELS/GSE14107/GSM354009.CEL	Wnt	parental PC9 (Lung adenocarcinoma cell line)	control	Wnt3a stimulation after serum starvation (0.2 %)	3 h	comment
ARR00314	GSE14107	GSE14107a	GSM354010	GPL571	linear	raw	CELS/GSE14107/GSM354010.CEL	Wnt	parental PC9 (Lung adenocarcinoma cell line)	control	Wnt3a stimulation after serum starvation (0.2 %)	3 h	comment
ARR00315	GSE14107	GSE14107a	GSM354011	GPL571	linear	raw	CELS/GSE14107/GSM354011.CEL	Wnt	parental PC9 (Lung adenocarcinoma cell line)	activating	Wnt3a stimulation after serum starvation (0.2 %)	3 h	comment
ARR00316	GSE14107	GSE14107a	GSM354012	GPL571	linear	raw	CELS/GSE14107/GSM354012.CEL	Wnt	parental PC9 (Lung adenocarcinoma cell line)	activating	Wnt3a stimulation after serum starvation (0.2 %)	3 h	comment
ARR00317	GSE17385	GSE17385	GSM434408	GPL570	log	raw	CELS/GSE17385/GSM434408.CEL	Wnt	Multiple myeloma line MM1.S	control	cells lentivirally infected with control shRNA or beta-catenin shRNA vectors	not specified	inhibition
ARR00318	GSE17385	GSE17385	GSM434409	GPL570	log	raw	CELS/GSE17385/GSM434409.CEL	Wnt	Multiple myeloma line MM1.S	control	cells lentivirally infected with control shRNA or beta-catenin shRNA vectors	not specified	inhibition
ARR00319	GSE17385	GSE17385	GSM434410	GPL570	log	raw	CELS/GSE17385/GSM434410.CEL	Wnt	Multiple myeloma line MM1.S	control	cells lentivirally infected with control shRNA or beta-catenin shRNA vectors	not specified	inhibition
ARR00320	GSE17385	GSE17385	GSM434411	GPL570	log	raw	CELS/GSE17385/GSM434411.CEL	Wnt	Multiple myeloma line MM1.S	inhibiting	cells lentivirally infected with control shRNA or beta-catenin shRNA vectors	not specified	inhibition
ARR00321	GSE17385	GSE17385	GSM434412	GPL570	log	raw	CELS/GSE17385/GSM434412.CEL	Wnt	Multiple myeloma line MM1.S	inhibiting	cells lentivirally infected with control shRNA or beta-catenin shRNA vectors	not specified	inhibition
ARR00322	GSE17385	GSE17385	GSM434413	GPL570	log	raw	CELS/GSE17385/GSM434413.CEL	Wnt	Multiple myeloma line MM1.S	inhibiting	cells lentivirally infected with control shRNA or beta-catenin shRNA vectors	not specified	inhibition
ARR00323	GSE14107	GSE14107b	GSM354017	GPL571	linear	raw	CELS/GSE14107/GSM354017.CEL	Wnt	parental H2030 (Lung adenocarcinoma cell line)	control	Wnt3a stimulation after serum starvation (0.2 %)	3 h	comment
ARR00324	GSE14107	GSE14107b	GSM354018	GPL571	linear	raw	CELS/GSE14107/GSM354018.CEL	Wnt	parental H2030 (Lung adenocarcinoma cell line)	control	Wnt3a stimulation after serum starvation (0.2 %)	3 h	comment
ARR00325	GSE14107	GSE14107b	GSM354019	GPL571	linear	raw	CELS/GSE14107/GSM354019.CEL	Wnt	parental H2030 (Lung adenocarcinoma cell line)	activating	Wnt3a stimulation after serum starvation (0.2 %)	3 h	comment
ARR00326	GSE14107	GSE14107b	GSM354020	GPL571	linear	raw	CELS/GSE14107/GSM354020.CEL	Wnt	parental H2030 (Lung adenocarcinoma cell line)	activating	Wnt3a stimulation after serum starvation (0.2 %)	3 h	comment
ARR00327	GSE11916	GSE11916	GSM301104	GPL570	linear	raw	CELS/GSE11916/GSM301104.CEL	Wnt	Huh7 (hepatocellular carcinoma derived)	control	High TCF activity Huh7 cell line was compared to control Huh7 cell line (TCF the crucial transcription factor for Wnt)	not specified	constitutive activation
ARR00328	GSE11916	GSE11916	GSM301105	GPL570	linear	raw	CELS/GSE11916/GSM301105.CEL	Wnt	Huh7 (hepatocellular carcinoma derived)	control	High TCF activity Huh7 cell line was compared to control Huh7 cell line (TCF the crucial transcription factor for Wnt)	not specified	constitutive activation
ARR00329	GSE11916	GSE11916	GSM301106	GPL570	linear	raw	CELS/GSE11916/GSM301106.CEL	Wnt	Huh7 (hepatocellular carcinoma derived)	control	High TCF activity Huh7 cell line was compared to control Huh7 cell line (TCF the crucial transcription factor for Wnt)	not specified	constitutive activation
ARR00330	GSE11916	GSE11916	GSM301119	GPL570	linear	raw	CELS/GSE11916/GSM301119.CEL	Wnt	Huh7 (hepatocellular carcinoma derived)	activating	High TCF activity Huh7 cell line was compared to control Huh7 cell line (TCF the crucial transcription factor for Wnt)	not specified	constitutive activation
ARR00331	GSE11916	GSE11916	GSM301132	GPL570	linear	raw	CELS/GSE11916/GSM301132.CEL	Wnt	Huh7 (hepatocellular carcinoma derived)	activating	High TCF activity Huh7 cell line was compared to control Huh7 cell line (TCF the crucial transcription factor for Wnt)	not specified	constitutive activation
ARR00332	GSE11916	GSE11916	GSM301133	GPL570	linear	raw	CELS/GSE11916/GSM301133.CEL	Wnt	Huh7 (hepatocellular carcinoma derived)	activating	High TCF activity Huh7 cell line was compared to control Huh7 cell line (TCF the crucial transcription factor for Wnt)	not specified	constitutive activation
ARR00333	GSE26351	GSE26351	GSM647150	GPL570	log	raw	CELS/GSE26351/GSM647150.CEL	Wnt	mobilized periphal blood CD34+ cells	control	0.5 µM BIO (GSK3 inhibitor)	2 h	3 replicates, BIO activates WNT pathway
ARR00334	GSE26351	GSE26351	GSM647151	GPL570	log	raw	CELS/GSE26351/GSM647151.CEL	Wnt	mobilized periphal blood CD34+ cells	control	0.5 µM BIO (GSK3 inhibitor)	2 h	3 replicates, BIO activates WNT pathway
ARR00335	GSE26351	GSE26351	GSM647152	GPL570	log	raw	CELS/GSE26351/GSM647152.CEL	Wnt	mobilized periphal blood CD34+ cells	control	0.5 µM BIO (GSK3 inhibitor)	2 h	3 replicates, BIO activates WNT pathway
ARR00336	GSE26351	GSE26351	GSM647153	GPL570	log	raw	CELS/GSE26351/GSM647153.CEL	Wnt	mobilized periphal blood CD34+ cells	activating	0.5 µM BIO (GSK3 inhibitor)	2 h	3 replicates, BIO activates WNT pathway
ARR00337	GSE26351	GSE26351	GSM647154	GPL570	log	raw	CELS/GSE26351/GSM647154.CEL	Wnt	mobilized periphal blood CD34+ cells	activating	0.5 µM BIO (GSK3 inhibitor)	2 h	3 replicates, BIO activates WNT pathway
ARR00338	GSE26351	GSE26351	GSM647155	GPL570	log	raw	CELS/GSE26351/GSM647155.CEL	Wnt	mobilized periphal blood CD34+ cells	activating	0.5 µM BIO (GSK3 inhibitor)	2 h	3 replicates, BIO activates WNT pathway
ARR00339	GSE27313	GSE27313	GSM675170	GPL570	log	raw	CELS/GSE27313/GSM675170.CEL	Wnt	mesenchymal stem cells	control	treated with Wnt3a	6 h	1 replicate each
ARR00340	GSE27313	GSE27313	GSM675171	GPL570	log	raw	CELS/GSE27313/GSM675171.CEL	Wnt	mesenchymal stem cells	activating	treated with Wnt3a	6 h	1 replicate each
ARR00341	GSE1473	GSE1473	GSM24858	GPL96	linear	raw	NA	Wnt	HEK293 (kidney cell)	activating	infected with RCAS-beta-cateninS37A or RCAS-GFP	not specified	late and early response expected
ARR00342	GSE1473	GSE1473	GSM24859	GPL96	linear	raw	NA	Wnt	HEK293 (kidney cell)	activating	infected with RCAS-beta-cateninS37A or RCAS-GFP	not specified	late and early response expected
ARR00343	GSE1473	GSE1473	GSM24860	GPL96	linear	raw	NA	Wnt	HEK293 (kidney cell)	activating	infected with RCAS-beta-cateninS37A or RCAS-GFP	not specified	late and early response expected
ARR00344	GSE1473	GSE1473	GSM24861	GPL96	linear	raw	NA	Wnt	HEK293 (kidney cell)	activating	infected with RCAS-beta-cateninS37A or RCAS-GFP	not specified	late and early response expected
ARR00345	GSE1473	GSE1473	GSM24862	GPL96	linear	raw	NA	Wnt	HEK293 (kidney cell)	control	infected with RCAS-beta-cateninS37A or RCAS-GFP	not specified	late and early response expected
ARR00346	GSE1473	GSE1473	GSM24863	GPL96	linear	raw	NA	Wnt	HEK293 (kidney cell)	control	infected with RCAS-beta-cateninS37A or RCAS-GFP	not specified	late and early response expected
ARR00347	GSE1473	GSE1473	GSM24864	GPL96	linear	raw	NA	Wnt	HEK293 (kidney cell)	control	infected with RCAS-beta-cateninS37A or RCAS-GFP	not specified	late and early response expected
ARR00348	GSE1473	GSE1473	GSM24865	GPL96	linear	raw	NA	Wnt	HEK293 (kidney cell)	control	infected with RCAS-beta-cateninS37A or RCAS-GFP	not specified	late and early response expected
ARR00349	GSE24708	GSE24708	GSM608778	GPL10191	log	raw	NA	Wnt	HEK293, transfected with siControl plasmid	control	treated with Wnt3a	7 h	2 replicates each
ARR00350	GSE24708	GSE24708	GSM608779	GPL10191	log	raw	NA	Wnt	HEK293, transfected with siControl plasmid	control	treated with Wnt3a	7 h	2 replicates each
ARR00351	GSE24708	GSE24708	GSM608780	GPL10191	log	raw	NA	Wnt	HEK293, transfected with siControl plasmid	activating	treated with Wnt3a	7 h	2 replicates each
ARR00352	GSE24708	GSE24708	GSM608781	GPL10191	log	raw	NA	Wnt	HEK293, transfected with siControl plasmid	activating	treated with Wnt3a	7 h	2 replicates each
ARR00353	GSE9105	GSE9105q	GSM230453	GPL96	log	normalized	CELS/GSE9105/GSM230453.CEL	Insulin	primary muscle cells	control	treated with euglycemic hyperinsulinemic clamp	4 h	1 replicate each, part of time series, 12 donors
ARR00354	GSE9105	GSE9105q	GSM230455	GPL96	log	normalized	CELS/GSE9105/GSM230455.CEL	Insulin	primary muscle cells	activating	treated with euglycemic hyperinsulinemic clamp	4 h	1 replicate each, part of time series, 12 donors
ARR00355	GSE9105	GSE9105d	GSM230432	GPL96	log	normalized	CELS/GSE9105/GSM230432.CEL	Insulin	primary muscle cells	control	treated with euglycemic hyperinsulinemic clamp	4 h	1 replicate each, part of time series, 12 donors
ARR00356	GSE9105	GSE9105d	GSM230434	GPL96	log	normalized	CELS/GSE9105/GSM230434.CEL	Insulin	primary muscle cells	activating	treated with euglycemic hyperinsulinemic clamp	4 h	1 replicate each, part of time series, 12 donors
ARR00357	GSE24422	GSE24422c	GSM601637	GPL570	linear	raw	CELS/GSE24422/GSM601637.CEL	Insulin	hMSC adipocytes, stromal fraction	control	treated with 20 nM Insulin	5 h	2 replicates each, different fractions of cells
ARR00358	GSE24422	GSE24422c	GSM601638	GPL570	linear	raw	CELS/GSE24422/GSM601638.CEL	Insulin	hMSC adipocytes, stromal fraction	control	treated with 20 nM Insulin	5 h	2 replicates each, different fractions of cells
ARR00359	GSE24422	GSE24422c	GSM601639	GPL570	linear	raw	CELS/GSE24422/GSM601639.CEL	Insulin	hMSC adipocytes, stromal fraction	activating	treated with 20 nM Insulin	5 h	2 replicates each, different fractions of cells
ARR00360	GSE24422	GSE24422c	GSM601640	GPL570	linear	raw	CELS/GSE24422/GSM601640.CEL	Insulin	hMSC adipocytes, stromal fraction	activating	treated with 20 nM Insulin	5 h	2 replicates each, different fractions of cells
ARR00361	GSE9105	GSE9105a	GSM230429	GPL96	log	normalized	CELS/GSE9105/GSM230429.CEL	Insulin	primary muscle cells	control	treated with euglycemic hyperinsulinemic clamp	0.5 h	1 replicate each, part of time series, 12 donors
ARR00362	GSE9105	GSE9105a	GSM230430	GPL96	log	normalized	CELS/GSE9105/GSM230430.CEL	Insulin	primary muscle cells	activating	treated with euglycemic hyperinsulinemic clamp	0.5 h	1 replicate each, part of time series, 12 donors
ARR00363	GSE9105	GSE9105e	GSM230435	GPL96	log	normalized	CELS/GSE9105/GSM230435.CEL	Insulin	primary muscle cells	control	treated with euglycemic hyperinsulinemic clamp	0.5 h	1 replicate each, part of time series, 12 donors
ARR00364	GSE9105	GSE9105e	GSM230436	GPL96	log	normalized	CELS/GSE9105/GSM230436.CEL	Insulin	primary muscle cells	activating	treated with euglycemic hyperinsulinemic clamp	0.5 h	1 replicate each, part of time series, 12 donors
ARR00365	GSE9105	GSE9105t	GSM230456	GPL96	log	normalized	CELS/GSE9105/GSM230456.CEL	Insulin	primary muscle cells	control	treated with euglycemic hyperinsulinemic clamp	4 h	1 replicate each, part of time series, 12 donors
ARR00366	GSE9105	GSE9105t	GSM230458	GPL96	log	normalized	CELS/GSE9105/GSM230458.CEL	Insulin	primary muscle cells	activating	treated with euglycemic hyperinsulinemic clamp	4 h	1 replicate each, part of time series, 12 donors
ARR00367	GSE9105	GSE9105u	GSM230459	GPL96	log	normalized	CELS/GSE9105/GSM230459.CEL	Insulin	primary muscle cells	control	treated with euglycemic hyperinsulinemic clamp	4 h	1 replicate each, part of time series, 12 donors
ARR00368	GSE9105	GSE9105u	GSM230461	GPL96	log	normalized	CELS/GSE9105/GSM230461.CEL	Insulin	primary muscle cells	activating	treated with euglycemic hyperinsulinemic clamp	4 h	1 replicate each, part of time series, 12 donors
ARR00369	GSE9105	GSE9105f	GSM230435	GPL96	log	normalized	CELS/GSE9105/GSM230435.CEL	Insulin	primary muscle cells	control	treated with euglycemic hyperinsulinemic clamp	4 h	1 replicate each, part of time series, 12 donors
ARR00370	GSE9105	GSE9105f	GSM230437	GPL96	log	normalized	CELS/GSE9105/GSM230437.CEL	Insulin	primary muscle cells	activating	treated with euglycemic hyperinsulinemic clamp	4 h	1 replicate each, part of time series, 12 donors
ARR00371	GSE30524	GSE30524	GSM756954	GPL570	linear	raw	CELS/GSE30524/GSM756954.CEL	Insulin	RPMI 8266 cells	control	treated with 0.375µM picropodophyllin, IGF1R inhibitor	6 h	1 replicate each
ARR00372	GSE30524	GSE30524	GSM756956	GPL570	linear	raw	CELS/GSE30524/GSM756956.CEL	Insulin	RPMI 8266 cells	inhibiting	treated with 0.375µM picropodophyllin, IGF1R inhibitor	6 h	1 replicate each
ARR00373	GSE26834	GSE26834	GSM659805	GPL571	linear	raw	CELS/GSE26834/GSM659805.CEL	Insulin	MCF-7 breast cancer cells	control	treated with IGF-1	3 h	2 replicates for control, 3 replicates for treatment
ARR00374	GSE26834	GSE26834	GSM659806	GPL571	linear	raw	CELS/GSE26834/GSM659806.CEL	Insulin	MCF-7 breast cancer cells	control	treated with IGF-1	3 h	2 replicates for control, 3 replicates for treatment
ARR00375	GSE26834	GSE26834	GSM659810	GPL571	linear	raw	CELS/GSE26834/GSM659810.CEL	Insulin	MCF-7 breast cancer cells	activating	treated with IGF-1	3 h	2 replicates for control, 3 replicates for treatment
ARR00376	GSE26834	GSE26834	GSM659811	GPL571	linear	raw	CELS/GSE26834/GSM659811.CEL	Insulin	MCF-7 breast cancer cells	activating	treated with IGF-1	3 h	2 replicates for control, 3 replicates for treatment
ARR00377	GSE26834	GSE26834	GSM659812	GPL571	linear	raw	CELS/GSE26834/GSM659812.CEL	Insulin	MCF-7 breast cancer cells	activating	treated with IGF-1	3 h	2 replicates for control, 3 replicates for treatment
ARR00378	GSE9105	GSE9105g	GSM230438	GPL96	log	normalized	CELS/GSE9105/GSM230438.CEL	Insulin	primary muscle cells	control	treated with euglycemic hyperinsulinemic clamp	4 h	1 replicate each, part of time series, 12 donors
ARR00379	GSE9105	GSE9105g	GSM230440	GPL96	log	normalized	CELS/GSE9105/GSM230440.CEL	Insulin	primary muscle cells	activating	treated with euglycemic hyperinsulinemic clamp	4 h	1 replicate each, part of time series, 12 donors
ARR00380	GSE9105	GSE9105b	GSM230429	GPL96	log	normalized	CELS/GSE9105/GSM230429.CEL	Insulin	primary muscle cells	control	treated with euglycemic hyperinsulinemic clamp	4 h	1 replicate each, part of time series, 12 donors
ARR00381	GSE9105	GSE9105b	GSM230431	GPL96	log	normalized	CELS/GSE9105/GSM230431.CEL	Insulin	primary muscle cells	activating	treated with euglycemic hyperinsulinemic clamp	4 h	1 replicate each, part of time series, 12 donors
ARR00382	GSE21989	GSE21989a	GSM546910	GPL570	log	normalized	CELS/GSE21989/GSM546910.CEL	Insulin	HUVECs	control	treated with Insulin	0.66 h	1 replicate each, part of time series
ARR00383	GSE21989	GSE21989a	GSM546915	GPL570	log	normalized	CELS/GSE21989/GSM546915.CEL	Insulin	HUVECs	activating	treated with Insulin	0.66 h	1 replicate each, part of time series
ARR00384	GSE9105	GSE9105c	GSM230432	GPL96	log	normalized	CELS/GSE9105/GSM230432.CEL	Insulin	primary muscle cells	control	treated with euglycemic hyperinsulinemic clamp	0.5 h	1 replicate each, part of time series, 12 donors
ARR00385	GSE9105	GSE9105c	GSM230433	GPL96	log	normalized	CELS/GSE9105/GSM230433.CEL	Insulin	primary muscle cells	activating	treated with euglycemic hyperinsulinemic clamp	0.5 h	1 replicate each, part of time series, 12 donors
ARR00386	GSE9105	GSE9105r	GSM230453	GPL96	log	normalized	CELS/GSE9105/GSM230453.CEL	Insulin	primary muscle cells	control	treated with euglycemic hyperinsulinemic clamp	0.5 h	1 replicate each, part of time series, 12 donors
ARR00387	GSE9105	GSE9105r	GSM230454	GPL96	log	normalized	CELS/GSE9105/GSM230454.CEL	Insulin	primary muscle cells	activating	treated with euglycemic hyperinsulinemic clamp	0.5 h	1 replicate each, part of time series, 12 donors
ARR00388	GSE21989	GSE21989c	GSM546912	GPL570	log	normalized	CELS/GSE21989/GSM546912.CEL	Insulin	HUVECs	control	treated with Insulin	3.33 h	1 replicate each, part of time series
ARR00389	GSE21989	GSE21989c	GSM546917	GPL570	log	normalized	CELS/GSE21989/GSM546917.CEL	Insulin	HUVECs	activating	treated with Insulin	3.33 h	1 replicate each, part of time series
ARR00390	GSE24422	GSE24422b	GSM601629	GPL570	linear	raw	CELS/GSE24422/GSM601629.CEL	Insulin	hMSC adipocytes, adipocyte fraction	control	treated with 20 nM Insulin	5 h	2 replicates each, different fractions of cells
ARR00391	GSE24422	GSE24422b	GSM601630	GPL570	linear	raw	CELS/GSE24422/GSM601630.CEL	Insulin	hMSC adipocytes, adipocyte fraction	control	treated with 20 nM Insulin	5 h	2 replicates each, different fractions of cells
ARR00392	GSE24422	GSE24422b	GSM601631	GPL570	linear	raw	CELS/GSE24422/GSM601631.CEL	Insulin	hMSC adipocytes, adipocyte fraction	activating	treated with 20 nM Insulin	5 h	2 replicates each, different fractions of cells
ARR00393	GSE24422	GSE24422b	GSM601632	GPL570	linear	raw	CELS/GSE24422/GSM601632.CEL	Insulin	hMSC adipocytes, adipocyte fraction	activating	treated with 20 nM Insulin	5 h	2 replicates each, different fractions of cells
ARR00394	GSE9105	GSE9105v	GSM230459	GPL96	log	normalized	CELS/GSE9105/GSM230459.CEL	Insulin	primary muscle cells	control	treated with euglycemic hyperinsulinemic clamp	0.5 h	1 replicate each, part of time series, 12 donors
ARR00395	GSE9105	GSE9105v	GSM230460	GPL96	log	normalized	CELS/GSE9105/GSM230460.CEL	Insulin	primary muscle cells	activating	treated with euglycemic hyperinsulinemic clamp	0.5 h	1 replicate each, part of time series, 12 donors
ARR00396	GSE9105	GSE9105i	GSM230441	GPL96	log	normalized	CELS/GSE9105/GSM230441.CEL	Insulin	primary muscle cells	control	treated with euglycemic hyperinsulinemic clamp	0.5 h	1 replicate each, part of time series, 12 donors
ARR00397	GSE9105	GSE9105i	GSM230442	GPL96	log	normalized	CELS/GSE9105/GSM230442.CEL	Insulin	primary muscle cells	activating	treated with euglycemic hyperinsulinemic clamp	0.5 h	1 replicate each, part of time series, 12 donors
ARR00398	GSE21727	GSE21727	GSM542107	GPL6104	log	normalized	NA	Insulin	trabecular bone cells	control	treated with IGF-1	2 h	3 replicates each
ARR00399	GSE21727	GSE21727	GSM542108	GPL6104	log	normalized	NA	Insulin	trabecular bone cells	control	treated with IGF-1	2 h	3 replicates each
ARR00400	GSE21727	GSE21727	GSM542109	GPL6104	log	normalized	NA	Insulin	trabecular bone cells	control	treated with IGF-1	2 h	3 replicates each
ARR00401	GSE21727	GSE21727	GSM542098	GPL6104	log	normalized	NA	Insulin	trabecular bone cells	activating	treated with IGF-1	2 h	3 replicates each
ARR00402	GSE21727	GSE21727	GSM542099	GPL6104	log	normalized	NA	Insulin	trabecular bone cells	activating	treated with IGF-1	2 h	3 replicates each
ARR00403	GSE21727	GSE21727	GSM542100	GPL6104	log	normalized	NA	Insulin	trabecular bone cells	activating	treated with IGF-1	2 h	3 replicates each
ARR00404	GSE9105	GSE9105j	GSM230441	GPL96	log	normalized	CELS/GSE9105/GSM230441.CEL	Insulin	primary muscle cells	control	treated with euglycemic hyperinsulinemic clamp	4 h	1 replicate each, part of time series, 12 donors
ARR00405	GSE9105	GSE9105j	GSM230443	GPL96	log	normalized	CELS/GSE9105/GSM230443.CEL	Insulin	primary muscle cells	activating	treated with euglycemic hyperinsulinemic clamp	4 h	1 replicate each, part of time series, 12 donors
ARR00406	GSE9105	GSE9105o	GSM230450	GPL96	log	normalized	CELS/GSE9105/GSM230450.CEL	Insulin	primary muscle cells	control	treated with euglycemic hyperinsulinemic clamp	0.5 h	1 replicate each, part of time series, 12 donors
ARR00407	GSE9105	GSE9105o	GSM230451	GPL96	log	normalized	CELS/GSE9105/GSM230451.CEL	Insulin	primary muscle cells	activating	treated with euglycemic hyperinsulinemic clamp	0.5 h	1 replicate each, part of time series, 12 donors
ARR00408	GSE9105	GSE9105n	GSM230447	GPL96	log	normalized	CELS/GSE9105/GSM230447.CEL	Insulin	primary muscle cells	control	treated with euglycemic hyperinsulinemic clamp	0.5 h	1 replicate each, part of time series, 12 donors
ARR00409	GSE9105	GSE9105n	GSM230448	GPL96	log	normalized	CELS/GSE9105/GSM230448.CEL	Insulin	primary muscle cells	activating	treated with euglycemic hyperinsulinemic clamp	0.5 h	1 replicate each, part of time series, 12 donors
ARR00410	GSE9105	GSE9105h	GSM230438	GPL96	log	normalized	CELS/GSE9105/GSM230438.CEL	Insulin	primary muscle cells	control	treated with euglycemic hyperinsulinemic clamp	0.5 h	1 replicate each, part of time series, 12 donors
ARR00411	GSE9105	GSE9105h	GSM230439	GPL96	log	normalized	CELS/GSE9105/GSM230439.CEL	Insulin	primary muscle cells	activating	treated with euglycemic hyperinsulinemic clamp	0.5 h	1 replicate each, part of time series, 12 donors
ARR00412	GSE9105	GSE9105x	GSM230462	GPL96	log	normalized	CELS/GSE9105/GSM230462.CEL	Insulin	primary muscle cells	control	treated with euglycemic hyperinsulinemic clamp	4 h	1 replicate each, part of time series, 12 donors
ARR00413	GSE9105	GSE9105x	GSM230464	GPL96	log	normalized	CELS/GSE9105/GSM230464.CEL	Insulin	primary muscle cells	activating	treated with euglycemic hyperinsulinemic clamp	4 h	1 replicate each, part of time series, 12 donors
ARR00414	GSE9105	GSE9105p	GSM230450	GPL96	log	normalized	CELS/GSE9105/GSM230450.CEL	Insulin	primary muscle cells	control	treated with euglycemic hyperinsulinemic clamp	4 h	1 replicate each, part of time series, 12 donors
ARR00415	GSE9105	GSE9105p	GSM230452	GPL96	log	normalized	CELS/GSE9105/GSM230452.CEL	Insulin	primary muscle cells	activating	treated with euglycemic hyperinsulinemic clamp	4 h	1 replicate each, part of time series, 12 donors
ARR00416	GSE9105	GSE9105w	GSM230462	GPL96	log	normalized	CELS/GSE9105/GSM230462.CEL	Insulin	primary muscle cells	control	treated with euglycemic hyperinsulinemic clamp	0.5 h	1 replicate each, part of time series, 12 donors
ARR00417	GSE9105	GSE9105w	GSM230463	GPL96	log	normalized	CELS/GSE9105/GSM230463.CEL	Insulin	primary muscle cells	activating	treated with euglycemic hyperinsulinemic clamp	0.5 h	1 replicate each, part of time series, 12 donors
ARR00418	GSE21989	GSE21989d	GSM546913	GPL570	log	normalized	CELS/GSE21989/GSM546913.CEL	Insulin	HUVECs	control	treated with Insulin	5.66 h	1 replicate each, part of time series
ARR00419	GSE21989	GSE21989d	GSM546918	GPL570	log	normalized	CELS/GSE21989/GSM546918.CEL	Insulin	HUVECs	activating	treated with Insulin	5.66 h	1 replicate each, part of time series
ARR00420	GSE9105	GSE9105m	GSM230447	GPL96	log	normalized	CELS/GSE9105/GSM230447.CEL	Insulin	primary muscle cells	control	treated with euglycemic hyperinsulinemic clamp	4 h	1 replicate each, part of time series, 12 donors
ARR00421	GSE9105	GSE9105m	GSM230449	GPL96	log	normalized	CELS/GSE9105/GSM230449.CEL	Insulin	primary muscle cells	activating	treated with euglycemic hyperinsulinemic clamp	4 h	1 replicate each, part of time series, 12 donors
ARR00422	GSE9105	GSE9105s	GSM230456	GPL96	log	normalized	CELS/GSE9105/GSM230456.CEL	Insulin	primary muscle cells	control	treated with euglycemic hyperinsulinemic clamp	0.5 h	1 replicate each, part of time series, 12 donors
ARR00423	GSE9105	GSE9105s	GSM230457	GPL96	log	normalized	CELS/GSE9105/GSM230457.CEL	Insulin	primary muscle cells	activating	treated with euglycemic hyperinsulinemic clamp	0.5 h	1 replicate each, part of time series, 12 donors
ARR00424	GSE21989	GSE21989b	GSM546911	GPL570	log	normalized	CELS/GSE21989/GSM546911.CEL	Insulin	HUVECs	control	treated with Insulin	1.66 h	1 replicate each, part of time series
ARR00425	GSE21989	GSE21989b	GSM546916	GPL570	log	normalized	CELS/GSE21989/GSM546916.CEL	Insulin	HUVECs	activating	treated with Insulin	1.66 h	1 replicate each, part of time series
ARR00426	GSE24422	GSE24422a	GSM601621	GPL570	linear	raw	CELS/GSE24422/GSM601621.CEL	Insulin	hMSC adipocytes, mixed fraction	control	treated with 20 nM Insulin	5 h	2 replicates each, different fractions of cells
ARR00427	GSE24422	GSE24422a	GSM601622	GPL570	linear	raw	CELS/GSE24422/GSM601622.CEL	Insulin	hMSC adipocytes, mixed fraction	control	treated with 20 nM Insulin	5 h	2 replicates each, different fractions of cells
ARR00428	GSE24422	GSE24422a	GSM601623	GPL570	linear	raw	CELS/GSE24422/GSM601623.CEL	Insulin	hMSC adipocytes, mixed fraction	activating	treated with 20 nM Insulin	5 h	2 replicates each, different fractions of cells
ARR00429	GSE24422	GSE24422a	GSM601624	GPL570	linear	raw	CELS/GSE24422/GSM601624.CEL	Insulin	hMSC adipocytes, mixed fraction	activating	treated with 20 nM Insulin	5 h	2 replicates each, different fractions of cells
ARR00430	GSE9105	GSE9105k	GSM230444	GPL96	log	normalized	CELS/GSE9105/GSM230444.CEL	Insulin	primary muscle cells	control	treated with euglycemic hyperinsulinemic clamp	0.5 h	1 replicate each, part of time series, 12 donors
ARR00431	GSE9105	GSE9105k	GSM230445	GPL96	log	normalized	CELS/GSE9105/GSM230445.CEL	Insulin	primary muscle cells	activating	treated with euglycemic hyperinsulinemic clamp	0.5 h	1 replicate each, part of time series, 12 donors
ARR00432	GSE9105	GSE9105l	GSM230444	GPL96	log	normalized	CELS/GSE9105/GSM230444.CEL	Insulin	primary muscle cells	control	treated with euglycemic hyperinsulinemic clamp	4 h	1 replicate each, part of time series, 12 donors
ARR00433	GSE9105	GSE9105l	GSM230446	GPL96	log	normalized	CELS/GSE9105/GSM230446.CEL	Insulin	primary muscle cells	activating	treated with euglycemic hyperinsulinemic clamp	4 h	1 replicate each, part of time series, 12 donors
ARR00434	GSE19123	GSE19123	GSM474352	GPL570	log	normalized	CELS/GSE19123/GSM474352.CEL	Hypoxia	MCF-7 cells	control	treated with 1% oxygen hypoxia	4 h	5 replicates each
ARR00435	GSE19123	GSE19123	GSM474353	GPL570	log	normalized	CELS/GSE19123/GSM474353.CEL	Hypoxia	MCF-7 cells	control	treated with 1% oxygen hypoxia	4 h	5 replicates each
ARR00436	GSE19123	GSE19123	GSM474354	GPL570	log	normalized	CELS/GSE19123/GSM474354.CEL	Hypoxia	MCF-7 cells	control	treated with 1% oxygen hypoxia	4 h	5 replicates each
ARR00437	GSE19123	GSE19123	GSM474355	GPL570	log	normalized	CELS/GSE19123/GSM474355.CEL	Hypoxia	MCF-7 cells	control	treated with 1% oxygen hypoxia	4 h	5 replicates each
ARR00438	GSE19123	GSE19123	GSM474356	GPL570	log	normalized	CELS/GSE19123/GSM474356.CEL	Hypoxia	MCF-7 cells	control	treated with 1% oxygen hypoxia	4 h	5 replicates each
ARR00439	GSE19123	GSE19123	GSM474367	GPL570	log	normalized	CELS/GSE19123/GSM474367.CEL	Hypoxia	MCF-7 cells	activating	treated with 1% oxygen hypoxia	4 h	5 replicates each
ARR00440	GSE19123	GSE19123	GSM474368	GPL570	log	normalized	CELS/GSE19123/GSM474368.CEL	Hypoxia	MCF-7 cells	activating	treated with 1% oxygen hypoxia	4 h	5 replicates each
ARR00441	GSE19123	GSE19123	GSM474369	GPL570	log	normalized	CELS/GSE19123/GSM474369.CEL	Hypoxia	MCF-7 cells	activating	treated with 1% oxygen hypoxia	4 h	5 replicates each
ARR00442	GSE19123	GSE19123	GSM474370	GPL570	log	normalized	CELS/GSE19123/GSM474370.CEL	Hypoxia	MCF-7 cells	activating	treated with 1% oxygen hypoxia	4 h	5 replicates each
ARR00443	GSE19123	GSE19123	GSM474371	GPL570	log	normalized	CELS/GSE19123/GSM474371.CEL	Hypoxia	MCF-7 cells	activating	treated with 1% oxygen hypoxia	4 h	5 replicates each
ARR00444	GSE5258	GSE5258	GSM118799	GPL96	log	raw	CELS/GSE5258/GSM118799.CEL	Hypoxia	MCF7 cells	control	treated with 0.1mM cobalt chloride	6 h	3 replicates each, cobald cloride induces HIF1
ARR00445	GSE5258	GSE5258	GSM118848	GPL96	log	raw	CELS/GSE5258/GSM118848.CEL	Hypoxia	MCF7 cells	control	treated with 0.1mM cobalt chloride	6 h	3 replicates each, cobald cloride induces HIF1
ARR00446	GSE5258	GSE5258	GSM118922	GPL96	log	raw	CELS/GSE5258/GSM118922.CEL	Hypoxia	MCF7 cells	control	treated with 0.1mM cobalt chloride	6 h	3 replicates each, cobald cloride induces HIF1
ARR00447	GSE5258	GSE5258	GSM118850	GPL96	log	raw	CELS/GSE5258/GSM118850.CEL	Hypoxia	MCF7 cells	activating	treated with 0.1mM cobalt chloride	6 h	3 replicates each, cobald cloride induces HIF1
ARR00448	GSE5258	GSE5258	GSM118855	GPL96	log	raw	CELS/GSE5258/GSM118855.CEL	Hypoxia	MCF7 cells	activating	treated with 0.1mM cobalt chloride	6 h	3 replicates each, cobald cloride induces HIF1
ARR00449	GSE5258	GSE5258	GSM118928	GPL96	log	raw	CELS/GSE5258/GSM118928.CEL	Hypoxia	MCF7 cells	activating	treated with 0.1mM cobalt chloride	6 h	3 replicates each, cobald cloride induces HIF1
ARR00450	GSE27813	GSE27813	GSM686788	GPL10558	log	normalized	NA	Hypoxia	MCF-7 cells	control	treated with 1% oxygen hypoxia	6 h	2 replicates each, contain control shRNA
ARR00451	GSE27813	GSE27813	GSM686789	GPL10558	log	normalized	NA	Hypoxia	MCF-7 cells	control	treated with 1% oxygen hypoxia	6 h	2 replicates each, contain control shRNA
ARR00452	GSE27813	GSE27813	GSM686790	GPL10558	log	normalized	NA	Hypoxia	MCF-7 cells	activating	treated with 1% oxygen hypoxia	6 h	2 replicates each, contain control shRNA
ARR00453	GSE27813	GSE27813	GSM686791	GPL10558	log	normalized	NA	Hypoxia	MCF-7 cells	activating	treated with 1% oxygen hypoxia	6 h	2 replicates each, contain control shRNA
ARR00454	GSE33521	GSE33521	GSM829385	GPL6480	log	normalized	NA	Hypoxia	HeLa cells	control	treated with 1% oxygen hypoxia	6 h	2 replicates each
ARR00455	GSE33521	GSE33521	GSM829386	GPL6480	log	normalized	NA	Hypoxia	HeLa cells	control	treated with 1% oxygen hypoxia	6 h	2 replicates each
ARR00456	GSE33521	GSE33521	GSM829387	GPL6480	log	normalized	NA	Hypoxia	HeLa cells	activating	treated with 1% oxygen hypoxia	6 h	2 replicates each
ARR00457	GSE33521	GSE33521	GSM829388	GPL6480	log	normalized	NA	Hypoxia	HeLa cells	activating	treated with 1% oxygen hypoxia	6 h	2 replicates each
ARR00458	GSE1056	GSE1056	GSM17082	GPL91	log	raw	NA	Hypoxia	Hep3B cells	control	treated with 1% oxygen hypoxia	2 h	2 replicates each
ARR00459	GSE1056	GSE1056	GSM17083	GPL91	log	raw	NA	Hypoxia	Hep3B cells	control	treated with 1% oxygen hypoxia	2 h	2 replicates each
ARR00460	GSE1056	GSE1056	GSM17088	GPL91	log	raw	NA	Hypoxia	Hep3B cells	activating	treated with 1% oxygen hypoxia	2 h	2 replicates each
ARR00461	GSE1056	GSE1056	GSM17089	GPL91	log	raw	NA	Hypoxia	Hep3B cells	activating	treated with 1% oxygen hypoxia	2 h	2 replicates each
ARR00462	GSE18494	GSE18494a	GSM460669	GPL9419	log	normalized	NA	Hypoxia	HepG2 cells	control	treated with 0.5% oxygen hypoxia	4 h	3 replicates each, different cell lines
ARR00463	GSE18494	GSE18494a	GSM460670	GPL9419	log	normalized	NA	Hypoxia	HepG2 cells	control	treated with 0.5% oxygen hypoxia	4 h	3 replicates each, different cell lines
ARR00464	GSE18494	GSE18494a	GSM460671	GPL9419	log	normalized	NA	Hypoxia	HepG2 cells	control	treated with 0.5% oxygen hypoxia	4 h	3 replicates each, different cell lines
ARR00465	GSE18494	GSE18494a	GSM460672	GPL9419	log	normalized	NA	Hypoxia	HepG2 cells	activating	treated with 0.5% oxygen hypoxia	4 h	3 replicates each, different cell lines
ARR00466	GSE18494	GSE18494a	GSM460673	GPL9419	log	normalized	NA	Hypoxia	HepG2 cells	activating	treated with 0.5% oxygen hypoxia	4 h	3 replicates each, different cell lines
ARR00467	GSE18494	GSE18494a	GSM460674	GPL9419	log	normalized	NA	Hypoxia	HepG2 cells	activating	treated with 0.5% oxygen hypoxia	4 h	3 replicates each, different cell lines
ARR00468	GSE17188	GSE17188b	GSM429897	GPL6480	linear	raw	NA	Hypoxia	MDA-MB-231 SCP2 cells	control	treated with 1% oxygen hypoxia	6 h	2 replicates each, different cell lines
ARR00469	GSE17188	GSE17188b	GSM429898	GPL6480	linear	raw	NA	Hypoxia	MDA-MB-231 SCP2 cells	control	treated with 1% oxygen hypoxia	6 h	2 replicates each, different cell lines
ARR00470	GSE17188	GSE17188b	GSM429899	GPL6480	linear	raw	NA	Hypoxia	MDA-MB-231 SCP2 cells	activating	treated with 1% oxygen hypoxia	6 h	2 replicates each, different cell lines
ARR00471	GSE17188	GSE17188b	GSM429900	GPL6480	linear	raw	NA	Hypoxia	MDA-MB-231 SCP2 cells	activating	treated with 1% oxygen hypoxia	6 h	2 replicates each, different cell lines
ARR00472	GSE18494	GSE18494c	GSM460693	GPL9419	log	normalized	NA	Hypoxia	MB231 cells	control	treated with 0.5% oxygen hypoxia	4 h	3 replicates each, different cell lines
ARR00473	GSE18494	GSE18494c	GSM460694	GPL9419	log	normalized	NA	Hypoxia	MB231 cells	control	treated with 0.5% oxygen hypoxia	4 h	3 replicates each, different cell lines
ARR00474	GSE18494	GSE18494c	GSM460695	GPL9419	log	normalized	NA	Hypoxia	MB231 cells	control	treated with 0.5% oxygen hypoxia	4 h	3 replicates each, different cell lines
ARR00475	GSE18494	GSE18494c	GSM460696	GPL9419	log	normalized	NA	Hypoxia	MB231 cells	activating	treated with 0.5% oxygen hypoxia	4 h	3 replicates each, different cell lines
ARR00476	GSE18494	GSE18494c	GSM460697	GPL9419	log	normalized	NA	Hypoxia	MB231 cells	activating	treated with 0.5% oxygen hypoxia	4 h	3 replicates each, different cell lines
ARR00477	GSE18494	GSE18494c	GSM460698	GPL9419	log	normalized	NA	Hypoxia	MB231 cells	activating	treated with 0.5% oxygen hypoxia	4 h	3 replicates each, different cell lines
ARR00478	GSE18494	GSE18494b	GSM460681	GPL9419	log	normalized	NA	Hypoxia	U87 cells	control	treated with 0.5% oxygen hypoxia	4 h	3 replicates each, different cell lines
ARR00479	GSE18494	GSE18494b	GSM460682	GPL9419	log	normalized	NA	Hypoxia	U87 cells	control	treated with 0.5% oxygen hypoxia	4 h	3 replicates each, different cell lines
ARR00480	GSE18494	GSE18494b	GSM460683	GPL9419	log	normalized	NA	Hypoxia	U87 cells	control	treated with 0.5% oxygen hypoxia	4 h	3 replicates each, different cell lines
ARR00481	GSE18494	GSE18494b	GSM460684	GPL9419	log	normalized	NA	Hypoxia	U87 cells	activating	treated with 0.5% oxygen hypoxia	4 h	3 replicates each, different cell lines
ARR00482	GSE18494	GSE18494b	GSM460685	GPL9419	log	normalized	NA	Hypoxia	U87 cells	activating	treated with 0.5% oxygen hypoxia	4 h	3 replicates each, different cell lines
ARR00483	GSE18494	GSE18494b	GSM460686	GPL9419	log	normalized	NA	Hypoxia	U87 cells	activating	treated with 0.5% oxygen hypoxia	4 h	3 replicates each, different cell lines
ARR00484	GSE28603	GSE28603a	GSM707909	GPL570	log	raw	CELS/GSE28603/GSM707909.CEL	Hypoxia	SGBS adipocytes	control	treated with 1% oxygen hypoxia	3 h	3 replicates each, part of time series
ARR00485	GSE28603	GSE28603a	GSM707913	GPL570	log	raw	CELS/GSE28603/GSM707913.CEL	Hypoxia	SGBS adipocytes	control	treated with 1% oxygen hypoxia	3 h	3 replicates each, part of time series
ARR00486	GSE28603	GSE28603a	GSM707917	GPL570	log	raw	CELS/GSE28603/GSM707917.CEL	Hypoxia	SGBS adipocytes	control	treated with 1% oxygen hypoxia	3 h	3 replicates each, part of time series
ARR00487	GSE28603	GSE28603a	GSM707910	GPL570	log	raw	CELS/GSE28603/GSM707910.CEL	Hypoxia	SGBS adipocytes	activating	treated with 1% oxygen hypoxia	3 h	3 replicates each, part of time series
ARR00488	GSE28603	GSE28603a	GSM707914	GPL570	log	raw	CELS/GSE28603/GSM707914.CEL	Hypoxia	SGBS adipocytes	activating	treated with 1% oxygen hypoxia	3 h	3 replicates each, part of time series
ARR00489	GSE28603	GSE28603a	GSM707918	GPL570	log	raw	CELS/GSE28603/GSM707918.CEL	Hypoxia	SGBS adipocytes	activating	treated with 1% oxygen hypoxia	3 h	3 replicates each, part of time series
ARR00490	GSE28603	GSE28603b	GSM707909	GPL570	log	raw	CELS/GSE28603/GSM707909.CEL	Hypoxia	SGBS adipocytes	control	treated with 1% oxygen hypoxia	6 h	3 replicates each, part of time series
ARR00491	GSE28603	GSE28603b	GSM707913	GPL570	log	raw	CELS/GSE28603/GSM707913.CEL	Hypoxia	SGBS adipocytes	control	treated with 1% oxygen hypoxia	6 h	3 replicates each, part of time series
ARR00492	GSE28603	GSE28603b	GSM707917	GPL570	log	raw	CELS/GSE28603/GSM707917.CEL	Hypoxia	SGBS adipocytes	control	treated with 1% oxygen hypoxia	6 h	3 replicates each, part of time series
ARR00493	GSE28603	GSE28603b	GSM707911	GPL570	log	raw	CELS/GSE28603/GSM707911.CEL	Hypoxia	SGBS adipocytes	activating	treated with 1% oxygen hypoxia	6 h	3 replicates each, part of time series
ARR00494	GSE28603	GSE28603b	GSM707915	GPL570	log	raw	CELS/GSE28603/GSM707915.CEL	Hypoxia	SGBS adipocytes	activating	treated with 1% oxygen hypoxia	6 h	3 replicates each, part of time series
ARR00495	GSE28603	GSE28603b	GSM707919	GPL570	log	raw	CELS/GSE28603/GSM707919.CEL	Hypoxia	SGBS adipocytes	activating	treated with 1% oxygen hypoxia	6 h	3 replicates each, part of time series
ARR00496	GSE17188	GSE17188a	GSM429891	GPL6480	linear	raw	NA	Hypoxia	MDA-MB-231 LM2 cells	control	treated with 1% oxygen hypoxia	6 h	2 replicates each, different cell lines
ARR00497	GSE17188	GSE17188a	GSM429892	GPL6480	linear	raw	NA	Hypoxia	MDA-MB-231 LM2 cells	control	treated with 1% oxygen hypoxia	6 h	2 replicates each, different cell lines
ARR00498	GSE17188	GSE17188a	GSM429893	GPL6480	linear	raw	NA	Hypoxia	MDA-MB-231 LM2 cells	activating	treated with 1% oxygen hypoxia	6 h	2 replicates each, different cell lines
ARR00499	GSE17188	GSE17188a	GSM429894	GPL6480	linear	raw	NA	Hypoxia	MDA-MB-231 LM2 cells	activating	treated with 1% oxygen hypoxia	6 h	2 replicates each, different cell lines
ARR00500	GSE25452	GSE25452	GSM624690	GPL5188	log	normalized	NA	Hypoxia	HEK293 cells	control	treated with 1% oxygen hypoxia	2 h	2 replicates each, contain control vector
ARR00501	GSE25452	GSE25452	GSM624691	GPL5188	log	normalized	NA	Hypoxia	HEK293 cells	control	treated with 1% oxygen hypoxia	2 h	2 replicates each, contain control vector
ARR00502	GSE25452	GSE25452	GSM624694	GPL5188	log	normalized	NA	Hypoxia	HEK293 cells	activating	treated with 1% oxygen hypoxia	2 h	2 replicates each, contain control vector
ARR00503	GSE25452	GSE25452	GSM624695	GPL5188	log	normalized	NA	Hypoxia	HEK293 cells	activating	treated with 1% oxygen hypoxia	2 h	2 replicates each, contain control vector
ARR00504	GSE16251	GSE16251aTNFa	GSM409180	GPL8601	linear	raw	NA	TNFa	primary PBMCs	control	treated with TNFa	0.5 h	1 replicate each, part of time series, time respective control
ARR00505	GSE16251	GSE16251aTNFa	GSM409184	GPL8601	linear	raw	NA	TNFa	primary PBMCs	activating	treated with TNFa	0.5 h	1 replicate each, part of time series, time respective control
ARR00506	GSE13837	GSE13837q	GSM348030	GPL570	linear	raw	CELS/GSE13837/GSM348030.CEL	TNFa	synovial fibroblasts, female, age 67, rheumatoid arthritis	control	treated with TNFa 10 ng/ml	2 h	always compared to the 0 h time point
ARR00507	GSE13837	GSE13837q	GSM348037	GPL570	linear	raw	CELS/GSE13837/GSM348037.CEL	TNFa	synovial fibroblasts, female, age 67, rheumatoid arthritis	control	treated with TNFa 10 ng/ml	2 h	always compared to the 0 h time point
ARR00508	GSE13837	GSE13837q	GSM348034	GPL570	linear	raw	CELS/GSE13837/GSM348034.CEL	TNFa	synovial fibroblasts, female, age 67, rheumatoid arthritis	activating	treated with TNFa 10 ng/ml	2 h	always compared to the 0 h time point
ARR00509	GSE27870	GSE27870g	GSM688449	GPL4044	log	raw	NA	TNFa	HUVEC (human umbilical vein endothelial cells)	control	treatment with 10ng/ml TNFa	6 h	3 replicates each, part of time series (1, 1.5, 2, 3, 4, 5, 6 h)
ARR00510	GSE27870	GSE27870g	GSM688450	GPL4044	log	raw	NA	TNFa	HUVEC (human umbilical vein endothelial cells)	control	treatment with 10ng/ml TNFa	6 h	3 replicates each, part of time series (1, 1.5, 2, 3, 4, 5, 6 h)
ARR00511	GSE27870	GSE27870g	GSM688451	GPL4044	log	raw	NA	TNFa	HUVEC (human umbilical vein endothelial cells)	control	treatment with 10ng/ml TNFa	6 h	3 replicates each, part of time series (1, 1.5, 2, 3, 4, 5, 6 h)
ARR00512	GSE27870	GSE27870g	GSM688470	GPL4044	log	raw	NA	TNFa	HUVEC (human umbilical vein endothelial cells)	activating	treatment with 10ng/ml TNFa	6 h	3 replicates each, part of time series (1, 1.5, 2, 3, 4, 5, 6 h)
ARR00513	GSE27870	GSE27870g	GSM688471	GPL4044	log	raw	NA	TNFa	HUVEC (human umbilical vein endothelial cells)	activating	treatment with 10ng/ml TNFa	6 h	3 replicates each, part of time series (1, 1.5, 2, 3, 4, 5, 6 h)
ARR00514	GSE27870	GSE27870g	GSM688472	GPL4044	log	raw	NA	TNFa	HUVEC (human umbilical vein endothelial cells)	activating	treatment with 10ng/ml TNFa	6 h	3 replicates each, part of time series (1, 1.5, 2, 3, 4, 5, 6 h)
ARR00515	GSE27870	GSE27870d	GSM688449	GPL4044	log	raw	NA	TNFa	HUVEC (human umbilical vein endothelial cells)	control	treatment with 10ng/ml TNFa	3 h	3 replicates each, part of time series (1, 1.5, 2, 3, 4, 5, 6 h)
ARR00516	GSE27870	GSE27870d	GSM688450	GPL4044	log	raw	NA	TNFa	HUVEC (human umbilical vein endothelial cells)	control	treatment with 10ng/ml TNFa	3 h	3 replicates each, part of time series (1, 1.5, 2, 3, 4, 5, 6 h)
ARR00517	GSE27870	GSE27870d	GSM688451	GPL4044	log	raw	NA	TNFa	HUVEC (human umbilical vein endothelial cells)	control	treatment with 10ng/ml TNFa	3 h	3 replicates each, part of time series (1, 1.5, 2, 3, 4, 5, 6 h)
ARR00518	GSE27870	GSE27870d	GSM688461	GPL4044	log	raw	NA	TNFa	HUVEC (human umbilical vein endothelial cells)	activating	treatment with 10ng/ml TNFa	3 h	3 replicates each, part of time series (1, 1.5, 2, 3, 4, 5, 6 h)
ARR00519	GSE27870	GSE27870d	GSM688462	GPL4044	log	raw	NA	TNFa	HUVEC (human umbilical vein endothelial cells)	activating	treatment with 10ng/ml TNFa	3 h	3 replicates each, part of time series (1, 1.5, 2, 3, 4, 5, 6 h)
ARR00520	GSE27870	GSE27870d	GSM688463	GPL4044	log	raw	NA	TNFa	HUVEC (human umbilical vein endothelial cells)	activating	treatment with 10ng/ml TNFa	3 h	3 replicates each, part of time series (1, 1.5, 2, 3, 4, 5, 6 h)
ARR00521	GSE9055	GSE9055a	GSM229941	GPL570	linear	raw	CELS/GSE9055/GSM229941.CEL	TNFa	HUVEC (Human umbilical vein cells)	control	treated with TNFa 10 ng/ml after 18 h serum starvation	0.5 h	time series every 15 min until 8 h
ARR00522	GSE9055	GSE9055a	GSM229910	GPL570	linear	raw	CELS/GSE9055/GSM229910.CEL	TNFa	HUVEC (Human umbilical vein cells)	activating	treated with TNFa 10 ng/ml after 18 h serum starvation	0.5 h	time series every 15 min until 8 h
ARR00523	GSE8166	GSE8166	GSM202176	GPL570	linear	raw	CELS/GSE8166/GSM202176.CEL	TNFa	human umbilical vein endothelial cells)	control	treated with TNFa 1ng/ml cultured in M199 medium	3 h	comment
ARR00524	GSE8166	GSE8166	GSM202183	GPL570	linear	raw	CELS/GSE8166/GSM202183.CEL	TNFa	human umbilical vein endothelial cells)	activating	treated with TNFa 1ng/ml cultured in M199 medium	3 h	comment
ARR00525	GSE13837	GSE13837c	GSM347191	GPL570	linear	raw	CELS/GSE13837/GSM347191.CEL	TNFa	synovial fibroblasts, female, age 65, rheumatoid arthritis	control	treated with TNFa 10 ng/ml	4 h	always compared to the 0 h time point
ARR00526	GSE13837	GSE13837c	GSM347193	GPL570	linear	raw	CELS/GSE13837/GSM347193.CEL	TNFa	synovial fibroblasts, female, age 65, rheumatoid arthritis	control	treated with TNFa 10 ng/ml	4 h	always compared to the 0 h time point
ARR00527	GSE13837	GSE13837c	GSM347332	GPL570	linear	raw	CELS/GSE13837/GSM347332.CEL	TNFa	synovial fibroblasts, female, age 65, rheumatoid arthritis	activating	treated with TNFa 10 ng/ml	4 h	always compared to the 0 h time point
ARR00528	GSE1474	GSE1474a	GSM24832	GPL96	log	raw	NA	TNFa	CaCo-2 (Colon cell line)	control	treated with TNFa	4 h	3 replicates each
ARR00529	GSE1474	GSE1474a	GSM24833	GPL96	log	raw	NA	TNFa	CaCo-2 (Colon cell line)	control	treated with TNFa	4 h	3 replicates each
ARR00530	GSE1474	GSE1474a	GSM24834	GPL96	log	raw	NA	TNFa	CaCo-2 (Colon cell line)	control	treated with TNFa	4 h	3 replicates each
ARR00531	GSE1474	GSE1474a	GSM24841	GPL96	log	raw	NA	TNFa	CaCo-2 (Colon cell line)	activating	treated with TNFa	4 h	3 replicates each
ARR00532	GSE1474	GSE1474a	GSM24842	GPL96	log	raw	NA	TNFa	CaCo-2 (Colon cell line)	activating	treated with TNFa	4 h	3 replicates each
ARR00533	GSE1474	GSE1474a	GSM24843	GPL96	log	raw	NA	TNFa	CaCo-2 (Colon cell line)	activating	treated with TNFa	4 h	3 replicates each
ARR00534	GSE13837	GSE13837b	GSM347191	GPL570	linear	raw	CELS/GSE13837/GSM347191.CEL	TNFa	synovial fibroblasts, female, age 65, rheumatoid arthritis	control	treated with TNFa 10 ng/ml	2 h	always compared to the 0 h time point
ARR00535	GSE13837	GSE13837b	GSM347193	GPL570	linear	raw	CELS/GSE13837/GSM347193.CEL	TNFa	synovial fibroblasts, female, age 65, rheumatoid arthritis	control	treated with TNFa 10 ng/ml	2 h	always compared to the 0 h time point
ARR00536	GSE13837	GSE13837b	GSM347328	GPL570	linear	raw	CELS/GSE13837/GSM347328.CEL	TNFa	synovial fibroblasts, female, age 65, rheumatoid arthritis	activating	treated with TNFa 10 ng/ml	2 h	always compared to the 0 h time point
ARR00537	GSE1541	GSE1541b	GSM26479	GPL201	linear	raw	NA	TNFa	A549 (Alveolar Epithelial Cells line)	control	treated with TNFa 20 ng/ml	4 h	comment
ARR00538	GSE1541	GSE1541b	GSM26480	GPL201	linear	raw	NA	TNFa	A549 (Alveolar Epithelial Cells line)	control	treated with TNFa 20 ng/ml	4 h	comment
ARR00539	GSE1541	GSE1541b	GSM26491	GPL201	linear	raw	NA	TNFa	A549 (Alveolar Epithelial Cells line)	activating	treated with TNFa 20 ng/ml	4 h	comment
ARR00540	GSE1541	GSE1541b	GSM26492	GPL201	linear	raw	NA	TNFa	A549 (Alveolar Epithelial Cells line)	activating	treated with TNFa 20 ng/ml	4 h	comment
ARR00541	GSE11115	GSE11115	GSM280387	GPL96	log	raw	CELS/GSE11115/GSM280387.CEL	TNFa	U3OS cells expressing additional estrogen receptor	control	treated with TNFa	1h h	3-4 replicates each, doxycyline induction of ER expression
ARR00542	GSE11115	GSE11115	GSM280388	GPL96	log	raw	CELS/GSE11115/GSM280388.CEL	TNFa	U3OS cells expressing additional estrogen receptor	control	treated with TNFa	1h h	3-4 replicates each, doxycyline induction of ER expression
ARR00543	GSE11115	GSE11115	GSM280389	GPL96	log	raw	CELS/GSE11115/GSM280389.CEL	TNFa	U3OS cells expressing additional estrogen receptor	control	treated with TNFa	1h h	3-4 replicates each, doxycyline induction of ER expression
ARR00544	GSE11115	GSE11115	GSM280379	GPL96	log	raw	CELS/GSE11115/GSM280379.CEL	TNFa	U3OS cells expressing additional estrogen receptor	activating	treated with TNFa	1h h	3-4 replicates each, doxycyline induction of ER expression
ARR00545	GSE11115	GSE11115	GSM280380	GPL96	log	raw	CELS/GSE11115/GSM280380.CEL	TNFa	U3OS cells expressing additional estrogen receptor	activating	treated with TNFa	1h h	3-4 replicates each, doxycyline induction of ER expression
ARR00546	GSE11115	GSE11115	GSM280381	GPL96	log	raw	CELS/GSE11115/GSM280381.CEL	TNFa	U3OS cells expressing additional estrogen receptor	activating	treated with TNFa	1h h	3-4 replicates each, doxycyline induction of ER expression
ARR00547	GSE11115	GSE11115	GSM280382	GPL96	log	raw	CELS/GSE11115/GSM280382.CEL	TNFa	U3OS cells expressing additional estrogen receptor	activating	treated with TNFa	1h h	3-4 replicates each, doxycyline induction of ER expression
ARR00548	GSE13837	GSE13837k	GSM347799	GPL570	linear	raw	CELS/GSE13837/GSM347799.CEL	TNFa	synovial fibroblasts, female, age 57, osteoarthritis	control	treated with TNFa 10 ng/ml	2 h	always compared to the 0 h time point
ARR00549	GSE13837	GSE13837k	GSM347840	GPL570	linear	raw	CELS/GSE13837/GSM347840.CEL	TNFa	synovial fibroblasts, female, age 57, osteoarthritis	control	treated with TNFa 10 ng/ml	2 h	always compared to the 0 h time point
ARR00550	GSE13837	GSE13837k	GSM347837	GPL570	linear	raw	CELS/GSE13837/GSM347837.CEL	TNFa	synovial fibroblasts, female, age 57, osteoarthritis	activating	treated with TNFa 10 ng/ml	2 h	always compared to the 0 h time point
ARR00551	GSE1474	GSE1474b	GSM24844	GPL96	log	raw	NA	TNFa	T84	control	treated with TNFa	4 h	3 replicates each
ARR00552	GSE1474	GSE1474b	GSM24845	GPL96	log	raw	NA	TNFa	T84	control	treated with TNFa	4 h	3 replicates each
ARR00553	GSE1474	GSE1474b	GSM24846	GPL96	log	raw	NA	TNFa	T84	control	treated with TNFa	4 h	3 replicates each
ARR00554	GSE1474	GSE1474b	GSM24853	GPL96	log	raw	NA	TNFa	T84	activating	treated with TNFa	4 h	3 replicates each
ARR00555	GSE1474	GSE1474b	GSM24854	GPL96	log	raw	NA	TNFa	T84	activating	treated with TNFa	4 h	3 replicates each
ARR00556	GSE1474	GSE1474b	GSM24855	GPL96	log	raw	NA	TNFa	T84	activating	treated with TNFa	4 h	3 replicates each
ARR00557	GSE28548	GSE28548	GSM707024	GPL570	log	normalized	CELS/GSE28548/GSM707024.CEL	TNFa	HEK293 cells	control	treated with TNFa	1 h	3 replicates each
ARR00558	GSE28548	GSE28548	GSM707025	GPL570	log	normalized	CELS/GSE28548/GSM707025.CEL	TNFa	HEK293 cells	control	treated with TNFa	1 h	3 replicates each
ARR00559	GSE28548	GSE28548	GSM707026	GPL570	log	normalized	CELS/GSE28548/GSM707026.CEL	TNFa	HEK293 cells	control	treated with TNFa	1 h	3 replicates each
ARR00560	GSE28548	GSE28548	GSM707027	GPL570	log	normalized	CELS/GSE28548/GSM707027.CEL	TNFa	HEK293 cells	activating	treated with TNFa	1 h	3 replicates each
ARR00561	GSE28548	GSE28548	GSM707028	GPL570	log	normalized	CELS/GSE28548/GSM707028.CEL	TNFa	HEK293 cells	activating	treated with TNFa	1 h	3 replicates each
ARR00562	GSE28548	GSE28548	GSM707029	GPL570	log	normalized	CELS/GSE28548/GSM707029.CEL	TNFa	HEK293 cells	activating	treated with TNFa	1 h	3 replicates each
ARR00563	GSE26868	GSE26868b	GSM661466	GPL570	linear	raw	CELS/GSE26868/GSM661466.CEL	TNFa	THP1 cells	control	treated with 10 ng/ml TNFa	2 h	3 replicates each, comparison 2 cell lines
ARR00564	GSE26868	GSE26868b	GSM661467	GPL570	linear	raw	CELS/GSE26868/GSM661467.CEL	TNFa	THP1 cells	control	treated with 10 ng/ml TNFa	2 h	3 replicates each, comparison 2 cell lines
ARR00565	GSE26868	GSE26868b	GSM661468	GPL570	linear	raw	CELS/GSE26868/GSM661468.CEL	TNFa	THP1 cells	control	treated with 10 ng/ml TNFa	2 h	3 replicates each, comparison 2 cell lines
ARR00566	GSE26868	GSE26868b	GSM661469	GPL570	linear	raw	CELS/GSE26868/GSM661469.CEL	TNFa	THP1 cells	activating	treated with 10 ng/ml TNFa	2 h	3 replicates each, comparison 2 cell lines
ARR00567	GSE26868	GSE26868b	GSM661470	GPL570	linear	raw	CELS/GSE26868/GSM661470.CEL	TNFa	THP1 cells	activating	treated with 10 ng/ml TNFa	2 h	3 replicates each, comparison 2 cell lines
ARR00568	GSE26868	GSE26868b	GSM661471	GPL570	linear	raw	CELS/GSE26868/GSM661471.CEL	TNFa	THP1 cells	activating	treated with 10 ng/ml TNFa	2 h	3 replicates each, comparison 2 cell lines
ARR00569	GSE13837	GSE13837i	GSM347764	GPL570	linear	raw	CELS/GSE13837/GSM347764.CEL	TNFa	synovial fibroblasts, male, age 65, osteoarthritis	control	treated with TNFa 10 ng/ml	4 h	always compared to the 0 h time point
ARR00570	GSE13837	GSE13837i	GSM347745	GPL570	linear	raw	CELS/GSE13837/GSM347745.CEL	TNFa	synovial fibroblasts, male, age 65, osteoarthritis	control	treated with TNFa 10 ng/ml	4 h	always compared to the 0 h time point
ARR00571	GSE13837	GSE13837i	GSM347748	GPL570	linear	raw	CELS/GSE13837/GSM347748.CEL	TNFa	synovial fibroblasts, male, age 65, osteoarthritis	activating	treated with TNFa 10 ng/ml	4 h	always compared to the 0 h time point
ARR00572	GSE27870	GSE27870f	GSM688449	GPL4044	log	raw	NA	TNFa	HUVEC (human umbilical vein endothelial cells)	control	treatment with 10ng/ml TNFa	5 h	3 replicates each, part of time series (1, 1.5, 2, 3, 4, 5, 6 h)
ARR00573	GSE27870	GSE27870f	GSM688450	GPL4044	log	raw	NA	TNFa	HUVEC (human umbilical vein endothelial cells)	control	treatment with 10ng/ml TNFa	5 h	3 replicates each, part of time series (1, 1.5, 2, 3, 4, 5, 6 h)
ARR00574	GSE27870	GSE27870f	GSM688451	GPL4044	log	raw	NA	TNFa	HUVEC (human umbilical vein endothelial cells)	control	treatment with 10ng/ml TNFa	5 h	3 replicates each, part of time series (1, 1.5, 2, 3, 4, 5, 6 h)
ARR00575	GSE27870	GSE27870f	GSM688467	GPL4044	log	raw	NA	TNFa	HUVEC (human umbilical vein endothelial cells)	activating	treatment with 10ng/ml TNFa	5 h	3 replicates each, part of time series (1, 1.5, 2, 3, 4, 5, 6 h)
ARR00576	GSE27870	GSE27870f	GSM688468	GPL4044	log	raw	NA	TNFa	HUVEC (human umbilical vein endothelial cells)	activating	treatment with 10ng/ml TNFa	5 h	3 replicates each, part of time series (1, 1.5, 2, 3, 4, 5, 6 h)
ARR00577	GSE27870	GSE27870f	GSM688469	GPL4044	log	raw	NA	TNFa	HUVEC (human umbilical vein endothelial cells)	activating	treatment with 10ng/ml TNFa	5 h	3 replicates each, part of time series (1, 1.5, 2, 3, 4, 5, 6 h)
ARR00578	GSE27870	GSE27870e	GSM688449	GPL4044	log	raw	NA	TNFa	HUVEC (human umbilical vein endothelial cells)	control	treatment with 10ng/ml TNFa	4 h	3 replicates each, part of time series (1, 1.5, 2, 3, 4, 5, 6 h)
ARR00579	GSE27870	GSE27870e	GSM688450	GPL4044	log	raw	NA	TNFa	HUVEC (human umbilical vein endothelial cells)	control	treatment with 10ng/ml TNFa	4 h	3 replicates each, part of time series (1, 1.5, 2, 3, 4, 5, 6 h)
ARR00580	GSE27870	GSE27870e	GSM688451	GPL4044	log	raw	NA	TNFa	HUVEC (human umbilical vein endothelial cells)	control	treatment with 10ng/ml TNFa	4 h	3 replicates each, part of time series (1, 1.5, 2, 3, 4, 5, 6 h)
ARR00581	GSE27870	GSE27870e	GSM688464	GPL4044	log	raw	NA	TNFa	HUVEC (human umbilical vein endothelial cells)	activating	treatment with 10ng/ml TNFa	4 h	3 replicates each, part of time series (1, 1.5, 2, 3, 4, 5, 6 h)
ARR00582	GSE27870	GSE27870e	GSM688465	GPL4044	log	raw	NA	TNFa	HUVEC (human umbilical vein endothelial cells)	activating	treatment with 10ng/ml TNFa	4 h	3 replicates each, part of time series (1, 1.5, 2, 3, 4, 5, 6 h)
ARR00583	GSE27870	GSE27870e	GSM688466	GPL4044	log	raw	NA	TNFa	HUVEC (human umbilical vein endothelial cells)	activating	treatment with 10ng/ml TNFa	4 h	3 replicates each, part of time series (1, 1.5, 2, 3, 4, 5, 6 h)
ARR00584	GSE13837	GSE13837g	GSM347764	GPL570	linear	raw	CELS/GSE13837/GSM347764.CEL	TNFa	synovial fibroblasts, male, age 65, osteoarthritis	control	treated with TNFa 10 ng/ml	1 h	always compared to the 0 h time point
ARR00585	GSE13837	GSE13837g	GSM347745	GPL570	linear	raw	CELS/GSE13837/GSM347745.CEL	TNFa	synovial fibroblasts, male, age 65, osteoarthritis	control	treated with TNFa 10 ng/ml	1 h	always compared to the 0 h time point
ARR00586	GSE13837	GSE13837g	GSM347746	GPL570	linear	raw	CELS/GSE13837/GSM347746.CEL	TNFa	synovial fibroblasts, male, age 65, osteoarthritis	activating	treated with TNFa 10 ng/ml	1 h	always compared to the 0 h time point
ARR00587	GSE2489	GSE2489b	GSM47305	GPL8300	linear	raw	NA	TNFa	Epidermis Keratinocytes	control	treated with TNFa	4 h	comment
ARR00588	GSE2489	GSE2489b	GSM47306	GPL8300	linear	raw	NA	TNFa	Epidermis Keratinocytes	control	treated with TNFa	4 h	comment
ARR00589	GSE2489	GSE2489b	GSM47312	GPL8300	linear	raw	NA	TNFa	Epidermis Keratinocytes	activating	treated with TNFa	4 h	comment
ARR00590	GSE13837	GSE13837f	GSM347340	GPL570	linear	raw	CELS/GSE13837/GSM347340.CEL	TNFa	synovial fibroblasts, male, age 56, osteoarthritis	control	treated with TNFa 10 ng/ml	4 h	always compared to the 0 h time point
ARR00591	GSE13837	GSE13837f	GSM347342	GPL570	linear	raw	CELS/GSE13837/GSM347342.CEL	TNFa	synovial fibroblasts, male, age 56, osteoarthritis	control	treated with TNFa 10 ng/ml	4 h	always compared to the 0 h time point
ARR00592	GSE13837	GSE13837f	GSM347739	GPL570	linear	raw	CELS/GSE13837/GSM347739.CEL	TNFa	synovial fibroblasts, male, age 56, osteoarthritis	activating	treated with TNFa 10 ng/ml	4 h	always compared to the 0 h time point
ARR00593	GSE13837	GSE13837j	GSM347799	GPL570	linear	raw	CELS/GSE13837/GSM347799.CEL	TNFa	synovial fibroblasts, female, age 57, osteoarthritis	control	treated with TNFa 10 ng/ml	1 h	always compared to the 0 h time point
ARR00594	GSE13837	GSE13837j	GSM347840	GPL570	linear	raw	CELS/GSE13837/GSM347840.CEL	TNFa	synovial fibroblasts, female, age 57, osteoarthritis	control	treated with TNFa 10 ng/ml	1 h	always compared to the 0 h time point
ARR00595	GSE13837	GSE13837j	GSM347819	GPL570	linear	raw	CELS/GSE13837/GSM347819.CEL	TNFa	synovial fibroblasts, female, age 57, osteoarthritis	activating	treated with TNFa 10 ng/ml	1 h	always compared to the 0 h time point
ARR00596	GSE26868	GSE26868a	GSM661462	GPL570	linear	raw	CELS/GSE26868/GSM661462.CEL	TNFa	HeLa cells	control	treated with 10 ng/ml TNFa	2 h	2 replicates each, comparison 2 cell lines
ARR00597	GSE26868	GSE26868a	GSM661463	GPL570	linear	raw	CELS/GSE26868/GSM661463.CEL	TNFa	HeLa cells	control	treated with 10 ng/ml TNFa	2 h	2 replicates each, comparison 2 cell lines
ARR00598	GSE26868	GSE26868a	GSM661464	GPL570	linear	raw	CELS/GSE26868/GSM661464.CEL	TNFa	HeLa cells	activating	treated with 10 ng/ml TNFa	2 h	2 replicates each, comparison 2 cell lines
ARR00599	GSE26868	GSE26868a	GSM661465	GPL570	linear	raw	CELS/GSE26868/GSM661465.CEL	TNFa	HeLa cells	activating	treated with 10 ng/ml TNFa	2 h	2 replicates each, comparison 2 cell lines
ARR00600	GSE2638	GSE2638	GSM50771	GPL96	log	raw	CELS/GSE2638/GSM50771.CEL	TNFa	HMECs	control	treated with 2ng/ml TNFa	5 h	3 replicates each
ARR00601	GSE2638	GSE2638	GSM50772	GPL96	log	raw	CELS/GSE2638/GSM50772.CEL	TNFa	HMECs	control	treated with 2ng/ml TNFa	5 h	3 replicates each
ARR00602	GSE2638	GSE2638	GSM50773	GPL96	log	raw	CELS/GSE2638/GSM50773.CEL	TNFa	HMECs	control	treated with 2ng/ml TNFa	5 h	3 replicates each
ARR00603	GSE2638	GSE2638	GSM50774	GPL96	log	raw	CELS/GSE2638/GSM50774.CEL	TNFa	HMECs	activating	treated with 2ng/ml TNFa	5 h	3 replicates each
ARR00604	GSE2638	GSE2638	GSM50775	GPL96	log	raw	CELS/GSE2638/GSM50775.CEL	TNFa	HMECs	activating	treated with 2ng/ml TNFa	5 h	3 replicates each
ARR00605	GSE2638	GSE2638	GSM50776	GPL96	log	raw	CELS/GSE2638/GSM50776.CEL	TNFa	HMECs	activating	treated with 2ng/ml TNFa	5 h	3 replicates each
ARR00606	GSE13837	GSE13837o	GSM347845	GPL570	linear	raw	CELS/GSE13837/GSM347845.CEL	TNFa	synovial fibroblasts, female, age 57, rheumatoid arthritis	control	treated with TNFa 10 ng/ml	4 h	always compared to the 0 h time point
ARR00607	GSE13837	GSE13837o	GSM348023	GPL570	linear	raw	CELS/GSE13837/GSM348023.CEL	TNFa	synovial fibroblasts, female, age 57, rheumatoid arthritis	control	treated with TNFa 10 ng/ml	4 h	always compared to the 0 h time point
ARR00608	GSE13837	GSE13837o	GSM348020	GPL570	linear	raw	CELS/GSE13837/GSM348020.CEL	TNFa	synovial fibroblasts, female, age 57, rheumatoid arthritis	activating	treated with TNFa 10 ng/ml	4 h	always compared to the 0 h time point
ARR00609	GSE27870	GSE27870b	GSM688449	GPL4044	log	raw	NA	TNFa	HUVEC (human umbilical vein endothelial cells)	control	treatment with 10ng/ml TNFa	1.5 h	3 replicates each, part of time series (1, 1.5, 2, 3, 4, 5, 6 h)
ARR00610	GSE27870	GSE27870b	GSM688450	GPL4044	log	raw	NA	TNFa	HUVEC (human umbilical vein endothelial cells)	control	treatment with 10ng/ml TNFa	1.5 h	3 replicates each, part of time series (1, 1.5, 2, 3, 4, 5, 6 h)
ARR00611	GSE27870	GSE27870b	GSM688451	GPL4044	log	raw	NA	TNFa	HUVEC (human umbilical vein endothelial cells)	control	treatment with 10ng/ml TNFa	1.5 h	3 replicates each, part of time series (1, 1.5, 2, 3, 4, 5, 6 h)
ARR00612	GSE27870	GSE27870b	GSM688455	GPL4044	log	raw	NA	TNFa	HUVEC (human umbilical vein endothelial cells)	activating	treatment with 10ng/ml TNFa	1.5 h	3 replicates each, part of time series (1, 1.5, 2, 3, 4, 5, 6 h)
ARR00613	GSE27870	GSE27870b	GSM688456	GPL4044	log	raw	NA	TNFa	HUVEC (human umbilical vein endothelial cells)	activating	treatment with 10ng/ml TNFa	1.5 h	3 replicates each, part of time series (1, 1.5, 2, 3, 4, 5, 6 h)
ARR00614	GSE27870	GSE27870b	GSM688457	GPL4044	log	raw	NA	TNFa	HUVEC (human umbilical vein endothelial cells)	activating	treatment with 10ng/ml TNFa	1.5 h	3 replicates each, part of time series (1, 1.5, 2, 3, 4, 5, 6 h)
ARR00615	GSE2624	GSE2624a	GSM50301	GPL8300	linear	raw	NA	TNFa	human cervical epithelioid carcinoma cell line HeLa expressing tTA pBI-EGFP- IkBa Mut	control	treated with TNFa 25ng/ml and Doxycyline (2 mg/ml) to take IKB-inhibition away	1 h	mutant cell line
ARR00616	GSE2624	GSE2624a	GSM50310	GPL8300	linear	raw	NA	TNFa	human cervical epithelioid carcinoma cell line HeLa expressing tTA pBI-EGFP- IkBa Mut	control	treated with TNFa 25ng/ml and Doxycyline (2 mg/ml) to take IKB-inhibition away	1 h	mutant cell line
ARR00617	GSE2624	GSE2624a	GSM50319	GPL8300	linear	raw	NA	TNFa	human cervical epithelioid carcinoma cell line HeLa expressing tTA pBI-EGFP- IkBa Mut	control	treated with TNFa 25ng/ml and Doxycyline (2 mg/ml) to take IKB-inhibition away	1 h	mutant cell line
ARR00618	GSE2624	GSE2624a	GSM50327	GPL8300	linear	raw	NA	TNFa	human cervical epithelioid carcinoma cell line HeLa expressing tTA pBI-EGFP- IkBa Mut	control	treated with TNFa 25ng/ml and Doxycyline (2 mg/ml) to take IKB-inhibition away	1 h	mutant cell line
ARR00619	GSE2624	GSE2624a	GSM50302	GPL8300	linear	raw	NA	TNFa	human cervical epithelioid carcinoma cell line HeLa expressing tTA pBI-EGFP- IkBa Mut	activating	treated with TNFa 25ng/ml and Doxycyline (2 mg/ml) to take IKB-inhibition away	1 h	mutant cell line
ARR00620	GSE2624	GSE2624a	GSM50312	GPL8300	linear	raw	NA	TNFa	human cervical epithelioid carcinoma cell line HeLa expressing tTA pBI-EGFP- IkBa Mut	activating	treated with TNFa 25ng/ml and Doxycyline (2 mg/ml) to take IKB-inhibition away	1 h	mutant cell line
ARR00621	GSE2624	GSE2624a	GSM50320	GPL8300	linear	raw	NA	TNFa	human cervical epithelioid carcinoma cell line HeLa expressing tTA pBI-EGFP- IkBa Mut	activating	treated with TNFa 25ng/ml and Doxycyline (2 mg/ml) to take IKB-inhibition away	1 h	mutant cell line
ARR00622	GSE2624	GSE2624a	GSM50328	GPL8300	linear	raw	NA	TNFa	human cervical epithelioid carcinoma cell line HeLa expressing tTA pBI-EGFP- IkBa Mut	activating	treated with TNFa 25ng/ml and Doxycyline (2 mg/ml) to take IKB-inhibition away	1 h	mutant cell line
ARR00623	GSE21727	GSE21727TNFa	GSM542107	GPL6104	log	normalized	NA	TNFa	trabecular bone cells	control	treated with TNFa	2 h	3 replicates each, time respective control
ARR00624	GSE21727	GSE21727TNFa	GSM542108	GPL6104	log	normalized	NA	TNFa	trabecular bone cells	control	treated with TNFa	2 h	3 replicates each, time respective control
ARR00625	GSE21727	GSE21727TNFa	GSM542109	GPL6104	log	normalized	NA	TNFa	trabecular bone cells	control	treated with TNFa	2 h	3 replicates each, time respective control
ARR00626	GSE21727	GSE21727TNFa	GSM542104	GPL6104	log	normalized	NA	TNFa	trabecular bone cells	activating	treated with TNFa	2 h	3 replicates each, time respective control
ARR00627	GSE21727	GSE21727TNFa	GSM542105	GPL6104	log	normalized	NA	TNFa	trabecular bone cells	activating	treated with TNFa	2 h	3 replicates each, time respective control
ARR00628	GSE21727	GSE21727TNFa	GSM542106	GPL6104	log	normalized	NA	TNFa	trabecular bone cells	activating	treated with TNFa	2 h	3 replicates each, time respective control
ARR00629	GSE13206	GSE13206b	GSM333597	GPL7490	linear	raw	NA	TNFa	HeLa cells	control	treated with 5 ng/ml TNFa	6 h	1 replicate each, part of time series, shControl transfected
ARR00630	GSE13206	GSE13206b	GSM333594	GPL7490	linear	raw	NA	TNFa	HeLa cells	activating	treated with 5 ng/ml TNFa	6 h	1 replicate each, part of time series, shControl transfected
ARR00631	GSE9055	GSE9055c	GSM229941	GPL570	linear	raw	CELS/GSE9055/GSM229941.CEL	TNFa	HUVEC (Human umbilical vein cells)	control	treated with TNFa 10 ng/ml after 18 h serum starvation	2 h	time series every 15 min until 8 h
ARR00632	GSE9055	GSE9055c	GSM229916	GPL570	linear	raw	CELS/GSE9055/GSM229916.CEL	TNFa	HUVEC (Human umbilical vein cells)	activating	treated with TNFa 10 ng/ml after 18 h serum starvation	2 h	time series every 15 min until 8 h
ARR00633	GSE13837	GSE13837n	GSM347845	GPL570	linear	raw	CELS/GSE13837/GSM347845.CEL	TNFa	synovial fibroblasts, female, age 57, rheumatoid arthritis	control	treated with TNFa 10 ng/ml	2 h	always compared to the 0 h time point
ARR00634	GSE13837	GSE13837n	GSM348023	GPL570	linear	raw	CELS/GSE13837/GSM348023.CEL	TNFa	synovial fibroblasts, female, age 57, rheumatoid arthritis	control	treated with TNFa 10 ng/ml	2 h	always compared to the 0 h time point
ARR00635	GSE13837	GSE13837n	GSM348018	GPL570	linear	raw	CELS/GSE13837/GSM348018.CEL	TNFa	synovial fibroblasts, female, age 57, rheumatoid arthritis	activating	treated with TNFa 10 ng/ml	2 h	always compared to the 0 h time point
ARR00636	GSE9055	GSE9055b	GSM229941	GPL570	linear	raw	CELS/GSE9055/GSM229941.CEL	TNFa	HUVEC (Human umbilical vein cells)	control	treated with TNFa 10 ng/ml after 18 h serum starvation	1 h	time series every 15 min until 8 h
ARR00637	GSE9055	GSE9055b	GSM229912	GPL570	linear	raw	CELS/GSE9055/GSM229912.CEL	TNFa	HUVEC (Human umbilical vein cells)	activating	treated with TNFa 10 ng/ml after 18 h serum starvation	1 h	time series every 15 min until 8 h
ARR00638	GSE13837	GSE13837p	GSM348030	GPL570	linear	raw	CELS/GSE13837/GSM348030.CEL	TNFa	synovial fibroblasts, female, age 67, rheumatoid arthritis	control	treated with TNFa 10 ng/ml	1 h	always compared to the 0 h time point
ARR00639	GSE13837	GSE13837p	GSM348037	GPL570	linear	raw	CELS/GSE13837/GSM348037.CEL	TNFa	synovial fibroblasts, female, age 67, rheumatoid arthritis	control	treated with TNFa 10 ng/ml	1 h	always compared to the 0 h time point
ARR00640	GSE13837	GSE13837p	GSM348031	GPL570	linear	raw	CELS/GSE13837/GSM348031.CEL	TNFa	synovial fibroblasts, female, age 67, rheumatoid arthritis	activating	treated with TNFa 10 ng/ml	1 h	always compared to the 0 h time point
ARR00641	GSE27870	GSE27870c	GSM688449	GPL4044	log	raw	NA	TNFa	HUVEC (human umbilical vein endothelial cells)	control	treatment with 10ng/ml TNFa	2 h	3 replicates each, part of time series (1, 1.5, 2, 3, 4, 5, 6 h)
ARR00642	GSE27870	GSE27870c	GSM688450	GPL4044	log	raw	NA	TNFa	HUVEC (human umbilical vein endothelial cells)	control	treatment with 10ng/ml TNFa	2 h	3 replicates each, part of time series (1, 1.5, 2, 3, 4, 5, 6 h)
ARR00643	GSE27870	GSE27870c	GSM688451	GPL4044	log	raw	NA	TNFa	HUVEC (human umbilical vein endothelial cells)	control	treatment with 10ng/ml TNFa	2 h	3 replicates each, part of time series (1, 1.5, 2, 3, 4, 5, 6 h)
ARR00644	GSE27870	GSE27870c	GSM688458	GPL4044	log	raw	NA	TNFa	HUVEC (human umbilical vein endothelial cells)	activating	treatment with 10ng/ml TNFa	2 h	3 replicates each, part of time series (1, 1.5, 2, 3, 4, 5, 6 h)
ARR00645	GSE27870	GSE27870c	GSM688459	GPL4044	log	raw	NA	TNFa	HUVEC (human umbilical vein endothelial cells)	activating	treatment with 10ng/ml TNFa	2 h	3 replicates each, part of time series (1, 1.5, 2, 3, 4, 5, 6 h)
ARR00646	GSE27870	GSE27870c	GSM688460	GPL4044	log	raw	NA	TNFa	HUVEC (human umbilical vein endothelial cells)	activating	treatment with 10ng/ml TNFa	2 h	3 replicates each, part of time series (1, 1.5, 2, 3, 4, 5, 6 h)
ARR00647	GSE1541	GSE1541a	GSM26477	GPL201	linear	raw	NA	TNFa	A549 (Alveolar Epithelial Cells line)	control	treated with TNFa 20 ng/ml	1 h	comment
ARR00648	GSE1541	GSE1541a	GSM26478	GPL201	linear	raw	NA	TNFa	A549 (Alveolar Epithelial Cells line)	control	treated with TNFa 20 ng/ml	1 h	comment
ARR00649	GSE1541	GSE1541a	GSM26489	GPL201	linear	raw	NA	TNFa	A549 (Alveolar Epithelial Cells line)	activating	treated with TNFa 20 ng/ml	1 h	comment
ARR00650	GSE1541	GSE1541a	GSM26490	GPL201	linear	raw	NA	TNFa	A549 (Alveolar Epithelial Cells line)	activating	treated with TNFa 20 ng/ml	1 h	comment
ARR00651	GSE13837	GSE13837r	GSM348030	GPL570	linear	raw	CELS/GSE13837/GSM348030.CEL	TNFa	synovial fibroblasts, female, age 67, rheumatoid arthritis	control	treated with TNFa 10 ng/ml	4 h	always compared to the 0 h time point
ARR00652	GSE13837	GSE13837r	GSM348037	GPL570	linear	raw	CELS/GSE13837/GSM348037.CEL	TNFa	synovial fibroblasts, female, age 67, rheumatoid arthritis	control	treated with TNFa 10 ng/ml	4 h	always compared to the 0 h time point
ARR00653	GSE13837	GSE13837r	GSM348035	GPL570	linear	raw	CELS/GSE13837/GSM348035.CEL	TNFa	synovial fibroblasts, female, age 67, rheumatoid arthritis	activating	treated with TNFa 10 ng/ml	4 h	always compared to the 0 h time point
ARR00654	GSE516	GSE516	GSM7735	GPL8300	linear	raw	NA	TNFa	human arthritic synoviocytes	control	treated with TNFa	4 h	comment
ARR00655	GSE516	GSE516	GSM7736	GPL8300	linear	raw	NA	TNFa	human arthritic synoviocytes	activating	treated with TNFa	4 h	comment
ARR00656	GSE13206	GSE13206a	GSM333597	GPL7490	linear	raw	NA	TNFa	HeLa cells	control	treated with 5 ng/ml TNFa	1.5 h	1 replicate each, part of time series, shControl transfected
ARR00657	GSE13206	GSE13206a	GSM333591	GPL7490	linear	raw	NA	TNFa	HeLa cells	activating	treated with 5 ng/ml TNFa	1.5 h	1 replicate each, part of time series, shControl transfected
ARR00658	GSE2624	GSE2624b	GSM50301	GPL8300	linear	raw	NA	TNFa	human cervical epithelioid carcinoma cell line HeLa expressing tTA pBI-EGFP- IkBa Mut	control	treated with TNFa 25ng/ml and Doxycyline (2 mg/ml) to take IKB-inhibition away	3 h	mutant cell line
ARR00659	GSE2624	GSE2624b	GSM50310	GPL8300	linear	raw	NA	TNFa	human cervical epithelioid carcinoma cell line HeLa expressing tTA pBI-EGFP- IkBa Mut	control	treated with TNFa 25ng/ml and Doxycyline (2 mg/ml) to take IKB-inhibition away	3 h	mutant cell line
ARR00660	GSE2624	GSE2624b	GSM50319	GPL8300	linear	raw	NA	TNFa	human cervical epithelioid carcinoma cell line HeLa expressing tTA pBI-EGFP- IkBa Mut	control	treated with TNFa 25ng/ml and Doxycyline (2 mg/ml) to take IKB-inhibition away	3 h	mutant cell line
ARR00661	GSE2624	GSE2624b	GSM50327	GPL8300	linear	raw	NA	TNFa	human cervical epithelioid carcinoma cell line HeLa expressing tTA pBI-EGFP- IkBa Mut	control	treated with TNFa 25ng/ml and Doxycyline (2 mg/ml) to take IKB-inhibition away	3 h	mutant cell line
ARR00662	GSE2624	GSE2624b	GSM50304	GPL8300	linear	raw	NA	TNFa	human cervical epithelioid carcinoma cell line HeLa expressing tTA pBI-EGFP- IkBa Mut	activating	treated with TNFa 25ng/ml and Doxycyline (2 mg/ml) to take IKB-inhibition away	3 h	mutant cell line
ARR00663	GSE2624	GSE2624b	GSM50313	GPL8300	linear	raw	NA	TNFa	human cervical epithelioid carcinoma cell line HeLa expressing tTA pBI-EGFP- IkBa Mut	activating	treated with TNFa 25ng/ml and Doxycyline (2 mg/ml) to take IKB-inhibition away	3 h	mutant cell line
ARR00664	GSE2624	GSE2624b	GSM50321	GPL8300	linear	raw	NA	TNFa	human cervical epithelioid carcinoma cell line HeLa expressing tTA pBI-EGFP- IkBa Mut	activating	treated with TNFa 25ng/ml and Doxycyline (2 mg/ml) to take IKB-inhibition away	3 h	mutant cell line
ARR00665	GSE2624	GSE2624b	GSM50329	GPL8300	linear	raw	NA	TNFa	human cervical epithelioid carcinoma cell line HeLa expressing tTA pBI-EGFP- IkBa Mut	activating	treated with TNFa 25ng/ml and Doxycyline (2 mg/ml) to take IKB-inhibition away	3 h	mutant cell line
ARR00666	GSE16251	GSE16251bTNFa	GSM409182	GPL8601	linear	raw	NA	TNFa	primary PBMCs	control	treated with TNFa	1 h	1 replicate each, part of time series, time respective control
ARR00667	GSE16251	GSE16251bTNFa	GSM409140	GPL8601	linear	raw	NA	TNFa	primary PBMCs	activating	treated with TNFa	1 h	1 replicate each, part of time series, time respective control
ARR00668	GSE13837	GSE13837e	GSM347340	GPL570	linear	raw	CELS/GSE13837/GSM347340.CEL	TNFa	synovial fibroblasts, male, age 56, osteoarthritis	control	treated with TNFa 10 ng/ml	2 h	always compared to the 0 h time point
ARR00669	GSE13837	GSE13837e	GSM347342	GPL570	linear	raw	CELS/GSE13837/GSM347342.CEL	TNFa	synovial fibroblasts, male, age 56, osteoarthritis	control	treated with TNFa 10 ng/ml	2 h	always compared to the 0 h time point
ARR00670	GSE13837	GSE13837e	GSM347738	GPL570	linear	raw	CELS/GSE13837/GSM347738.CEL	TNFa	synovial fibroblasts, male, age 56, osteoarthritis	activating	treated with TNFa 10 ng/ml	2 h	always compared to the 0 h time point
ARR00671	GSE9055	GSE9055d	GSM229941	GPL570	linear	raw	CELS/GSE9055/GSM229941.CEL	TNFa	HUVEC (Human umbilical vein cells)	control	treated with TNFa 10 ng/ml after 18 h serum starvation	4 h	time series every 15 min until 8 h
ARR00672	GSE9055	GSE9055d	GSM229924	GPL570	linear	raw	CELS/GSE9055/GSM229924.CEL	TNFa	HUVEC (Human umbilical vein cells)	activating	treated with TNFa 10 ng/ml after 18 h serum starvation	4 h	time series every 15 min until 8 h
ARR00673	GSE27870	GSE27870a	GSM688449	GPL4044	log	raw	NA	TNFa	HUVEC (human umbilical vein endothelial cells)	control	treatment with 10ng/ml TNFa	1 h	3 replicates each, part of time series (1, 1.5, 2, 3, 4, 5, 6 h)
ARR00674	GSE27870	GSE27870a	GSM688450	GPL4044	log	raw	NA	TNFa	HUVEC (human umbilical vein endothelial cells)	control	treatment with 10ng/ml TNFa	1 h	3 replicates each, part of time series (1, 1.5, 2, 3, 4, 5, 6 h)
ARR00675	GSE27870	GSE27870a	GSM688451	GPL4044	log	raw	NA	TNFa	HUVEC (human umbilical vein endothelial cells)	control	treatment with 10ng/ml TNFa	1 h	3 replicates each, part of time series (1, 1.5, 2, 3, 4, 5, 6 h)
ARR00676	GSE27870	GSE27870a	GSM688452	GPL4044	log	raw	NA	TNFa	HUVEC (human umbilical vein endothelial cells)	activating	treatment with 10ng/ml TNFa	1 h	3 replicates each, part of time series (1, 1.5, 2, 3, 4, 5, 6 h)
ARR00677	GSE27870	GSE27870a	GSM688453	GPL4044	log	raw	NA	TNFa	HUVEC (human umbilical vein endothelial cells)	activating	treatment with 10ng/ml TNFa	1 h	3 replicates each, part of time series (1, 1.5, 2, 3, 4, 5, 6 h)
ARR00678	GSE27870	GSE27870a	GSM688454	GPL4044	log	raw	NA	TNFa	HUVEC (human umbilical vein endothelial cells)	activating	treatment with 10ng/ml TNFa	1 h	3 replicates each, part of time series (1, 1.5, 2, 3, 4, 5, 6 h)
ARR00679	GSE13837	GSE13837h	GSM347764	GPL570	linear	raw	CELS/GSE13837/GSM347764.CEL	TNFa	synovial fibroblasts, male, age 65, osteoarthritis	control	treated with TNFa 10 ng/ml	2 h	always compared to the 0 h time point
ARR00680	GSE13837	GSE13837h	GSM347745	GPL570	linear	raw	CELS/GSE13837/GSM347745.CEL	TNFa	synovial fibroblasts, male, age 65, osteoarthritis	control	treated with TNFa 10 ng/ml	2 h	always compared to the 0 h time point
ARR00681	GSE13837	GSE13837h	GSM347747	GPL570	linear	raw	CELS/GSE13837/GSM347747.CEL	TNFa	synovial fibroblasts, male, age 65, osteoarthritis	activating	treated with TNFa 10 ng/ml	2 h	always compared to the 0 h time point
ARR00682	GSE13837	GSE13837a	GSM347191	GPL570	linear	raw	CELS/GSE13837/GSM347191.CEL	TNFa	synovial fibroblasts, female, age 65, rheumatoid arthritis	control	treated with TNFa 10 ng/ml	1 h	always compared to the 0 h time point
ARR00683	GSE13837	GSE13837a	GSM347193	GPL570	linear	raw	CELS/GSE13837/GSM347193.CEL	TNFa	synovial fibroblasts, female, age 65, rheumatoid arthritis	control	treated with TNFa 10 ng/ml	1 h	always compared to the 0 h time point
ARR00684	GSE13837	GSE13837a	GSM347196	GPL570	linear	raw	CELS/GSE13837/GSM347196.CEL	TNFa	synovial fibroblasts, female, age 65, rheumatoid arthritis	activating	treated with TNFa 10 ng/ml	1 h	always compared to the 0 h time point
ARR00685	GSE2639	GSE2639	GSM50777	GPL96	log	raw	CELS/GSE2639/GSM50777.CEL	TNFa	HUVECs	control	treated with 2ng/ml TNFa	5 h	4 replicates each
ARR00686	GSE2639	GSE2639	GSM50778	GPL96	log	raw	CELS/GSE2639/GSM50778.CEL	TNFa	HUVECs	control	treated with 2ng/ml TNFa	5 h	4 replicates each
ARR00687	GSE2639	GSE2639	GSM50779	GPL96	log	raw	CELS/GSE2639/GSM50779.CEL	TNFa	HUVECs	control	treated with 2ng/ml TNFa	5 h	4 replicates each
ARR00688	GSE2639	GSE2639	GSM50780	GPL96	log	raw	CELS/GSE2639/GSM50780.CEL	TNFa	HUVECs	control	treated with 2ng/ml TNFa	5 h	4 replicates each
ARR00689	GSE2639	GSE2639	GSM50781	GPL96	log	raw	CELS/GSE2639/GSM50781.CEL	TNFa	HUVECs	activating	treated with 2ng/ml TNFa	5 h	4 replicates each
ARR00690	GSE2639	GSE2639	GSM50782	GPL96	log	raw	CELS/GSE2639/GSM50782.CEL	TNFa	HUVECs	activating	treated with 2ng/ml TNFa	5 h	4 replicates each
ARR00691	GSE2639	GSE2639	GSM50783	GPL96	log	raw	CELS/GSE2639/GSM50783.CEL	TNFa	HUVECs	activating	treated with 2ng/ml TNFa	5 h	4 replicates each
ARR00692	GSE2639	GSE2639	GSM50784	GPL96	log	raw	CELS/GSE2639/GSM50784.CEL	TNFa	HUVECs	activating	treated with 2ng/ml TNFa	5 h	4 replicates each
ARR00693	GSE13837	GSE13837m	GSM347845	GPL570	linear	raw	CELS/GSE13837/GSM347845.CEL	TNFa	synovial fibroblasts, female, age 57, rheumatoid arthritis	control	treated with TNFa 10 ng/ml	1 h	always compared to the 0 h time point
ARR00694	GSE13837	GSE13837m	GSM348023	GPL570	linear	raw	CELS/GSE13837/GSM348023.CEL	TNFa	synovial fibroblasts, female, age 57, rheumatoid arthritis	control	treated with TNFa 10 ng/ml	1 h	always compared to the 0 h time point
ARR00695	GSE13837	GSE13837m	GSM348017	GPL570	linear	raw	CELS/GSE13837/GSM348017.CEL	TNFa	synovial fibroblasts, female, age 57, rheumatoid arthritis	activating	treated with TNFa 10 ng/ml	1 h	always compared to the 0 h time point
ARR00696	GSE13837	GSE13837l	GSM347799	GPL570	linear	raw	CELS/GSE13837/GSM347799.CEL	TNFa	synovial fibroblasts, female, age 57, osteoarthritis	control	treated with TNFa 10 ng/ml	4 h	always compared to the 0 h time point
ARR00697	GSE13837	GSE13837l	GSM347840	GPL570	linear	raw	CELS/GSE13837/GSM347840.CEL	TNFa	synovial fibroblasts, female, age 57, osteoarthritis	control	treated with TNFa 10 ng/ml	4 h	always compared to the 0 h time point
ARR00698	GSE13837	GSE13837l	GSM347838	GPL570	linear	raw	CELS/GSE13837/GSM347838.CEL	TNFa	synovial fibroblasts, female, age 57, osteoarthritis	activating	treated with TNFa 10 ng/ml	4 h	always compared to the 0 h time point
ARR00699	GSE16251	GSE16251cTNFa	GSM409178	GPL8601	linear	raw	NA	TNFa	primary PBMCs	control	treated with TNFa	4 h	1 replicate each, part of time series, time respective control
ARR00700	GSE16251	GSE16251cTNFa	GSM409174	GPL8601	linear	raw	NA	TNFa	primary PBMCs	activating	treated with TNFa	4 h	1 replicate each, part of time series, time respective control
ARR00701	GSE16650	GSE16650	GSM417770	GPL570	log	raw	CELS/GSE16650/GSM417770.CEL	TNFa	Beas-B2 (Human Bronchial Epithelial Cells)	control	treated with TNFa 20 ng/ml	4 h	2 replicates each
ARR00702	GSE16650	GSE16650	GSM417776	GPL570	log	raw	CELS/GSE16650/GSM417776.CEL	TNFa	Beas-B2 (Human Bronchial Epithelial Cells)	control	treated with TNFa 20 ng/ml	4 h	2 replicates each
ARR00703	GSE16650	GSE16650	GSM417774	GPL570	log	raw	CELS/GSE16650/GSM417774.CEL	TNFa	Beas-B2 (Human Bronchial Epithelial Cells)	activating	treated with TNFa 20 ng/ml	4 h	2 replicates each
ARR00704	GSE16650	GSE16650	GSM417780	GPL570	log	raw	CELS/GSE16650/GSM417780.CEL	TNFa	Beas-B2 (Human Bronchial Epithelial Cells)	activating	treated with TNFa 20 ng/ml	4 h	2 replicates each
ARR00705	GSE2489	GSE2489a	GSM47302	GPL8300	linear	raw	NA	TNFa	Epidermis Keratinocytes	control	treated with TNFa	1 h	comment
ARR00706	GSE2489	GSE2489a	GSM47304	GPL8300	linear	raw	NA	TNFa	Epidermis Keratinocytes	control	treated with TNFa	1 h	comment
ARR00707	GSE2489	GSE2489a	GSM47311	GPL8300	linear	raw	NA	TNFa	Epidermis Keratinocytes	activating	treated with TNFa	1 h	comment
ARR00708	GSE13837	GSE13837d	GSM347340	GPL570	linear	raw	CELS/GSE13837/GSM347340.CEL	TNFa	synovial fibroblasts, male, age 56, osteoarthritis	control	treated with TNFa 10 ng/ml	1 h	always compared to the 0 h time point
ARR00709	GSE13837	GSE13837d	GSM347342	GPL570	linear	raw	CELS/GSE13837/GSM347342.CEL	TNFa	synovial fibroblasts, male, age 56, osteoarthritis	control	treated with TNFa 10 ng/ml	1 h	always compared to the 0 h time point
ARR00710	GSE13837	GSE13837d	GSM347737	GPL570	linear	raw	CELS/GSE13837/GSM347737.CEL	TNFa	synovial fibroblasts, male, age 56, osteoarthritis	activating	treated with TNFa 10 ng/ml	1 h	always compared to the 0 h time point
ARR00711	GSE22807	GSE22807	GSM563798	GPL6244	log	raw	CELS/GSE22807/GSM563798.CEL	TNFa	DU145 prostate cancer cells	control	treated with 10 ng/ml TNFa	1.5 h	2 replicates each
ARR00712	GSE22807	GSE22807	GSM563799	GPL6244	log	raw	CELS/GSE22807/GSM563799.CEL	TNFa	DU145 prostate cancer cells	control	treated with 10 ng/ml TNFa	1.5 h	2 replicates each
ARR00713	GSE22807	GSE22807	GSM563802	GPL6244	log	raw	CELS/GSE22807/GSM563802.CEL	TNFa	DU145 prostate cancer cells	activating	treated with 10 ng/ml TNFa	1.5 h	2 replicates each
ARR00714	GSE22807	GSE22807	GSM563803	GPL6244	log	raw	CELS/GSE22807/GSM563803.CEL	TNFa	DU145 prostate cancer cells	activating	treated with 10 ng/ml TNFa	1.5 h	2 replicates each
ARR00715	GSE1805	GSE1805b	GSM31117	GPL8300	log	raw	NA	TGFb	M091	control	treated with TGF-beta	4 h	2 replicates each, part of time series
ARR00716	GSE1805	GSE1805b	GSM31119	GPL8300	log	raw	NA	TGFb	M091	control	treated with TGF-beta	4 h	2 replicates each, part of time series
ARR00717	GSE1805	GSE1805b	GSM31126	GPL8300	log	raw	NA	TGFb	M091	activating	treated with TGF-beta	4 h	2 replicates each, part of time series
ARR00718	GSE1805	GSE1805b	GSM31127	GPL8300	log	raw	NA	TGFb	M091	activating	treated with TGF-beta	4 h	2 replicates each, part of time series
ARR00719	GSE17708	GSE17708d	GSM442026	GPL570	linear	raw	CELS/GSE17708/GSM442026.CEL	TGFb	A549 lung carcinoma cell line	control	treated with 5ng/ml TGF-beta	4 h	3 replicates each, part of time series
ARR00720	GSE17708	GSE17708d	GSM442027	GPL570	linear	raw	CELS/GSE17708/GSM442027.CEL	TGFb	A549 lung carcinoma cell line	control	treated with 5ng/ml TGF-beta	4 h	3 replicates each, part of time series
ARR00721	GSE17708	GSE17708d	GSM442028	GPL570	linear	raw	CELS/GSE17708/GSM442028.CEL	TGFb	A549 lung carcinoma cell line	control	treated with 5ng/ml TGF-beta	4 h	3 replicates each, part of time series
ARR00722	GSE17708	GSE17708d	GSM442037	GPL570	linear	raw	CELS/GSE17708/GSM442037.CEL	TGFb	A549 lung carcinoma cell line	activating	treated with 5ng/ml TGF-beta	4 h	3 replicates each, part of time series
ARR00723	GSE17708	GSE17708d	GSM442038	GPL570	linear	raw	CELS/GSE17708/GSM442038.CEL	TGFb	A549 lung carcinoma cell line	activating	treated with 5ng/ml TGF-beta	4 h	3 replicates each, part of time series
ARR00724	GSE17708	GSE17708d	GSM442039	GPL570	linear	raw	CELS/GSE17708/GSM442039.CEL	TGFb	A549 lung carcinoma cell line	activating	treated with 5ng/ml TGF-beta	4 h	3 replicates each, part of time series
ARR00725	GSE13837	GSE13837b3	GSM347340	GPL570	log	raw	CELS/GSE13837/GSM347340.CEL	TGFb	primary synovial fibroblasts	control	treated with 10ng/ml TGF-beta	4 h	1 replicate each, part of time series, several patients
ARR00726	GSE13837	GSE13837b3	GSM347735	GPL570	log	raw	CELS/GSE13837/GSM347735.CEL	TGFb	primary synovial fibroblasts	activating	treated with 10ng/ml TGF-beta	4 h	1 replicate each, part of time series, several patients
ARR00727	GSE23935	GSE23935d	GSM589939	GPL570	log	raw	CELS/GSE23935/GSM589939.CEL	TGFb	primary glioblastoma	control	treated with LY2109761, TGF-beta receptor inhibitor	3 h	1 replicate each
ARR00728	GSE23935	GSE23935d	GSM589940	GPL570	log	raw	CELS/GSE23935/GSM589940.CEL	TGFb	primary glioblastoma	inhibiting	treated with LY2109761, TGF-beta receptor inhibitor	3 h	1 replicate each
ARR00729	GSE5151	GSE5151	GSM116323	GPL8300	log	raw	NA	TGFb	dendritic cells	control	treated with 10 ng/ml TGF-beta1	4 h	1 replicate
ARR00730	GSE5151	GSE5151	GSM116324	GPL8300	log	raw	NA	TGFb	dendritic cells	activating	treated with 10 ng/ml TGF-beta1	4 h	1 replicate
ARR00731	GSE23935	GSE23935e	GSM589941	GPL570	log	raw	CELS/GSE23935/GSM589941.CEL	TGFb	primary glioblastoma	control	treated with LY2109761, TGF-beta receptor inhibitor	3 h	1 replicate each
ARR00732	GSE23935	GSE23935e	GSM589942	GPL570	log	raw	CELS/GSE23935/GSM589942.CEL	TGFb	primary glioblastoma	inhibiting	treated with LY2109761, TGF-beta receptor inhibitor	3 h	1 replicate each
ARR00733	GSE1805	GSE1805a	GSM31117	GPL8300	log	raw	NA	TGFb	M091	control	treated with 10 ng/ml TGF-beta	2 h	3 replicates each, part of time series
ARR00734	GSE1805	GSE1805a	GSM31119	GPL8300	log	raw	NA	TGFb	M091	control	treated with 10 ng/ml TGF-beta	2 h	3 replicates each, part of time series
ARR00735	GSE1805	GSE1805a	GSM31120	GPL8300	log	raw	NA	TGFb	M091	control	treated with 10 ng/ml TGF-beta	2 h	3 replicates each, part of time series
ARR00736	GSE1805	GSE1805a	GSM31122	GPL8300	log	raw	NA	TGFb	M091	activating	treated with 10 ng/ml TGF-beta	2 h	3 replicates each, part of time series
ARR00737	GSE1805	GSE1805a	GSM31123	GPL8300	log	raw	NA	TGFb	M091	activating	treated with 10 ng/ml TGF-beta	2 h	3 replicates each, part of time series
ARR00738	GSE1805	GSE1805a	GSM31124	GPL8300	log	raw	NA	TGFb	M091	activating	treated with 10 ng/ml TGF-beta	2 h	3 replicates each, part of time series
ARR00739	GSE23935	GSE23935k	GSM589953	GPL570	log	raw	CELS/GSE23935/GSM589953.CEL	TGFb	primary glioblastoma	control	treated with LY2109761, TGF-beta receptor inhibitor	3 h	1 replicate each
ARR00740	GSE23935	GSE23935k	GSM589954	GPL570	log	raw	CELS/GSE23935/GSM589954.CEL	TGFb	primary glioblastoma	inhibiting	treated with LY2109761, TGF-beta receptor inhibitor	3 h	1 replicate each
ARR00741	GSE17708	GSE17708a	GSM442026	GPL570	linear	raw	CELS/GSE17708/GSM442026.CEL	TGFb	A549 lung carcinoma cell line	control	treated with 5ng/ml TGF-beta	0.5 h	3 replicates each, part of time series
ARR00742	GSE17708	GSE17708a	GSM442027	GPL570	linear	raw	CELS/GSE17708/GSM442027.CEL	TGFb	A549 lung carcinoma cell line	control	treated with 5ng/ml TGF-beta	0.5 h	3 replicates each, part of time series
ARR00743	GSE17708	GSE17708a	GSM442028	GPL570	linear	raw	CELS/GSE17708/GSM442028.CEL	TGFb	A549 lung carcinoma cell line	control	treated with 5ng/ml TGF-beta	0.5 h	3 replicates each, part of time series
ARR00744	GSE17708	GSE17708a	GSM442029	GPL570	linear	raw	CELS/GSE17708/GSM442029.CEL	TGFb	A549 lung carcinoma cell line	activating	treated with 5ng/ml TGF-beta	0.5 h	3 replicates each, part of time series
ARR00745	GSE17708	GSE17708a	GSM442030	GPL570	linear	raw	CELS/GSE17708/GSM442030.CEL	TGFb	A549 lung carcinoma cell line	activating	treated with 5ng/ml TGF-beta	0.5 h	3 replicates each, part of time series
ARR00746	GSE17708	GSE17708a	GSM442031	GPL570	linear	raw	CELS/GSE17708/GSM442031.CEL	TGFb	A549 lung carcinoma cell line	activating	treated with 5ng/ml TGF-beta	0.5 h	3 replicates each, part of time series
ARR00747	GSE13837	GSE13837b1	GSM347340	GPL570	log	raw	CELS/GSE13837/GSM347340.CEL	TGFb	primary synovial fibroblasts	control	treated with 10ng/ml TGF-beta	1 h	1 replicate each, part of time series, several patients
ARR00748	GSE13837	GSE13837b1	GSM347733	GPL570	log	raw	CELS/GSE13837/GSM347733.CEL	TGFb	primary synovial fibroblasts	activating	treated with 10ng/ml TGF-beta	1 h	1 replicate each, part of time series, several patients
ARR00749	GSE5150	GSE5150b	GSM116315	GPL8300	log	raw	NA	TGFb	CD34+ hematopoietic stem/progenitor cells	control	treated with TGF-beta	4 h	1 replicate each, part of time series
ARR00750	GSE5150	GSE5150b	GSM116317	GPL8300	log	raw	NA	TGFb	CD34+ hematopoietic stem/progenitor cells	activating	treated with TGF-beta	4 h	1 replicate each, part of time series
ARR00751	GSE13837	GSE13837d2	GSM347845	GPL570	log	raw	CELS/GSE13837/GSM347845.CEL	TGFb	primary synovial fibroblasts	control	treated with 10ng/ml TGF-beta	2 h	1 replicate each, part of time series, several patients
ARR00752	GSE13837	GSE13837d2	GSM347842	GPL570	log	raw	CELS/GSE13837/GSM347842.CEL	TGFb	primary synovial fibroblasts	activating	treated with 10ng/ml TGF-beta	2 h	1 replicate each, part of time series, several patients
ARR00753	GSE13837	GSE13837e3	GSM348030	GPL570	log	raw	CELS/GSE13837/GSM348030.CEL	TGFb	primary synovial fibroblasts	control	treated with 10ng/ml TGF-beta	4 h	1 replicate each, part of time series, several patients
ARR00754	GSE13837	GSE13837e3	GSM348028	GPL570	log	raw	CELS/GSE13837/GSM348028.CEL	TGFb	primary synovial fibroblasts	activating	treated with 10ng/ml TGF-beta	4 h	1 replicate each, part of time series, several patients
ARR00755	GSE23935	GSE23935j	GSM589951	GPL570	log	raw	CELS/GSE23935/GSM589951.CEL	TGFb	primary glioblastoma	control	treated with LY2109761, TGF-beta receptor inhibitor	3 h	1 replicate each
ARR00756	GSE23935	GSE23935j	GSM589952	GPL570	log	raw	CELS/GSE23935/GSM589952.CEL	TGFb	primary glioblastoma	inhibiting	treated with LY2109761, TGF-beta receptor inhibitor	3 h	1 replicate each
ARR00757	GSE8730	GSE8730a	GSM216537	GPL570	log	raw	CELS/GSE8730/GSM216537.CEL	TGFb	odontoblasts	control	treated with TGF-beta1	1 h	1 replicate
ARR00758	GSE8730	GSE8730a	GSM216538	GPL570	log	raw	CELS/GSE8730/GSM216538.CEL	TGFb	odontoblasts	activating	treated with TGF-beta1	1 h	1 replicate
ARR00759	GSE17708	GSE17708b	GSM442026	GPL570	linear	raw	CELS/GSE17708/GSM442026.CEL	TGFb	A549 lung carcinoma cell line	control	treated with 5ng/ml TGF-beta	1 h	3 replicates each, part of time series
ARR00760	GSE17708	GSE17708b	GSM442027	GPL570	linear	raw	CELS/GSE17708/GSM442027.CEL	TGFb	A549 lung carcinoma cell line	control	treated with 5ng/ml TGF-beta	1 h	3 replicates each, part of time series
ARR00761	GSE17708	GSE17708b	GSM442028	GPL570	linear	raw	CELS/GSE17708/GSM442028.CEL	TGFb	A549 lung carcinoma cell line	control	treated with 5ng/ml TGF-beta	1 h	3 replicates each, part of time series
ARR00762	GSE17708	GSE17708b	GSM442032	GPL570	linear	raw	CELS/GSE17708/GSM442032.CEL	TGFb	A549 lung carcinoma cell line	activating	treated with 5ng/ml TGF-beta	1 h	3 replicates each, part of time series
ARR00763	GSE17708	GSE17708b	GSM442033	GPL570	linear	raw	CELS/GSE17708/GSM442033.CEL	TGFb	A549 lung carcinoma cell line	activating	treated with 5ng/ml TGF-beta	1 h	3 replicates each, part of time series
ARR00764	GSE17708	GSE17708b	GSM442034	GPL570	linear	raw	CELS/GSE17708/GSM442034.CEL	TGFb	A549 lung carcinoma cell line	activating	treated with 5ng/ml TGF-beta	1 h	3 replicates each, part of time series
ARR00765	GSE17860	GSE17860	GSM445699	GPL4133	linear	raw	NA	TGFb	osteoblast cell line	control	treated with 10ng/ml TGF-beta	6 h	3 replicates each
ARR00766	GSE17860	GSE17860	GSM445701	GPL4133	linear	raw	NA	TGFb	osteoblast cell line	control	treated with 10ng/ml TGF-beta	6 h	3 replicates each
ARR00767	GSE17860	GSE17860	GSM445703	GPL4133	linear	raw	NA	TGFb	osteoblast cell line	control	treated with 10ng/ml TGF-beta	6 h	3 replicates each
ARR00768	GSE17860	GSE17860	GSM445698	GPL4133	linear	raw	NA	TGFb	osteoblast cell line	activating	treated with 10ng/ml TGF-beta	6 h	3 replicates each
ARR00769	GSE17860	GSE17860	GSM445700	GPL4133	linear	raw	NA	TGFb	osteoblast cell line	activating	treated with 10ng/ml TGF-beta	6 h	3 replicates each
ARR00770	GSE17860	GSE17860	GSM445702	GPL4133	linear	raw	NA	TGFb	osteoblast cell line	activating	treated with 10ng/ml TGF-beta	6 h	3 replicates each
ARR00771	GSE13837	GSE13837a2	GSM347191	GPL570	log	raw	CELS/GSE13837/GSM347191.CEL	TGFb	primary synovial fibroblasts	control	treated with 10ng/ml TGF-beta	2 h	1 replicate each, part of time series, several patients
ARR00772	GSE13837	GSE13837a2	GSM347197	GPL570	log	raw	CELS/GSE13837/GSM347197.CEL	TGFb	primary synovial fibroblasts	activating	treated with 10ng/ml TGF-beta	2 h	1 replicate each, part of time series, several patients
ARR00773	GSE27526	GSE27526	GSM687585	GPL570	linear	raw	CELS/GSE27526/GSM687585.CEL	TGFb	A2780	control	treated with 10ng/ml TGF-beta1	3 h	3 replicates each
ARR00774	GSE27526	GSE27526	GSM687586	GPL570	linear	raw	CELS/GSE27526/GSM687586.CEL	TGFb	A2780	control	treated with 10ng/ml TGF-beta1	3 h	3 replicates each
ARR00775	GSE27526	GSE27526	GSM687587	GPL570	linear	raw	CELS/GSE27526/GSM687587.CEL	TGFb	A2780	control	treated with 10ng/ml TGF-beta1	3 h	3 replicates each
ARR00776	GSE27526	GSE27526	GSM687582	GPL570	linear	raw	CELS/GSE27526/GSM687582.CEL	TGFb	A2780	activating	treated with 10ng/ml TGF-beta1	3 h	3 replicates each
ARR00777	GSE27526	GSE27526	GSM687583	GPL570	linear	raw	CELS/GSE27526/GSM687583.CEL	TGFb	A2780	activating	treated with 10ng/ml TGF-beta1	3 h	3 replicates each
ARR00778	GSE27526	GSE27526	GSM687584	GPL570	linear	raw	CELS/GSE27526/GSM687584.CEL	TGFb	A2780	activating	treated with 10ng/ml TGF-beta1	3 h	3 replicates each
ARR00779	GSE13837	GSE13837c2	GSM347799	GPL570	log	raw	CELS/GSE13837/GSM347799.CEL	TGFb	primary synovial fibroblasts	control	treated with 10ng/ml TGF-beta	2 h	1 replicate each, part of time series, several patients
ARR00780	GSE13837	GSE13837c2	GSM347766	GPL570	log	raw	CELS/GSE13837/GSM347766.CEL	TGFb	primary synovial fibroblasts	activating	treated with 10ng/ml TGF-beta	2 h	1 replicate each, part of time series, several patients
ARR00781	GSE17708	GSE17708c	GSM442026	GPL570	linear	raw	CELS/GSE17708/GSM442026.CEL	TGFb	A549 lung carcinoma cell line	control	treated with 5ng/ml TGF-beta	2 h	3 replicates each, part of time series
ARR00782	GSE17708	GSE17708c	GSM442027	GPL570	linear	raw	CELS/GSE17708/GSM442027.CEL	TGFb	A549 lung carcinoma cell line	control	treated with 5ng/ml TGF-beta	2 h	3 replicates each, part of time series
ARR00783	GSE17708	GSE17708c	GSM442035	GPL570	linear	raw	CELS/GSE17708/GSM442035.CEL	TGFb	A549 lung carcinoma cell line	activating	treated with 5ng/ml TGF-beta	2 h	3 replicates each, part of time series
ARR00784	GSE17708	GSE17708c	GSM442036	GPL570	linear	raw	CELS/GSE17708/GSM442036.CEL	TGFb	A549 lung carcinoma cell line	activating	treated with 5ng/ml TGF-beta	2 h	3 replicates each, part of time series
ARR00785	GSE30004	GSE30004a	GSM742529	GPL6244	log	raw	CELS/GSE30004/GSM742529.CEL	TGFb	primary vascular smooth muscle cells	control	treated with 1ng/ml TGF-beta	6 h	3 replicates each
ARR00786	GSE30004	GSE30004a	GSM742533	GPL6244	log	raw	CELS/GSE30004/GSM742533.CEL	TGFb	primary vascular smooth muscle cells	control	treated with 1ng/ml TGF-beta	6 h	3 replicates each
ARR00787	GSE30004	GSE30004a	GSM742537	GPL6244	log	raw	CELS/GSE30004/GSM742537.CEL	TGFb	primary vascular smooth muscle cells	control	treated with 1ng/ml TGF-beta	6 h	3 replicates each
ARR00788	GSE30004	GSE30004a	GSM742517	GPL6244	log	raw	CELS/GSE30004/GSM742517.CEL	TGFb	primary vascular smooth muscle cells	activating	treated with 1ng/ml TGF-beta	6 h	3 replicates each
ARR00789	GSE30004	GSE30004a	GSM742521	GPL6244	log	raw	CELS/GSE30004/GSM742521.CEL	TGFb	primary vascular smooth muscle cells	activating	treated with 1ng/ml TGF-beta	6 h	3 replicates each
ARR00790	GSE30004	GSE30004a	GSM742525	GPL6244	log	raw	CELS/GSE30004/GSM742525.CEL	TGFb	primary vascular smooth muscle cells	activating	treated with 1ng/ml TGF-beta	6 h	3 replicates each
ARR00791	GSE28590	GSE28590	GSM707672	GPL570	log	raw	CELS/GSE28590/GSM707672.CEL	TGFb	HepG2 hepatoblastoma cells	control	treated with 3ng/ml TGF-beta	1.5 h	1 replicate each
ARR00792	GSE28590	GSE28590	GSM707673	GPL570	log	raw	CELS/GSE28590/GSM707673.CEL	TGFb	HepG2 hepatoblastoma cells	activating	treated with 3ng/ml TGF-beta	1.5 h	1 replicate each
ARR00793	GSE1802	GSE1802a	GSM31092	GPL96	log	raw	NA	TGFb	human umbilical cord blood CD34+ cells	control	treated with TGF-beta	2 h	3 replicates each, part of time series
ARR00794	GSE1802	GSE1802a	GSM31094	GPL96	log	raw	NA	TGFb	human umbilical cord blood CD34+ cells	control	treated with TGF-beta	2 h	3 replicates each, part of time series
ARR00795	GSE1802	GSE1802a	GSM31095	GPL96	log	raw	NA	TGFb	human umbilical cord blood CD34+ cells	control	treated with TGF-beta	2 h	3 replicates each, part of time series
ARR00796	GSE1802	GSE1802a	GSM31096	GPL96	log	raw	NA	TGFb	human umbilical cord blood CD34+ cells	activating	treated with TGF-beta	2 h	3 replicates each, part of time series
ARR00797	GSE1802	GSE1802a	GSM31097	GPL96	log	raw	NA	TGFb	human umbilical cord blood CD34+ cells	activating	treated with TGF-beta	2 h	3 replicates each, part of time series
ARR00798	GSE1802	GSE1802a	GSM31098	GPL96	log	raw	NA	TGFb	human umbilical cord blood CD34+ cells	activating	treated with TGF-beta	2 h	3 replicates each, part of time series
ARR00799	GSE23935	GSE23935b	GSM589935	GPL570	log	raw	CELS/GSE23935/GSM589935.CEL	TGFb	primary glioblastoma	control	treated with LY2109761, TGF-beta receptor inhibitor	3 h	1 replicate each
ARR00800	GSE23935	GSE23935b	GSM589936	GPL570	log	raw	CELS/GSE23935/GSM589936.CEL	TGFb	primary glioblastoma	inhibiting	treated with LY2109761, TGF-beta receptor inhibitor	3 h	1 replicate each
ARR00801	GSE1802	GSE1802b	GSM31092	GPL96	log	raw	NA	TGFb	human umbilical cord blood CD34+ cells	control	treated with TGF-beta	4 h	4 replicates each, part of time series
ARR00802	GSE1802	GSE1802b	GSM31093	GPL96	log	raw	NA	TGFb	human umbilical cord blood CD34+ cells	control	treated with TGF-beta	4 h	4 replicates each, part of time series
ARR00803	GSE1802	GSE1802b	GSM31094	GPL96	log	raw	NA	TGFb	human umbilical cord blood CD34+ cells	control	treated with TGF-beta	4 h	4 replicates each, part of time series
ARR00804	GSE1802	GSE1802b	GSM31095	GPL96	log	raw	NA	TGFb	human umbilical cord blood CD34+ cells	control	treated with TGF-beta	4 h	4 replicates each, part of time series
ARR00805	GSE1802	GSE1802b	GSM31099	GPL96	log	raw	NA	TGFb	human umbilical cord blood CD34+ cells	activating	treated with TGF-beta	4 h	4 replicates each, part of time series
ARR00806	GSE1802	GSE1802b	GSM31100	GPL96	log	raw	NA	TGFb	human umbilical cord blood CD34+ cells	activating	treated with TGF-beta	4 h	4 replicates each, part of time series
ARR00807	GSE1802	GSE1802b	GSM31101	GPL96	log	raw	NA	TGFb	human umbilical cord blood CD34+ cells	activating	treated with TGF-beta	4 h	4 replicates each, part of time series
ARR00808	GSE1802	GSE1802b	GSM31102	GPL96	log	raw	NA	TGFb	human umbilical cord blood CD34+ cells	activating	treated with TGF-beta	4 h	4 replicates each, part of time series
ARR00809	GSE23935	GSE23935i	GSM589949	GPL570	log	raw	CELS/GSE23935/GSM589949.CEL	TGFb	primary glioblastoma	control	treated with LY2109761, TGF-beta receptor inhibitor	3 h	1 replicate each
ARR00810	GSE23935	GSE23935i	GSM589950	GPL570	log	raw	CELS/GSE23935/GSM589950.CEL	TGFb	primary glioblastoma	inhibiting	treated with LY2109761, TGF-beta receptor inhibitor	3 h	1 replicate each
ARR00811	GSE23935	GSE23935c	GSM589937	GPL570	log	raw	CELS/GSE23935/GSM589937.CEL	TGFb	primary glioblastoma	control	treated with LY2109761, TGF-beta receptor inhibitor	3 h	1 replicate each
ARR00812	GSE23935	GSE23935c	GSM589938	GPL570	log	raw	CELS/GSE23935/GSM589938.CEL	TGFb	primary glioblastoma	inhibiting	treated with LY2109761, TGF-beta receptor inhibitor	3 h	1 replicate each
ARR00813	GSE8730	GSE8730b	GSM216541	GPL96	log	raw	CELS/GSE8730/GSM216541.CEL	TGFb	pulp tissue	control	treated with TGF-beta1	1 h	1 replicate, part of time series
ARR00814	GSE8730	GSE8730b	GSM216546	GPL96	log	raw	CELS/GSE8730/GSM216546.CEL	TGFb	pulp tissue	activating	treated with TGF-beta1	1 h	1 replicate, part of time series
ARR00815	GSE23935	GSE23935h	GSM589947	GPL570	log	raw	CELS/GSE23935/GSM589947.CEL	TGFb	primary glioblastoma	control	treated with LY2109761, TGF-beta receptor inhibitor	3 h	1 replicate each
ARR00816	GSE23935	GSE23935h	GSM589948	GPL570	log	raw	CELS/GSE23935/GSM589948.CEL	TGFb	primary glioblastoma	inhibiting	treated with LY2109761, TGF-beta receptor inhibitor	3 h	1 replicate each
ARR00817	GSE23935	GSE23935f	GSM589943	GPL570	log	raw	CELS/GSE23935/GSM589943.CEL	TGFb	primary glioblastoma	control	treated with LY2109761, TGF-beta receptor inhibitor	3 h	1 replicate each
ARR00818	GSE23935	GSE23935f	GSM589944	GPL570	log	raw	CELS/GSE23935/GSM589944.CEL	TGFb	primary glioblastoma	inhibiting	treated with LY2109761, TGF-beta receptor inhibitor	3 h	1 replicate each
ARR00819	GSE23935	GSE23935g	GSM589945	GPL570	log	raw	CELS/GSE23935/GSM589945.CEL	TGFb	primary glioblastoma	control	treated with LY2109761, TGF-beta receptor inhibitor	3 h	1 replicate each
ARR00820	GSE23935	GSE23935g	GSM589946	GPL570	log	raw	CELS/GSE23935/GSM589946.CEL	TGFb	primary glioblastoma	inhibiting	treated with LY2109761, TGF-beta receptor inhibitor	3 h	1 replicate each
ARR00821	GSE13837	GSE13837c3	GSM347799	GPL570	log	raw	CELS/GSE13837/GSM347799.CEL	TGFb	primary synovial fibroblasts	control	treated with 10ng/ml TGF-beta	4 h	1 replicate each, part of time series, several patients
ARR00822	GSE13837	GSE13837c3	GSM347767	GPL570	log	raw	CELS/GSE13837/GSM347767.CEL	TGFb	primary synovial fibroblasts	activating	treated with 10ng/ml TGF-beta	4 h	1 replicate each, part of time series, several patients
ARR00823	GSE5150	GSE5150a	GSM116315	GPL8300	log	raw	NA	TGFb	CD34+ hematopoietic stem/progenitor cells	control	treated with TGF-beta	2 h	1 replicate each, part of time series
ARR00824	GSE5150	GSE5150a	GSM116316	GPL8300	log	raw	NA	TGFb	CD34+ hematopoietic stem/progenitor cells	activating	treated with TGF-beta	2 h	1 replicate each, part of time series
ARR00825	GSE14491	GSE14491	GSM361954	GPL570	linear	raw	CELS/GSE14491/GSM361954.CEL	TGFb	MDA-MB-231 metastatic breast cell line	control	treated with 5µg/ml TGF-beta	3 h	4 replicate each, transfected with shGFP
ARR00826	GSE14491	GSE14491	GSM361955	GPL570	linear	raw	CELS/GSE14491/GSM361955.CEL	TGFb	MDA-MB-231 metastatic breast cell line	control	treated with 5µg/ml TGF-beta	3 h	4 replicate each, transfected with shGFP
ARR00827	GSE14491	GSE14491	GSM361956	GPL570	linear	raw	CELS/GSE14491/GSM361956.CEL	TGFb	MDA-MB-231 metastatic breast cell line	control	treated with 5µg/ml TGF-beta	3 h	4 replicate each, transfected with shGFP
ARR00828	GSE14491	GSE14491	GSM361957	GPL570	linear	raw	CELS/GSE14491/GSM361957.CEL	TGFb	MDA-MB-231 metastatic breast cell line	control	treated with 5µg/ml TGF-beta	3 h	4 replicate each, transfected with shGFP
ARR00829	GSE14491	GSE14491	GSM361958	GPL570	linear	raw	CELS/GSE14491/GSM361958.CEL	TGFb	MDA-MB-231 metastatic breast cell line	activating	treated with 5µg/ml TGF-beta	3 h	4 replicate each, transfected with shGFP
ARR00830	GSE14491	GSE14491	GSM361959	GPL570	linear	raw	CELS/GSE14491/GSM361959.CEL	TGFb	MDA-MB-231 metastatic breast cell line	activating	treated with 5µg/ml TGF-beta	3 h	4 replicate each, transfected with shGFP
ARR00831	GSE14491	GSE14491	GSM361960	GPL570	linear	raw	CELS/GSE14491/GSM361960.CEL	TGFb	MDA-MB-231 metastatic breast cell line	activating	treated with 5µg/ml TGF-beta	3 h	4 replicate each, transfected with shGFP
ARR00832	GSE14491	GSE14491	GSM361961	GPL570	linear	raw	CELS/GSE14491/GSM361961.CEL	TGFb	MDA-MB-231 metastatic breast cell line	activating	treated with 5µg/ml TGF-beta	3 h	4 replicate each, transfected with shGFP
ARR00833	GSE13837	GSE13837e1	GSM348030	GPL570	log	raw	CELS/GSE13837/GSM348030.CEL	TGFb	primary synovial fibroblasts	control	treated with 10ng/ml TGF-beta	1 h	1 replicate each, part of time series, several patients
ARR00834	GSE13837	GSE13837e1	GSM348024	GPL570	log	raw	CELS/GSE13837/GSM348024.CEL	TGFb	primary synovial fibroblasts	activating	treated with 10ng/ml TGF-beta	1 h	1 replicate each, part of time series, several patients
ARR00835	GSE23935	GSE23935a	GSM589933	GPL570	log	raw	CELS/GSE23935/GSM589933.CEL	TGFb	primary glioblastoma	control	treated with LY2109761, TGF-beta receptor inhibitor	3 h	1 replicate each
ARR00836	GSE23935	GSE23935a	GSM589934	GPL570	log	raw	CELS/GSE23935/GSM589934.CEL	TGFb	primary glioblastoma	inhibiting	treated with LY2109761, TGF-beta receptor inhibitor	3 h	1 replicate each
ARR00837	GSE13837	GSE13837a3	GSM347191	GPL570	log	raw	CELS/GSE13837/GSM347191.CEL	TGFb	primary synovial fibroblasts	control	treated with 10ng/ml TGF-beta	4 h	1 replicate each, part of time series, several patients
ARR00838	GSE13837	GSE13837a3	GSM347330	GPL570	log	raw	CELS/GSE13837/GSM347330.CEL	TGFb	primary synovial fibroblasts	activating	treated with 10ng/ml TGF-beta	4 h	1 replicate each, part of time series, several patients
ARR00839	GSE8730	GSE8730c	GSM216543	GPL96	log	raw	CELS/GSE8730/GSM216543.CEL	TGFb	pulp tissue	control	treated with TGF-beta1	5 h	1 replicate, part of time series
ARR00840	GSE8730	GSE8730c	GSM216547	GPL96	log	raw	CELS/GSE8730/GSM216547.CEL	TGFb	pulp tissue	activating	treated with TGF-beta1	5 h	1 replicate, part of time series
ARR00841	GSE6653	GSE6653a	GSM154124	GPL570	log	raw	CELS/GSE6653/GSM154124.CEL	TGFb	IOSE - immortalized ovarian surface epithelial cells	control	treated with TGF-beta1	3 h	2 replicates each, part of time series
ARR00842	GSE6653	GSE6653a	GSM154125	GPL570	log	raw	CELS/GSE6653/GSM154125.CEL	TGFb	IOSE - immortalized ovarian surface epithelial cells	control	treated with TGF-beta1	3 h	2 replicates each, part of time series
ARR00843	GSE6653	GSE6653a	GSM154126	GPL570	log	raw	CELS/GSE6653/GSM154126.CEL	TGFb	IOSE - immortalized ovarian surface epithelial cells	activating	treated with TGF-beta1	3 h	2 replicates each, part of time series
ARR00844	GSE6653	GSE6653a	GSM154127	GPL570	log	raw	CELS/GSE6653/GSM154127.CEL	TGFb	IOSE - immortalized ovarian surface epithelial cells	activating	treated with TGF-beta1	3 h	2 replicates each, part of time series
ARR00845	GSE13837	GSE13837b2	GSM347340	GPL570	log	raw	CELS/GSE13837/GSM347340.CEL	TGFb	primary synovial fibroblasts	control	treated with 10ng/ml TGF-beta	2 h	1 replicate each, part of time series, several patients
ARR00846	GSE13837	GSE13837b2	GSM347734	GPL570	log	raw	CELS/GSE13837/GSM347734.CEL	TGFb	primary synovial fibroblasts	activating	treated with 10ng/ml TGF-beta	2 h	1 replicate each, part of time series, several patients
ARR00847	GSE13837	GSE13837d1	GSM347845	GPL570	log	raw	CELS/GSE13837/GSM347845.CEL	TGFb	primary synovial fibroblasts	control	treated with 10ng/ml TGF-beta	1 h	1 replicate each, part of time series, several patients
ARR00848	GSE13837	GSE13837d1	GSM347841	GPL570	log	raw	CELS/GSE13837/GSM347841.CEL	TGFb	primary synovial fibroblasts	activating	treated with 10ng/ml TGF-beta	1 h	1 replicate each, part of time series, several patients
ARR00849	GSE13837	GSE13837a1	GSM347191	GPL570	log	raw	CELS/GSE13837/GSM347191.CEL	TGFb	primary synovial fibroblasts	control	treated with 10ng/ml TGF-beta	1 h	1 replicate each, part of time series, several patients
ARR00850	GSE13837	GSE13837a1	GSM347194	GPL570	log	raw	CELS/GSE13837/GSM347194.CEL	TGFb	primary synovial fibroblasts	activating	treated with 10ng/ml TGF-beta	1 h	1 replicate each, part of time series, several patients
ARR00851	GSE6653	GSE6653b	GSM154124	GPL570	log	raw	CELS/GSE6653/GSM154124.CEL	TGFb	IOSE - immortalized ovarian surface epithelial cells	control	treated with TGF-beta1	6 h	2 replicates each, part of time series
ARR00852	GSE6653	GSE6653b	GSM154125	GPL570	log	raw	CELS/GSE6653/GSM154125.CEL	TGFb	IOSE - immortalized ovarian surface epithelial cells	control	treated with TGF-beta1	6 h	2 replicates each, part of time series
ARR00853	GSE6653	GSE6653b	GSM154128	GPL570	log	raw	CELS/GSE6653/GSM154128.CEL	TGFb	IOSE - immortalized ovarian surface epithelial cells	activating	treated with TGF-beta1	6 h	2 replicates each, part of time series
ARR00854	GSE6653	GSE6653b	GSM154129	GPL570	log	raw	CELS/GSE6653/GSM154129.CEL	TGFb	IOSE - immortalized ovarian surface epithelial cells	activating	treated with TGF-beta1	6 h	2 replicates each, part of time series
ARR00855	GSE13837	GSE13837d3	GSM347845	GPL570	log	raw	CELS/GSE13837/GSM347845.CEL	TGFb	primary synovial fibroblasts	control	treated with 10ng/ml TGF-beta	4 h	1 replicate each, part of time series, several patients
ARR00856	GSE13837	GSE13837d3	GSM347843	GPL570	log	raw	CELS/GSE13837/GSM347843.CEL	TGFb	primary synovial fibroblasts	activating	treated with 10ng/ml TGF-beta	4 h	1 replicate each, part of time series, several patients
ARR00857	GSE1724	GSE1724	GSM29911	GPL8300	log	raw	NA	TGFb	lung fibroblasts	control	treated with 4 ng/ml TGF-beta	4 h	3 replicates each
ARR00858	GSE1724	GSE1724	GSM29915	GPL8300	log	raw	NA	TGFb	lung fibroblasts	control	treated with 4 ng/ml TGF-beta	4 h	3 replicates each
ARR00859	GSE1724	GSE1724	GSM29918	GPL8300	log	raw	NA	TGFb	lung fibroblasts	control	treated with 4 ng/ml TGF-beta	4 h	3 replicates each
ARR00860	GSE1724	GSE1724	GSM29913	GPL8300	log	raw	NA	TGFb	lung fibroblasts	activating	treated with 4 ng/ml TGF-beta	4 h	3 replicates each
ARR00861	GSE1724	GSE1724	GSM29916	GPL8300	log	raw	NA	TGFb	lung fibroblasts	activating	treated with 4 ng/ml TGF-beta	4 h	3 replicates each
ARR00862	GSE1724	GSE1724	GSM29919	GPL8300	log	raw	NA	TGFb	lung fibroblasts	activating	treated with 4 ng/ml TGF-beta	4 h	3 replicates each
ARR00863	GSE30004	GSE30004b	GSM742530	GPL6244	log	raw	CELS/GSE30004/GSM742530.CEL	TGFb	primary vascular smooth muscle cells	control	treated with 1ng/ml TGF-beta	6 h	3 replicates each
ARR00864	GSE30004	GSE30004b	GSM742534	GPL6244	log	raw	CELS/GSE30004/GSM742534.CEL	TGFb	primary vascular smooth muscle cells	control	treated with 1ng/ml TGF-beta	6 h	3 replicates each
ARR00865	GSE30004	GSE30004b	GSM742538	GPL6244	log	raw	CELS/GSE30004/GSM742538.CEL	TGFb	primary vascular smooth muscle cells	control	treated with 1ng/ml TGF-beta	6 h	3 replicates each
ARR00866	GSE30004	GSE30004b	GSM742518	GPL6244	log	raw	CELS/GSE30004/GSM742518.CEL	TGFb	primary vascular smooth muscle cells	activating	treated with 1ng/ml TGF-beta	6 h	3 replicates each
ARR00867	GSE30004	GSE30004b	GSM742522	GPL6244	log	raw	CELS/GSE30004/GSM742522.CEL	TGFb	primary vascular smooth muscle cells	activating	treated with 1ng/ml TGF-beta	6 h	3 replicates each
ARR00868	GSE30004	GSE30004b	GSM742526	GPL6244	log	raw	CELS/GSE30004/GSM742526.CEL	TGFb	primary vascular smooth muscle cells	activating	treated with 1ng/ml TGF-beta	6 h	3 replicates each
ARR00869	GSE30004	GSE30004c	GSM742531	GPL6244	log	raw	CELS/GSE30004/GSM742531.CEL	TGFb	primary vascular smooth muscle cells	control	treated with 1ng/ml TGF-beta	6 h	3 replicates each
ARR00870	GSE30004	GSE30004c	GSM742535	GPL6244	log	raw	CELS/GSE30004/GSM742535.CEL	TGFb	primary vascular smooth muscle cells	control	treated with 1ng/ml TGF-beta	6 h	3 replicates each
ARR00871	GSE30004	GSE30004c	GSM742539	GPL6244	log	raw	CELS/GSE30004/GSM742539.CEL	TGFb	primary vascular smooth muscle cells	control	treated with 1ng/ml TGF-beta	6 h	3 replicates each
ARR00872	GSE30004	GSE30004c	GSM742519	GPL6244	log	raw	CELS/GSE30004/GSM742519.CEL	TGFb	primary vascular smooth muscle cells	activating	treated with 1ng/ml TGF-beta	6 h	3 replicates each
ARR00873	GSE30004	GSE30004c	GSM742523	GPL6244	log	raw	CELS/GSE30004/GSM742523.CEL	TGFb	primary vascular smooth muscle cells	activating	treated with 1ng/ml TGF-beta	6 h	3 replicates each
ARR00874	GSE30004	GSE30004c	GSM742527	GPL6244	log	raw	CELS/GSE30004/GSM742527.CEL	TGFb	primary vascular smooth muscle cells	activating	treated with 1ng/ml TGF-beta	6 h	3 replicates each
ARR00875	GSE13837	GSE13837c1	GSM347799	GPL570	log	raw	CELS/GSE13837/GSM347799.CEL	TGFb	primary synovial fibroblasts	control	treated with 10ng/ml TGF-beta	1 h	1 replicate each, part of time series, several patients
ARR00876	GSE13837	GSE13837c1	GSM347765	GPL570	log	raw	CELS/GSE13837/GSM347765.CEL	TGFb	primary synovial fibroblasts	activating	treated with 10ng/ml TGF-beta	1 h	1 replicate each, part of time series, several patients
ARR00877	GSE13837	GSE13837e2	GSM348030	GPL570	log	raw	CELS/GSE13837/GSM348030.CEL	TGFb	primary synovial fibroblasts	control	treated with 10ng/ml TGF-beta	2 h	1 replicate each, part of time series, several patients
ARR00878	GSE13837	GSE13837e2	GSM348027	GPL570	log	raw	CELS/GSE13837/GSM348027.CEL	TGFb	primary synovial fibroblasts	activating	treated with 10ng/ml TGF-beta	2 h	1 replicate each, part of time series, several patients
ARR00879	GSE10778	GSE10778a	GSM272113	GPL96	linear	raw	CELS/GSE10778/GSM272113.CEL	both	human umbilical vein endothelial cells (HUVEC)	control	Treatment with EGF	0.5 h	time series 30 min, 1 h, 2.5 h 6 h / same with VEGF
ARR00880	GSE10778	GSE10778a	GSM272118	GPL96	linear	raw	CELS/GSE10778/GSM272118.CEL	both	human umbilical vein endothelial cells (HUVEC)	activating	Treatment with EGF	0.5 h	time series 30 min, 1 h, 2.5 h 6 h / same with VEGF
ARR00881	GSE6521	GSE6521d	GSM149913	GPL570	linear	raw	CELS/GSE6521/GSM149913.CEL	both	MCF-7 breast cancer cells	control	Treatment with HRG (heregulin ErbB3 Ligand)	0.75 h	comment
ARR00882	GSE6521	GSE6521d	GSM149919	GPL570	linear	raw	CELS/GSE6521/GSM149919.CEL	both	MCF-7 breast cancer cells	activating	Treatment with HRG (heregulin ErbB3 Ligand)	0.75 h	comment
ARR00883	GSE6462	GSE6462d	GSM148517	GPL571	linear	raw	CELS/GSE6462/GSM148517.CEL	both	MCF-7 (human breast cancer)	control	treatment with 10 nm HRG= heregulin Erb3/4 Ligand	1.5 h	none
ARR00884	GSE6462	GSE6462d	GSM148572	GPL571	linear	raw	CELS/GSE6462/GSM148572.CEL	both	MCF-7 (human breast cancer)	activating	treatment with 10 nm HRG= heregulin Erb3/4 Ligand	1.5 h	none
ARR00885	GSE13009	GSE13009j	GSM325937	GPL571	linear	raw	CELS/GSE13009/GSM325937.CEL	both	MCF7 human breast cancer cells	control	Treatment with HRG	6 h	time series: 10,15,20,30,45,60,90 min, 2, 3, 4, 6...72 h
ARR00886	GSE13009	GSE13009j	GSM325992	GPL571	linear	raw	CELS/GSE13009/GSM325992.CEL	both	MCF7 human breast cancer cells	activating	Treatment with HRG	6 h	time series: 10,15,20,30,45,60,90 min, 2, 3, 4, 6...72 h
ARR00887	GSE13009	GSE13009j	GSM325993	GPL571	linear	raw	CELS/GSE13009/GSM325993.CEL	both	MCF7 human breast cancer cells	activating	Treatment with HRG	6 h	time series: 10,15,20,30,45,60,90 min, 2, 3, 4, 6...72 h
ARR00888	GSE10778	GSE10778b	GSM272113	GPL96	linear	raw	CELS/GSE10778/GSM272113.CEL	both	human umbilical vein endothelial cells (HUVEC)	control	Treatment with EGF	1 h	time series 30 min, 1 h, 2.5 h 6 h / same with VEGF
ARR00889	GSE10778	GSE10778b	GSM272119	GPL96	linear	raw	CELS/GSE10778/GSM272119.CEL	both	human umbilical vein endothelial cells (HUVEC)	activating	Treatment with EGF	1 h	time series 30 min, 1 h, 2.5 h 6 h / same with VEGF
ARR00890	GSE8471	GSE8471	GSM210180	GPL570	linear	raw	CELS/GSE8471/GSM210180.CEL	both	MCF7	control	HRG stimulated (ErbB Ligand)	2 h after stimulation	comment
ARR00891	GSE8471	GSE8471	GSM210181	GPL570	linear	raw	CELS/GSE8471/GSM210181.CEL	both	MCF7	activating	HRG stimulated (ErbB Ligand)	2 h after stimulation	comment
ARR00892	GSE7403	GSE7403a	GSM178575	GPL96	linear	raw	CELS/GSE7403/GSM178575.CEL	both	SH-SY5Y (Neuroblastoma cells)	control	PDGF treatment with 60 min prior DMSO treatment	0.5 h	none
ARR00893	GSE7403	GSE7403a	GSM178576	GPL96	linear	raw	CELS/GSE7403/GSM178576.CEL	both	SH-SY5Y (Neuroblastoma cells)	control	PDGF treatment with 60 min prior DMSO treatment	0.5 h	none
ARR00894	GSE7403	GSE7403a	GSM178569	GPL96	linear	raw	CELS/GSE7403/GSM178569.CEL	both	SH-SY5Y (Neuroblastoma cells)	activating	PDGF treatment with 60 min prior DMSO treatment	0.5 h	none
ARR00895	GSE7403	GSE7403a	GSM178570	GPL96	linear	raw	CELS/GSE7403/GSM178570.CEL	both	SH-SY5Y (Neuroblastoma cells)	activating	PDGF treatment with 60 min prior DMSO treatment	0.5 h	none
ARR00896	GSE13009	GSE13009a	GSM325937	GPL571	linear	raw	CELS/GSE13009/GSM325937.CEL	both	MCF7 human breast cancer cells	control	Treatment with EGF	0.5 h	time series: 10,15,20,30,45,60,90 min, 2, 3, 4, 6...72 h
ARR00897	GSE13009	GSE13009a	GSM325944	GPL571	linear	raw	CELS/GSE13009/GSM325944.CEL	both	MCF7 human breast cancer cells	activating	Treatment with EGF	0.5 h	time series: 10,15,20,30,45,60,90 min, 2, 3, 4, 6...72 h
ARR00898	GSE13009	GSE13009a	GSM325945	GPL571	linear	raw	CELS/GSE13009/GSM325945.CEL	both	MCF7 human breast cancer cells	activating	Treatment with EGF	0.5 h	time series: 10,15,20,30,45,60,90 min, 2, 3, 4, 6...72 h
ARR00899	GSE13009	GSE13009c	GSM325937	GPL571	linear	raw	CELS/GSE13009/GSM325937.CEL	both	MCF7 human breast cancer cells	control	Treatment with EGF	2 h	time series: 10,15,20,30,45,60,90 min, 2, 3, 4, 6...72 h
ARR00900	GSE13009	GSE13009c	GSM325952	GPL571	linear	raw	CELS/GSE13009/GSM325952.CEL	both	MCF7 human breast cancer cells	activating	Treatment with EGF	2 h	time series: 10,15,20,30,45,60,90 min, 2, 3, 4, 6...72 h
ARR00901	GSE13009	GSE13009c	GSM325953	GPL571	linear	raw	CELS/GSE13009/GSM325953.CEL	both	MCF7 human breast cancer cells	activating	Treatment with EGF	2 h	time series: 10,15,20,30,45,60,90 min, 2, 3, 4, 6...72 h
ARR00902	GSE6462	GSE6462a	GSM148516	GPL571	linear	raw	CELS/GSE6462/GSM148516.CEL	both	MCF-7 (human breast cancer)	control	treatment with EGF (10nm)	0.75 h	none
ARR00903	GSE6462	GSE6462a	GSM148543	GPL571	linear	raw	CELS/GSE6462/GSM148543.CEL	both	MCF-7 (human breast cancer)	activating	treatment with EGF (10nm)	0.75 h	none
ARR00904	GSE6783	GSE6783d	GSM156764	GPL96	linear	raw	CELS/GSE6783/GSM156764.CEL	both	HELA (Human cervical carcinoma cell line)	control	EGF treatment after 24 h serum starvation (Control 0 h)	4 h	none
ARR00905	GSE6783	GSE6783d	GSM156769	GPL96	linear	raw	CELS/GSE6783/GSM156769.CEL	both	HELA (Human cervical carcinoma cell line)	activating	EGF treatment after 24 h serum starvation (Control 0 h)	4 h	none
ARR00906	GSE12764	GSE12764b	GSM320243	GPL570	log	raw	CELS/GSE12764/GSM320243.CEL	both	MCF10A cells	control	transfected with HRAS(G12V)	24 h	3 replicates each, probably activating PI3K and MAPKs
ARR00907	GSE12764	GSE12764b	GSM320244	GPL570	log	raw	CELS/GSE12764/GSM320244.CEL	both	MCF10A cells	control	transfected with HRAS(G12V)	24 h	3 replicates each, probably activating PI3K and MAPKs
ARR00908	GSE12764	GSE12764b	GSM320245	GPL570	log	raw	CELS/GSE12764/GSM320245.CEL	both	MCF10A cells	control	transfected with HRAS(G12V)	24 h	3 replicates each, probably activating PI3K and MAPKs
ARR00909	GSE12764	GSE12764b	GSM320246	GPL570	log	raw	CELS/GSE12764/GSM320246.CEL	both	MCF10A cells	control	transfected with HRAS(G12V)	24 h	3 replicates each, probably activating PI3K and MAPKs
ARR00910	GSE12764	GSE12764b	GSM320247	GPL570	log	raw	CELS/GSE12764/GSM320247.CEL	both	MCF10A cells	control	transfected with HRAS(G12V)	24 h	3 replicates each, probably activating PI3K and MAPKs
ARR00911	GSE12764	GSE12764b	GSM320248	GPL570	log	raw	CELS/GSE12764/GSM320248.CEL	both	MCF10A cells	control	transfected with HRAS(G12V)	24 h	3 replicates each, probably activating PI3K and MAPKs
ARR00912	GSE12764	GSE12764b	GSM320249	GPL570	log	raw	CELS/GSE12764/GSM320249.CEL	both	MCF10A cells	activating	transfected with HRAS(G12V)	24 h	3 replicates each, probably activating PI3K and MAPKs
ARR00913	GSE12764	GSE12764b	GSM320250	GPL570	log	raw	CELS/GSE12764/GSM320250.CEL	both	MCF10A cells	activating	transfected with HRAS(G12V)	24 h	3 replicates each, probably activating PI3K and MAPKs
ARR00914	GSE12764	GSE12764b	GSM320251	GPL570	log	raw	CELS/GSE12764/GSM320251.CEL	both	MCF10A cells	activating	transfected with HRAS(G12V)	24 h	3 replicates each, probably activating PI3K and MAPKs
ARR00915	GSE12764	GSE12764b	GSM320252	GPL570	log	raw	CELS/GSE12764/GSM320252.CEL	both	MCF10A cells	activating	transfected with HRAS(G12V)	24 h	3 replicates each, probably activating PI3K and MAPKs
ARR00916	GSE12764	GSE12764b	GSM320253	GPL570	log	raw	CELS/GSE12764/GSM320253.CEL	both	MCF10A cells	activating	transfected with HRAS(G12V)	24 h	3 replicates each, probably activating PI3K and MAPKs
ARR00917	GSE7403	GSE7403g	GSM178606	GPL96	linear	raw	CELS/GSE7403/GSM178606.CEL	both	SH-SY5Y (Neuroblastoma cells)	control	PDGF treatment with 60 min prior DMSO treatment	4 h	none
ARR00918	GSE7403	GSE7403g	GSM178607	GPL96	linear	raw	CELS/GSE7403/GSM178607.CEL	both	SH-SY5Y (Neuroblastoma cells)	control	PDGF treatment with 60 min prior DMSO treatment	4 h	none
ARR00919	GSE7403	GSE7403g	GSM178600	GPL96	linear	raw	CELS/GSE7403/GSM178600.CEL	both	SH-SY5Y (Neuroblastoma cells)	activating	PDGF treatment with 60 min prior DMSO treatment	4 h	none
ARR00920	GSE7403	GSE7403g	GSM178601	GPL96	linear	raw	CELS/GSE7403/GSM178601.CEL	both	SH-SY5Y (Neuroblastoma cells)	activating	PDGF treatment with 60 min prior DMSO treatment	4 h	none
ARR00921	GSE7403	GSE7403e	GSM178590	GPL96	linear	raw	CELS/GSE7403/GSM178590.CEL	both	SH-SY5Y (Neuroblastoma cells)	control	PDGF treatment with 60 min prior DMSO treatment	2 h	none
ARR00922	GSE7403	GSE7403e	GSM178591	GPL96	linear	raw	CELS/GSE7403/GSM178591.CEL	both	SH-SY5Y (Neuroblastoma cells)	control	PDGF treatment with 60 min prior DMSO treatment	2 h	none
ARR00923	GSE7403	GSE7403e	GSM178584	GPL96	linear	raw	CELS/GSE7403/GSM178584.CEL	both	SH-SY5Y (Neuroblastoma cells)	activating	PDGF treatment with 60 min prior DMSO treatment	2 h	none
ARR00924	GSE7403	GSE7403e	GSM178585	GPL96	linear	raw	CELS/GSE7403/GSM178585.CEL	both	SH-SY5Y (Neuroblastoma cells)	activating	PDGF treatment with 60 min prior DMSO treatment	2 h	none
ARR00925	GSE11729	GSE11729b	GSM297647	GPL570	log	raw	CELS/GSE11729/GSM297647.CEL	both	H1299 human non-small cell lung cancer cells	control	Treatment with EGF	1 h	time series: 30 min, 1, 2, 4, 6 and 10 h
ARR00926	GSE11729	GSE11729b	GSM297649	GPL570	log	raw	CELS/GSE11729/GSM297649.CEL	both	H1299 human non-small cell lung cancer cells	activating	Treatment with EGF	1 h	time series: 30 min, 1, 2, 4, 6 and 10 h
ARR00927	GSE6783	GSE6783b	GSM156764	GPL96	linear	raw	CELS/GSE6783/GSM156764.CEL	both	HELA (Human cervical carcinoma cell line)	control	EGF treatment after 24 h serum starvation (Control 0 h)	1 h	none
ARR00928	GSE6783	GSE6783b	GSM156767	GPL96	linear	raw	CELS/GSE6783/GSM156767.CEL	both	HELA (Human cervical carcinoma cell line)	activating	EGF treatment after 24 h serum starvation (Control 0 h)	1 h	none
ARR00929	GSE10778	GSE10778c	GSM272113	GPL96	linear	raw	CELS/GSE10778/GSM272113.CEL	both	human umbilical vein endothelial cells (HUVEC)	control	Treatment with EGF	2.5 h	time series 30 min, 1 h, 2.5 h 6 h / same with VEGF
ARR00930	GSE10778	GSE10778c	GSM272120	GPL96	linear	raw	CELS/GSE10778/GSM272120.CEL	both	human umbilical vein endothelial cells (HUVEC)	activating	Treatment with EGF	2.5 h	time series 30 min, 1 h, 2.5 h 6 h / same with VEGF
ARR00931	GSE7403	GSE7403c	GSM178583	GPL96	linear	raw	CELS/GSE7403/GSM178583.CEL	both	SH-SY5Y (Neuroblastoma cells)	control	PDGF treatment with 60 min prior DMSO treatment	1 h	none
ARR00932	GSE7403	GSE7403c	GSM178577	GPL96	linear	raw	CELS/GSE7403/GSM178577.CEL	both	SH-SY5Y (Neuroblastoma cells)	activating	PDGF treatment with 60 min prior DMSO treatment	1 h	none
ARR00933	GSE7403	GSE7403c	GSM178578	GPL96	linear	raw	CELS/GSE7403/GSM178578.CEL	both	SH-SY5Y (Neuroblastoma cells)	activating	PDGF treatment with 60 min prior DMSO treatment	1 h	none
ARR00934	GSE13009	GSE13009e	GSM325937	GPL571	linear	raw	CELS/GSE13009/GSM325937.CEL	both	MCF7 human breast cancer cells	control	Treatment with HRG	0.5 h	time series: 10,15,20,30,45,60,90 min, 2, 3, 4, 6...72 h
ARR00935	GSE13009	GSE13009e	GSM325978	GPL571	linear	raw	CELS/GSE13009/GSM325978.CEL	both	MCF7 human breast cancer cells	activating	Treatment with HRG	0.5 h	time series: 10,15,20,30,45,60,90 min, 2, 3, 4, 6...72 h
ARR00936	GSE13009	GSE13009e	GSM325979	GPL571	linear	raw	CELS/GSE13009/GSM325979.CEL	both	MCF7 human breast cancer cells	activating	Treatment with HRG	0.5 h	time series: 10,15,20,30,45,60,90 min, 2, 3, 4, 6...72 h
ARR00937	GSE13009	GSE13009h	GSM325937	GPL571	linear	raw	CELS/GSE13009/GSM325937.CEL	both	MCF7 human breast cancer cells	control	Treatment with HRG	4 h	time series: 10,15,20,30,45,60,90 min, 2, 3, 4, 6...72 h
ARR00938	GSE13009	GSE13009h	GSM325990	GPL571	linear	raw	CELS/GSE13009/GSM325990.CEL	both	MCF7 human breast cancer cells	activating	Treatment with HRG	4 h	time series: 10,15,20,30,45,60,90 min, 2, 3, 4, 6...72 h
ARR00939	GSE13009	GSE13009h	GSM325991	GPL571	linear	raw	CELS/GSE13009/GSM325991.CEL	both	MCF7 human breast cancer cells	activating	Treatment with HRG	4 h	time series: 10,15,20,30,45,60,90 min, 2, 3, 4, 6...72 h
ARR00940	GSE6462	GSE6462c	GSM148517	GPL571	linear	raw	CELS/GSE6462/GSM148517.CEL	both	MCF-7 (human breast cancer)	control	treatment with 10 nm HRG= heregulin Erb3/4 Ligand	0.75 h	none
ARR00941	GSE6462	GSE6462c	GSM148570	GPL571	linear	raw	CELS/GSE6462/GSM148570.CEL	both	MCF-7 (human breast cancer)	activating	treatment with 10 nm HRG= heregulin Erb3/4 Ligand	0.75 h	none
ARR00942	GSE13168	GSE13168b	GSM332914	GPL96	log	normalized	CELS/GSE13168/GSM332914.CEL	both	airway smooth muscle cells	control	treated with EGF	8 h	1 replicate each, contain control vector, 4 donors
ARR00943	GSE13168	GSE13168b	GSM332922	GPL96	log	normalized	CELS/GSE13168/GSM332922.CEL	both	airway smooth muscle cells	activating	treated with EGF	8 h	1 replicate each, contain control vector, 4 donors
ARR00944	GSE3542	GSE3542a	GSM81189	GPL96	log	raw	CELS/GSE3542/GSM81189.CEL	both	MCF-7 (breast cancer cells)	control	co-transfected with constituitively active erbB-2	not specified	none
ARR00945	GSE3542	GSE3542a	GSM81190	GPL96	log	raw	CELS/GSE3542/GSM81190.CEL	both	MCF-7 (breast cancer cells)	control	co-transfected with constituitively active erbB-2	not specified	none
ARR00946	GSE3542	GSE3542a	GSM81191	GPL96	log	raw	CELS/GSE3542/GSM81191.CEL	both	MCF-7 (breast cancer cells)	control	co-transfected with constituitively active erbB-2	not specified	none
ARR00947	GSE3542	GSE3542a	GSM81195	GPL96	log	raw	NA	both	MCF-7 (breast cancer cells)	activating	co-transfected with constituitively active erbB-2	not specified	none
ARR00948	GSE3542	GSE3542a	GSM81196	GPL96	log	raw	NA	both	MCF-7 (breast cancer cells)	activating	co-transfected with constituitively active erbB-2	not specified	none
ARR00949	GSE3542	GSE3542a	GSM81197	GPL96	log	raw	NA	both	MCF-7 (breast cancer cells)	activating	co-transfected with constituitively active erbB-2	not specified	none
ARR00950	GSE3542	GSE3542d	GSM81189	GPL96	log	raw	CELS/GSE3542/GSM81189.CEL	both	MCF-7 (breast cancer cells)	control	co-transfected with ligand-inducible EGFR	not specified	none
ARR00951	GSE3542	GSE3542d	GSM81190	GPL96	log	raw	CELS/GSE3542/GSM81190.CEL	both	MCF-7 (breast cancer cells)	control	co-transfected with ligand-inducible EGFR	not specified	none
ARR00952	GSE3542	GSE3542d	GSM81191	GPL96	log	raw	CELS/GSE3542/GSM81191.CEL	both	MCF-7 (breast cancer cells)	control	co-transfected with ligand-inducible EGFR	not specified	none
ARR00953	GSE3542	GSE3542d	GSM81201	GPL96	log	raw	NA	both	MCF-7 (breast cancer cells)	activating	co-transfected with ligand-inducible EGFR	not specified	none
ARR00954	GSE3542	GSE3542d	GSM81202	GPL96	log	raw	NA	both	MCF-7 (breast cancer cells)	activating	co-transfected with ligand-inducible EGFR	not specified	none
ARR00955	GSE3542	GSE3542d	GSM81203	GPL96	log	raw	NA	both	MCF-7 (breast cancer cells)	activating	co-transfected with ligand-inducible EGFR	not specified	none
ARR00956	GSE13009	GSE13009b	GSM325937	GPL571	linear	raw	CELS/GSE13009/GSM325937.CEL	both	MCF7 human breast cancer cells	control	Treatment with EGF	1 h	time series: 10,15,20,30,45,60,90 min, 2, 3, 4, 6...72 h
ARR00957	GSE13009	GSE13009b	GSM325948	GPL571	linear	raw	CELS/GSE13009/GSM325948.CEL	both	MCF7 human breast cancer cells	activating	Treatment with EGF	1 h	time series: 10,15,20,30,45,60,90 min, 2, 3, 4, 6...72 h
ARR00958	GSE13009	GSE13009b	GSM325949	GPL571	linear	raw	CELS/GSE13009/GSM325949.CEL	both	MCF7 human breast cancer cells	activating	Treatment with EGF	1 h	time series: 10,15,20,30,45,60,90 min, 2, 3, 4, 6...72 h
ARR00959	GSE6784	GSE6784b	GSM156771	GPL571	linear	raw	CELS/GSE6784/GSM156771.CEL	both	MCF-10A (mammary epithelial cell line)	control	EGF treatment after 24 h serum starvation (Control 0 h)	1 h	none
ARR00960	GSE6784	GSE6784b	GSM156774	GPL571	linear	raw	CELS/GSE6784/GSM156774.CEL	both	MCF-10A (mammary epithelial cell line)	activating	EGF treatment after 24 h serum starvation (Control 0 h)	1 h	none
ARR00961	GSE6784	GSE6784a	GSM156771	GPL571	linear	raw	CELS/GSE6784/GSM156771.CEL	both	MCF-10A (mammary epithelial cell line)	control	EGF treatment after 24 h serum starvation (Control 0 h)	0.33 h	none
ARR00962	GSE6784	GSE6784a	GSM156772	GPL571	linear	raw	CELS/GSE6784/GSM156772.CEL	both	MCF-10A (mammary epithelial cell line)	activating	EGF treatment after 24 h serum starvation (Control 0 h)	0.33 h	none
ARR00963	GSE13009	GSE13009i	GSM325937	GPL571	linear	raw	CELS/GSE13009/GSM325937.CEL	both	MCF7 human breast cancer cells	control	Treatment with EGF	6 h	time series: 10,15,20,30,45,60,90 min, 2, 3, 4, 6...72 h
ARR00964	GSE13009	GSE13009i	GSM325958	GPL571	linear	raw	CELS/GSE13009/GSM325958.CEL	both	MCF7 human breast cancer cells	activating	Treatment with EGF	6 h	time series: 10,15,20,30,45,60,90 min, 2, 3, 4, 6...72 h
ARR00965	GSE13009	GSE13009i	GSM325959	GPL571	linear	raw	CELS/GSE13009/GSM325959.CEL	both	MCF7 human breast cancer cells	activating	Treatment with EGF	6 h	time series: 10,15,20,30,45,60,90 min, 2, 3, 4, 6...72 h
ARR00966	GSE14256	GSE14256a	GSM356969	GPL571	linear	raw	CELS/GSE14256/GSM356969.CEL	both	Human foreskin fibroblasts (AG01518)	control	Treatment with platelet-derived growth factor-BB (PDGF-BB)	1 h	comment
ARR00967	GSE14256	GSE14256a	GSM356970	GPL571	linear	raw	CELS/GSE14256/GSM356970.CEL	both	Human foreskin fibroblasts (AG01518)	control	Treatment with platelet-derived growth factor-BB (PDGF-BB)	1 h	comment
ARR00968	GSE14256	GSE14256a	GSM356966	GPL571	linear	raw	CELS/GSE14256/GSM356966.CEL	both	Human foreskin fibroblasts (AG01518)	activating	Treatment with platelet-derived growth factor-BB (PDGF-BB)	1 h	comment
ARR00969	GSE14256	GSE14256a	GSM356973	GPL571	linear	raw	CELS/GSE14256/GSM356973.CEL	both	Human foreskin fibroblasts (AG01518)	activating	Treatment with platelet-derived growth factor-BB (PDGF-BB)	1 h	comment
ARR00970	GSE6784	GSE6784d	GSM156771	GPL571	linear	raw	CELS/GSE6784/GSM156771.CEL	both	MCF-10A (mammary epithelial cell line)	control	EGF treatment after 24 h serum starvation (Control 0 h)	4 h	none
ARR00971	GSE6784	GSE6784d	GSM156776	GPL571	linear	raw	CELS/GSE6784/GSM156776.CEL	both	MCF-10A (mammary epithelial cell line)	activating	EGF treatment after 24 h serum starvation (Control 0 h)	4 h	none
ARR00972	GSE20277	GSE20277	GSM508433	GPL6480	linear	raw	NA	both	HeLa cells	control	treated with EGF	0.66 h	3 replicates each
ARR00973	GSE20277	GSE20277	GSM508434	GPL6480	linear	raw	NA	both	HeLa cells	control	treated with EGF	0.66 h	3 replicates each
ARR00974	GSE20277	GSE20277	GSM508435	GPL6480	linear	raw	NA	both	HeLa cells	control	treated with EGF	0.66 h	3 replicates each
ARR00975	GSE20277	GSE20277	GSM507245	GPL6480	linear	raw	NA	both	HeLa cells	activating	treated with EGF	0.66 h	3 replicates each
ARR00976	GSE20277	GSE20277	GSM507246	GPL6480	linear	raw	NA	both	HeLa cells	activating	treated with EGF	0.66 h	3 replicates each
ARR00977	GSE20277	GSE20277	GSM507247	GPL6480	linear	raw	NA	both	HeLa cells	activating	treated with EGF	0.66 h	3 replicates each
ARR00978	GSE6521	GSE6521e	GSM149913	GPL570	linear	raw	CELS/GSE6521/GSM149913.CEL	both	MCF-7 breast cancer cells	control	Treatment with HRG (heregulin ErbB3 Ligand)	1.5 h	comment
ARR00979	GSE6521	GSE6521e	GSM149921	GPL570	linear	raw	CELS/GSE6521/GSM149921.CEL	both	MCF-7 breast cancer cells	activating	Treatment with HRG (heregulin ErbB3 Ligand)	1.5 h	comment
ARR00980	GSE11729	GSE11729a	GSM297647	GPL570	log	raw	CELS/GSE11729/GSM297647.CEL	both	H1299 human non-small cell lung cancer cells	control	Treatment with EGF	0.5 h	time series: 30 min, 1, 2, 4, 6 and 10 h
ARR00981	GSE11729	GSE11729a	GSM297648	GPL570	log	raw	CELS/GSE11729/GSM297648.CEL	both	H1299 human non-small cell lung cancer cells	activating	Treatment with EGF	0.5 h	time series: 30 min, 1, 2, 4, 6 and 10 h
ARR00982	GSE13168	GSE13168c	GSM332915	GPL96	log	normalized	CELS/GSE13168/GSM332915.CEL	both	airway smooth muscle cells	control	treated with EGF	8 h	1 replicate each, contain control vector, 4 donors
ARR00983	GSE13168	GSE13168c	GSM332923	GPL96	log	normalized	CELS/GSE13168/GSM332923.CEL	both	airway smooth muscle cells	activating	treated with EGF	8 h	1 replicate each, contain control vector, 4 donors
ARR00984	GSE14934	GSE14934a	GSM373089	GPL571	linear	raw	CELS/GSE14934/GSM373089.CEL	both	HEK-HT (kidney)	control	Ras (G12V) activation mutants	not specified	comment
ARR00985	GSE14934	GSE14934a	GSM373094	GPL571	linear	raw	CELS/GSE14934/GSM373094.CEL	both	HEK-HT (kidney)	control	Ras (G12V) activation mutants	not specified	comment
ARR00986	GSE14934	GSE14934a	GSM373099	GPL571	linear	raw	CELS/GSE14934/GSM373099.CEL	both	HEK-HT (kidney)	control	Ras (G12V) activation mutants	not specified	comment
ARR00987	GSE14934	GSE14934a	GSM373104	GPL571	linear	raw	CELS/GSE14934/GSM373104.CEL	both	HEK-HT (kidney)	control	Ras (G12V) activation mutants	not specified	comment
ARR00988	GSE14934	GSE14934a	GSM373109	GPL571	linear	raw	CELS/GSE14934/GSM373109.CEL	both	HEK-HT (kidney)	control	Ras (G12V) activation mutants	not specified	comment
ARR00989	GSE14934	GSE14934a	GSM373090	GPL571	linear	raw	CELS/GSE14934/GSM373090.CEL	both	HEK-HT (kidney)	activating	Ras (G12V) activation mutants	not specified	comment
ARR00990	GSE14934	GSE14934a	GSM373095	GPL571	linear	raw	CELS/GSE14934/GSM373095.CEL	both	HEK-HT (kidney)	activating	Ras (G12V) activation mutants	not specified	comment
ARR00991	GSE14934	GSE14934a	GSM373100	GPL571	linear	raw	CELS/GSE14934/GSM373100.CEL	both	HEK-HT (kidney)	activating	Ras (G12V) activation mutants	not specified	comment
ARR00992	GSE14934	GSE14934a	GSM373105	GPL571	linear	raw	CELS/GSE14934/GSM373105.CEL	both	HEK-HT (kidney)	activating	Ras (G12V) activation mutants	not specified	comment
ARR00993	GSE14934	GSE14934a	GSM373110	GPL571	linear	raw	CELS/GSE14934/GSM373110.CEL	both	HEK-HT (kidney)	activating	Ras (G12V) activation mutants	not specified	comment
ARR00994	GSE13168	GSE13168a	GSM332913	GPL96	log	normalized	CELS/GSE13168/GSM332913.CEL	both	airway smooth muscle cells	control	treated with EGF	8 h	1 replicate each, contain control vector, 4 donors
ARR00995	GSE13168	GSE13168a	GSM332921	GPL96	log	normalized	CELS/GSE13168/GSM332921.CEL	both	airway smooth muscle cells	activating	treated with EGF	8 h	1 replicate each, contain control vector, 4 donors
ARR00996	GSE11729	GSE11729e	GSM297647	GPL570	log	raw	CELS/GSE11729/GSM297647.CEL	both	H1299 human non-small cell lung cancer cells	control	Treatment with EGF	6 h	time series: 30 min, 1, 2, 4, 6 and 10 h
ARR00997	GSE11729	GSE11729e	GSM297652	GPL570	log	raw	CELS/GSE11729/GSM297652.CEL	both	H1299 human non-small cell lung cancer cells	activating	Treatment with EGF	6 h	time series: 30 min, 1, 2, 4, 6 and 10 h
ARR00998	GSE6783	GSE6783a	GSM156764	GPL96	linear	raw	CELS/GSE6783/GSM156764.CEL	both	HELA (Human cervical carcinoma cell line)	control	EGF treatment after 24 h serum starvation (Control 0 h)	0.33 h	none
ARR00999	GSE6783	GSE6783a	GSM156765	GPL96	linear	raw	CELS/GSE6783/GSM156765.CEL	both	HELA (Human cervical carcinoma cell line)	activating	EGF treatment after 24 h serum starvation (Control 0 h)	0.33 h	none
ARR01000	GSE11729	GSE11729d	GSM297647	GPL570	log	raw	CELS/GSE11729/GSM297647.CEL	both	H1299 human non-small cell lung cancer cells	control	Treatment with EGF	4 h	time series: 30 min, 1, 2, 4, 6 and 10 h
ARR01001	GSE11729	GSE11729d	GSM297651	GPL570	log	raw	CELS/GSE11729/GSM297651.CEL	both	H1299 human non-small cell lung cancer cells	activating	Treatment with EGF	4 h	time series: 30 min, 1, 2, 4, 6 and 10 h
ARR01002	GSE6462	GSE6462b	GSM148516	GPL571	linear	raw	CELS/GSE6462/GSM148516.CEL	both	MCF-7 (human breast cancer)	control	treatment with EGF (10nm)	1.5 h	none
ARR01003	GSE6462	GSE6462b	GSM148544	GPL571	linear	raw	CELS/GSE6462/GSM148544.CEL	both	MCF-7 (human breast cancer)	activating	treatment with EGF (10nm)	1.5 h	none
ARR01004	GSE13009	GSE13009f	GSM325937	GPL571	linear	raw	CELS/GSE13009/GSM325937.CEL	both	MCF7 human breast cancer cells	control	Treatment with HRG	1 h	time series: 10,15,20,30,45,60,90 min, 2, 3, 4, 6...72 h
ARR01005	GSE13009	GSE13009f	GSM325982	GPL571	linear	raw	CELS/GSE13009/GSM325982.CEL	both	MCF7 human breast cancer cells	activating	Treatment with HRG	1 h	time series: 10,15,20,30,45,60,90 min, 2, 3, 4, 6...72 h
ARR01006	GSE13009	GSE13009f	GSM325983	GPL571	linear	raw	CELS/GSE13009/GSM325983.CEL	both	MCF7 human breast cancer cells	activating	Treatment with HRG	1 h	time series: 10,15,20,30,45,60,90 min, 2, 3, 4, 6...72 h
ARR01007	GSE33710	GSE33710	GSM833183	GPL96	log	raw	CELS/GSE33710/GSM833183.CEL	both	WI-38 cells	control	RASv12 overexpression	not indicated	3 replicates each
ARR01008	GSE33710	GSE33710	GSM833184	GPL96	log	raw	CELS/GSE33710/GSM833184.CEL	both	WI-38 cells	control	RASv12 overexpression	not indicated	3 replicates each
ARR01009	GSE33710	GSE33710	GSM833185	GPL96	log	raw	CELS/GSE33710/GSM833185.CEL	both	WI-38 cells	control	RASv12 overexpression	not indicated	3 replicates each
ARR01010	GSE33710	GSE33710	GSM833186	GPL96	log	raw	CELS/GSE33710/GSM833186.CEL	both	WI-38 cells	activating	RASv12 overexpression	not indicated	3 replicates each
ARR01011	GSE33710	GSE33710	GSM833187	GPL96	log	raw	CELS/GSE33710/GSM833187.CEL	both	WI-38 cells	activating	RASv12 overexpression	not indicated	3 replicates each
ARR01012	GSE33710	GSE33710	GSM833188	GPL96	log	raw	CELS/GSE33710/GSM833188.CEL	both	WI-38 cells	activating	RASv12 overexpression	not indicated	3 replicates each
ARR01013	GSE13009	GSE13009g	GSM325937	GPL571	linear	raw	CELS/GSE13009/GSM325937.CEL	both	MCF7 human breast cancer cells	control	Treatment with HRG	2 h	time series: 10,15,20,30,45,60,90 min, 2, 3, 4, 6...72 h
ARR01014	GSE13009	GSE13009g	GSM325986	GPL571	linear	raw	CELS/GSE13009/GSM325986.CEL	both	MCF7 human breast cancer cells	activating	Treatment with HRG	2 h	time series: 10,15,20,30,45,60,90 min, 2, 3, 4, 6...72 h
ARR01015	GSE13009	GSE13009g	GSM325987	GPL571	linear	raw	CELS/GSE13009/GSM325987.CEL	both	MCF7 human breast cancer cells	activating	Treatment with HRG	2 h	time series: 10,15,20,30,45,60,90 min, 2, 3, 4, 6...72 h
ARR01016	GSE13009	GSE13009d	GSM325937	GPL571	linear	raw	CELS/GSE13009/GSM325937.CEL	both	MCF7 human breast cancer cells	control	Treatment with EGF	4 h	time series: 10,15,20,30,45,60,90 min, 2, 3, 4, 6...72 h
ARR01017	GSE13009	GSE13009d	GSM325956	GPL571	linear	raw	CELS/GSE13009/GSM325956.CEL	both	MCF7 human breast cancer cells	activating	Treatment with EGF	4 h	time series: 10,15,20,30,45,60,90 min, 2, 3, 4, 6...72 h
ARR01018	GSE13009	GSE13009d	GSM325957	GPL571	linear	raw	CELS/GSE13009/GSM325957.CEL	both	MCF7 human breast cancer cells	activating	Treatment with EGF	4 h	time series: 10,15,20,30,45,60,90 min, 2, 3, 4, 6...72 h
ARR01019	GSE6784	GSE6784c	GSM156771	GPL571	linear	raw	CELS/GSE6784/GSM156771.CEL	both	MCF-10A (mammary epithelial cell line)	control	EGF treatment after 24 h serum starvation (Control 0 h)	2 h	none
ARR01020	GSE6784	GSE6784c	GSM156775	GPL571	linear	raw	CELS/GSE6784/GSM156775.CEL	both	MCF-10A (mammary epithelial cell line)	activating	EGF treatment after 24 h serum starvation (Control 0 h)	2 h	none
ARR01021	GSE13168	GSE13168d	GSM332916	GPL96	log	normalized	CELS/GSE13168/GSM332916.CEL	both	airway smooth muscle cells	control	treated with EGF	8 h	1 replicate each, contain control vector, 4 donors
ARR01022	GSE13168	GSE13168d	GSM332924	GPL96	log	normalized	CELS/GSE13168/GSM332924.CEL	both	airway smooth muscle cells	activating	treated with EGF	8 h	1 replicate each, contain control vector, 4 donors
ARR01023	GSE11729	GSE11729c	GSM297647	GPL570	log	raw	CELS/GSE11729/GSM297647.CEL	both	H1299 human non-small cell lung cancer cells	control	Treatment with EGF	2 h	time series: 30 min, 1, 2, 4, 6 and 10 h
ARR01024	GSE11729	GSE11729c	GSM297650	GPL570	log	raw	CELS/GSE11729/GSM297650.CEL	both	H1299 human non-small cell lung cancer cells	activating	Treatment with EGF	2 h	time series: 30 min, 1, 2, 4, 6 and 10 h
ARR01025	GSE14256	GSE14256b	GSM356969	GPL571	linear	raw	CELS/GSE14256/GSM356969.CEL	both	Human foreskin fibroblasts (AG01518)	control	Treatment with bFGF (basic fibroblast growth factor)	1 h	comment
ARR01026	GSE14256	GSE14256b	GSM356970	GPL571	linear	raw	CELS/GSE14256/GSM356970.CEL	both	Human foreskin fibroblasts (AG01518)	control	Treatment with bFGF (basic fibroblast growth factor)	1 h	comment
ARR01027	GSE14256	GSE14256b	GSM356968	GPL571	linear	raw	CELS/GSE14256/GSM356968.CEL	both	Human foreskin fibroblasts (AG01518)	activating	Treatment with bFGF (basic fibroblast growth factor)	1 h	comment
ARR01028	GSE14256	GSE14256b	GSM356971	GPL571	linear	raw	CELS/GSE14256/GSM356971.CEL	both	Human foreskin fibroblasts (AG01518)	activating	Treatment with bFGF (basic fibroblast growth factor)	1 h	comment
ARR01029	GSE6783	GSE6783c	GSM156764	GPL96	linear	raw	CELS/GSE6783/GSM156764.CEL	both	HELA (Human cervical carcinoma cell line)	control	EGF treatment after 24 h serum starvation (Control 0 h)	2 h	none
ARR01030	GSE6783	GSE6783c	GSM156768	GPL96	linear	raw	CELS/GSE6783/GSM156768.CEL	both	HELA (Human cervical carcinoma cell line)	activating	EGF treatment after 24 h serum starvation (Control 0 h)	2 h	none
ARR01031	GSE14500	GSE14500a	GSM362155	GPL8300	linear	raw	NA	RAR	HL60 neutrophil progenitor cells	control	treated with 1µM all-trans retinoid acid	2 h	1 replicate each, part of time series, time respective control
ARR01032	GSE14500	GSE14500a	GSM362143	GPL8300	linear	raw	NA	RAR	HL60 neutrophil progenitor cells	activating	treated with 1µM all-trans retinoid acid	2 h	1 replicate each, part of time series, time respective control
ARR01033	GSE14500	GSE14500b	GSM362156	GPL8300	linear	raw	NA	RAR	HL60 neutrophil progenitor cells	control	treated with 1µM all-trans retinoid acid	4 h	1 replicate each, part of time series, time respective control
ARR01034	GSE14500	GSE14500b	GSM362144	GPL8300	linear	raw	NA	RAR	HL60 neutrophil progenitor cells	activating	treated with 1µM all-trans retinoid acid	4 h	1 replicate each, part of time series, time respective control
ARR01035	GSE14426	GSE14426b	GSM360288	GPL6102	log	normalized	NA	RAR	pancreatic stellate cell line	control	treated with 1µM all-trans retinoid acid	4 h	3 replicates each, part of time series, time resolved controls
ARR01036	GSE14426	GSE14426b	GSM360289	GPL6102	log	normalized	NA	RAR	pancreatic stellate cell line	control	treated with 1µM all-trans retinoid acid	4 h	3 replicates each, part of time series, time resolved controls
ARR01037	GSE14426	GSE14426b	GSM360290	GPL6102	log	normalized	NA	RAR	pancreatic stellate cell line	control	treated with 1µM all-trans retinoid acid	4 h	3 replicates each, part of time series, time resolved controls
ARR01038	GSE14426	GSE14426b	GSM360291	GPL6102	log	normalized	NA	RAR	pancreatic stellate cell line	activating	treated with 1µM all-trans retinoid acid	4 h	3 replicates each, part of time series, time resolved controls
ARR01039	GSE14426	GSE14426b	GSM360292	GPL6102	log	normalized	NA	RAR	pancreatic stellate cell line	activating	treated with 1µM all-trans retinoid acid	4 h	3 replicates each, part of time series, time resolved controls
ARR01040	GSE14426	GSE14426b	GSM360293	GPL6102	log	normalized	NA	RAR	pancreatic stellate cell line	activating	treated with 1µM all-trans retinoid acid	4 h	3 replicates each, part of time series, time resolved controls
ARR01041	GSE22298	GSE22298b	GSM555040	GPL571	log	raw	CELS/GSE22298/GSM555040.CEL	RAR	primary epidermal karatinocytes	control	treated with 1µM all-trans retinoid acid	4 h	1 replicate each, part of time series, time resolved controls
ARR01042	GSE22298	GSE22298b	GSM555045	GPL571	log	raw	CELS/GSE22298/GSM555045.CEL	RAR	primary epidermal karatinocytes	activating	treated with 1µM all-trans retinoid acid	4 h	1 replicate each, part of time series, time resolved controls
ARR01043	GSE24731	GSE24731	GSM609174	GPL4133	linear	raw	NA	RAR	HL60 leukemia cells	control	treated with 100nM retinoid acid	4 h	4 replicates each, contain control vector
ARR01044	GSE24731	GSE24731	GSM609175	GPL4133	linear	raw	NA	RAR	HL60 leukemia cells	control	treated with 100nM retinoid acid	4 h	4 replicates each, contain control vector
ARR01045	GSE24731	GSE24731	GSM609176	GPL4133	linear	raw	NA	RAR	HL60 leukemia cells	control	treated with 100nM retinoid acid	4 h	4 replicates each, contain control vector
ARR01046	GSE24731	GSE24731	GSM609177	GPL4133	linear	raw	NA	RAR	HL60 leukemia cells	control	treated with 100nM retinoid acid	4 h	4 replicates each, contain control vector
ARR01047	GSE24731	GSE24731	GSM609185	GPL4133	linear	raw	NA	RAR	HL60 leukemia cells	activating	treated with 100nM retinoid acid	4 h	4 replicates each, contain control vector
ARR01048	GSE24731	GSE24731	GSM609186	GPL4133	linear	raw	NA	RAR	HL60 leukemia cells	activating	treated with 100nM retinoid acid	4 h	4 replicates each, contain control vector
ARR01049	GSE24731	GSE24731	GSM609187	GPL4133	linear	raw	NA	RAR	HL60 leukemia cells	activating	treated with 100nM retinoid acid	4 h	4 replicates each, contain control vector
ARR01050	GSE24731	GSE24731	GSM609188	GPL4133	linear	raw	NA	RAR	HL60 leukemia cells	activating	treated with 100nM retinoid acid	4 h	4 replicates each, contain control vector
ARR01051	GSE14426	GSE14426a	GSM360282	GPL6102	log	normalized	NA	RAR	pancreatic stellate cell line	control	treated with 1µM all-trans retinoid acid	0.5 h	3 replicates each, part of time series, time resolved controls
ARR01052	GSE14426	GSE14426a	GSM360283	GPL6102	log	normalized	NA	RAR	pancreatic stellate cell line	control	treated with 1µM all-trans retinoid acid	0.5 h	3 replicates each, part of time series, time resolved controls
ARR01053	GSE14426	GSE14426a	GSM360284	GPL6102	log	normalized	NA	RAR	pancreatic stellate cell line	control	treated with 1µM all-trans retinoid acid	0.5 h	3 replicates each, part of time series, time resolved controls
ARR01054	GSE14426	GSE14426a	GSM360285	GPL6102	log	normalized	NA	RAR	pancreatic stellate cell line	activating	treated with 1µM all-trans retinoid acid	0.5 h	3 replicates each, part of time series, time resolved controls
ARR01055	GSE14426	GSE14426a	GSM360286	GPL6102	log	normalized	NA	RAR	pancreatic stellate cell line	activating	treated with 1µM all-trans retinoid acid	0.5 h	3 replicates each, part of time series, time resolved controls
ARR01056	GSE14426	GSE14426a	GSM360287	GPL6102	log	normalized	NA	RAR	pancreatic stellate cell line	activating	treated with 1µM all-trans retinoid acid	0.5 h	3 replicates each, part of time series, time resolved controls
ARR01057	GSE19201	GSE19201	GSM475993	GPL570	log	normalized	CELS/GSE19201/GSM475993.CEL	RAR	NB4 cells	control	treated with all-trans retinoid acid	4 h	1 replicate each
ARR01058	GSE19201	GSE19201	GSM475994	GPL570	log	normalized	CELS/GSE19201/GSM475994.CEL	RAR	NB4 cells	activating	treated with all-trans retinoid acid	4 h	1 replicate each
ARR01059	GSE29213	GSE29213	GSM722534	GPL10332	linear	raw	NA	RAR	NB4 leukemia cells	control	treated with 10nM retinoid acid	4 h	4 replicates each, contain control vector
ARR01060	GSE29213	GSE29213	GSM722535	GPL10332	linear	raw	NA	RAR	NB4 leukemia cells	control	treated with 10nM retinoid acid	4 h	4 replicates each, contain control vector
ARR01061	GSE29213	GSE29213	GSM722536	GPL10332	linear	raw	NA	RAR	NB4 leukemia cells	control	treated with 10nM retinoid acid	4 h	4 replicates each, contain control vector
ARR01062	GSE29213	GSE29213	GSM722537	GPL10332	linear	raw	NA	RAR	NB4 leukemia cells	control	treated with 10nM retinoid acid	4 h	4 replicates each, contain control vector
ARR01063	GSE29213	GSE29213	GSM722538	GPL10332	linear	raw	NA	RAR	NB4 leukemia cells	activating	treated with 10nM retinoid acid	4 h	4 replicates each, contain control vector
ARR01064	GSE29213	GSE29213	GSM722539	GPL10332	linear	raw	NA	RAR	NB4 leukemia cells	activating	treated with 10nM retinoid acid	4 h	4 replicates each, contain control vector
ARR01065	GSE29213	GSE29213	GSM722540	GPL10332	linear	raw	NA	RAR	NB4 leukemia cells	activating	treated with 10nM retinoid acid	4 h	4 replicates each, contain control vector
ARR01066	GSE29213	GSE29213	GSM722541	GPL10332	linear	raw	NA	RAR	NB4 leukemia cells	activating	treated with 10nM retinoid acid	4 h	4 replicates each, contain control vector
ARR01067	GSE22298	GSE22298a	GSM555039	GPL571	log	raw	CELS/GSE22298/GSM555039.CEL	RAR	primary epidermal karatinocytes	control	treated with 1µM all-trans retinoid acid	1 h	1 replicate each, part of time series, time resolved controls
ARR01068	GSE22298	GSE22298a	GSM555044	GPL571	log	raw	CELS/GSE22298/GSM555044.CEL	RAR	primary epidermal karatinocytes	activating	treated with 1µM all-trans retinoid acid	1 h	1 replicate each, part of time series, time resolved controls
ARR01069	GSE6521	GSE6521c	GSM149913	GPL570	linear	raw	CELS/GSE6521/GSM149913.CEL	PI3K	MCF-7 breast cancer cells	control	Treatment with U0126 (MEK inhibitor) + HRG (heregulin ErbB3 Ligand)	1.5 h	besides PI3K also all non Raf Ras targets activated
ARR01070	GSE6521	GSE6521c	GSM149935	GPL570	linear	raw	CELS/GSE6521/GSM149935.CEL	PI3K	MCF-7 breast cancer cells	activating	Treatment with U0126 (MEK inhibitor) + HRG (heregulin ErbB3 Ligand)	1.5 h	besides PI3K also all non Raf Ras targets activated
ARR01071	GSE10086	GSE10086a	GSM254931	GPL571	log	raw	CELS/GSE10086/GSM254931.CEL	PI3K	MDA468 cells	control	treated with PD0325901, MEK inhibitor	8 h	1 replicate each, mainly activating PI3K pathway, 12 different cell lines
ARR01072	GSE10086	GSE10086a	GSM254932	GPL571	log	raw	CELS/GSE10086/GSM254932.CEL	PI3K	MDA468 cells	activating	treated with PD0325901, MEK inhibitor	8 h	1 replicate each, mainly activating PI3K pathway, 12 different cell lines
ARR01073	GSE6521	GSE6521b	GSM149913	GPL570	linear	raw	CELS/GSE6521/GSM149913.CEL	PI3K	MCF-7 breast cancer cells	control	Treatment with U0126 (MEK inhibitor) + HRG (heregulin ErbB3 Ligand)	0.75 h	besides PI3K also all non Raf Ras targets activated
ARR01074	GSE6521	GSE6521b	GSM149933	GPL570	linear	raw	CELS/GSE6521/GSM149933.CEL	PI3K	MCF-7 breast cancer cells	activating	Treatment with U0126 (MEK inhibitor) + HRG (heregulin ErbB3 Ligand)	0.75 h	besides PI3K also all non Raf Ras targets activated
ARR01075	GSE7562	GSE7562b	GSM183436	GPL570	linear	raw	CELS/GSE7562/GSM183436.CEL	PI3K	HCC827	control	PTEN hcRNA knockdown	not specified (until log Phase)	comment
ARR01076	GSE7562	GSE7562b	GSM183437	GPL570	linear	raw	CELS/GSE7562/GSM183437.CEL	PI3K	HCC827	control	PTEN hcRNA knockdown	not specified (until log Phase)	comment
ARR01077	GSE7562	GSE7562b	GSM183438	GPL570	linear	raw	CELS/GSE7562/GSM183438.CEL	PI3K	HCC827	activating	PTEN hcRNA knockdown	not specified (until log Phase)	comment
ARR01078	GSE7562	GSE7562b	GSM183439	GPL570	linear	raw	CELS/GSE7562/GSM183439.CEL	PI3K	HCC827	activating	PTEN hcRNA knockdown	not specified (until log Phase)	comment
ARR01079	GSE7562	GSE7562a	GSM183432	GPL570	linear	raw	CELS/GSE7562/GSM183432.CEL	PI3K	A431	control	PTEN hcRNA knockdown	not specified (until log Phase)	comment
ARR01080	GSE7562	GSE7562a	GSM183433	GPL570	linear	raw	CELS/GSE7562/GSM183433.CEL	PI3K	A431	control	PTEN hcRNA knockdown	not specified (until log Phase)	comment
ARR01081	GSE7562	GSE7562a	GSM183434	GPL570	linear	raw	CELS/GSE7562/GSM183434.CEL	PI3K	A431	activating	PTEN hcRNA knockdown	not specified (until log Phase)	comment
ARR01082	GSE7562	GSE7562a	GSM183435	GPL570	linear	raw	CELS/GSE7562/GSM183435.CEL	PI3K	A431	activating	PTEN hcRNA knockdown	not specified (until log Phase)	comment
ARR01083	GSE26599	GSE26599	GSM654640	GPL570	log	raw	CELS/GSE26599/GSM654640.CEL	PI3K	HB4a cells	control	treated with rapamycin	not indicated	5 replicates each, rapamycin inhibits mTOR --> inhibition of PI3K pathway
ARR01084	GSE26599	GSE26599	GSM654641	GPL570	log	raw	CELS/GSE26599/GSM654641.CEL	PI3K	HB4a cells	control	treated with rapamycin	not indicated	5 replicates each, rapamycin inhibits mTOR --> inhibition of PI3K pathway
ARR01085	GSE26599	GSE26599	GSM654642	GPL570	log	raw	CELS/GSE26599/GSM654642.CEL	PI3K	HB4a cells	control	treated with rapamycin	not indicated	5 replicates each, rapamycin inhibits mTOR --> inhibition of PI3K pathway
ARR01086	GSE26599	GSE26599	GSM654643	GPL570	log	raw	CELS/GSE26599/GSM654643.CEL	PI3K	HB4a cells	control	treated with rapamycin	not indicated	5 replicates each, rapamycin inhibits mTOR --> inhibition of PI3K pathway
ARR01087	GSE26599	GSE26599	GSM654644	GPL570	log	raw	CELS/GSE26599/GSM654644.CEL	PI3K	HB4a cells	control	treated with rapamycin	not indicated	5 replicates each, rapamycin inhibits mTOR --> inhibition of PI3K pathway
ARR01088	GSE26599	GSE26599	GSM654650	GPL570	log	raw	CELS/GSE26599/GSM654650.CEL	PI3K	HB4a cells	inhibiting	treated with rapamycin	not indicated	5 replicates each, rapamycin inhibits mTOR --> inhibition of PI3K pathway
ARR01089	GSE26599	GSE26599	GSM654651	GPL570	log	raw	CELS/GSE26599/GSM654651.CEL	PI3K	HB4a cells	inhibiting	treated with rapamycin	not indicated	5 replicates each, rapamycin inhibits mTOR --> inhibition of PI3K pathway
ARR01090	GSE26599	GSE26599	GSM654652	GPL570	log	raw	CELS/GSE26599/GSM654652.CEL	PI3K	HB4a cells	inhibiting	treated with rapamycin	not indicated	5 replicates each, rapamycin inhibits mTOR --> inhibition of PI3K pathway
ARR01091	GSE26599	GSE26599	GSM654653	GPL570	log	raw	CELS/GSE26599/GSM654653.CEL	PI3K	HB4a cells	inhibiting	treated with rapamycin	not indicated	5 replicates each, rapamycin inhibits mTOR --> inhibition of PI3K pathway
ARR01092	GSE26599	GSE26599	GSM654654	GPL570	log	raw	CELS/GSE26599/GSM654654.CEL	PI3K	HB4a cells	inhibiting	treated with rapamycin	not indicated	5 replicates each, rapamycin inhibits mTOR --> inhibition of PI3K pathway
ARR01093	GSE7403	GSE7403f	GSM178590	GPL96	linear	raw	CELS/GSE7403/GSM178590.CEL	PI3K	SH-SY5Y (Neuroblastoma cells)	control	PDGF treatment with 60 min prior U0126 treatment	2 h	none
ARR01094	GSE7403	GSE7403f	GSM178591	GPL96	linear	raw	CELS/GSE7403/GSM178591.CEL	PI3K	SH-SY5Y (Neuroblastoma cells)	control	PDGF treatment with 60 min prior U0126 treatment	2 h	none
ARR01095	GSE7403	GSE7403f	GSM178586	GPL96	linear	raw	CELS/GSE7403/GSM178586.CEL	PI3K	SH-SY5Y (Neuroblastoma cells)	activating	PDGF treatment with 60 min prior U0126 treatment	2 h	none
ARR01096	GSE7403	GSE7403f	GSM178587	GPL96	linear	raw	CELS/GSE7403/GSM178587.CEL	PI3K	SH-SY5Y (Neuroblastoma cells)	activating	PDGF treatment with 60 min prior U0126 treatment	2 h	none
ARR01097	GSE10086	GSE10086h	GSM254945	GPL571	log	raw	CELS/GSE10086/GSM254945.CEL	PI3K	MALME3M cells	control	treated with PD0325901, MEK inhibitor	8 h	1 replicate each, mainly activating PI3K pathway, 12 different cell lines
ARR01098	GSE10086	GSE10086h	GSM254946	GPL571	log	raw	CELS/GSE10086/GSM254946.CEL	PI3K	MALME3M cells	activating	treated with PD0325901, MEK inhibitor	8 h	1 replicate each, mainly activating PI3K pathway, 12 different cell lines
ARR01099	GSE10086	GSE10086i	GSM254947	GPL571	log	raw	CELS/GSE10086/GSM254947.CEL	PI3K	SKMEL1 cells	control	treated with PD0325901, MEK inhibitor	8 h	1 replicate each, mainly activating PI3K pathway, 12 different cell lines
ARR01100	GSE10086	GSE10086i	GSM254948	GPL571	log	raw	CELS/GSE10086/GSM254948.CEL	PI3K	SKMEL1 cells	activating	treated with PD0325901, MEK inhibitor	8 h	1 replicate each, mainly activating PI3K pathway, 12 different cell lines
ARR01101	GSE7403	GSE7403b	GSM178575	GPL96	linear	raw	CELS/GSE7403/GSM178575.CEL	PI3K	SH-SY5Y (Neuroblastoma cells)	control	PDGF treatment with 60 min prior U0126 treatment	0.5 h	none
ARR01102	GSE7403	GSE7403b	GSM178576	GPL96	linear	raw	CELS/GSE7403/GSM178576.CEL	PI3K	SH-SY5Y (Neuroblastoma cells)	control	PDGF treatment with 60 min prior U0126 treatment	0.5 h	none
ARR01103	GSE7403	GSE7403b	GSM178571	GPL96	linear	raw	CELS/GSE7403/GSM178571.CEL	PI3K	SH-SY5Y (Neuroblastoma cells)	activating	PDGF treatment with 60 min prior U0126 treatment	0.5 h	none
ARR01104	GSE7403	GSE7403b	GSM178572	GPL96	linear	raw	CELS/GSE7403/GSM178572.CEL	PI3K	SH-SY5Y (Neuroblastoma cells)	activating	PDGF treatment with 60 min prior U0126 treatment	0.5 h	none
ARR01105	GSE10086	GSE10086d	GSM254937	GPL571	log	raw	CELS/GSE10086/GSM254937.CEL	PI3K	BT474 cells	control	treated with PD0325901, MEK inhibitor	8 h	1 replicate each, mainly activating PI3K pathway, 12 different cell lines
ARR01106	GSE10086	GSE10086d	GSM254938	GPL571	log	raw	CELS/GSE10086/GSM254938.CEL	PI3K	BT474 cells	activating	treated with PD0325901, MEK inhibitor	8 h	1 replicate each, mainly activating PI3K pathway, 12 different cell lines
ARR01107	GSE10086	GSE10086b	GSM254933	GPL571	log	raw	CELS/GSE10086/GSM254933.CEL	PI3K	H1650 cells	control	treated with PD0325901, MEK inhibitor	8 h	1 replicate each, mainly activating PI3K pathway, 12 different cell lines
ARR01108	GSE10086	GSE10086b	GSM254934	GPL571	log	raw	CELS/GSE10086/GSM254934.CEL	PI3K	H1650 cells	activating	treated with PD0325901, MEK inhibitor	8 h	1 replicate each, mainly activating PI3K pathway, 12 different cell lines
ARR01109	GSE10086	GSE10086f	GSM254941	GPL571	log	raw	CELS/GSE10086/GSM254941.CEL	PI3K	COLO205 cells	control	treated with PD0325901, MEK inhibitor	8 h	1 replicate each, mainly activating PI3K pathway, 12 different cell lines
ARR01110	GSE10086	GSE10086f	GSM254942	GPL571	log	raw	CELS/GSE10086/GSM254942.CEL	PI3K	COLO205 cells	activating	treated with PD0325901, MEK inhibitor	8 h	1 replicate each, mainly activating PI3K pathway, 12 different cell lines
ARR01111	GSE3737	GSE3737	GSM86082	GPL96	linear	raw	CELS/GSE3737/GSM86082.CEL	PI3K	PC3 (prostate cancer cell)	control	treatment with arachidonic acid (AA) should activate PI3K	2 h	none
ARR01112	GSE3737	GSE3737	GSM86085	GPL96	linear	raw	CELS/GSE3737/GSM86085.CEL	PI3K	PC3 (prostate cancer cell)	activating	treatment with arachidonic acid (AA) should activate PI3K	2 h	none
ARR01113	GSE3737	GSE3737	GSM86086	GPL96	linear	raw	CELS/GSE3737/GSM86086.CEL	PI3K	PC3 (prostate cancer cell)	activating	treatment with arachidonic acid (AA) should activate PI3K	2 h	none
ARR01114	GSE10086	GSE10086k	GSM254951	GPL571	log	raw	CELS/GSE10086/GSM254951.CEL	PI3K	SKMEL19 cells	control	treated with PD0325901, MEK inhibitor	8 h	1 replicate each, mainly activating PI3K pathway, 12 different cell lines
ARR01115	GSE10086	GSE10086k	GSM254952	GPL571	log	raw	CELS/GSE10086/GSM254952.CEL	PI3K	SKMEL19 cells	activating	treated with PD0325901, MEK inhibitor	8 h	1 replicate each, mainly activating PI3K pathway, 12 different cell lines
ARR01116	GSE14934	GSE14934c	GSM373089	GPL571	linear	raw	CELS/GSE14934/GSM373089.CEL	PI3K	HEK-HT (kidney)	control	Ras (G12V,Y40C) activation mutants	not specified	mutants said to be mostly activating PI3K
ARR01117	GSE14934	GSE14934c	GSM373094	GPL571	linear	raw	CELS/GSE14934/GSM373094.CEL	PI3K	HEK-HT (kidney)	control	Ras (G12V,Y40C) activation mutants	not specified	mutants said to be mostly activating PI3K
ARR01118	GSE14934	GSE14934c	GSM373099	GPL571	linear	raw	CELS/GSE14934/GSM373099.CEL	PI3K	HEK-HT (kidney)	control	Ras (G12V,Y40C) activation mutants	not specified	mutants said to be mostly activating PI3K
ARR01119	GSE14934	GSE14934c	GSM373104	GPL571	linear	raw	CELS/GSE14934/GSM373104.CEL	PI3K	HEK-HT (kidney)	control	Ras (G12V,Y40C) activation mutants	not specified	mutants said to be mostly activating PI3K
ARR01120	GSE14934	GSE14934c	GSM373109	GPL571	linear	raw	CELS/GSE14934/GSM373109.CEL	PI3K	HEK-HT (kidney)	control	Ras (G12V,Y40C) activation mutants	not specified	mutants said to be mostly activating PI3K
ARR01121	GSE14934	GSE14934c	GSM373093	GPL571	linear	raw	CELS/GSE14934/GSM373093.CEL	PI3K	HEK-HT (kidney)	activating	Ras (G12V,Y40C) activation mutants	not specified	mutants said to be mostly activating PI3K
ARR01122	GSE14934	GSE14934c	GSM373098	GPL571	linear	raw	CELS/GSE14934/GSM373098.CEL	PI3K	HEK-HT (kidney)	activating	Ras (G12V,Y40C) activation mutants	not specified	mutants said to be mostly activating PI3K
ARR01123	GSE14934	GSE14934c	GSM373103	GPL571	linear	raw	CELS/GSE14934/GSM373103.CEL	PI3K	HEK-HT (kidney)	activating	Ras (G12V,Y40C) activation mutants	not specified	mutants said to be mostly activating PI3K
ARR01124	GSE14934	GSE14934c	GSM373108	GPL571	linear	raw	CELS/GSE14934/GSM373108.CEL	PI3K	HEK-HT (kidney)	activating	Ras (G12V,Y40C) activation mutants	not specified	mutants said to be mostly activating PI3K
ARR01125	GSE14934	GSE14934c	GSM373113	GPL571	linear	raw	CELS/GSE14934/GSM373113.CEL	PI3K	HEK-HT (kidney)	activating	Ras (G12V,Y40C) activation mutants	not specified	mutants said to be mostly activating PI3K
ARR01126	GSE10086	GSE10086g	GSM254943	GPL571	log	raw	CELS/GSE10086/GSM254943.CEL	PI3K	HT29 cells	control	treated with PD0325901, MEK inhibitor	8 h	1 replicate each, mainly activating PI3K pathway, 12 different cell lines
ARR01127	GSE10086	GSE10086g	GSM254944	GPL571	log	raw	CELS/GSE10086/GSM254944.CEL	PI3K	HT29 cells	activating	treated with PD0325901, MEK inhibitor	8 h	1 replicate each, mainly activating PI3K pathway, 12 different cell lines
ARR01128	GSE17785	GSE17785b	GSM443978	GPL570	log	normalized	CELS/GSE17785/GSM443978.CEL	PI3K	MCF10A cells	control	treated with GDC-0941. a PI3K inhibitor	4 h	3 replicates each
ARR01129	GSE17785	GSE17785b	GSM443979	GPL570	log	normalized	CELS/GSE17785/GSM443979.CEL	PI3K	MCF10A cells	control	treated with GDC-0941. a PI3K inhibitor	4 h	3 replicates each
ARR01130	GSE17785	GSE17785b	GSM443980	GPL570	log	normalized	CELS/GSE17785/GSM443980.CEL	PI3K	MCF10A cells	control	treated with GDC-0941. a PI3K inhibitor	4 h	3 replicates each
ARR01131	GSE17785	GSE17785b	GSM443981	GPL570	log	normalized	CELS/GSE17785/GSM443981.CEL	PI3K	MCF10A cells	inhibiting	treated with GDC-0941. a PI3K inhibitor	4 h	3 replicates each
ARR01132	GSE17785	GSE17785b	GSM443982	GPL570	log	normalized	CELS/GSE17785/GSM443982.CEL	PI3K	MCF10A cells	inhibiting	treated with GDC-0941. a PI3K inhibitor	4 h	3 replicates each
ARR01133	GSE17785	GSE17785b	GSM443983	GPL570	log	normalized	CELS/GSE17785/GSM443983.CEL	PI3K	MCF10A cells	inhibiting	treated with GDC-0941. a PI3K inhibitor	4 h	3 replicates each
ARR01134	GSE17785	GSE17785a	GSM443978	GPL570	log	normalized	CELS/GSE17785/GSM443978.CEL	PI3K	MCF10A cells	control	PI3K activated mutants	not indicated	3 replicates each
ARR01135	GSE17785	GSE17785a	GSM443979	GPL570	log	normalized	CELS/GSE17785/GSM443979.CEL	PI3K	MCF10A cells	control	PI3K activated mutants	not indicated	3 replicates each
ARR01136	GSE17785	GSE17785a	GSM443980	GPL570	log	normalized	CELS/GSE17785/GSM443980.CEL	PI3K	MCF10A cells	control	PI3K activated mutants	not indicated	3 replicates each
ARR01137	GSE17785	GSE17785a	GSM443984	GPL570	log	normalized	CELS/GSE17785/GSM443984.CEL	PI3K	MCF10A cells	activating	PI3K activated mutants	not indicated	3 replicates each
ARR01138	GSE17785	GSE17785a	GSM443985	GPL570	log	normalized	CELS/GSE17785/GSM443985.CEL	PI3K	MCF10A cells	activating	PI3K activated mutants	not indicated	3 replicates each
ARR01139	GSE17785	GSE17785a	GSM443986	GPL570	log	normalized	CELS/GSE17785/GSM443986.CEL	PI3K	MCF10A cells	activating	PI3K activated mutants	not indicated	3 replicates each
ARR01140	GSE7562	GSE7562c	GSM183440	GPL570	linear	raw	CELS/GSE7562/GSM183440.CEL	PI3K	SKBR3	control	PTEN hcRNA knockdown	not specified (until log Phase)	none
ARR01141	GSE7562	GSE7562c	GSM183441	GPL570	linear	raw	CELS/GSE7562/GSM183441.CEL	PI3K	SKBR3	control	PTEN hcRNA knockdown	not specified (until log Phase)	none
ARR01142	GSE7562	GSE7562c	GSM183442	GPL570	linear	raw	CELS/GSE7562/GSM183442.CEL	PI3K	SKBR3	activating	PTEN hcRNA knockdown	not specified (until log Phase)	none
ARR01143	GSE7562	GSE7562c	GSM183443	GPL570	linear	raw	CELS/GSE7562/GSM183443.CEL	PI3K	SKBR3	activating	PTEN hcRNA knockdown	not specified (until log Phase)	none
ARR01144	GSE10086	GSE10086c	GSM254935	GPL571	log	raw	CELS/GSE10086/GSM254935.CEL	PI3K	A431 cells	control	treated with PD0325901, MEK inhibitor	8 h	1 replicate each, mainly activating PI3K pathway, 12 different cell lines
ARR01145	GSE10086	GSE10086c	GSM254936	GPL571	log	raw	CELS/GSE10086/GSM254936.CEL	PI3K	A431 cells	activating	treated with PD0325901, MEK inhibitor	8 h	1 replicate each, mainly activating PI3K pathway, 12 different cell lines
ARR01146	GSE10086	GSE10086l	GSM254953	GPL571	log	raw	CELS/GSE10086/GSM254953.CEL	PI3K	SKMEL28 cells	control	treated with PD0325901, MEK inhibitor	8 h	1 replicate each, mainly activating PI3K pathway, 12 different cell lines
ARR01147	GSE10086	GSE10086l	GSM254954	GPL571	log	raw	CELS/GSE10086/GSM254954.CEL	PI3K	SKMEL28 cells	activating	treated with PD0325901, MEK inhibitor	8 h	1 replicate each, mainly activating PI3K pathway, 12 different cell lines
ARR01148	GSE10086	GSE10086e	GSM254939	GPL571	log	raw	CELS/GSE10086/GSM254939.CEL	PI3K	SKBR3 cells	control	treated with PD0325901, MEK inhibitor	8 h	1 replicate each, mainly activating PI3K pathway, 12 different cell lines
ARR01149	GSE10086	GSE10086e	GSM254940	GPL571	log	raw	CELS/GSE10086/GSM254940.CEL	PI3K	SKBR3 cells	activating	treated with PD0325901, MEK inhibitor	8 h	1 replicate each, mainly activating PI3K pathway, 12 different cell lines
ARR01150	GSE7403	GSE7403h	GSM178606	GPL96	linear	raw	CELS/GSE7403/GSM178606.CEL	PI3K	SH-SY5Y (Neuroblastoma cells)	control	PDGF treatment with 60 min prior U0126 treatment	4 h	none
ARR01151	GSE7403	GSE7403h	GSM178607	GPL96	linear	raw	CELS/GSE7403/GSM178607.CEL	PI3K	SH-SY5Y (Neuroblastoma cells)	control	PDGF treatment with 60 min prior U0126 treatment	4 h	none
ARR01152	GSE7403	GSE7403h	GSM178602	GPL96	linear	raw	CELS/GSE7403/GSM178602.CEL	PI3K	SH-SY5Y (Neuroblastoma cells)	activating	PDGF treatment with 60 min prior U0126 treatment	4 h	none
ARR01153	GSE7403	GSE7403h	GSM178603	GPL96	linear	raw	CELS/GSE7403/GSM178603.CEL	PI3K	SH-SY5Y (Neuroblastoma cells)	activating	PDGF treatment with 60 min prior U0126 treatment	4 h	none
ARR01154	GSE7403	GSE7403d	GSM178583	GPL96	linear	raw	CELS/GSE7403/GSM178583.CEL	PI3K	SH-SY5Y (Neuroblastoma cells)	control	PDGF treatment with 60 min prior U0126 treatment	1 h	none
ARR01155	GSE7403	GSE7403d	GSM178579	GPL96	linear	raw	CELS/GSE7403/GSM178579.CEL	PI3K	SH-SY5Y (Neuroblastoma cells)	activating	PDGF treatment with 60 min prior U0126 treatment	1 h	none
ARR01156	GSE7403	GSE7403d	GSM178580	GPL96	linear	raw	CELS/GSE7403/GSM178580.CEL	PI3K	SH-SY5Y (Neuroblastoma cells)	activating	PDGF treatment with 60 min prior U0126 treatment	1 h	none
ARR01157	GSE10086	GSE10086j	GSM254949	GPL571	log	raw	CELS/GSE10086/GSM254949.CEL	PI3K	SKMEL5 cells	control	treated with PD0325901, MEK inhibitor	8 h	1 replicate each, mainly activating PI3K pathway, 12 different cell lines
ARR01158	GSE10086	GSE10086j	GSM254950	GPL571	log	raw	CELS/GSE10086/GSM254950.CEL	PI3K	SKMEL5 cells	activating	treated with PD0325901, MEK inhibitor	8 h	1 replicate each, mainly activating PI3K pathway, 12 different cell lines
ARR01159	GSE9988	GSE9988j	GSM252476	GPL570	linear	raw	CELS/GSE9988/GSM252476.CEL	NFkB	Human monocytes (donor 11)	control	treated with LPS	2 h	10 anonymous donors in this set
ARR01160	GSE9988	GSE9988j	GSM252453	GPL570	linear	raw	CELS/GSE9988/GSM252453.CEL	NFkB	Human monocytes (donor 11)	activating	treated with LPS	2 h	10 anonymous donors in this set
ARR01161	GSE3037	GSE3037e	GSM66871	GPL96	log	raw	NA	NFkB	primary periphal blood neutrophils	control	treated with LPS	1 h	1 replicate each, 8 individuals
ARR01162	GSE3037	GSE3037e	GSM66887	GPL96	log	raw	NA	NFkB	primary periphal blood neutrophils	activating	treated with LPS	1 h	1 replicate each, 8 individuals
ARR01163	GSE3491	GSE3491a	GSM78606	GPL8300	log	raw	NA	NFkB	GENDER: MALE TISSUE: WHOLE BLOOD LPS RESPONSE: HIGH	control	treated with LPS 10 NG/ML	4 h	three patients with high LPS response rate
ARR01164	GSE3491	GSE3491a	GSM78607	GPL8300	log	raw	NA	NFkB	GENDER: MALE TISSUE: WHOLE BLOOD LPS RESPONSE: HIGH	activating	treated with LPS 10 NG/ML	4 h	three patients with high LPS response rate
ARR01165	GSE4748	GSE4748	GSM107453	GPL570	log	raw	NA	NFkB	Monocyte derived dendritic cells	control	treated with LPS 0.5 g/ml	3 h	comment
ARR01166	GSE4748	GSE4748	GSM107458	GPL570	log	raw	NA	NFkB	Monocyte derived dendritic cells	control	treated with LPS 0.5 g/ml	3 h	comment
ARR01167	GSE4748	GSE4748	GSM107455	GPL570	log	raw	NA	NFkB	Monocyte derived dendritic cells	activating	treated with LPS 0.5 g/ml	3 h	comment
ARR01168	GSE4748	GSE4748	GSM107460	GPL570	log	raw	NA	NFkB	Monocyte derived dendritic cells	activating	treated with LPS 0.5 g/ml	3 h	comment
ARR01169	GSE8190	GSE8190a	GSM202420	GPL1708	linear	raw	NA	NFkB	epithelial cells	control	treated with LPS	4 h	2 replicates each, 14 individuals
ARR01170	GSE8190	GSE8190a	GSM202421	GPL1708	linear	raw	NA	NFkB	epithelial cells	control	treated with LPS	4 h	2 replicates each, 14 individuals
ARR01171	GSE8190	GSE8190a	GSM202416	GPL1708	linear	raw	NA	NFkB	epithelial cells	activating	treated with LPS	4 h	2 replicates each, 14 individuals
ARR01172	GSE8190	GSE8190a	GSM202417	GPL1708	linear	raw	NA	NFkB	epithelial cells	activating	treated with LPS	4 h	2 replicates each, 14 individuals
ARR01173	GSE22248	GSE22248c	GSM553742	GPL6883	log	normalized	NA	NFkB	PBMCs	control	treated with LPS	4 h	1 replicates each, 4 individuals
ARR01174	GSE22248	GSE22248c	GSM553743	GPL6883	log	normalized	NA	NFkB	PBMCs	activating	treated with LPS	4 h	1 replicates each, 4 individuals
ARR01175	GSE8190	GSE8190g	GSM202486	GPL1708	linear	raw	NA	NFkB	epithelial cells	control	treated with LPS	4 h	2 replicates each, 14 individuals
ARR01176	GSE8190	GSE8190g	GSM202487	GPL1708	linear	raw	NA	NFkB	epithelial cells	control	treated with LPS	4 h	2 replicates each, 14 individuals
ARR01177	GSE8190	GSE8190g	GSM202482	GPL1708	linear	raw	NA	NFkB	epithelial cells	activating	treated with LPS	4 h	2 replicates each, 14 individuals
ARR01178	GSE8190	GSE8190g	GSM202483	GPL1708	linear	raw	NA	NFkB	epithelial cells	activating	treated with LPS	4 h	2 replicates each, 14 individuals
ARR01179	GSE20114	GSE20114d	GSM502615	GPL570	linear	raw	NA	NFkB	primary blood cells	control	treated with LPS	4 h	1 replicate each, 4 donors
ARR01180	GSE20114	GSE20114d	GSM502623	GPL570	linear	raw	NA	NFkB	primary blood cells	activating	treated with LPS	4 h	1 replicate each, 4 donors
ARR01181	GSE16193	GSE16193	GSM406482	GPL570	log	raw	CELS/GSE16193/GSM406482.CEL	NFkB	THP1 monocytic cell line	control	treated with  1 µg/ml LPS	1 h	5 replicates each
ARR01182	GSE16193	GSE16193	GSM406483	GPL570	log	raw	CELS/GSE16193/GSM406483.CEL	NFkB	THP1 monocytic cell line	control	treated with  1 µg/ml LPS	1 h	5 replicates each
ARR01183	GSE16193	GSE16193	GSM406484	GPL570	log	raw	CELS/GSE16193/GSM406484.CEL	NFkB	THP1 monocytic cell line	control	treated with  1 µg/ml LPS	1 h	5 replicates each
ARR01184	GSE16193	GSE16193	GSM406485	GPL570	log	raw	CELS/GSE16193/GSM406485.CEL	NFkB	THP1 monocytic cell line	control	treated with  1 µg/ml LPS	1 h	5 replicates each
ARR01185	GSE16193	GSE16193	GSM406486	GPL570	log	raw	CELS/GSE16193/GSM406486.CEL	NFkB	THP1 monocytic cell line	control	treated with  1 µg/ml LPS	1 h	5 replicates each
ARR01186	GSE16193	GSE16193	GSM406497	GPL570	log	raw	CELS/GSE16193/GSM406497.CEL	NFkB	THP1 monocytic cell line	activating	treated with  1 µg/ml LPS	1 h	5 replicates each
ARR01187	GSE16193	GSE16193	GSM406498	GPL570	log	raw	CELS/GSE16193/GSM406498.CEL	NFkB	THP1 monocytic cell line	activating	treated with  1 µg/ml LPS	1 h	5 replicates each
ARR01188	GSE16193	GSE16193	GSM406499	GPL570	log	raw	CELS/GSE16193/GSM406499.CEL	NFkB	THP1 monocytic cell line	activating	treated with  1 µg/ml LPS	1 h	5 replicates each
ARR01189	GSE16193	GSE16193	GSM406500	GPL570	log	raw	CELS/GSE16193/GSM406500.CEL	NFkB	THP1 monocytic cell line	activating	treated with  1 µg/ml LPS	1 h	5 replicates each
ARR01190	GSE16193	GSE16193	GSM406501	GPL570	log	raw	CELS/GSE16193/GSM406501.CEL	NFkB	THP1 monocytic cell line	activating	treated with  1 µg/ml LPS	1 h	5 replicates each
ARR01191	GSE14000	GSE14000c	GSM351537	GPL570	log	raw	CELS/GSE14000/GSM351537.CEL	NFkB	primary blood cells	control	treated with LPS	4 h	1 replicate each, 4 donors
ARR01192	GSE14000	GSE14000c	GSM351539	GPL570	log	raw	CELS/GSE14000/GSM351539.CEL	NFkB	primary blood cells	activating	treated with LPS	4 h	1 replicate each, 4 donors
ARR01193	GSE3982	GSE3982	GSM90838	GPL96	log	raw	NA	NFkB	macrophages derived from monocytes	control	treated with LPS	4 h	2 replicates each
ARR01194	GSE3982	GSE3982	GSM90839	GPL96	log	raw	NA	NFkB	macrophages derived from monocytes	control	treated with LPS	4 h	2 replicates each
ARR01195	GSE3982	GSE3982	GSM90840	GPL96	log	raw	NA	NFkB	macrophages derived from monocytes	activating	treated with LPS	4 h	2 replicates each
ARR01196	GSE3982	GSE3982	GSM90841	GPL96	log	raw	NA	NFkB	macrophages derived from monocytes	activating	treated with LPS	4 h	2 replicates each
ARR01197	GSE19738	GSE19738x	GSM492873	GPL6848	linear	raw	NA	NFkB	whole blood cells	control	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01198	GSE19738	GSE19738x	GSM492940	GPL6848	linear	raw	NA	NFkB	whole blood cells	activating	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01199	GSE19738	GSE19738b	GSM492851	GPL6848	linear	raw	NA	NFkB	whole blood cells	control	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01200	GSE19738	GSE19738b	GSM492918	GPL6848	linear	raw	NA	NFkB	whole blood cells	activating	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01201	GSE3037	GSE3037h	GSM66874	GPL96	log	raw	NA	NFkB	primary periphal blood neutrophils	control	treated with LPS	1 h	1 replicate each, 8 individuals
ARR01202	GSE3037	GSE3037h	GSM66890	GPL96	log	raw	NA	NFkB	primary periphal blood neutrophils	activating	treated with LPS	1 h	1 replicate each, 8 individuals
ARR01203	GSE19738	GSE19738j	GSM492859	GPL6848	linear	raw	NA	NFkB	whole blood cells	control	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01204	GSE19738	GSE19738j	GSM492926	GPL6848	linear	raw	NA	NFkB	whole blood cells	activating	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01205	GSE19738	GSE19738v	GSM492871	GPL6848	linear	raw	NA	NFkB	whole blood cells	control	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01206	GSE19738	GSE19738v	GSM492938	GPL6848	linear	raw	NA	NFkB	whole blood cells	activating	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01207	GSE9988	GSE9988d	GSM252479	GPL570	linear	raw	CELS/GSE9988/GSM252479.CEL	NFkB	Human monocytes (donor 4)	control	treated with LPS	2 h	10 anonymous donors in this set
ARR01208	GSE9988	GSE9988d	GSM252444	GPL570	linear	raw	CELS/GSE9988/GSM252444.CEL	NFkB	Human monocytes (donor 4)	activating	treated with LPS	2 h	10 anonymous donors in this set
ARR01209	GSE8190	GSE8190i	GSM202516	GPL1708	linear	raw	NA	NFkB	epithelial cells	control	treated with LPS	4 h	2 replicates each, 14 individuals
ARR01210	GSE8190	GSE8190i	GSM202517	GPL1708	linear	raw	NA	NFkB	epithelial cells	control	treated with LPS	4 h	2 replicates each, 14 individuals
ARR01211	GSE8190	GSE8190i	GSM202512	GPL1708	linear	raw	NA	NFkB	epithelial cells	activating	treated with LPS	4 h	2 replicates each, 14 individuals
ARR01212	GSE8190	GSE8190i	GSM202513	GPL1708	linear	raw	NA	NFkB	epithelial cells	activating	treated with LPS	4 h	2 replicates each, 14 individuals
ARR01213	GSE2396	GSE2396	GSM45116	GPL571	log	raw	CELS/GSE2396/GSM45116.CEL	NFkB	human gammadelta T cells	control	treated with LPS	4 h	4 cell cultures pooled
ARR01214	GSE2396	GSE2396	GSM45117	GPL571	log	raw	CELS/GSE2396/GSM45117.CEL	NFkB	human gammadelta T cells	activating	treated with LPS	4 h	4 cell cultures pooled
ARR01215	GSE3037	GSE3037b	GSM66868	GPL96	log	raw	NA	NFkB	primary periphal blood neutrophils	control	treated with LPS	1 h	1 replicate each, 8 individuals
ARR01216	GSE3037	GSE3037b	GSM66884	GPL96	log	raw	NA	NFkB	primary periphal blood neutrophils	activating	treated with LPS	1 h	1 replicate each, 8 individuals
ARR01217	GSE3037	GSE3037f	GSM66872	GPL96	log	raw	NA	NFkB	primary periphal blood neutrophils	control	treated with LPS	1 h	1 replicate each, 8 individuals
ARR01218	GSE3037	GSE3037f	GSM66888	GPL96	log	raw	NA	NFkB	primary periphal blood neutrophils	activating	treated with LPS	1 h	1 replicate each, 8 individuals
ARR01219	GSE19738	GSE19738n	GSM492863	GPL6848	linear	raw	NA	NFkB	whole blood cells	control	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01220	GSE19738	GSE19738n	GSM492930	GPL6848	linear	raw	NA	NFkB	whole blood cells	activating	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01221	GSE23371	GSE23371	GSM573357	GPL570	linear	raw	CELS/GSE23371/GSM573357.CEL	NFkB	dendritic cells	control	treated with LPS	6 h	3 technical replicates each
ARR01222	GSE23371	GSE23371	GSM573358	GPL570	linear	raw	CELS/GSE23371/GSM573358.CEL	NFkB	dendritic cells	control	treated with LPS	6 h	3 technical replicates each
ARR01223	GSE23371	GSE23371	GSM573359	GPL570	linear	raw	CELS/GSE23371/GSM573359.CEL	NFkB	dendritic cells	control	treated with LPS	6 h	3 technical replicates each
ARR01224	GSE23371	GSE23371	GSM573360	GPL570	linear	raw	CELS/GSE23371/GSM573360.CEL	NFkB	dendritic cells	activating	treated with LPS	6 h	3 technical replicates each
ARR01225	GSE23371	GSE23371	GSM573361	GPL570	linear	raw	CELS/GSE23371/GSM573361.CEL	NFkB	dendritic cells	activating	treated with LPS	6 h	3 technical replicates each
ARR01226	GSE23371	GSE23371	GSM573362	GPL570	linear	raw	CELS/GSE23371/GSM573362.CEL	NFkB	dendritic cells	activating	treated with LPS	6 h	3 technical replicates each
ARR01227	GSE1541	GSE1541bNFkB	GSM26479	GPL201	linear	raw	NA	NFkB	A549 (Alveolar Epithelial Cells line)	control	treated with LPS	4 h	comment
ARR01228	GSE1541	GSE1541bNFkB	GSM26480	GPL201	linear	raw	NA	NFkB	A549 (Alveolar Epithelial Cells line)	control	treated with LPS	4 h	comment
ARR01229	GSE1541	GSE1541bNFkB	GSM26483	GPL201	linear	raw	NA	NFkB	A549 (Alveolar Epithelial Cells line)	activating	treated with LPS	4 h	comment
ARR01230	GSE1541	GSE1541bNFkB	GSM26484	GPL201	linear	raw	NA	NFkB	A549 (Alveolar Epithelial Cells line)	activating	treated with LPS	4 h	comment
ARR01231	GSE9988	GSE9988c	GSM252480	GPL570	linear	raw	CELS/GSE9988/GSM252480.CEL	NFkB	Human monocytes (donor 3)	control	treated with LPS	2 h	10 anonymous donors in this set
ARR01232	GSE9988	GSE9988c	GSM252447	GPL570	linear	raw	CELS/GSE9988/GSM252447.CEL	NFkB	Human monocytes (donor 3)	activating	treated with LPS	2 h	10 anonymous donors in this set
ARR01233	GSE19738	GSE19738a9	GSM492883	GPL6848	linear	raw	NA	NFkB	whole blood cells	control	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01234	GSE19738	GSE19738a9	GSM492950	GPL6848	linear	raw	NA	NFkB	whole blood cells	activating	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01235	GSE5504	GSE5504a	GSM126988	GPL570	log	raw	NA	NFkB	human peripheral blood derived monocytes	control	treated with LPS	2 h	comment
ARR01236	GSE5504	GSE5504a	GSM126993	GPL570	log	raw	NA	NFkB	human peripheral blood derived monocytes	control	treated with LPS	2 h	comment
ARR01237	GSE5504	GSE5504a	GSM126994	GPL570	log	raw	NA	NFkB	human peripheral blood derived monocytes	activating	treated with LPS	2 h	comment
ARR01238	GSE5504	GSE5504a	GSM126995	GPL570	log	raw	NA	NFkB	human peripheral blood derived monocytes	activating	treated with LPS	2 h	comment
ARR01239	GSE32390	GSE32390cNFkB	GSM801681	GPL10558	log	normalized	NA	NFkB	fibroblasts	control	treated with poly I:C	4 h	1 replicate each, 3 individuals
ARR01240	GSE32390	GSE32390cNFkB	GSM801674	GPL10558	log	normalized	NA	NFkB	fibroblasts	activating	treated with poly I:C	4 h	1 replicate each, 3 individuals
ARR01241	GSE19627	GSE19627	GSM489343	GPL570	linear	raw	CELS/GSE19627/GSM489343.CEL	NFkB	THP1 monocytes	control	treated with  LPS	4 h	3 replicates each
ARR01242	GSE19627	GSE19627	GSM489344	GPL570	linear	raw	CELS/GSE19627/GSM489344.CEL	NFkB	THP1 monocytes	control	treated with  LPS	4 h	3 replicates each
ARR01243	GSE19627	GSE19627	GSM489345	GPL570	linear	raw	CELS/GSE19627/GSM489345.CEL	NFkB	THP1 monocytes	control	treated with  LPS	4 h	3 replicates each
ARR01244	GSE19627	GSE19627	GSM489337	GPL570	linear	raw	CELS/GSE19627/GSM489337.CEL	NFkB	THP1 monocytes	activating	treated with  LPS	4 h	3 replicates each
ARR01245	GSE19627	GSE19627	GSM489338	GPL570	linear	raw	CELS/GSE19627/GSM489338.CEL	NFkB	THP1 monocytes	activating	treated with  LPS	4 h	3 replicates each
ARR01246	GSE19627	GSE19627	GSM489339	GPL570	linear	raw	CELS/GSE19627/GSM489339.CEL	NFkB	THP1 monocytes	activating	treated with  LPS	4 h	3 replicates each
ARR01247	GSE14419	GSE14419b	GSM360143	GPL571	log	raw	CELS/GSE14419/GSM360143.CEL	NFkB	primary macrophages	control	treated with zymosan A	3 h	1 replicate each, 4 donors
ARR01248	GSE14419	GSE14419b	GSM360145	GPL571	log	raw	CELS/GSE14419/GSM360145.CEL	NFkB	primary macrophages	activating	treated with zymosan A	3 h	1 replicate each, 4 donors
ARR01249	GSE8190	GSE8190f	GSM202476	GPL1708	linear	raw	NA	NFkB	epithelial cells	control	treated with LPS	4 h	2 replicates each, 14 individuals
ARR01250	GSE8190	GSE8190f	GSM202477	GPL1708	linear	raw	NA	NFkB	epithelial cells	control	treated with LPS	4 h	2 replicates each, 14 individuals
ARR01251	GSE8190	GSE8190f	GSM202472	GPL1708	linear	raw	NA	NFkB	epithelial cells	activating	treated with LPS	4 h	2 replicates each, 14 individuals
ARR01252	GSE8190	GSE8190f	GSM202473	GPL1708	linear	raw	NA	NFkB	epithelial cells	activating	treated with LPS	4 h	2 replicates each, 14 individuals
ARR01253	GSE19738	GSE19738i	GSM492858	GPL6848	linear	raw	NA	NFkB	whole blood cells	control	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01254	GSE19738	GSE19738i	GSM492925	GPL6848	linear	raw	NA	NFkB	whole blood cells	activating	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01255	GSE3037	GSE3037a	GSM66867	GPL96	log	raw	NA	NFkB	primary periphal blood neutrophils	control	treated with LPS	1 h	1 replicate each, 8 individuals
ARR01256	GSE3037	GSE3037a	GSM66884	GPL96	log	raw	NA	NFkB	primary periphal blood neutrophils	activating	treated with LPS	1 h	1 replicate each, 8 individuals
ARR01257	GSE19738	GSE19738s	GSM492868	GPL6848	linear	raw	NA	NFkB	whole blood cells	control	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01258	GSE19738	GSE19738s	GSM492935	GPL6848	linear	raw	NA	NFkB	whole blood cells	activating	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01259	GSE32390	GSE32390bNFkB	GSM801680	GPL10558	log	normalized	NA	NFkB	fibroblasts	control	treated with poly I:C	4 h	1 replicate each, 3 individuals
ARR01260	GSE32390	GSE32390bNFkB	GSM801684	GPL10558	log	normalized	NA	NFkB	fibroblasts	activating	treated with poly I:C	4 h	1 replicate each, 3 individuals
ARR01261	GSE3982	GSE3982a	GSM90843	GPL96	linear	raw	NA	NFkB	Human CD16+, CCR3- peripheral blood neutrophils	control	treated with LPS 100 ng/ml	1 h	none
ARR01262	GSE3982	GSE3982a	GSM90844	GPL96	linear	raw	NA	NFkB	Human CD16+, CCR3- peripheral blood neutrophils	control	treated with LPS 100 ng/ml	1 h	none
ARR01263	GSE3982	GSE3982a	GSM90847	GPL96	linear	raw	NA	NFkB	Human CD16+, CCR3- peripheral blood neutrophils	activating	treated with LPS 100 ng/ml	1 h	none
ARR01264	GSE19738	GSE19738f	GSM492855	GPL6848	linear	raw	NA	NFkB	whole blood cells	control	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01265	GSE19738	GSE19738f	GSM492922	GPL6848	linear	raw	NA	NFkB	whole blood cells	activating	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01266	GSE19738	GSE19738q	GSM492866	GPL6848	linear	raw	NA	NFkB	whole blood cells	control	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01267	GSE19738	GSE19738q	GSM492933	GPL6848	linear	raw	NA	NFkB	whole blood cells	activating	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01268	GSE10316	GSE10316b	GSM260689	GPL570	log	raw	CELS/GSE10316/GSM260689.CEL	NFkB	monocyte derived dendritic cells	control	treated with 50 µg/ml polyI:C	4 h	1 replicate each
ARR01269	GSE10316	GSE10316b	GSM260693	GPL570	log	raw	CELS/GSE10316/GSM260693.CEL	NFkB	monocyte derived dendritic cells	activating	treated with 50 µg/ml polyI:C	4 h	1 replicate each
ARR01270	GSE2706	GSE2706	GSM52346	GPL570	linear	raw	NA	NFkB	Monocyte derived dendritic cells	control	treated with LPS	2 h	3 replicates
ARR01271	GSE2706	GSE2706	GSM52353	GPL570	linear	raw	NA	NFkB	Monocyte derived dendritic cells	control	treated with LPS	2 h	3 replicates
ARR01272	GSE2706	GSE2706	GSM52360	GPL570	linear	raw	NA	NFkB	Monocyte derived dendritic cells	control	treated with LPS	2 h	3 replicates
ARR01273	GSE2706	GSE2706	GSM52340	GPL570	linear	raw	NA	NFkB	Monocyte derived dendritic cells	activating	treated with LPS	2 h	3 replicates
ARR01274	GSE2706	GSE2706	GSM52347	GPL570	linear	raw	NA	NFkB	Monocyte derived dendritic cells	activating	treated with LPS	2 h	3 replicates
ARR01275	GSE2706	GSE2706	GSM52354	GPL570	linear	raw	NA	NFkB	Monocyte derived dendritic cells	activating	treated with LPS	2 h	3 replicates
ARR01276	GSE5504	GSE5504b	GSM126988	GPL570	log	raw	NA	NFkB	human peripheral blood derived monocytes	control	treated with LPS	4 h	comment
ARR01277	GSE5504	GSE5504b	GSM126993	GPL570	log	raw	NA	NFkB	human peripheral blood derived monocytes	control	treated with LPS	4 h	comment
ARR01278	GSE5504	GSE5504b	GSM126996	GPL570	log	raw	NA	NFkB	human peripheral blood derived monocytes	activating	treated with LPS	4 h	comment
ARR01279	GSE5504	GSE5504b	GSM126997	GPL570	log	raw	NA	NFkB	human peripheral blood derived monocytes	activating	treated with LPS	4 h	comment
ARR01280	GSE14419	GSE14419d	GSM360186	GPL571	log	raw	CELS/GSE14419/GSM360186.CEL	NFkB	primary macrophages	control	treated with zymosan A	3 h	1 replicate each, 4 donors
ARR01281	GSE14419	GSE14419d	GSM360188	GPL571	log	raw	CELS/GSE14419/GSM360188.CEL	NFkB	primary macrophages	activating	treated with zymosan A	3 h	1 replicate each, 4 donors
ARR01282	GSE19738	GSE19738a2	GSM492876	GPL6848	linear	raw	NA	NFkB	whole blood cells	control	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01283	GSE19738	GSE19738a2	GSM492943	GPL6848	linear	raw	NA	NFkB	whole blood cells	activating	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01284	GSE9988	GSE9988e	GSM252482	GPL570	linear	raw	CELS/GSE9988/GSM252482.CEL	NFkB	Human monocytes (donor 5)	control	treated with LPS	2 h	10 anonymous donors in this set
ARR01285	GSE9988	GSE9988e	GSM252450	GPL570	linear	raw	CELS/GSE9988/GSM252450.CEL	NFkB	Human monocytes (donor 5)	activating	treated with LPS	2 h	10 anonymous donors in this set
ARR01286	GSE19738	GSE19738e	GSM492854	GPL6848	linear	raw	NA	NFkB	whole blood cells	control	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01287	GSE19738	GSE19738e	GSM492921	GPL6848	linear	raw	NA	NFkB	whole blood cells	activating	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01288	GSE9988	GSE9988g	GSM252483	GPL570	linear	raw	CELS/GSE9988/GSM252483.CEL	NFkB	Human monocytes (donor 7)	control	treated with LPS	2 h	10 anonymous donors in this set
ARR01289	GSE9988	GSE9988g	GSM252443	GPL570	linear	raw	CELS/GSE9988/GSM252443.CEL	NFkB	Human monocytes (donor 7)	activating	treated with LPS	2 h	10 anonymous donors in this set
ARR01290	GSE19738	GSE19738a3	GSM492877	GPL6848	linear	raw	NA	NFkB	whole blood cells	control	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01291	GSE19738	GSE19738a3	GSM492944	GPL6848	linear	raw	NA	NFkB	whole blood cells	activating	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01292	GSE19315	GSE19315	GSM479983	GPL570	log	raw	CELS/GSE19315/GSM479983.CEL	NFkB	THP1 monocytic cell line	control	treated with LPS	6 h	3 replicates each
ARR01293	GSE19315	GSE19315	GSM479984	GPL570	log	raw	CELS/GSE19315/GSM479984.CEL	NFkB	THP1 monocytic cell line	control	treated with LPS	6 h	3 replicates each
ARR01294	GSE19315	GSE19315	GSM479985	GPL570	log	raw	CELS/GSE19315/GSM479985.CEL	NFkB	THP1 monocytic cell line	control	treated with LPS	6 h	3 replicates each
ARR01295	GSE19315	GSE19315	GSM479986	GPL570	log	raw	CELS/GSE19315/GSM479986.CEL	NFkB	THP1 monocytic cell line	activating	treated with LPS	6 h	3 replicates each
ARR01296	GSE19315	GSE19315	GSM479987	GPL570	log	raw	CELS/GSE19315/GSM479987.CEL	NFkB	THP1 monocytic cell line	activating	treated with LPS	6 h	3 replicates each
ARR01297	GSE19315	GSE19315	GSM479988	GPL570	log	raw	CELS/GSE19315/GSM479988.CEL	NFkB	THP1 monocytic cell line	activating	treated with LPS	6 h	3 replicates each
ARR01298	GSE8190	GSE8190d	GSM202440	GPL1708	linear	raw	NA	NFkB	epithelial cells	control	treated with LPS	4 h	2 replicates each, 14 individuals
ARR01299	GSE8190	GSE8190d	GSM202441	GPL1708	linear	raw	NA	NFkB	epithelial cells	control	treated with LPS	4 h	2 replicates each, 14 individuals
ARR01300	GSE8190	GSE8190d	GSM202436	GPL1708	linear	raw	NA	NFkB	epithelial cells	activating	treated with LPS	4 h	2 replicates each, 14 individuals
ARR01301	GSE8190	GSE8190d	GSM202437	GPL1708	linear	raw	NA	NFkB	epithelial cells	activating	treated with LPS	4 h	2 replicates each, 14 individuals
ARR01302	GSE3037	GSE3037g	GSM66873	GPL96	log	raw	NA	NFkB	primary periphal blood neutrophils	control	treated with LPS	1 h	1 replicate each, 8 individuals
ARR01303	GSE3037	GSE3037g	GSM66889	GPL96	log	raw	NA	NFkB	primary periphal blood neutrophils	activating	treated with LPS	1 h	1 replicate each, 8 individuals
ARR01304	GSE19738	GSE19738g	GSM492856	GPL6848	linear	raw	NA	NFkB	whole blood cells	control	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01305	GSE19738	GSE19738g	GSM492923	GPL6848	linear	raw	NA	NFkB	whole blood cells	activating	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01306	GSE22248	GSE22248d	GSM553745	GPL6883	log	normalized	NA	NFkB	PBMCs	control	treated with LPS	4 h	1 replicates each, 4 individuals
ARR01307	GSE22248	GSE22248d	GSM553746	GPL6883	log	normalized	NA	NFkB	PBMCs	activating	treated with LPS	4 h	1 replicates each, 4 individuals
ARR01308	GSE32390	GSE32390e	GSM801688	GPL10558	log	normalized	NA	NFkB	PBMCs	control	treated with 3 µg/ml R848	2 h	1 replicate each, R848 is a relative specific TLR7/8 agonist
ARR01309	GSE32390	GSE32390e	GSM801685	GPL10558	log	normalized	NA	NFkB	PBMCs	activating	treated with 3 µg/ml R848	2 h	1 replicate each, R848 is a relative specific TLR7/8 agonist
ARR01310	GSE7850	GSE7850f	GSM190537	GPL201	log	raw	NA	NFkB	Choroidal endothelial cell	control	treated with LPS 10 100 ng/mL	4 h	three different patients 2 different tissues
ARR01311	GSE7850	GSE7850f	GSM190538	GPL201	log	raw	NA	NFkB	Choroidal endothelial cell	control	treated with LPS 10 100 ng/mL	4 h	three different patients 2 different tissues
ARR01312	GSE7850	GSE7850f	GSM190539	GPL201	log	raw	NA	NFkB	Choroidal endothelial cell	activating	treated with LPS 10 100 ng/mL	4 h	three different patients 2 different tissues
ARR01313	GSE7850	GSE7850f	GSM190540	GPL201	log	raw	NA	NFkB	Choroidal endothelial cell	activating	treated with LPS 10 100 ng/mL	4 h	three different patients 2 different tissues
ARR01314	GSE3982	GSE3982b	GSM90838	GPL96	linear	raw	NA	NFkB	Macrophages differentiated from isolated CD14+ monocytes in the presence of GM-CSF	control	treated with LPS 100 ng/ml	4 h	none
ARR01315	GSE3982	GSE3982b	GSM90839	GPL96	linear	raw	NA	NFkB	Macrophages differentiated from isolated CD14+ monocytes in the presence of GM-CSF	control	treated with LPS 100 ng/ml	4 h	none
ARR01316	GSE3982	GSE3982b	GSM90840	GPL96	linear	raw	NA	NFkB	Macrophages differentiated from isolated CD14+ monocytes in the presence of GM-CSF	activating	treated with LPS 100 ng/ml	4 h	none
ARR01317	GSE3982	GSE3982b	GSM90841	GPL96	linear	raw	NA	NFkB	Macrophages differentiated from isolated CD14+ monocytes in the presence of GM-CSF	activating	treated with LPS 100 ng/ml	4 h	none
ARR01318	GSE19738	GSE19738a4	GSM492878	GPL6848	linear	raw	NA	NFkB	whole blood cells	control	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01319	GSE19738	GSE19738a4	GSM492945	GPL6848	linear	raw	NA	NFkB	whole blood cells	activating	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01320	GSE14000	GSE14000b	GSM351530	GPL570	log	raw	CELS/GSE14000/GSM351530.CEL	NFkB	primary blood cells	control	treated with LPS	4 h	1 replicate each, 4 donors
ARR01321	GSE14000	GSE14000b	GSM351532	GPL570	log	raw	CELS/GSE14000/GSM351532.CEL	NFkB	primary blood cells	activating	treated with LPS	4 h	1 replicate each, 4 donors
ARR01322	GSE20114	GSE20114a	GSM502612	GPL570	linear	raw	NA	NFkB	primary blood cells	control	treated with LPS	4 h	1 replicate each, 4 donors
ARR01323	GSE20114	GSE20114a	GSM502620	GPL570	linear	raw	NA	NFkB	primary blood cells	activating	treated with LPS	4 h	1 replicate each, 4 donors
ARR01324	GSE22248	GSE22248b	GSM553739	GPL6883	log	normalized	NA	NFkB	PBMCs	control	treated with LPS	4 h	1 replicates each, 4 individuals
ARR01325	GSE22248	GSE22248b	GSM553740	GPL6883	log	normalized	NA	NFkB	PBMCs	activating	treated with LPS	4 h	1 replicates each, 4 individuals
ARR01326	GSE8190	GSE8190l	GSM202594	GPL1708	linear	raw	NA	NFkB	epithelial cells	control	treated with LPS	4 h	2 replicates each, 14 individuals
ARR01327	GSE8190	GSE8190l	GSM202665	GPL1708	linear	raw	NA	NFkB	epithelial cells	control	treated with LPS	4 h	2 replicates each, 14 individuals
ARR01328	GSE8190	GSE8190l	GSM202592	GPL1708	linear	raw	NA	NFkB	epithelial cells	activating	treated with LPS	4 h	2 replicates each, 14 individuals
ARR01329	GSE8190	GSE8190l	GSM202663	GPL1708	linear	raw	NA	NFkB	epithelial cells	activating	treated with LPS	4 h	2 replicates each, 14 individuals
ARR01330	GSE19738	GSE19738m	GSM492862	GPL6848	linear	raw	NA	NFkB	whole blood cells	control	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01331	GSE19738	GSE19738m	GSM492929	GPL6848	linear	raw	NA	NFkB	whole blood cells	activating	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01332	GSE20114	GSE20114b	GSM502613	GPL570	linear	raw	NA	NFkB	primary blood cells	control	treated with LPS	4 h	1 replicate each, 4 donors
ARR01333	GSE20114	GSE20114b	GSM502621	GPL570	linear	raw	NA	NFkB	primary blood cells	activating	treated with LPS	4 h	1 replicate each, 4 donors
ARR01334	GSE32390	GSE32390aNFkB	GSM801677	GPL10558	log	normalized	NA	NFkB	fibroblasts	control	treated with poly I:C	4 h	1 replicate each, 3 individuals
ARR01335	GSE32390	GSE32390aNFkB	GSM801667	GPL10558	log	normalized	NA	NFkB	fibroblasts	activating	treated with poly I:C	4 h	1 replicate each, 3 individuals
ARR01336	GSE3720	GSE3720b	GSM85810	GPL571	linear	raw	NA	NFkB	expanded peripheral blood Vd2 gd T lymphocytes	control	treated with LPS 10 mg/mL	4 h	3 week culture with Vd1 mab 0.1mg/mL, pan gd mAb 0.1 mg/mL, and IL-15 10ng/mL
ARR01337	GSE3720	GSE3720b	GSM85811	GPL571	linear	raw	NA	NFkB	expanded peripheral blood Vd2 gd T lymphocytes	control	treated with LPS 10 mg/mL	4 h	3 week culture with Vd1 mab 0.1mg/mL, pan gd mAb 0.1 mg/mL, and IL-15 10ng/mL
ARR01338	GSE3720	GSE3720b	GSM85812	GPL571	linear	raw	NA	NFkB	expanded peripheral blood Vd2 gd T lymphocytes	activating	treated with LPS 10 mg/mL	4 h	3 week culture with Vd1 mab 0.1mg/mL, pan gd mAb 0.1 mg/mL, and IL-15 10ng/mL
ARR01339	GSE3720	GSE3720b	GSM85813	GPL571	linear	raw	NA	NFkB	expanded peripheral blood Vd2 gd T lymphocytes	activating	treated with LPS 10 mg/mL	4 h	3 week culture with Vd1 mab 0.1mg/mL, pan gd mAb 0.1 mg/mL, and IL-15 10ng/mL
ARR01340	GSE19738	GSE19738a7	GSM492881	GPL6848	linear	raw	NA	NFkB	whole blood cells	control	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01341	GSE19738	GSE19738a7	GSM492948	GPL6848	linear	raw	NA	NFkB	whole blood cells	activating	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01342	GSE1541	GSE1541aNFkB	GSM26477	GPL201	linear	raw	NA	NFkB	A549 (Alveolar Epithelial Cells line)	control	treated with LPS	1 h	comment
ARR01343	GSE1541	GSE1541aNFkB	GSM26478	GPL201	linear	raw	NA	NFkB	A549 (Alveolar Epithelial Cells line)	control	treated with LPS	1 h	comment
ARR01344	GSE1541	GSE1541aNFkB	GSM26481	GPL201	linear	raw	NA	NFkB	A549 (Alveolar Epithelial Cells line)	activating	treated with LPS	1 h	comment
ARR01345	GSE1541	GSE1541aNFkB	GSM26482	GPL201	linear	raw	NA	NFkB	A549 (Alveolar Epithelial Cells line)	activating	treated with LPS	1 h	comment
ARR01346	GSE8190	GSE8190h	GSM202510	GPL1708	linear	raw	NA	NFkB	epithelial cells	control	treated with LPS	4 h	2 replicates each, 14 individuals
ARR01347	GSE8190	GSE8190h	GSM202511	GPL1708	linear	raw	NA	NFkB	epithelial cells	control	treated with LPS	4 h	2 replicates each, 14 individuals
ARR01348	GSE8190	GSE8190h	GSM202506	GPL1708	linear	raw	NA	NFkB	epithelial cells	activating	treated with LPS	4 h	2 replicates each, 14 individuals
ARR01349	GSE8190	GSE8190h	GSM202507	GPL1708	linear	raw	NA	NFkB	epithelial cells	activating	treated with LPS	4 h	2 replicates each, 14 individuals
ARR01350	GSE7850	GSE7850b	GSM190521	GPL201	log	raw	NA	NFkB	Choroidal endothelial cell	control	treated with LPS 10 100 ng/mL	4 h	three different patients 2 different tissues
ARR01351	GSE7850	GSE7850b	GSM190522	GPL201	log	raw	NA	NFkB	Choroidal endothelial cell	control	treated with LPS 10 100 ng/mL	4 h	three different patients 2 different tissues
ARR01352	GSE7850	GSE7850b	GSM190523	GPL201	log	raw	NA	NFkB	Choroidal endothelial cell	activating	treated with LPS 10 100 ng/mL	4 h	three different patients 2 different tissues
ARR01353	GSE7850	GSE7850b	GSM190524	GPL201	log	raw	NA	NFkB	Choroidal endothelial cell	activating	treated with LPS 10 100 ng/mL	4 h	three different patients 2 different tissues
ARR01354	GSE14000	GSE14000a	GSM349874	GPL570	log	raw	CELS/GSE14000/GSM349874.CEL	NFkB	primary blood cells	control	treated with LPS	4 h	1 replicate each, 4 donors
ARR01355	GSE14000	GSE14000a	GSM349876	GPL570	log	raw	CELS/GSE14000/GSM349876.CEL	NFkB	primary blood cells	activating	treated with LPS	4 h	1 replicate each, 4 donors
ARR01356	GSE18047	GSE18047c	GSM451270	GPL570	log	raw	CELS/GSE18047/GSM451270.CEL	NFkB	SACHI (Multiple Myeloma Cell Line)	control	transfected with NIK	undefined	overexpression directly above NFkB
ARR01357	GSE18047	GSE18047c	GSM451273	GPL570	log	raw	CELS/GSE18047/GSM451273.CEL	NFkB	SACHI (Multiple Myeloma Cell Line)	control	transfected with NIK	undefined	overexpression directly above NFkB
ARR01358	GSE18047	GSE18047c	GSM451276	GPL570	log	raw	CELS/GSE18047/GSM451276.CEL	NFkB	SACHI (Multiple Myeloma Cell Line)	control	transfected with NIK	undefined	overexpression directly above NFkB
ARR01359	GSE18047	GSE18047c	GSM451271	GPL570	log	raw	CELS/GSE18047/GSM451271.CEL	NFkB	SACHI (Multiple Myeloma Cell Line)	activating	transfected with NIK	undefined	overexpression directly above NFkB
ARR01360	GSE18047	GSE18047c	GSM451274	GPL570	log	raw	CELS/GSE18047/GSM451274.CEL	NFkB	SACHI (Multiple Myeloma Cell Line)	activating	transfected with NIK	undefined	overexpression directly above NFkB
ARR01361	GSE18047	GSE18047c	GSM451277	GPL570	log	raw	CELS/GSE18047/GSM451277.CEL	NFkB	SACHI (Multiple Myeloma Cell Line)	activating	transfected with NIK	undefined	overexpression directly above NFkB
ARR01362	GSE19738	GSE19738a6	GSM492880	GPL6848	linear	raw	NA	NFkB	whole blood cells	control	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01363	GSE19738	GSE19738a6	GSM492947	GPL6848	linear	raw	NA	NFkB	whole blood cells	activating	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01364	GSE19738	GSE19738a8	GSM492882	GPL6848	linear	raw	NA	NFkB	whole blood cells	control	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01365	GSE19738	GSE19738a8	GSM492949	GPL6848	linear	raw	NA	NFkB	whole blood cells	activating	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01366	GSE19738	GSE19738o	GSM492864	GPL6848	linear	raw	NA	NFkB	whole blood cells	control	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01367	GSE19738	GSE19738o	GSM492931	GPL6848	linear	raw	NA	NFkB	whole blood cells	activating	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01368	GSE24897	GSE24897	GSM612262	GPL570	log	normalized	CELS/GSE24897/GSM612262.CEL	NFkB	macrophages	control	treated with  PG-LPS	2 h	3 replicates each
ARR01369	GSE24897	GSE24897	GSM612263	GPL570	log	normalized	CELS/GSE24897/GSM612263.CEL	NFkB	macrophages	control	treated with  PG-LPS	2 h	3 replicates each
ARR01370	GSE24897	GSE24897	GSM612264	GPL570	log	normalized	CELS/GSE24897/GSM612264.CEL	NFkB	macrophages	control	treated with  PG-LPS	2 h	3 replicates each
ARR01371	GSE24897	GSE24897	GSM612268	GPL570	log	normalized	CELS/GSE24897/GSM612268.CEL	NFkB	macrophages	activating	treated with  PG-LPS	2 h	3 replicates each
ARR01372	GSE24897	GSE24897	GSM612269	GPL570	log	normalized	CELS/GSE24897/GSM612269.CEL	NFkB	macrophages	activating	treated with  PG-LPS	2 h	3 replicates each
ARR01373	GSE24897	GSE24897	GSM612270	GPL570	log	normalized	CELS/GSE24897/GSM612270.CEL	NFkB	macrophages	activating	treated with  PG-LPS	2 h	3 replicates each
ARR01374	GSE18047	GSE18047a	GSM451261	GPL570	log	raw	CELS/GSE18047/GSM451261.CEL	NFkB	H929 (Multiple Myeloma Cell Line)	control	transfected with NIK	undefined	overexpression directly above NFkB
ARR01375	GSE18047	GSE18047a	GSM451264	GPL570	log	raw	CELS/GSE18047/GSM451264.CEL	NFkB	H929 (Multiple Myeloma Cell Line)	control	transfected with NIK	undefined	overexpression directly above NFkB
ARR01376	GSE18047	GSE18047a	GSM451267	GPL570	log	raw	CELS/GSE18047/GSM451267.CEL	NFkB	H929 (Multiple Myeloma Cell Line)	control	transfected with NIK	undefined	overexpression directly above NFkB
ARR01377	GSE18047	GSE18047a	GSM451262	GPL570	log	raw	CELS/GSE18047/GSM451262.CEL	NFkB	H929 (Multiple Myeloma Cell Line)	activating	transfected with NIK	undefined	overexpression directly above NFkB
ARR01378	GSE18047	GSE18047a	GSM451265	GPL570	log	raw	CELS/GSE18047/GSM451265.CEL	NFkB	H929 (Multiple Myeloma Cell Line)	activating	transfected with NIK	undefined	overexpression directly above NFkB
ARR01379	GSE18047	GSE18047a	GSM451268	GPL570	log	raw	CELS/GSE18047/GSM451268.CEL	NFkB	H929 (Multiple Myeloma Cell Line)	activating	transfected with NIK	undefined	overexpression directly above NFkB
ARR01380	GSE19738	GSE19738h	GSM492857	GPL6848	linear	raw	NA	NFkB	whole blood cells	control	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01381	GSE19738	GSE19738h	GSM492924	GPL6848	linear	raw	NA	NFkB	whole blood cells	activating	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01382	GSE19738	GSE19738z	GSM492875	GPL6848	linear	raw	NA	NFkB	whole blood cells	control	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01383	GSE19738	GSE19738z	GSM492942	GPL6848	linear	raw	NA	NFkB	whole blood cells	activating	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01384	GSE7850	GSE7850a	GSM190517	GPL201	log	raw	NA	NFkB	Retinal endothelial cell	control	treated with LPS 10 100 ng/mL	4 h	three different patients 2 different tissues
ARR01385	GSE7850	GSE7850a	GSM190518	GPL201	log	raw	NA	NFkB	Retinal endothelial cell	control	treated with LPS 10 100 ng/mL	4 h	three different patients 2 different tissues
ARR01386	GSE7850	GSE7850a	GSM190519	GPL201	log	raw	NA	NFkB	Retinal endothelial cell	activating	treated with LPS 10 100 ng/mL	4 h	three different patients 2 different tissues
ARR01387	GSE7850	GSE7850a	GSM190520	GPL201	log	raw	NA	NFkB	Retinal endothelial cell	activating	treated with LPS 10 100 ng/mL	4 h	three different patients 2 different tissues
ARR01388	GSE19738	GSE19738p	GSM492865	GPL6848	linear	raw	NA	NFkB	whole blood cells	control	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01389	GSE19738	GSE19738p	GSM492932	GPL6848	linear	raw	NA	NFkB	whole blood cells	activating	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01390	GSE9988	GSE9988b	GSM252481	GPL570	linear	raw	CELS/GSE9988/GSM252481.CEL	NFkB	Human monocytes (donor 2)	control	treated with LPS	2 h	10 anonymous donors in this set
ARR01391	GSE9988	GSE9988b	GSM252448	GPL570	linear	raw	CELS/GSE9988/GSM252448.CEL	NFkB	Human monocytes (donor 2)	activating	treated with LPS	2 h	10 anonymous donors in this set
ARR01392	GSE25155	GSE25155a	GSM618017	GPL570	linear	raw	CELS/GSE25155/GSM618017.CEL	NFkB	HEK TLR2 transfected	control	treated with 10µg/ml H. pylori LPS	2 h	2 replicates each, part of time series
ARR01393	GSE25155	GSE25155a	GSM618018	GPL570	linear	raw	CELS/GSE25155/GSM618018.CEL	NFkB	HEK TLR2 transfected	control	treated with 10µg/ml H. pylori LPS	2 h	2 replicates each, part of time series
ARR01394	GSE25155	GSE25155a	GSM618019	GPL570	linear	raw	CELS/GSE25155/GSM618019.CEL	NFkB	HEK TLR2 transfected	activating	treated with 10µg/ml H. pylori LPS	2 h	2 replicates each, part of time series
ARR01395	GSE25155	GSE25155a	GSM618020	GPL570	linear	raw	CELS/GSE25155/GSM618020.CEL	NFkB	HEK TLR2 transfected	activating	treated with 10µg/ml H. pylori LPS	2 h	2 replicates each, part of time series
ARR01396	GSE14419	GSE14419a	GSM360139	GPL571	log	raw	CELS/GSE14419/GSM360139.CEL	NFkB	primary macrophages	control	treated with zymosan A	3 h	1 replicate each, 4 donors
ARR01397	GSE14419	GSE14419a	GSM360141	GPL571	log	raw	CELS/GSE14419/GSM360141.CEL	NFkB	primary macrophages	activating	treated with zymosan A	3 h	1 replicate each, 4 donors
ARR01398	GSE8190	GSE8190k	GSM202591	GPL1708	linear	raw	NA	NFkB	epithelial cells	control	treated with LPS	4 h	2 replicates each, 14 individuals
ARR01399	GSE8190	GSE8190k	GSM202662	GPL1708	linear	raw	NA	NFkB	epithelial cells	control	treated with LPS	4 h	2 replicates each, 14 individuals
ARR01400	GSE8190	GSE8190k	GSM202589	GPL1708	linear	raw	NA	NFkB	epithelial cells	activating	treated with LPS	4 h	2 replicates each, 14 individuals
ARR01401	GSE8190	GSE8190k	GSM202660	GPL1708	linear	raw	NA	NFkB	epithelial cells	activating	treated with LPS	4 h	2 replicates each, 14 individuals
ARR01402	GSE19738	GSE19738k	GSM492860	GPL6848	linear	raw	NA	NFkB	whole blood cells	control	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01403	GSE19738	GSE19738k	GSM492927	GPL6848	linear	raw	NA	NFkB	whole blood cells	activating	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01404	GSE3037	GSE3037d	GSM66870	GPL96	log	raw	NA	NFkB	primary periphal blood neutrophils	control	treated with LPS	1 h	1 replicate each, 8 individuals
ARR01405	GSE3037	GSE3037d	GSM66886	GPL96	log	raw	NA	NFkB	primary periphal blood neutrophils	activating	treated with LPS	1 h	1 replicate each, 8 individuals
ARR01406	GSE22248	GSE22248a	GSM553736	GPL6883	log	normalized	NA	NFkB	PBMCs	control	treated with LPS	4 h	1 replicates each, 4 individuals
ARR01407	GSE22248	GSE22248a	GSM553737	GPL6883	log	normalized	NA	NFkB	PBMCs	activating	treated with LPS	4 h	1 replicates each, 4 individuals
ARR01408	GSE8190	GSE8190e	GSM202452	GPL1708	linear	raw	NA	NFkB	epithelial cells	control	treated with LPS	4 h	2 replicates each, 14 individuals
ARR01409	GSE8190	GSE8190e	GSM202453	GPL1708	linear	raw	NA	NFkB	epithelial cells	control	treated with LPS	4 h	2 replicates each, 14 individuals
ARR01410	GSE8190	GSE8190e	GSM202448	GPL1708	linear	raw	NA	NFkB	epithelial cells	activating	treated with LPS	4 h	2 replicates each, 14 individuals
ARR01411	GSE8190	GSE8190e	GSM202449	GPL1708	linear	raw	NA	NFkB	epithelial cells	activating	treated with LPS	4 h	2 replicates each, 14 individuals
ARR01412	GSE19738	GSE19738t	GSM492869	GPL6848	linear	raw	NA	NFkB	whole blood cells	control	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01413	GSE19738	GSE19738t	GSM492936	GPL6848	linear	raw	NA	NFkB	whole blood cells	activating	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01414	GSE19738	GSE19738l	GSM492861	GPL6848	linear	raw	NA	NFkB	whole blood cells	control	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01415	GSE19738	GSE19738l	GSM492928	GPL6848	linear	raw	NA	NFkB	whole blood cells	activating	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01416	GSE5883	GSE5883	GSM114564	GPL570	linear	raw	NA	NFkB	HMVEC-L (Microvascular endothelial cells, lung)	control	treated with LPS 10 ng	4 h	4 replicates each
ARR01417	GSE5883	GSE5883	GSM114565	GPL570	linear	raw	NA	NFkB	HMVEC-L (Microvascular endothelial cells, lung)	control	treated with LPS 10 ng	4 h	4 replicates each
ARR01418	GSE5883	GSE5883	GSM114566	GPL570	linear	raw	NA	NFkB	HMVEC-L (Microvascular endothelial cells, lung)	control	treated with LPS 10 ng	4 h	4 replicates each
ARR01419	GSE5883	GSE5883	GSM114567	GPL570	linear	raw	NA	NFkB	HMVEC-L (Microvascular endothelial cells, lung)	control	treated with LPS 10 ng	4 h	4 replicates each
ARR01420	GSE5883	GSE5883	GSM114552	GPL570	linear	raw	NA	NFkB	HMVEC-L (Microvascular endothelial cells, lung)	activating	treated with LPS 10 ng	4 h	4 replicates each
ARR01421	GSE5883	GSE5883	GSM114553	GPL570	linear	raw	NA	NFkB	HMVEC-L (Microvascular endothelial cells, lung)	activating	treated with LPS 10 ng	4 h	4 replicates each
ARR01422	GSE5883	GSE5883	GSM114554	GPL570	linear	raw	NA	NFkB	HMVEC-L (Microvascular endothelial cells, lung)	activating	treated with LPS 10 ng	4 h	4 replicates each
ARR01423	GSE5883	GSE5883	GSM114555	GPL570	linear	raw	NA	NFkB	HMVEC-L (Microvascular endothelial cells, lung)	activating	treated with LPS 10 ng	4 h	4 replicates each
ARR01424	GSE32390	GSE32390dNFkB	GSM801688	GPL10558	log	normalized	NA	NFkB	PBMCs	control	treated with 10 ng/ml LPS	2 h	1 replicate each
ARR01425	GSE32390	GSE32390dNFkB	GSM801685	GPL10558	log	normalized	NA	NFkB	PBMCs	activating	treated with 10 ng/ml LPS	2 h	1 replicate each
ARR01426	GSE19738	GSE19738y	GSM492874	GPL6848	linear	raw	NA	NFkB	whole blood cells	control	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01427	GSE19738	GSE19738y	GSM492941	GPL6848	linear	raw	NA	NFkB	whole blood cells	activating	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01428	GSE3140	GSE3140a	GSM70121	GPL201	log	raw	NA	NFkB	mononuclear cells from adult peripheral blood	control	treated with 5 µg/ml LPS	4 h	3 replicates each, time might not be exact but probably 4h or 2h
ARR01429	GSE3140	GSE3140a	GSM70122	GPL201	log	raw	NA	NFkB	mononuclear cells from adult peripheral blood	control	treated with 5 µg/ml LPS	4 h	3 replicates each, time might not be exact but probably 4h or 2h
ARR01430	GSE3140	GSE3140a	GSM70123	GPL201	log	raw	NA	NFkB	mononuclear cells from adult peripheral blood	control	treated with 5 µg/ml LPS	4 h	3 replicates each, time might not be exact but probably 4h or 2h
ARR01431	GSE3140	GSE3140a	GSM70124	GPL201	log	raw	NA	NFkB	mononuclear cells from adult peripheral blood	activating	treated with 5 µg/ml LPS	4 h	3 replicates each, time might not be exact but probably 4h or 2h
ARR01432	GSE3140	GSE3140a	GSM71079	GPL201	log	raw	NA	NFkB	mononuclear cells from adult peripheral blood	activating	treated with 5 µg/ml LPS	4 h	3 replicates each, time might not be exact but probably 4h or 2h
ARR01433	GSE3140	GSE3140a	GSM71080	GPL201	log	raw	NA	NFkB	mononuclear cells from adult peripheral blood	activating	treated with 5 µg/ml LPS	4 h	3 replicates each, time might not be exact but probably 4h or 2h
ARR01434	GSE8608	GSE8608	GSM213500	GPL570	log	raw	CELS/GSE8608/GSM213500.CEL	NFkB	monocyte-derived macrophages of 13 male healthy subjects	control	treated with LPS 10ng/ml	4 h	comment
ARR01435	GSE8608	GSE8608	GSM213511	GPL570	log	raw	CELS/GSE8608/GSM213511.CEL	NFkB	monocyte-derived macrophages of 13 male healthy subjects	activating	treated with LPS 10ng/ml	4 h	comment
ARR01436	GSE29700	GSE29700	GSM736728	GPL570	log	normalized	CELS/GSE29700/GSM736728.CEL	NFkB	BL-2 burkitt lymphoma cell line	control	treated with LPS	6 h	3 replicates each
ARR01437	GSE29700	GSE29700	GSM736729	GPL570	log	normalized	CELS/GSE29700/GSM736729.CEL	NFkB	BL-2 burkitt lymphoma cell line	control	treated with LPS	6 h	3 replicates each
ARR01438	GSE29700	GSE29700	GSM736730	GPL570	log	normalized	CELS/GSE29700/GSM736730.CEL	NFkB	BL-2 burkitt lymphoma cell line	control	treated with LPS	6 h	3 replicates each
ARR01439	GSE29700	GSE29700	GSM736731	GPL570	log	normalized	CELS/GSE29700/GSM736731.CEL	NFkB	BL-2 burkitt lymphoma cell line	activating	treated with LPS	6 h	3 replicates each
ARR01440	GSE29700	GSE29700	GSM736732	GPL570	log	normalized	CELS/GSE29700/GSM736732.CEL	NFkB	BL-2 burkitt lymphoma cell line	activating	treated with LPS	6 h	3 replicates each
ARR01441	GSE29700	GSE29700	GSM736733	GPL570	log	normalized	CELS/GSE29700/GSM736733.CEL	NFkB	BL-2 burkitt lymphoma cell line	activating	treated with LPS	6 h	3 replicates each
ARR01442	GSE19738	GSE19738d	GSM492853	GPL6848	linear	raw	NA	NFkB	whole blood cells	control	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01443	GSE19738	GSE19738d	GSM492920	GPL6848	linear	raw	NA	NFkB	whole blood cells	activating	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01444	GSE10316	GSE10316	GSM260689	GPL570	linear	raw	CELS/GSE10316/GSM260689.CEL	NFkB	monocyte-derived dendritic cells	control	treated with LPS 1 g/ml	4 h	immature cells
ARR01445	GSE10316	GSE10316	GSM260690	GPL570	linear	raw	CELS/GSE10316/GSM260690.CEL	NFkB	monocyte-derived dendritic cells	activating	treated with LPS 1 g/ml	4 h	immature cells
ARR01446	GSE7850	GSE7850d	GSM190529	GPL201	log	raw	NA	NFkB	Choroidal endothelial cell	control	treated with LPS 10 100 ng/mL	4 h	three different patients 2 different tissues
ARR01447	GSE7850	GSE7850d	GSM190530	GPL201	log	raw	NA	NFkB	Choroidal endothelial cell	control	treated with LPS 10 100 ng/mL	4 h	three different patients 2 different tissues
ARR01448	GSE7850	GSE7850d	GSM190531	GPL201	log	raw	NA	NFkB	Choroidal endothelial cell	activating	treated with LPS 10 100 ng/mL	4 h	three different patients 2 different tissues
ARR01449	GSE7850	GSE7850d	GSM190532	GPL201	log	raw	NA	NFkB	Choroidal endothelial cell	activating	treated with LPS 10 100 ng/mL	4 h	three different patients 2 different tissues
ARR01450	GSE3491	GSE3491b	GSM79057	GPL8300	log	raw	NA	NFkB	GENDER: MALE TISSUE: WHOLE BLOOD LPS RESPONSE: HIGH	control	treated with LPS 10 NG/ML	4 h	three patients with high LPS response rate
ARR01451	GSE3491	GSE3491b	GSM79058	GPL8300	log	raw	NA	NFkB	GENDER: MALE TISSUE: WHOLE BLOOD LPS RESPONSE: HIGH	activating	treated with LPS 10 NG/ML	4 h	three patients with high LPS response rate
ARR01452	GSE3720	GSE3720a	GSM85804	GPL571	linear	raw	NA	NFkB	expanded peripheral blood Vd1 gd T lymphocytes	control	treated with LPS 10 mg/mL	4 h	3 week culture with Vd1 mab 0.1mg/mL, pan gd mAb 0.1 mg/mL, and IL-15 10ng/mL
ARR01453	GSE3720	GSE3720a	GSM85805	GPL571	linear	raw	NA	NFkB	expanded peripheral blood Vd1 gd T lymphocytes	control	treated with LPS 10 mg/mL	4 h	3 week culture with Vd1 mab 0.1mg/mL, pan gd mAb 0.1 mg/mL, and IL-15 10ng/mL
ARR01454	GSE3720	GSE3720a	GSM85806	GPL571	linear	raw	NA	NFkB	expanded peripheral blood Vd1 gd T lymphocytes	activating	treated with LPS 10 mg/mL	4 h	3 week culture with Vd1 mab 0.1mg/mL, pan gd mAb 0.1 mg/mL, and IL-15 10ng/mL
ARR01455	GSE3720	GSE3720a	GSM85807	GPL571	linear	raw	NA	NFkB	expanded peripheral blood Vd1 gd T lymphocytes	activating	treated with LPS 10 mg/mL	4 h	3 week culture with Vd1 mab 0.1mg/mL, pan gd mAb 0.1 mg/mL, and IL-15 10ng/mL
ARR01456	GSE9988	GSE9988i	GSM252484	GPL570	linear	raw	CELS/GSE9988/GSM252484.CEL	NFkB	Human monocytes (donor 9)	control	treated with LPS	2 h	10 anonymous donors in this set
ARR01457	GSE9988	GSE9988i	GSM252449	GPL570	linear	raw	CELS/GSE9988/GSM252449.CEL	NFkB	Human monocytes (donor 9)	activating	treated with LPS	2 h	10 anonymous donors in this set
ARR01458	GSE7850	GSE7850c	GSM190525	GPL201	log	raw	NA	NFkB	Retinal endothelial cell	control	treated with LPS 10 100 ng/mL	4 h	three different patients 2 different tissues
ARR01459	GSE7850	GSE7850c	GSM190526	GPL201	log	raw	NA	NFkB	Retinal endothelial cell	control	treated with LPS 10 100 ng/mL	4 h	three different patients 2 different tissues
ARR01460	GSE7850	GSE7850c	GSM190527	GPL201	log	raw	NA	NFkB	Retinal endothelial cell	activating	treated with LPS 10 100 ng/mL	4 h	three different patients 2 different tissues
ARR01461	GSE7850	GSE7850c	GSM190528	GPL201	log	raw	NA	NFkB	Retinal endothelial cell	activating	treated with LPS 10 100 ng/mL	4 h	three different patients 2 different tissues
ARR01462	GSE10316	GSE10316a	GSM260689	GPL570	log	raw	CELS/GSE10316/GSM260689.CEL	NFkB	monocyte derived dendritic cells	control	treated with 1 µg/ml LPS	4 h	1 replicate each
ARR01463	GSE10316	GSE10316a	GSM260690	GPL570	log	raw	CELS/GSE10316/GSM260690.CEL	NFkB	monocyte derived dendritic cells	activating	treated with 1 µg/ml LPS	4 h	1 replicate each
ARR01464	GSE14419	GSE14419c	GSM360182	GPL571	log	raw	CELS/GSE14419/GSM360182.CEL	NFkB	primary macrophages	control	treated with zymosan A	3 h	1 replicate each, 4 donors
ARR01465	GSE14419	GSE14419c	GSM360184	GPL571	log	raw	CELS/GSE14419/GSM360184.CEL	NFkB	primary macrophages	activating	treated with zymosan A	3 h	1 replicate each, 4 donors
ARR01466	GSE14000	GSE14000d	GSM351622	GPL570	log	raw	CELS/GSE14000/GSM351622.CEL	NFkB	primary blood cells	control	treated with LPS	4 h	1 replicate each, 4 donors
ARR01467	GSE14000	GSE14000d	GSM351638	GPL570	log	raw	CELS/GSE14000/GSM351638.CEL	NFkB	primary blood cells	activating	treated with LPS	4 h	1 replicate each, 4 donors
ARR01468	GSE9988	GSE9988f	GSM252478	GPL570	linear	raw	CELS/GSE9988/GSM252478.CEL	NFkB	Human monocytes (donor 6)	control	treated with LPS	2 h	10 anonymous donors in this set
ARR01469	GSE9988	GSE9988f	GSM252452	GPL570	linear	raw	CELS/GSE9988/GSM252452.CEL	NFkB	Human monocytes (donor 6)	activating	treated with LPS	2 h	10 anonymous donors in this set
ARR01470	GSE9916	GSE9916	GSM250931	GPL570	log	normalized	CELS/GSE9916/GSM250931.CEL	NFkB	THP-1 cell line	control	treated with 1 µg/ml LPS	4 h	3 replicates each
ARR01471	GSE9916	GSE9916	GSM250932	GPL570	log	normalized	CELS/GSE9916/GSM250932.CEL	NFkB	THP-1 cell line	control	treated with 1 µg/ml LPS	4 h	3 replicates each
ARR01472	GSE9916	GSE9916	GSM250933	GPL570	log	normalized	CELS/GSE9916/GSM250933.CEL	NFkB	THP-1 cell line	control	treated with 1 µg/ml LPS	4 h	3 replicates each
ARR01473	GSE9916	GSE9916	GSM250940	GPL570	log	normalized	CELS/GSE9916/GSM250940.CEL	NFkB	THP-1 cell line	activating	treated with 1 µg/ml LPS	4 h	3 replicates each
ARR01474	GSE9916	GSE9916	GSM250941	GPL570	log	normalized	CELS/GSE9916/GSM250941.CEL	NFkB	THP-1 cell line	activating	treated with 1 µg/ml LPS	4 h	3 replicates each
ARR01475	GSE9916	GSE9916	GSM250942	GPL570	log	normalized	CELS/GSE9916/GSM250942.CEL	NFkB	THP-1 cell line	activating	treated with 1 µg/ml LPS	4 h	3 replicates each
ARR01476	GSE3140	GSE3140b	GSM71081	GPL201	log	raw	NA	NFkB	mononuclear cells from cord blood	control	treated with 5 µg/ml LPS	4 h	3 replicates each, time might not be exact but probably 4h or 2h
ARR01477	GSE3140	GSE3140b	GSM71082	GPL201	log	raw	NA	NFkB	mononuclear cells from cord blood	control	treated with 5 µg/ml LPS	4 h	3 replicates each, time might not be exact but probably 4h or 2h
ARR01478	GSE3140	GSE3140b	GSM71083	GPL201	log	raw	NA	NFkB	mononuclear cells from cord blood	control	treated with 5 µg/ml LPS	4 h	3 replicates each, time might not be exact but probably 4h or 2h
ARR01479	GSE3140	GSE3140b	GSM71084	GPL201	log	raw	NA	NFkB	mononuclear cells from cord blood	activating	treated with 5 µg/ml LPS	4 h	3 replicates each, time might not be exact but probably 4h or 2h
ARR01480	GSE3140	GSE3140b	GSM71085	GPL201	log	raw	NA	NFkB	mononuclear cells from cord blood	activating	treated with 5 µg/ml LPS	4 h	3 replicates each, time might not be exact but probably 4h or 2h
ARR01481	GSE3140	GSE3140b	GSM71086	GPL201	log	raw	NA	NFkB	mononuclear cells from cord blood	activating	treated with 5 µg/ml LPS	4 h	3 replicates each, time might not be exact but probably 4h or 2h
ARR01482	GSE3037	GSE3037c	GSM66869	GPL96	log	raw	NA	NFkB	primary periphal blood neutrophils	control	treated with LPS	1 h	1 replicate each, 8 individuals
ARR01483	GSE3037	GSE3037c	GSM66885	GPL96	log	raw	NA	NFkB	primary periphal blood neutrophils	activating	treated with LPS	1 h	1 replicate each, 8 individuals
ARR01484	GSE3491	GSE3491c	GSM79064	GPL8300	log	raw	NA	NFkB	GENDER: FEMALE TISSUE: WHOLE BLOOD LPS RESPONSE: HIGH	control	treated with LPS 10 NG/ML	4 h	three patients with high LPS response rate
ARR01485	GSE3491	GSE3491c	GSM79067	GPL8300	log	raw	NA	NFkB	GENDER: FEMALE TISSUE: WHOLE BLOOD LPS RESPONSE: HIGH	activating	treated with LPS 10 NG/ML	4 h	three patients with high LPS response rate
ARR01486	GSE18047	GSE18047b	GSM451261	GPL570	log	raw	CELS/GSE18047/GSM451261.CEL	NFkB	H929 (Multiple Myeloma Cell Line)	control	transfected with IKKB	undefined	overexpression directly above NFkB
ARR01487	GSE18047	GSE18047b	GSM451264	GPL570	log	raw	CELS/GSE18047/GSM451264.CEL	NFkB	H929 (Multiple Myeloma Cell Line)	control	transfected with IKKB	undefined	overexpression directly above NFkB
ARR01488	GSE18047	GSE18047b	GSM451267	GPL570	log	raw	CELS/GSE18047/GSM451267.CEL	NFkB	H929 (Multiple Myeloma Cell Line)	control	transfected with IKKB	undefined	overexpression directly above NFkB
ARR01489	GSE18047	GSE18047b	GSM451263	GPL570	log	raw	CELS/GSE18047/GSM451263.CEL	NFkB	H929 (Multiple Myeloma Cell Line)	activating	transfected with IKKB	undefined	overexpression directly above NFkB
ARR01490	GSE18047	GSE18047b	GSM451266	GPL570	log	raw	CELS/GSE18047/GSM451266.CEL	NFkB	H929 (Multiple Myeloma Cell Line)	activating	transfected with IKKB	undefined	overexpression directly above NFkB
ARR01491	GSE18047	GSE18047b	GSM451269	GPL570	log	raw	CELS/GSE18047/GSM451269.CEL	NFkB	H929 (Multiple Myeloma Cell Line)	activating	transfected with IKKB	undefined	overexpression directly above NFkB
ARR01492	GSE20114	GSE20114c	GSM502614	GPL570	linear	raw	NA	NFkB	primary blood cells	control	treated with LPS	4 h	1 replicate each, 4 donors
ARR01493	GSE20114	GSE20114c	GSM502622	GPL570	linear	raw	NA	NFkB	primary blood cells	activating	treated with LPS	4 h	1 replicate each, 4 donors
ARR01494	GSE19738	GSE19738w	GSM492872	GPL6848	linear	raw	NA	NFkB	whole blood cells	control	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01495	GSE19738	GSE19738w	GSM492939	GPL6848	linear	raw	NA	NFkB	whole blood cells	activating	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01496	GSE19738	GSE19738r	GSM492867	GPL6848	linear	raw	NA	NFkB	whole blood cells	control	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01497	GSE19738	GSE19738r	GSM492934	GPL6848	linear	raw	NA	NFkB	whole blood cells	activating	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01498	GSE8190	GSE8190c	GSM202430	GPL1708	linear	raw	NA	NFkB	epithelial cells	control	treated with LPS	4 h	2 replicates each, 14 individuals
ARR01499	GSE8190	GSE8190c	GSM202431	GPL1708	linear	raw	NA	NFkB	epithelial cells	control	treated with LPS	4 h	2 replicates each, 14 individuals
ARR01500	GSE8190	GSE8190c	GSM202432	GPL1708	linear	raw	NA	NFkB	epithelial cells	activating	treated with LPS	4 h	2 replicates each, 14 individuals
ARR01501	GSE8190	GSE8190c	GSM202433	GPL1708	linear	raw	NA	NFkB	epithelial cells	activating	treated with LPS	4 h	2 replicates each, 14 individuals
ARR01502	GSE9988	GSE9988a	GSM252485	GPL570	linear	raw	CELS/GSE9988/GSM252485.CEL	NFkB	Human monocytes (donor 1)	control	treated with LPS	2 h	10 anonymous donors in this set
ARR01503	GSE9988	GSE9988a	GSM252451	GPL570	linear	raw	CELS/GSE9988/GSM252451.CEL	NFkB	Human monocytes (donor 1)	activating	treated with LPS	2 h	10 anonymous donors in this set
ARR01504	GSE7850	GSE7850e	GSM190533	GPL201	log	raw	NA	NFkB	Retinal endothelial cell	control	treated with LPS 10 100 ng/mL	4 h	three different patients 2 different tissues
ARR01505	GSE7850	GSE7850e	GSM190534	GPL201	log	raw	NA	NFkB	Retinal endothelial cell	control	treated with LPS 10 100 ng/mL	4 h	three different patients 2 different tissues
ARR01506	GSE7850	GSE7850e	GSM190535	GPL201	log	raw	NA	NFkB	Retinal endothelial cell	activating	treated with LPS 10 100 ng/mL	4 h	three different patients 2 different tissues
ARR01507	GSE7850	GSE7850e	GSM190536	GPL201	log	raw	NA	NFkB	Retinal endothelial cell	activating	treated with LPS 10 100 ng/mL	4 h	three different patients 2 different tissues
ARR01508	GSE19738	GSE19738c	GSM492852	GPL6848	linear	raw	NA	NFkB	whole blood cells	control	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01509	GSE19738	GSE19738c	GSM492919	GPL6848	linear	raw	NA	NFkB	whole blood cells	activating	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01510	GSE18047	GSE18047d	GSM451270	GPL570	log	raw	CELS/GSE18047/GSM451270.CEL	NFkB	SACHI (Multiple Myeloma Cell Line)	control	transfected with IKKB	undefined	overexpression directly above NFkB
ARR01511	GSE18047	GSE18047d	GSM451273	GPL570	log	raw	CELS/GSE18047/GSM451273.CEL	NFkB	SACHI (Multiple Myeloma Cell Line)	control	transfected with IKKB	undefined	overexpression directly above NFkB
ARR01512	GSE18047	GSE18047d	GSM451276	GPL570	log	raw	CELS/GSE18047/GSM451276.CEL	NFkB	SACHI (Multiple Myeloma Cell Line)	control	transfected with IKKB	undefined	overexpression directly above NFkB
ARR01513	GSE18047	GSE18047d	GSM451272	GPL570	log	raw	CELS/GSE18047/GSM451272.CEL	NFkB	SACHI (Multiple Myeloma Cell Line)	activating	transfected with IKKB	undefined	overexpression directly above NFkB
ARR01514	GSE18047	GSE18047d	GSM451275	GPL570	log	raw	CELS/GSE18047/GSM451275.CEL	NFkB	SACHI (Multiple Myeloma Cell Line)	activating	transfected with IKKB	undefined	overexpression directly above NFkB
ARR01515	GSE18047	GSE18047d	GSM451278	GPL570	log	raw	CELS/GSE18047/GSM451278.CEL	NFkB	SACHI (Multiple Myeloma Cell Line)	activating	transfected with IKKB	undefined	overexpression directly above NFkB
ARR01516	GSE9988	GSE9988h	GSM252477	GPL570	linear	raw	CELS/GSE9988/GSM252477.CEL	NFkB	Human monocytes (donor 8)	control	treated with LPS	2 h	10 anonymous donors in this set
ARR01517	GSE9988	GSE9988h	GSM252454	GPL570	linear	raw	CELS/GSE9988/GSM252454.CEL	NFkB	Human monocytes (donor 8)	activating	treated with LPS	2 h	10 anonymous donors in this set
ARR01518	GSE19738	GSE19738a	GSM492850	GPL6848	linear	raw	NA	NFkB	whole blood cells	control	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01519	GSE19738	GSE19738a	GSM492917	GPL6848	linear	raw	NA	NFkB	whole blood cells	activating	treated with LPS	5-6 h	1 replicate each, 34 individuals
ARR01520	GSE20198	GSE20198a	GSM506700	GPL96	log	raw	CELS/GSE20198/GSM506700.CEL	JAK-STAT	activated cord blood CD4+ T cells	control	treated with IFNa	2 h	1 replicate, part of time series
ARR01521	GSE20198	GSE20198a	GSM506701	GPL96	log	raw	CELS/GSE20198/GSM506701.CEL	JAK-STAT	activated cord blood CD4+ T cells	activating	treated with IFNa	2 h	1 replicate, part of time series
ARR01522	GSE16253	GSE16253g	GSM409237	GPL8601	linear	raw	NA	JAK-STAT	primary CD4+ T cells	control	treated with 0.6 pM IFNg	0.5 h	1 replicate, time respective control, part of time series, different cell lines
ARR01523	GSE16253	GSE16253g	GSM409276	GPL8601	linear	raw	NA	JAK-STAT	primary CD4+ T cells	activating	treated with 0.6 pM IFNg	0.5 h	1 replicate, time respective control, part of time series, different cell lines
ARR01524	GSE23591	GSE23591h	GSM578595	GPL6244	linear	raw	CELS/GSE23591/GSM578595.CEL	JAK-STAT	MedB1 lymphoma derived cell line	control	treated with 20 ng/ml IL-13	0.5 h	1 replicate, time resolved controls, part of time series
ARR01525	GSE23591	GSE23591h	GSM578596	GPL6244	linear	raw	CELS/GSE23591/GSM578596.CEL	JAK-STAT	MedB1 lymphoma derived cell line	activating	treated with 20 ng/ml IL-13	0.5 h	1 replicate, time resolved controls, part of time series
ARR01526	GSE16450	GSE16450b	GSM413558	GPL570	log	raw	CELS/GSE16450/GSM413558.CEL	JAK-STAT	mature BE(2)-C neuroblastoma cell line	control	treated with IFNa-A/D	6 h	3 replicates
ARR01527	GSE16450	GSE16450b	GSM413559	GPL570	log	raw	CELS/GSE16450/GSM413559.CEL	JAK-STAT	mature BE(2)-C neuroblastoma cell line	control	treated with IFNa-A/D	6 h	3 replicates
ARR01528	GSE16450	GSE16450b	GSM413560	GPL570	log	raw	CELS/GSE16450/GSM413560.CEL	JAK-STAT	mature BE(2)-C neuroblastoma cell line	control	treated with IFNa-A/D	6 h	3 replicates
ARR01529	GSE16450	GSE16450b	GSM413561	GPL570	log	raw	CELS/GSE16450/GSM413561.CEL	JAK-STAT	mature BE(2)-C neuroblastoma cell line	activating	treated with IFNa-A/D	6 h	3 replicates
ARR01530	GSE16450	GSE16450b	GSM413562	GPL570	log	raw	CELS/GSE16450/GSM413562.CEL	JAK-STAT	mature BE(2)-C neuroblastoma cell line	activating	treated with IFNa-A/D	6 h	3 replicates
ARR01531	GSE16450	GSE16450b	GSM413563	GPL570	log	raw	CELS/GSE16450/GSM413563.CEL	JAK-STAT	mature BE(2)-C neuroblastoma cell line	activating	treated with IFNa-A/D	6 h	3 replicates
ARR01532	GSE10685	GSE10685	GSM269808	GPL570	log	raw	CELS/GSE10685/GSM269808.CEL	JAK-STAT	skeletal muscle biopsies	control	patients treated with IL-6 infusion	3 h	3 donors
ARR01533	GSE10685	GSE10685	GSM269811	GPL570	log	raw	CELS/GSE10685/GSM269811.CEL	JAK-STAT	skeletal muscle biopsies	control	patients treated with IL-6 infusion	3 h	3 donors
ARR01534	GSE10685	GSE10685	GSM269932	GPL570	log	raw	CELS/GSE10685/GSM269932.CEL	JAK-STAT	skeletal muscle biopsies	control	patients treated with IL-6 infusion	3 h	3 donors
ARR01535	GSE10685	GSE10685	GSM269809	GPL570	log	raw	CELS/GSE10685/GSM269809.CEL	JAK-STAT	skeletal muscle biopsies	activating	patients treated with IL-6 infusion	3 h	3 donors
ARR01536	GSE10685	GSE10685	GSM269834	GPL570	log	raw	CELS/GSE10685/GSM269834.CEL	JAK-STAT	skeletal muscle biopsies	activating	patients treated with IL-6 infusion	3 h	3 donors
ARR01537	GSE10685	GSE10685	GSM269933	GPL570	log	raw	CELS/GSE10685/GSM269933.CEL	JAK-STAT	skeletal muscle biopsies	activating	patients treated with IL-6 infusion	3 h	3 donors
ARR01538	GSE3920	GSE3920b	GSM89636	GPL96	log	raw	NA	JAK-STAT	HUVECs	control	treated with IFNb	5 h	2 replicates
ARR01539	GSE3920	GSE3920b	GSM89639	GPL96	log	raw	NA	JAK-STAT	HUVECs	control	treated with IFNb	5 h	2 replicates
ARR01540	GSE3920	GSE3920b	GSM89638	GPL96	log	raw	NA	JAK-STAT	HUVECs	activating	treated with IFNb	5 h	2 replicates
ARR01541	GSE3920	GSE3920b	GSM89641	GPL96	log	raw	NA	JAK-STAT	HUVECs	activating	treated with IFNb	5 h	2 replicates
ARR01542	GSE8685	GSE8685b	GSM215347	GPL570	log	raw	CELS/GSE8685/GSM215347.CEL	JAK-STAT	Sez-4 cell line	control	treated with 20ng/ml IL-15	4 h	3 replicates, different IL treatments, after 16h IL2 starvation
ARR01543	GSE8685	GSE8685b	GSM215348	GPL570	log	raw	CELS/GSE8685/GSM215348.CEL	JAK-STAT	Sez-4 cell line	control	treated with 20ng/ml IL-15	4 h	3 replicates, different IL treatments, after 16h IL2 starvation
ARR01544	GSE8685	GSE8685b	GSM215349	GPL570	log	raw	CELS/GSE8685/GSM215349.CEL	JAK-STAT	Sez-4 cell line	control	treated with 20ng/ml IL-15	4 h	3 replicates, different IL treatments, after 16h IL2 starvation
ARR01545	GSE8685	GSE8685b	GSM215353	GPL570	log	raw	CELS/GSE8685/GSM215353.CEL	JAK-STAT	Sez-4 cell line	activating	treated with 20ng/ml IL-15	4 h	3 replicates, different IL treatments, after 16h IL2 starvation
ARR01546	GSE8685	GSE8685b	GSM215354	GPL570	log	raw	CELS/GSE8685/GSM215354.CEL	JAK-STAT	Sez-4 cell line	activating	treated with 20ng/ml IL-15	4 h	3 replicates, different IL treatments, after 16h IL2 starvation
ARR01547	GSE8685	GSE8685b	GSM215355	GPL570	log	raw	CELS/GSE8685/GSM215355.CEL	JAK-STAT	Sez-4 cell line	activating	treated with 20ng/ml IL-15	4 h	3 replicates, different IL treatments, after 16h IL2 starvation
ARR01548	GSE14632	GSE14632b	GSM636652	GPL6104	linear	raw	NA	JAK-STAT	HepG2 hepatocarcinoma cell line	control	treated with 20ng/ml IL-6	2 h	2 replicates, part of time series, 4h serum starvation before treatment
ARR01549	GSE14632	GSE14632b	GSM636653	GPL6104	linear	raw	NA	JAK-STAT	HepG2 hepatocarcinoma cell line	control	treated with 20ng/ml IL-6	2 h	2 replicates, part of time series, 4h serum starvation before treatment
ARR01550	GSE14632	GSE14632b	GSM636656	GPL6104	linear	raw	NA	JAK-STAT	HepG2 hepatocarcinoma cell line	activating	treated with 20ng/ml IL-6	2 h	2 replicates, part of time series, 4h serum starvation before treatment
ARR01551	GSE14632	GSE14632b	GSM636657	GPL6104	linear	raw	NA	JAK-STAT	HepG2 hepatocarcinoma cell line	activating	treated with 20ng/ml IL-6	2 h	2 replicates, part of time series, 4h serum starvation before treatment
ARR01552	GSE16252	GSE16252k	GSM409194	GPL8601	linear	raw	NA	JAK-STAT	primary PBMCs	control	treated with 0.006 pM IFNg	2 h	1 replicate, time respective control, part of time and concentration series
ARR01553	GSE16252	GSE16252k	GSM409201	GPL8601	linear	raw	NA	JAK-STAT	primary PBMCs	activating	treated with 0.006 pM IFNg	2 h	1 replicate, time respective control, part of time and concentration series
ARR01554	GSE16450	GSE16450a	GSM413549	GPL570	log	raw	CELS/GSE16450/GSM413549.CEL	JAK-STAT	immature BE(2)-C neuroblastoma cell line	control	treated with IFNa-A/D	6 h	3 replicates
ARR01555	GSE16450	GSE16450a	GSM413550	GPL570	log	raw	CELS/GSE16450/GSM413550.CEL	JAK-STAT	immature BE(2)-C neuroblastoma cell line	control	treated with IFNa-A/D	6 h	3 replicates
ARR01556	GSE16450	GSE16450a	GSM413551	GPL570	log	raw	CELS/GSE16450/GSM413551.CEL	JAK-STAT	immature BE(2)-C neuroblastoma cell line	control	treated with IFNa-A/D	6 h	3 replicates
ARR01557	GSE16450	GSE16450a	GSM413552	GPL570	log	raw	CELS/GSE16450/GSM413552.CEL	JAK-STAT	immature BE(2)-C neuroblastoma cell line	activating	treated with IFNa-A/D	6 h	3 replicates
ARR01558	GSE16450	GSE16450a	GSM413553	GPL570	log	raw	CELS/GSE16450/GSM413553.CEL	JAK-STAT	immature BE(2)-C neuroblastoma cell line	activating	treated with IFNa-A/D	6 h	3 replicates
ARR01559	GSE16450	GSE16450a	GSM413554	GPL570	log	raw	CELS/GSE16450/GSM413554.CEL	JAK-STAT	immature BE(2)-C neuroblastoma cell line	activating	treated with IFNa-A/D	6 h	3 replicates
ARR01560	GSE16252	GSE16252f	GSM409199	GPL8601	linear	raw	NA	JAK-STAT	primary PBMCs	control	treated with 60 pM IFNg	1 h	1 replicate, time respective control, part of time and concentration series
ARR01561	GSE16252	GSE16252f	GSM409209	GPL8601	linear	raw	NA	JAK-STAT	primary PBMCs	activating	treated with 60 pM IFNg	1 h	1 replicate, time respective control, part of time and concentration series
ARR01562	GSE22325	GSE22325b	GSM555847	GPL570	linear	raw	CELS/GSE22325/GSM555847.CEL	JAK-STAT	HUVECs	control	treated with 100 U/ml IL-6	4 h	1 replicate each, time resolved control
ARR01563	GSE22325	GSE22325b	GSM555858	GPL570	linear	raw	CELS/GSE22325/GSM555858.CEL	JAK-STAT	HUVECs	activating	treated with 100 U/ml IL-6	4 h	1 replicate each, time resolved control
ARR01564	GSE33264	GSE33264c	GSM823074	GPL4133	log	normalized	NA	JAK-STAT	Calu-3 cells	control	treated with 500 U/ml IFNg	3 h	3 replicates each, part of time series with 2 treatment conditions
ARR01565	GSE33264	GSE33264c	GSM823075	GPL4133	log	normalized	NA	JAK-STAT	Calu-3 cells	control	treated with 500 U/ml IFNg	3 h	3 replicates each, part of time series with 2 treatment conditions
ARR01566	GSE33264	GSE33264c	GSM823076	GPL4133	log	normalized	NA	JAK-STAT	Calu-3 cells	control	treated with 500 U/ml IFNg	3 h	3 replicates each, part of time series with 2 treatment conditions
ARR01567	GSE33264	GSE33264c	GSM823050	GPL4133	log	normalized	NA	JAK-STAT	Calu-3 cells	activating	treated with 500 U/ml IFNg	3 h	3 replicates each, part of time series with 2 treatment conditions
ARR01568	GSE33264	GSE33264c	GSM823051	GPL4133	log	normalized	NA	JAK-STAT	Calu-3 cells	activating	treated with 500 U/ml IFNg	3 h	3 replicates each, part of time series with 2 treatment conditions
ARR01569	GSE33264	GSE33264c	GSM823052	GPL4133	log	normalized	NA	JAK-STAT	Calu-3 cells	activating	treated with 500 U/ml IFNg	3 h	3 replicates each, part of time series with 2 treatment conditions
ARR01570	GSE20272	GSE20272b	GSM508294	GPL570	log	raw	NA	JAK-STAT	Caov-3 ovarian cancer cell line	control	treated with IL-6	1 h	1 replicate, 2 different cell lines
ARR01571	GSE20272	GSE20272b	GSM508295	GPL570	log	raw	NA	JAK-STAT	Caov-3 ovarian cancer cell line	activating	treated with IL-6	1 h	1 replicate, 2 different cell lines
ARR01572	GSE21760	GSE21760b	GSM542389	GPL570	log	normalized	CELS/GSE21760/GSM542389.CEL	JAK-STAT	HeLa cells	control	treated with IFNg	4 h	1 replicate, part of time series
ARR01573	GSE21760	GSE21760b	GSM542391	GPL570	log	normalized	CELS/GSE21760/GSM542391.CEL	JAK-STAT	HeLa cells	activating	treated with IFNg	4 h	1 replicate, part of time series
ARR01574	GSE16251	GSE16251a	GSM409172	GPL8601	linear	raw	NA	JAK-STAT	primary PBMCs	control	treated with IFNa	4 h	1 replicate, time respective control, part of time
ARR01575	GSE16251	GSE16251a	GSM409178	GPL8601	linear	raw	NA	JAK-STAT	primary PBMCs	activating	treated with IFNa	4 h	1 replicate, time respective control, part of time
ARR01576	GSE22325	GSE22325a	GSM555847	GPL570	linear	raw	CELS/GSE22325/GSM555847.CEL	JAK-STAT	HUVECs	control	treated with 100 U/ml IL-3	4 h	1 replicate each, time resolved control
ARR01577	GSE22325	GSE22325a	GSM555854	GPL570	linear	raw	CELS/GSE22325/GSM555854.CEL	JAK-STAT	HUVECs	activating	treated with 100 U/ml IL-3	4 h	1 replicate each, time resolved control
ARR01578	GSE16251	GSE16251e	GSM409178	GPL8601	linear	raw	NA	JAK-STAT	primary PBMCs	control	treated with IIL12	4 h	1 replicate, time respective control, part of time
ARR01579	GSE16251	GSE16251e	GSM409152	GPL8601	linear	raw	NA	JAK-STAT	primary PBMCs	activating	treated with IIL12	4 h	1 replicate, time respective control, part of time
ARR01580	GSE16253	GSE16253k	GSM409223	GPL8601	linear	raw	NA	JAK-STAT	primary NK cells	control	treated with 0.6 pM IFNg	1 h	1 replicate, time respective control, part of time series, different cell lines
ARR01581	GSE16253	GSE16253k	GSM409273	GPL8601	linear	raw	NA	JAK-STAT	primary NK cells	activating	treated with 0.6 pM IFNg	1 h	1 replicate, time respective control, part of time series, different cell lines
ARR01582	GSE23307	GSE23307c	GSM571902	GPL6104	log	normalized	NA	JAK-STAT	primary monocytes	control	treated with IFN-b	3 h	1 replicate each, respective time control, 2 individuals
ARR01583	GSE23307	GSE23307c	GSM571901	GPL6104	log	normalized	NA	JAK-STAT	primary monocytes	activating	treated with IFN-b	3 h	1 replicate each, respective time control, 2 individuals
ARR01584	GSE23307	GSE23307b	GSM571904	GPL6104	log	normalized	NA	JAK-STAT	primary B cells	control	treated with IFN-b	3 h	1 replicate each, respective time control, 2 individuals
ARR01585	GSE23307	GSE23307b	GSM571903	GPL6104	log	normalized	NA	JAK-STAT	primary B cells	activating	treated with IFN-b	3 h	1 replicate each, respective time control, 2 individuals
ARR01586	GSE1432	GSE1432c	GSM26927	GPL96	linear	raw	NA	JAK-STAT	primary human microglial cells W	control	treated with IFN-gamma (respective time control)	1 h	comment
ARR01587	GSE1432	GSE1432c	GSM23895	GPL96	linear	raw	NA	JAK-STAT	primary human microglial cells W	activating	treated with IFN-gamma (respective time control)	1 h	comment
ARR01588	GSE5542	GSE5542a	GSM128888	GPL96	log	raw	NA	JAK-STAT	A549 cell line	control	treated with 500U Infergen (Interferon type 1)	6 h	4 replicates
ARR01589	GSE5542	GSE5542a	GSM128893	GPL96	log	raw	NA	JAK-STAT	A549 cell line	control	treated with 500U Infergen (Interferon type 1)	6 h	4 replicates
ARR01590	GSE5542	GSE5542a	GSM128902	GPL96	log	raw	NA	JAK-STAT	A549 cell line	control	treated with 500U Infergen (Interferon type 1)	6 h	4 replicates
ARR01591	GSE5542	GSE5542a	GSM128911	GPL96	log	raw	NA	JAK-STAT	A549 cell line	control	treated with 500U Infergen (Interferon type 1)	6 h	4 replicates
ARR01592	GSE5542	GSE5542a	GSM128884	GPL96	log	raw	NA	JAK-STAT	A549 cell line	activating	treated with 500U Infergen (Interferon type 1)	6 h	4 replicates
ARR01593	GSE5542	GSE5542a	GSM128890	GPL96	log	raw	NA	JAK-STAT	A549 cell line	activating	treated with 500U Infergen (Interferon type 1)	6 h	4 replicates
ARR01594	GSE5542	GSE5542a	GSM128899	GPL96	log	raw	NA	JAK-STAT	A549 cell line	activating	treated with 500U Infergen (Interferon type 1)	6 h	4 replicates
ARR01595	GSE5542	GSE5542a	GSM128908	GPL96	log	raw	NA	JAK-STAT	A549 cell line	activating	treated with 500U Infergen (Interferon type 1)	6 h	4 replicates
ARR01596	GSE16251	GSE16251c	GSM409180	GPL8601	linear	raw	NA	JAK-STAT	primary PBMCs	control	treated with IIL12	0.5 h	1 replicate, time respective control, part of time
ARR01597	GSE16251	GSE16251c	GSM409183	GPL8601	linear	raw	NA	JAK-STAT	primary PBMCs	activating	treated with IIL12	0.5 h	1 replicate, time respective control, part of time
ARR01598	GSE3920	GSE3920a	GSM89636	GPL96	log	raw	NA	JAK-STAT	HUVECs	control	treated with IFNa	5 h	5 replicates
ARR01599	GSE3920	GSE3920a	GSM89639	GPL96	log	raw	NA	JAK-STAT	HUVECs	control	treated with IFNa	5 h	5 replicates
ARR01600	GSE3920	GSE3920a	GSM89642	GPL96	log	raw	NA	JAK-STAT	HUVECs	control	treated with IFNa	5 h	5 replicates
ARR01601	GSE3920	GSE3920a	GSM89643	GPL96	log	raw	NA	JAK-STAT	HUVECs	control	treated with IFNa	5 h	5 replicates
ARR01602	GSE3920	GSE3920a	GSM89644	GPL96	log	raw	NA	JAK-STAT	HUVECs	control	treated with IFNa	5 h	5 replicates
ARR01603	GSE3920	GSE3920a	GSM89637	GPL96	log	raw	NA	JAK-STAT	HUVECs	activating	treated with IFNa	5 h	5 replicates
ARR01604	GSE3920	GSE3920a	GSM89640	GPL96	log	raw	NA	JAK-STAT	HUVECs	activating	treated with IFNa	5 h	5 replicates
ARR01605	GSE3920	GSE3920a	GSM89645	GPL96	log	raw	NA	JAK-STAT	HUVECs	activating	treated with IFNa	5 h	5 replicates
ARR01606	GSE3920	GSE3920a	GSM89646	GPL96	log	raw	NA	JAK-STAT	HUVECs	activating	treated with IFNa	5 h	5 replicates
ARR01607	GSE3920	GSE3920a	GSM89647	GPL96	log	raw	NA	JAK-STAT	HUVECs	activating	treated with IFNa	5 h	5 replicates
ARR01608	GSE23591	GSE23591i	GSM578597	GPL6244	linear	raw	CELS/GSE23591/GSM578597.CEL	JAK-STAT	MedB1 lymphoma derived cell line	control	treated with 20 ng/ml IL-13	1 h	1 replicate, time resolved controls, part of time series
ARR01609	GSE23591	GSE23591i	GSM578598	GPL6244	linear	raw	CELS/GSE23591/GSM578598.CEL	JAK-STAT	MedB1 lymphoma derived cell line	activating	treated with 20 ng/ml IL-13	1 h	1 replicate, time resolved controls, part of time series
ARR01610	GSE23591	GSE23591j	GSM578599	GPL6244	linear	raw	CELS/GSE23591/GSM578599.CEL	JAK-STAT	MedB1 lymphoma derived cell line	control	treated with 20 ng/ml IL-13	1.5 h	1 replicate, time resolved controls, part of time series
ARR01611	GSE23591	GSE23591j	GSM578600	GPL6244	linear	raw	CELS/GSE23591/GSM578600.CEL	JAK-STAT	MedB1 lymphoma derived cell line	activating	treated with 20 ng/ml IL-13	1.5 h	1 replicate, time resolved controls, part of time series
ARR01612	GSE31193	GSE31193	GSM773317	GPL570	log	raw	CELS/GSE31193/GSM773317.CEL	JAK-STAT	primary hepatocytes	control	treated with 10 U/ml IFN-a	6 h	3 replicates
ARR01613	GSE31193	GSE31193	GSM773318	GPL570	log	raw	CELS/GSE31193/GSM773318.CEL	JAK-STAT	primary hepatocytes	control	treated with 10 U/ml IFN-a	6 h	3 replicates
ARR01614	GSE31193	GSE31193	GSM773319	GPL570	log	raw	CELS/GSE31193/GSM773319.CEL	JAK-STAT	primary hepatocytes	control	treated with 10 U/ml IFN-a	6 h	3 replicates
ARR01615	GSE31193	GSE31193	GSM773323	GPL570	log	raw	CELS/GSE31193/GSM773323.CEL	JAK-STAT	primary hepatocytes	activating	treated with 10 U/ml IFN-a	6 h	3 replicates
ARR01616	GSE31193	GSE31193	GSM773324	GPL570	log	raw	CELS/GSE31193/GSM773324.CEL	JAK-STAT	primary hepatocytes	activating	treated with 10 U/ml IFN-a	6 h	3 replicates
ARR01617	GSE31193	GSE31193	GSM773325	GPL570	log	raw	CELS/GSE31193/GSM773325.CEL	JAK-STAT	primary hepatocytes	activating	treated with 10 U/ml IFN-a	6 h	3 replicates
ARR01618	GSE16253	GSE16253o	GSM409249	GPL8601	linear	raw	NA	JAK-STAT	primary CD8+ T cells	control	treated with 0.6 pM IFNg	4 h	1 replicate, time respective control, part of time series, different cell lines
ARR01619	GSE16253	GSE16253o	GSM409282	GPL8601	linear	raw	NA	JAK-STAT	primary CD8+ T cells	activating	treated with 0.6 pM IFNg	4 h	1 replicate, time respective control, part of time series, different cell lines
ARR01620	GSE8515	GSE8515	GSM211500	GPL96	linear	raw	CELS/GSE8515/GSM211500.CEL	JAK-STAT	human monocyte-derived macrophages	control	treated with IL-6	4 h	5 replicates each
ARR01621	GSE8515	GSE8515	GSM211501	GPL96	linear	raw	CELS/GSE8515/GSM211501.CEL	JAK-STAT	human monocyte-derived macrophages	control	treated with IL-6	4 h	5 replicates each
ARR01622	GSE8515	GSE8515	GSM211502	GPL96	linear	raw	CELS/GSE8515/GSM211502.CEL	JAK-STAT	human monocyte-derived macrophages	control	treated with IL-6	4 h	5 replicates each
ARR01623	GSE8515	GSE8515	GSM211503	GPL96	linear	raw	CELS/GSE8515/GSM211503.CEL	JAK-STAT	human monocyte-derived macrophages	control	treated with IL-6	4 h	5 replicates each
ARR01624	GSE8515	GSE8515	GSM211504	GPL96	linear	raw	CELS/GSE8515/GSM211504.CEL	JAK-STAT	human monocyte-derived macrophages	control	treated with IL-6	4 h	5 replicates each
ARR01625	GSE8515	GSE8515	GSM211510	GPL96	linear	raw	CELS/GSE8515/GSM211510.CEL	JAK-STAT	human monocyte-derived macrophages	activating	treated with IL-6	4 h	5 replicates each
ARR01626	GSE8515	GSE8515	GSM211511	GPL96	linear	raw	CELS/GSE8515/GSM211511.CEL	JAK-STAT	human monocyte-derived macrophages	activating	treated with IL-6	4 h	5 replicates each
ARR01627	GSE8515	GSE8515	GSM211512	GPL96	linear	raw	CELS/GSE8515/GSM211512.CEL	JAK-STAT	human monocyte-derived macrophages	activating	treated with IL-6	4 h	5 replicates each
ARR01628	GSE8515	GSE8515	GSM211513	GPL96	linear	raw	CELS/GSE8515/GSM211513.CEL	JAK-STAT	human monocyte-derived macrophages	activating	treated with IL-6	4 h	5 replicates each
ARR01629	GSE8515	GSE8515	GSM211514	GPL96	linear	raw	CELS/GSE8515/GSM211514.CEL	JAK-STAT	human monocyte-derived macrophages	activating	treated with IL-6	4 h	5 replicates each
ARR01630	GSE23591	GSE23591f	GSM578585	GPL6244	linear	raw	CELS/GSE23591/GSM578585.CEL	JAK-STAT	L1236 lymphoma derived cell line	control	treated with 40 ng/ml IL-13	4 h	1 replicate, time resolved controls, part of time series
ARR01631	GSE23591	GSE23591f	GSM578586	GPL6244	linear	raw	CELS/GSE23591/GSM578586.CEL	JAK-STAT	L1236 lymphoma derived cell line	activating	treated with 40 ng/ml IL-13	4 h	1 replicate, time resolved controls, part of time series
ARR01632	GSE26949	GSE26949	GSM663476	GPL11670	linear	raw	NA	JAK-STAT	peripheral blood EPCs/CACs	control	treated with IFNa	6 h	6 replicates each
ARR01633	GSE26949	GSE26949	GSM663477	GPL11670	linear	raw	NA	JAK-STAT	peripheral blood EPCs/CACs	control	treated with IFNa	6 h	6 replicates each
ARR01634	GSE26949	GSE26949	GSM663478	GPL11670	linear	raw	NA	JAK-STAT	peripheral blood EPCs/CACs	control	treated with IFNa	6 h	6 replicates each
ARR01635	GSE26949	GSE26949	GSM663479	GPL11670	linear	raw	NA	JAK-STAT	peripheral blood EPCs/CACs	control	treated with IFNa	6 h	6 replicates each
ARR01636	GSE26949	GSE26949	GSM663480	GPL11670	linear	raw	NA	JAK-STAT	peripheral blood EPCs/CACs	control	treated with IFNa	6 h	6 replicates each
ARR01637	GSE26949	GSE26949	GSM663481	GPL11670	linear	raw	NA	JAK-STAT	peripheral blood EPCs/CACs	control	treated with IFNa	6 h	6 replicates each
ARR01638	GSE26949	GSE26949	GSM663482	GPL11670	linear	raw	NA	JAK-STAT	peripheral blood EPCs/CACs	activating	treated with IFNa	6 h	6 replicates each
ARR01639	GSE26949	GSE26949	GSM663483	GPL11670	linear	raw	NA	JAK-STAT	peripheral blood EPCs/CACs	activating	treated with IFNa	6 h	6 replicates each
ARR01640	GSE26949	GSE26949	GSM663484	GPL11670	linear	raw	NA	JAK-STAT	peripheral blood EPCs/CACs	activating	treated with IFNa	6 h	6 replicates each
ARR01641	GSE26949	GSE26949	GSM663485	GPL11670	linear	raw	NA	JAK-STAT	peripheral blood EPCs/CACs	activating	treated with IFNa	6 h	6 replicates each
ARR01642	GSE26949	GSE26949	GSM663486	GPL11670	linear	raw	NA	JAK-STAT	peripheral blood EPCs/CACs	activating	treated with IFNa	6 h	6 replicates each
ARR01643	GSE26949	GSE26949	GSM663487	GPL11670	linear	raw	NA	JAK-STAT	peripheral blood EPCs/CACs	activating	treated with IFNa	6 h	6 replicates each
ARR01644	GSE16253	GSE16253b	GSM409228	GPL8601	linear	raw	NA	JAK-STAT	primary monocytes	control	treated with 0.6 pM IFNg	4 h	1 replicate, time respective control, part of time series, different cell lines
ARR01645	GSE16253	GSE16253b	GSM409257	GPL8601	linear	raw	NA	JAK-STAT	primary monocytes	activating	treated with 0.6 pM IFNg	4 h	1 replicate, time respective control, part of time series, different cell lines
ARR01646	GSE23591	GSE23591n	GSM578607	GPL6244	linear	raw	CELS/GSE23591/GSM578607.CEL	JAK-STAT	MedB1 lymphoma derived cell line	control	treated with 20 ng/ml IL-13	6 h	1 replicate, time resolved controls, part of time series
ARR01647	GSE23591	GSE23591n	GSM578608	GPL6244	linear	raw	CELS/GSE23591/GSM578608.CEL	JAK-STAT	MedB1 lymphoma derived cell line	activating	treated with 20 ng/ml IL-13	6 h	1 replicate, time resolved controls, part of time series
ARR01648	GSE5542	GSE5542b	GSM128888	GPL96	log	raw	NA	JAK-STAT	A549 cell line	control	treated with 500U IFN-g1b	6 h	4 replicates
ARR01649	GSE5542	GSE5542b	GSM128893	GPL96	log	raw	NA	JAK-STAT	A549 cell line	control	treated with 500U IFN-g1b	6 h	4 replicates
ARR01650	GSE5542	GSE5542b	GSM128902	GPL96	log	raw	NA	JAK-STAT	A549 cell line	control	treated with 500U IFN-g1b	6 h	4 replicates
ARR01651	GSE5542	GSE5542b	GSM128911	GPL96	log	raw	NA	JAK-STAT	A549 cell line	control	treated with 500U IFN-g1b	6 h	4 replicates
ARR01652	GSE5542	GSE5542b	GSM128885	GPL96	log	raw	NA	JAK-STAT	A549 cell line	activating	treated with 500U IFN-g1b	6 h	4 replicates
ARR01653	GSE5542	GSE5542b	GSM128891	GPL96	log	raw	NA	JAK-STAT	A549 cell line	activating	treated with 500U IFN-g1b	6 h	4 replicates
ARR01654	GSE5542	GSE5542b	GSM128900	GPL96	log	raw	NA	JAK-STAT	A549 cell line	activating	treated with 500U IFN-g1b	6 h	4 replicates
ARR01655	GSE5542	GSE5542b	GSM128909	GPL96	log	raw	NA	JAK-STAT	A549 cell line	activating	treated with 500U IFN-g1b	6 h	4 replicates
ARR01656	GSE23591	GSE23591m	GSM578605	GPL6244	linear	raw	CELS/GSE23591/GSM578605.CEL	JAK-STAT	MedB1 lymphoma derived cell line	control	treated with 20 ng/ml IL-13	4 h	1 replicate, time resolved controls, part of time series
ARR01657	GSE23591	GSE23591m	GSM578606	GPL6244	linear	raw	CELS/GSE23591/GSM578606.CEL	JAK-STAT	MedB1 lymphoma derived cell line	activating	treated with 20 ng/ml IL-13	4 h	1 replicate, time resolved controls, part of time series
ARR01658	GSE16252	GSE16252h	GSM409197	GPL8601	linear	raw	NA	JAK-STAT	primary PBMCs	control	treated with 60 pM IFNg	4 h	1 replicate, time respective control, part of time and concentration series
ARR01659	GSE16252	GSE16252h	GSM409208	GPL8601	linear	raw	NA	JAK-STAT	primary PBMCs	activating	treated with 60 pM IFNg	4 h	1 replicate, time respective control, part of time and concentration series
ARR01660	GSE26951	GSE26951	GSM663500	GPL11670	linear	raw	NA	JAK-STAT	bone marrow EPCs	control	treated with IFNa	6 h	5 replicates each
ARR01661	GSE26951	GSE26951	GSM663501	GPL11670	linear	raw	NA	JAK-STAT	bone marrow EPCs	control	treated with IFNa	6 h	5 replicates each
ARR01662	GSE26951	GSE26951	GSM663502	GPL11670	linear	raw	NA	JAK-STAT	bone marrow EPCs	control	treated with IFNa	6 h	5 replicates each
ARR01663	GSE26951	GSE26951	GSM663503	GPL11670	linear	raw	NA	JAK-STAT	bone marrow EPCs	control	treated with IFNa	6 h	5 replicates each
ARR01664	GSE26951	GSE26951	GSM663504	GPL11670	linear	raw	NA	JAK-STAT	bone marrow EPCs	control	treated with IFNa	6 h	5 replicates each
ARR01665	GSE26951	GSE26951	GSM663505	GPL11670	linear	raw	NA	JAK-STAT	bone marrow EPCs	activating	treated with IFNa	6 h	5 replicates each
ARR01666	GSE26951	GSE26951	GSM663506	GPL11670	linear	raw	NA	JAK-STAT	bone marrow EPCs	activating	treated with IFNa	6 h	5 replicates each
ARR01667	GSE26951	GSE26951	GSM663507	GPL11670	linear	raw	NA	JAK-STAT	bone marrow EPCs	activating	treated with IFNa	6 h	5 replicates each
ARR01668	GSE26951	GSE26951	GSM663508	GPL11670	linear	raw	NA	JAK-STAT	bone marrow EPCs	activating	treated with IFNa	6 h	5 replicates each
ARR01669	GSE26951	GSE26951	GSM663509	GPL11670	linear	raw	NA	JAK-STAT	bone marrow EPCs	activating	treated with IFNa	6 h	5 replicates each
ARR01670	GSE23591	GSE23591l	GSM578603	GPL6244	linear	raw	CELS/GSE23591/GSM578603.CEL	JAK-STAT	MedB1 lymphoma derived cell line	control	treated with 20 ng/ml IL-13	3 h	1 replicate, time resolved controls, part of time series
ARR01671	GSE23591	GSE23591l	GSM578604	GPL6244	linear	raw	CELS/GSE23591/GSM578604.CEL	JAK-STAT	MedB1 lymphoma derived cell line	activating	treated with 20 ng/ml IL-13	3 h	1 replicate, time resolved controls, part of time series
ARR01672	GSE16252	GSE16252g	GSM409194	GPL8601	linear	raw	NA	JAK-STAT	primary PBMCs	control	treated with 60 pM IFNg	2 h	1 replicate, time respective control, part of time and concentration series
ARR01673	GSE16252	GSE16252g	GSM409212	GPL8601	linear	raw	NA	JAK-STAT	primary PBMCs	activating	treated with 60 pM IFNg	2 h	1 replicate, time respective control, part of time and concentration series
ARR01674	GSE16253	GSE16253f	GSM409234	GPL8601	linear	raw	NA	JAK-STAT	primary B cells	control	treated with 0.6 pM IFNg	4 h	1 replicate, time respective control, part of time series, different cell lines
ARR01675	GSE16253	GSE16253f	GSM409279	GPL8601	linear	raw	NA	JAK-STAT	primary B cells	activating	treated with 0.6 pM IFNg	4 h	1 replicate, time respective control, part of time series, different cell lines
ARR01676	GSE16252	GSE16252b	GSM409199	GPL8601	linear	raw	NA	JAK-STAT	primary PBMCs	control	treated with 0.6 pM IFNg	1 h	1 replicate, time respective control, part of time and concentration series
ARR01677	GSE16252	GSE16252b	GSM409190	GPL8601	linear	raw	NA	JAK-STAT	primary PBMCs	activating	treated with 0.6 pM IFNg	1 h	1 replicate, time respective control, part of time and concentration series
ARR01678	GSE1925	GSE1925a	GSM34595	GPL8300	linear	raw	NA	JAK-STAT	primary human CD14+ macrophages Pool1	control	treated with IFN-gamma	3 h	none
ARR01679	GSE1925	GSE1925a	GSM34596	GPL8300	linear	raw	NA	JAK-STAT	primary human CD14+ macrophages Pool1	activating	treated with IFN-gamma	3 h	none
ARR01680	GSE1925	GSE1925b	GSM34601	GPL8300	linear	raw	NA	JAK-STAT	primary human CD14+ macrophages Pool2	control	treated with IFN-gamma	3 h	comment
ARR01681	GSE1925	GSE1925b	GSM34602	GPL8300	linear	raw	NA	JAK-STAT	primary human CD14+ macrophages Pool2	activating	treated with IFN-gamma	3 h	comment
ARR01682	GSE23591	GSE23591c	GSM578579	GPL6244	linear	raw	CELS/GSE23591/GSM578579.CEL	JAK-STAT	L1236 lymphoma derived cell line	control	treated with 40 ng/ml IL-13	1.5 h	1 replicate, time resolved controls, part of time series
ARR01683	GSE23591	GSE23591c	GSM578580	GPL6244	linear	raw	CELS/GSE23591/GSM578580.CEL	JAK-STAT	L1236 lymphoma derived cell line	activating	treated with 40 ng/ml IL-13	1.5 h	1 replicate, time resolved controls, part of time series
ARR01684	GSE23591	GSE23591e	GSM578583	GPL6244	linear	raw	CELS/GSE23591/GSM578583.CEL	JAK-STAT	L1236 lymphoma derived cell line	control	treated with 40 ng/ml IL-13	3 h	1 replicate, time resolved controls, part of time series
ARR01685	GSE23591	GSE23591e	GSM578584	GPL6244	linear	raw	CELS/GSE23591/GSM578584.CEL	JAK-STAT	L1236 lymphoma derived cell line	activating	treated with 40 ng/ml IL-13	3 h	1 replicate, time resolved controls, part of time series
ARR01686	GSE14632	GSE14632a	GSM636652	GPL6104	linear	raw	NA	JAK-STAT	HepG2 hepatocarcinoma cell line	control	treated with 20ng/ml IL-6	1 h	2 replicates, part of time series, 4h serum starvation before treatment
ARR01687	GSE14632	GSE14632a	GSM636653	GPL6104	linear	raw	NA	JAK-STAT	HepG2 hepatocarcinoma cell line	control	treated with 20ng/ml IL-6	1 h	2 replicates, part of time series, 4h serum starvation before treatment
ARR01688	GSE14632	GSE14632a	GSM636654	GPL6104	linear	raw	NA	JAK-STAT	HepG2 hepatocarcinoma cell line	activating	treated with 20ng/ml IL-6	1 h	2 replicates, part of time series, 4h serum starvation before treatment
ARR01689	GSE14632	GSE14632a	GSM636655	GPL6104	linear	raw	NA	JAK-STAT	HepG2 hepatocarcinoma cell line	activating	treated with 20ng/ml IL-6	1 h	2 replicates, part of time series, 4h serum starvation before treatment
ARR01690	GSE23307	GSE23307a	GSM571900	GPL6104	log	normalized	NA	JAK-STAT	primary B cells	control	treated with IFN-b	3 h	1 replicate each, respective time control, 2 individuals
ARR01691	GSE23307	GSE23307a	GSM571899	GPL6104	log	normalized	NA	JAK-STAT	primary B cells	activating	treated with IFN-b	3 h	1 replicate each, respective time control, 2 individuals
ARR01692	GSE16755	GSE16755	GSM419987	GPL570	log	raw	CELS/GSE16755/GSM419987.CEL	JAK-STAT	macrophages	control	treated with IFNa	unknown	3 replicates
ARR01693	GSE16755	GSE16755	GSM419988	GPL570	log	raw	CELS/GSE16755/GSM419988.CEL	JAK-STAT	macrophages	control	treated with IFNa	unknown	3 replicates
ARR01694	GSE16755	GSE16755	GSM419989	GPL570	log	raw	CELS/GSE16755/GSM419989.CEL	JAK-STAT	macrophages	control	treated with IFNa	unknown	3 replicates
ARR01695	GSE16755	GSE16755	GSM419990	GPL570	log	raw	CELS/GSE16755/GSM419990.CEL	JAK-STAT	macrophages	activating	treated with IFNa	unknown	3 replicates
ARR01696	GSE16755	GSE16755	GSM419991	GPL570	log	raw	CELS/GSE16755/GSM419991.CEL	JAK-STAT	macrophages	activating	treated with IFNa	unknown	3 replicates
ARR01697	GSE16755	GSE16755	GSM419992	GPL570	log	raw	CELS/GSE16755/GSM419992.CEL	JAK-STAT	macrophages	activating	treated with IFNa	unknown	3 replicates
ARR01698	GSE33264	GSE33264d	GSM823077	GPL4133	log	normalized	NA	JAK-STAT	Calu-3 cells	control	treated with 500 U/ml IFNg	6 h	3 replicates each, part of time series with 2 treatment conditions
ARR01699	GSE33264	GSE33264d	GSM823078	GPL4133	log	normalized	NA	JAK-STAT	Calu-3 cells	control	treated with 500 U/ml IFNg	6 h	3 replicates each, part of time series with 2 treatment conditions
ARR01700	GSE33264	GSE33264d	GSM823079	GPL4133	log	normalized	NA	JAK-STAT	Calu-3 cells	control	treated with 500 U/ml IFNg	6 h	3 replicates each, part of time series with 2 treatment conditions
ARR01701	GSE33264	GSE33264d	GSM823053	GPL4133	log	normalized	NA	JAK-STAT	Calu-3 cells	activating	treated with 500 U/ml IFNg	6 h	3 replicates each, part of time series with 2 treatment conditions
ARR01702	GSE33264	GSE33264d	GSM823054	GPL4133	log	normalized	NA	JAK-STAT	Calu-3 cells	activating	treated with 500 U/ml IFNg	6 h	3 replicates each, part of time series with 2 treatment conditions
ARR01703	GSE33264	GSE33264d	GSM823055	GPL4133	log	normalized	NA	JAK-STAT	Calu-3 cells	activating	treated with 500 U/ml IFNg	6 h	3 replicates each, part of time series with 2 treatment conditions
ARR01704	GSE24409	GSE24409a	GSM601484	GPL6480	linear	raw	NA	JAK-STAT	dermal fibroblasts	control	treated with 50 nM IL-4	2 h	3 replicates control, 1 replicate treatment, part of time series
ARR01705	GSE24409	GSE24409a	GSM601485	GPL6480	linear	raw	NA	JAK-STAT	dermal fibroblasts	control	treated with 50 nM IL-4	2 h	3 replicates control, 1 replicate treatment, part of time series
ARR01706	GSE24409	GSE24409a	GSM601486	GPL6480	linear	raw	NA	JAK-STAT	dermal fibroblasts	control	treated with 50 nM IL-4	2 h	3 replicates control, 1 replicate treatment, part of time series
ARR01707	GSE24409	GSE24409a	GSM601487	GPL6480	linear	raw	NA	JAK-STAT	dermal fibroblasts	activating	treated with 50 nM IL-4	2 h	3 replicates control, 1 replicate treatment, part of time series
ARR01708	GSE16253	GSE16253j	GSM409218	GPL8601	linear	raw	NA	JAK-STAT	primary NK cells	control	treated with 0.6 pM IFNg	4 h	1 replicate, time respective control, part of time series, different cell lines
ARR01709	GSE16253	GSE16253j	GSM409271	GPL8601	linear	raw	NA	JAK-STAT	primary NK cells	activating	treated with 0.6 pM IFNg	4 h	1 replicate, time respective control, part of time series, different cell lines
ARR01710	GSE23591	GSE23591g	GSM578587	GPL6244	linear	raw	CELS/GSE23591/GSM578587.CEL	JAK-STAT	L1236 lymphoma derived cell line	control	treated with 40 ng/ml IL-13	6 h	1 replicate, time resolved controls, part of time series
ARR01711	GSE23591	GSE23591g	GSM578588	GPL6244	linear	raw	CELS/GSE23591/GSM578588.CEL	JAK-STAT	L1236 lymphoma derived cell line	activating	treated with 40 ng/ml IL-13	6 h	1 replicate, time resolved controls, part of time series
ARR01712	GSE16253	GSE16253l	GSM409235	GPL8601	linear	raw	NA	JAK-STAT	primary NK cells	control	treated with 0.6 pM IFNg	0.5 h	1 replicate, time respective control, part of time series, different cell lines
ARR01713	GSE16253	GSE16253l	GSM409274	GPL8601	linear	raw	NA	JAK-STAT	primary NK cells	activating	treated with 0.6 pM IFNg	0.5 h	1 replicate, time respective control, part of time series, different cell lines
ARR01714	GSE16252	GSE16252c	GSM409194	GPL8601	linear	raw	NA	JAK-STAT	primary PBMCs	control	treated with 0.6 pM IFNg	2 h	1 replicate, time respective control, part of time and concentration series
ARR01715	GSE16252	GSE16252c	GSM409187	GPL8601	linear	raw	NA	JAK-STAT	primary PBMCs	activating	treated with 0.6 pM IFNg	2 h	1 replicate, time respective control, part of time and concentration series
ARR01716	GSE23591	GSE23591k	GSM578601	GPL6244	linear	raw	CELS/GSE23591/GSM578601.CEL	JAK-STAT	MedB1 lymphoma derived cell line	control	treated with 20 ng/ml IL-13	2 h	1 replicate, time resolved controls, part of time series
ARR01717	GSE23591	GSE23591k	GSM578602	GPL6244	linear	raw	CELS/GSE23591/GSM578602.CEL	JAK-STAT	MedB1 lymphoma derived cell line	activating	treated with 20 ng/ml IL-13	2 h	1 replicate, time resolved controls, part of time series
ARR01718	GSE16252	GSE16252j	GSM409199	GPL8601	linear	raw	NA	JAK-STAT	primary PBMCs	control	treated with 0.006 pM IFNg	1 h	1 replicate, time respective control, part of time and concentration series
ARR01719	GSE16252	GSE16252j	GSM409191	GPL8601	linear	raw	NA	JAK-STAT	primary PBMCs	activating	treated with 0.006 pM IFNg	1 h	1 replicate, time respective control, part of time and concentration series
ARR01720	GSE20272	GSE20272a	GSM508291	GPL570	log	raw	NA	JAK-STAT	SKOV-3 ovarian cancer cell line	control	treated with IL-6	1 h	1 replicate, 2 different cell lines
ARR01721	GSE20272	GSE20272a	GSM508292	GPL570	log	raw	NA	JAK-STAT	SKOV-3 ovarian cancer cell line	activating	treated with IL-6	1 h	1 replicate, 2 different cell lines
ARR01722	GSE16253	GSE16253h	GSM409261	GPL8601	linear	raw	NA	JAK-STAT	primary CD4+ T cells	control	treated with 0.6 pM IFNg	1 h	1 replicate, time respective control, part of time series, different cell lines
ARR01723	GSE16253	GSE16253h	GSM409264	GPL8601	linear	raw	NA	JAK-STAT	primary CD4+ T cells	activating	treated with 0.6 pM IFNg	1 h	1 replicate, time respective control, part of time series, different cell lines
ARR01724	GSE33264	GSE33264b	GSM823065	GPL4133	log	normalized	NA	JAK-STAT	Calu-3 cells	control	treated with 1000 U/ml IFNa	6 h	3 replicates each, part of time series with 2 treatment conditions
ARR01725	GSE33264	GSE33264b	GSM823066	GPL4133	log	normalized	NA	JAK-STAT	Calu-3 cells	control	treated with 1000 U/ml IFNa	6 h	3 replicates each, part of time series with 2 treatment conditions
ARR01726	GSE33264	GSE33264b	GSM823067	GPL4133	log	normalized	NA	JAK-STAT	Calu-3 cells	control	treated with 1000 U/ml IFNa	6 h	3 replicates each, part of time series with 2 treatment conditions
ARR01727	GSE33264	GSE33264b	GSM823041	GPL4133	log	normalized	NA	JAK-STAT	Calu-3 cells	activating	treated with 1000 U/ml IFNa	6 h	3 replicates each, part of time series with 2 treatment conditions
ARR01728	GSE33264	GSE33264b	GSM823042	GPL4133	log	normalized	NA	JAK-STAT	Calu-3 cells	activating	treated with 1000 U/ml IFNa	6 h	3 replicates each, part of time series with 2 treatment conditions
ARR01729	GSE33264	GSE33264b	GSM823043	GPL4133	log	normalized	NA	JAK-STAT	Calu-3 cells	activating	treated with 1000 U/ml IFNa	6 h	3 replicates each, part of time series with 2 treatment conditions
ARR01730	GSE23591	GSE23591b	GSM578577	GPL6244	linear	raw	CELS/GSE23591/GSM578577.CEL	JAK-STAT	L1236 lymphoma derived cell line	control	treated with 40 ng/ml IL-13	1 h	1 replicate, time resolved controls, part of time series
ARR01731	GSE23591	GSE23591b	GSM578578	GPL6244	linear	raw	CELS/GSE23591/GSM578578.CEL	JAK-STAT	L1236 lymphoma derived cell line	activating	treated with 40 ng/ml IL-13	1 h	1 replicate, time resolved controls, part of time series
ARR01732	GSE8687	GSE8687	GSM215362	GPL570	linear	raw	CELS/GSE8687/GSM215362.CEL	JAK-STAT	Sez-4	control	starved of IL-2 and activated with IL-2	4 h after stimulation (16 h IL-2 pre-starvation)	comment
ARR01733	GSE8687	GSE8687	GSM215363	GPL570	linear	raw	CELS/GSE8687/GSM215363.CEL	JAK-STAT	Sez-4	control	starved of IL-2 and activated with IL-2	4 h after stimulation (16 h IL-2 pre-starvation)	comment
ARR01734	GSE8687	GSE8687	GSM215361	GPL570	linear	raw	CELS/GSE8687/GSM215361.CEL	JAK-STAT	Sez-4	control	starved of IL-2 and activated with IL-2	4 h after stimulation (16 h IL-2 pre-starvation)	comment
ARR01735	GSE8687	GSE8687	GSM215365	GPL570	linear	raw	CELS/GSE8687/GSM215365.CEL	JAK-STAT	Sez-4	activating	starved of IL-2 and activated with IL-2	4 h after stimulation (16 h IL-2 pre-starvation)	comment
ARR01736	GSE8687	GSE8687	GSM215366	GPL570	linear	raw	CELS/GSE8687/GSM215366.CEL	JAK-STAT	Sez-4	activating	starved of IL-2 and activated with IL-2	4 h after stimulation (16 h IL-2 pre-starvation)	comment
ARR01737	GSE8687	GSE8687	GSM215364	GPL570	linear	raw	CELS/GSE8687/GSM215364.CEL	JAK-STAT	Sez-4	activating	starved of IL-2 and activated with IL-2	4 h after stimulation (16 h IL-2 pre-starvation)	comment
ARR01738	GSE16253	GSE16253c	GSM409269	GPL8601	linear	raw	NA	JAK-STAT	primary monocytes	control	treated with 0.6 pM IFNg	1 h	1 replicate, time respective control, part of time series, different cell lines
ARR01739	GSE16253	GSE16253c	GSM409275	GPL8601	linear	raw	NA	JAK-STAT	primary monocytes	activating	treated with 0.6 pM IFNg	1 h	1 replicate, time respective control, part of time series, different cell lines
ARR01740	GSE21760	GSE21760a	GSM542389	GPL570	log	normalized	CELS/GSE21760/GSM542389.CEL	JAK-STAT	HeLa cells	control	treated with IFNg	2 h	1 replicate, part of time series
ARR01741	GSE21760	GSE21760a	GSM542390	GPL570	log	normalized	CELS/GSE21760/GSM542390.CEL	JAK-STAT	HeLa cells	activating	treated with IFNg	2 h	1 replicate, part of time series
ARR01742	GSE3920	GSE3920e	GSM89654	GPL96	log	raw	NA	JAK-STAT	fibroblasts	control	treated with IFNg	5 h	2 replicates
ARR01743	GSE3920	GSE3920e	GSM89655	GPL96	log	raw	NA	JAK-STAT	fibroblasts	control	treated with IFNg	5 h	2 replicates
ARR01744	GSE3920	GSE3920e	GSM89657	GPL96	log	raw	NA	JAK-STAT	fibroblasts	activating	treated with IFNg	5 h	2 replicates
ARR01745	GSE3920	GSE3920e	GSM89658	GPL96	log	raw	NA	JAK-STAT	fibroblasts	activating	treated with IFNg	5 h	2 replicates
ARR01746	GSE4885	GSE4885a	GSM109801	GPL96	log	raw	CELS/GSE4885/GSM109801.CEL	JAK-STAT	HepG2 hepatocellular carcinoma cells	control	treated with IL-6	1 h	2 replicates, part of time series
ARR01747	GSE4885	GSE4885a	GSM109802	GPL96	log	raw	CELS/GSE4885/GSM109802.CEL	JAK-STAT	HepG2 hepatocellular carcinoma cells	control	treated with IL-6	1 h	2 replicates, part of time series
ARR01748	GSE4885	GSE4885a	GSM109803	GPL96	log	raw	CELS/GSE4885/GSM109803.CEL	JAK-STAT	HepG2 hepatocellular carcinoma cells	activating	treated with IL-6	1 h	2 replicates, part of time series
ARR01749	GSE4885	GSE4885a	GSM109804	GPL96	log	raw	CELS/GSE4885/GSM109804.CEL	JAK-STAT	HepG2 hepatocellular carcinoma cells	activating	treated with IL-6	1 h	2 replicates, part of time series
ARR01750	GSE8685	GSE8685a	GSM215347	GPL570	log	raw	CELS/GSE8685/GSM215347.CEL	JAK-STAT	Sez-4 cell line	control	treated with 200U IL-2	4 h	3 replicates, different IL treatments, after 16h IL2 starvation
ARR01751	GSE8685	GSE8685a	GSM215348	GPL570	log	raw	CELS/GSE8685/GSM215348.CEL	JAK-STAT	Sez-4 cell line	control	treated with 200U IL-2	4 h	3 replicates, different IL treatments, after 16h IL2 starvation
ARR01752	GSE8685	GSE8685a	GSM215349	GPL570	log	raw	CELS/GSE8685/GSM215349.CEL	JAK-STAT	Sez-4 cell line	control	treated with 200U IL-2	4 h	3 replicates, different IL treatments, after 16h IL2 starvation
ARR01753	GSE8685	GSE8685a	GSM215350	GPL570	log	raw	CELS/GSE8685/GSM215350.CEL	JAK-STAT	Sez-4 cell line	activating	treated with 200U IL-2	4 h	3 replicates, different IL treatments, after 16h IL2 starvation
ARR01754	GSE8685	GSE8685a	GSM215351	GPL570	log	raw	CELS/GSE8685/GSM215351.CEL	JAK-STAT	Sez-4 cell line	activating	treated with 200U IL-2	4 h	3 replicates, different IL treatments, after 16h IL2 starvation
ARR01755	GSE8685	GSE8685a	GSM215352	GPL570	log	raw	CELS/GSE8685/GSM215352.CEL	JAK-STAT	Sez-4 cell line	activating	treated with 200U IL-2	4 h	3 replicates, different IL treatments, after 16h IL2 starvation
ARR01756	GSE15743	GSE15743b	GSM394093	GPL570	log	raw	CELS/GSE15743/GSM394093.CEL	JAK-STAT	primary NK cells	control	treated with 100 ng/ml IFNa-2b	6 h	1 replicate, 2 concentrations
ARR01757	GSE15743	GSE15743b	GSM394095	GPL570	log	raw	CELS/GSE15743/GSM394095.CEL	JAK-STAT	primary NK cells	activating	treated with 100 ng/ml IFNa-2b	6 h	1 replicate, 2 concentrations
ARR01758	GSE21760	GSE21760c	GSM542389	GPL570	log	normalized	CELS/GSE21760/GSM542389.CEL	JAK-STAT	HeLa cells	control	treated with IFNg	6 h	1 replicate, part of time series
ARR01759	GSE21760	GSE21760c	GSM542392	GPL570	log	normalized	CELS/GSE21760/GSM542392.CEL	JAK-STAT	HeLa cells	activating	treated with IFNg	6 h	1 replicate, part of time series
ARR01760	GSE31264	GSE31264	GSM774851	GPL570	log	raw	CELS/GSE31264/GSM774851.CEL	JAK-STAT	primary hepatocytes	control	treated with 10 U/ml IFN-a	6 h	1 replicate
ARR01761	GSE31264	GSE31264	GSM774852	GPL570	log	raw	CELS/GSE31264/GSM774852.CEL	JAK-STAT	primary hepatocytes	activating	treated with 10 U/ml IFN-a	6 h	1 replicate
ARR01762	GSE15743	GSE15743a	GSM394093	GPL570	log	raw	CELS/GSE15743/GSM394093.CEL	JAK-STAT	primary NK cells	control	treated with 1 ng/ml IFNa-2b	6 h	1 replicate, 2 concentrations
ARR01763	GSE15743	GSE15743a	GSM394094	GPL570	log	raw	CELS/GSE15743/GSM394094.CEL	JAK-STAT	primary NK cells	activating	treated with 1 ng/ml IFNa-2b	6 h	1 replicate, 2 concentrations
ARR01764	GSE1432	GSE1432b	GSM26926	GPL96	linear	raw	NA	JAK-STAT	primary human microglial cells B18	control	treated with IFN-gamma (respective time control)	1 h	comment
ARR01765	GSE1432	GSE1432b	GSM23887	GPL96	linear	raw	NA	JAK-STAT	primary human microglial cells B18	activating	treated with IFN-gamma (respective time control)	1 h	comment
ARR01766	GSE20198	GSE20198b	GSM506702	GPL96	log	raw	CELS/GSE20198/GSM506702.CEL	JAK-STAT	activated cord blood CD4+ T cells	control	treated with IFNa	6 h	1 replicate, part of time series
ARR01767	GSE20198	GSE20198b	GSM506703	GPL96	log	raw	CELS/GSE20198/GSM506703.CEL	JAK-STAT	activated cord blood CD4+ T cells	activating	treated with IFNa	6 h	1 replicate, part of time series
ARR01768	GSE24403	GSE24403b	GSM601439	GPL6480	linear	raw	NA	JAK-STAT	dermal fibroblasts	control	treated with 50 nM IL-13	4 h	3 replicates control, 1 replicate treatment, part of time series
ARR01769	GSE24403	GSE24403b	GSM601440	GPL6480	linear	raw	NA	JAK-STAT	dermal fibroblasts	control	treated with 50 nM IL-13	4 h	3 replicates control, 1 replicate treatment, part of time series
ARR01770	GSE24403	GSE24403b	GSM601441	GPL6480	linear	raw	NA	JAK-STAT	dermal fibroblasts	control	treated with 50 nM IL-13	4 h	3 replicates control, 1 replicate treatment, part of time series
ARR01771	GSE24403	GSE24403b	GSM601443	GPL6480	linear	raw	NA	JAK-STAT	dermal fibroblasts	activating	treated with 50 nM IL-13	4 h	3 replicates control, 1 replicate treatment, part of time series
ARR01772	GSE14632	GSE14632c	GSM636652	GPL6104	linear	raw	NA	JAK-STAT	HepG2 hepatocarcinoma cell line	control	treated with 20ng/ml IL-6	4 h	2 replicates, part of time series, 4h serum starvation before treatment
ARR01773	GSE14632	GSE14632c	GSM636653	GPL6104	linear	raw	NA	JAK-STAT	HepG2 hepatocarcinoma cell line	control	treated with 20ng/ml IL-6	4 h	2 replicates, part of time series, 4h serum starvation before treatment
ARR01774	GSE14632	GSE14632c	GSM636658	GPL6104	linear	raw	NA	JAK-STAT	HepG2 hepatocarcinoma cell line	activating	treated with 20ng/ml IL-6	4 h	2 replicates, part of time series, 4h serum starvation before treatment
ARR01775	GSE14632	GSE14632c	GSM636659	GPL6104	linear	raw	NA	JAK-STAT	HepG2 hepatocarcinoma cell line	activating	treated with 20ng/ml IL-6	4 h	2 replicates, part of time series, 4h serum starvation before treatment
ARR01776	GSE16253	GSE16253a	GSM409215	GPL8601	linear	raw	NA	JAK-STAT	primary monocytes	control	treated with 0.6 pM IFNg	0.5 h	1 replicate, time respective control, part of time series, different cell lines
ARR01777	GSE16253	GSE16253a	GSM409267	GPL8601	linear	raw	NA	JAK-STAT	primary monocytes	activating	treated with 0.6 pM IFNg	0.5 h	1 replicate, time respective control, part of time series, different cell lines
ARR01778	GSE3183	GSE3183	GSM47468	GPL96	linear	raw	CELS/GSE3183/GSM47468.CEL	JAK-STAT	A549 (Human bronchial cell line)	control	treated with IL-13	4 h	3 replicates each
ARR01779	GSE3183	GSE3183	GSM47462	GPL96	linear	raw	CELS/GSE3183/GSM47462.CEL	JAK-STAT	A549 (Human bronchial cell line)	control	treated with IL-13	4 h	3 replicates each
ARR01780	GSE3183	GSE3183	GSM47472	GPL96	linear	raw	CELS/GSE3183/GSM47472.CEL	JAK-STAT	A549 (Human bronchial cell line)	control	treated with IL-13	4 h	3 replicates each
ARR01781	GSE3183	GSE3183	GSM47461	GPL96	linear	raw	CELS/GSE3183/GSM47461.CEL	JAK-STAT	A549 (Human bronchial cell line)	activating	treated with IL-13	4 h	3 replicates each
ARR01782	GSE3183	GSE3183	GSM47464	GPL96	linear	raw	CELS/GSE3183/GSM47464.CEL	JAK-STAT	A549 (Human bronchial cell line)	activating	treated with IL-13	4 h	3 replicates each
ARR01783	GSE3183	GSE3183	GSM47473	GPL96	linear	raw	CELS/GSE3183/GSM47473.CEL	JAK-STAT	A549 (Human bronchial cell line)	activating	treated with IL-13	4 h	3 replicates each
ARR01784	GSE16252	GSE16252i	GSM409200	GPL8601	linear	raw	NA	JAK-STAT	primary PBMCs	control	treated with 0.006 pM IFNg	0.5 h	1 replicate, time respective control, part of time and concentration series
ARR01785	GSE16252	GSE16252i	GSM409193	GPL8601	linear	raw	NA	JAK-STAT	primary PBMCs	activating	treated with 0.006 pM IFNg	0.5 h	1 replicate, time respective control, part of time and concentration series
ARR01786	GSE3920	GSE3920c	GSM89636	GPL96	log	raw	NA	JAK-STAT	HUVECs	control	treated with IFNg	5 h	3 replicates
ARR01787	GSE3920	GSE3920c	GSM89639	GPL96	log	raw	NA	JAK-STAT	HUVECs	control	treated with IFNg	5 h	3 replicates
ARR01788	GSE3920	GSE3920c	GSM89642	GPL96	log	raw	NA	JAK-STAT	HUVECs	control	treated with IFNg	5 h	3 replicates
ARR01789	GSE3920	GSE3920c	GSM89648	GPL96	log	raw	NA	JAK-STAT	HUVECs	activating	treated with IFNg	5 h	3 replicates
ARR01790	GSE3920	GSE3920c	GSM89649	GPL96	log	raw	NA	JAK-STAT	HUVECs	activating	treated with IFNg	5 h	3 replicates
ARR01791	GSE3920	GSE3920c	GSM89650	GPL96	log	raw	NA	JAK-STAT	HUVECs	activating	treated with IFNg	5 h	3 replicates
ARR01792	GSE1432	GSE1432d	GSM26925	GPL96	linear	raw	NA	JAK-STAT	primary human microglial cells O	control	treated with IFN-gamma (respective time control)	1 h	comment
ARR01793	GSE1432	GSE1432d	GSM23893	GPL96	linear	raw	NA	JAK-STAT	primary human microglial cells O	activating	treated with IFN-gamma (respective time control)	1 h	comment
ARR01794	GSE8685	GSE8685c	GSM215347	GPL570	log	raw	CELS/GSE8685/GSM215347.CEL	JAK-STAT	Sez-4 cell line	control	treated with 100ng/ml IL-21	4 h	3 replicates, different IL treatments, after 16h IL2 starvation
ARR01795	GSE8685	GSE8685c	GSM215348	GPL570	log	raw	CELS/GSE8685/GSM215348.CEL	JAK-STAT	Sez-4 cell line	control	treated with 100ng/ml IL-21	4 h	3 replicates, different IL treatments, after 16h IL2 starvation
ARR01796	GSE8685	GSE8685c	GSM215349	GPL570	log	raw	CELS/GSE8685/GSM215349.CEL	JAK-STAT	Sez-4 cell line	control	treated with 100ng/ml IL-21	4 h	3 replicates, different IL treatments, after 16h IL2 starvation
ARR01797	GSE8685	GSE8685c	GSM215356	GPL570	log	raw	CELS/GSE8685/GSM215356.CEL	JAK-STAT	Sez-4 cell line	activating	treated with 100ng/ml IL-21	4 h	3 replicates, different IL treatments, after 16h IL2 starvation
ARR01798	GSE8685	GSE8685c	GSM215357	GPL570	log	raw	CELS/GSE8685/GSM215357.CEL	JAK-STAT	Sez-4 cell line	activating	treated with 100ng/ml IL-21	4 h	3 replicates, different IL treatments, after 16h IL2 starvation
ARR01799	GSE8685	GSE8685c	GSM215358	GPL570	log	raw	CELS/GSE8685/GSM215358.CEL	JAK-STAT	Sez-4 cell line	activating	treated with 100ng/ml IL-21	4 h	3 replicates, different IL treatments, after 16h IL2 starvation
ARR01800	GSE440	GSE440	GSM6709	GPL8300	linear	raw	NA	JAK-STAT	Foreskin keratinocytes	control	treated with IFN-gamma (respective time control)	1 h	2 Controls existent on the web page only 1 in the whole  download script just taken that one
ARR01801	GSE440	GSE440	GSM7765	GPL8300	linear	raw	NA	JAK-STAT	Foreskin keratinocytes	activating	treated with IFN-gamma (respective time control)	1 h	2 Controls existent on the web page only 1 in the whole  download script just taken that one
ARR01802	GSE3920	GSE3920d	GSM89654	GPL96	log	raw	NA	JAK-STAT	fibroblasts	control	treated with IFNa	5 h	3 replicates
ARR01803	GSE3920	GSE3920d	GSM89655	GPL96	log	raw	NA	JAK-STAT	fibroblasts	control	treated with IFNa	5 h	3 replicates
ARR01804	GSE3920	GSE3920d	GSM89656	GPL96	log	raw	NA	JAK-STAT	fibroblasts	control	treated with IFNa	5 h	3 replicates
ARR01805	GSE3920	GSE3920d	GSM89651	GPL96	log	raw	NA	JAK-STAT	fibroblasts	activating	treated with IFNa	5 h	3 replicates
ARR01806	GSE3920	GSE3920d	GSM89652	GPL96	log	raw	NA	JAK-STAT	fibroblasts	activating	treated with IFNa	5 h	3 replicates
ARR01807	GSE3920	GSE3920d	GSM89653	GPL96	log	raw	NA	JAK-STAT	fibroblasts	activating	treated with IFNa	5 h	3 replicates
ARR01808	GSE16252	GSE16252d	GSM409197	GPL8601	linear	raw	NA	JAK-STAT	primary PBMCs	control	treated with 0.6 pM IFNg	4 h	1 replicate, time respective control, part of time and concentration series
ARR01809	GSE16252	GSE16252d	GSM409213	GPL8601	linear	raw	NA	JAK-STAT	primary PBMCs	activating	treated with 0.6 pM IFNg	4 h	1 replicate, time respective control, part of time and concentration series
ARR01810	GSE23591	GSE23591a	GSM578575	GPL6244	linear	raw	CELS/GSE23591/GSM578575.CEL	JAK-STAT	L1236 lymphoma derived cell line	control	treated with 40 ng/ml IL-13	0.5 h	1 replicate, time resolved controls, part of time series
ARR01811	GSE23591	GSE23591a	GSM578576	GPL6244	linear	raw	CELS/GSE23591/GSM578576.CEL	JAK-STAT	L1236 lymphoma derived cell line	activating	treated with 40 ng/ml IL-13	0.5 h	1 replicate, time resolved controls, part of time series
ARR01812	GSE16251	GSE16251d	GSM409182	GPL8601	linear	raw	NA	JAK-STAT	primary PBMCs	control	treated with IIL12	1 h	1 replicate, time respective control, part of time
ARR01813	GSE16251	GSE16251d	GSM409157	GPL8601	linear	raw	NA	JAK-STAT	primary PBMCs	activating	treated with IIL12	1 h	1 replicate, time respective control, part of time
ARR01814	GSE16253	GSE16253n	GSM409256	GPL8601	linear	raw	NA	JAK-STAT	primary CD8+ T cells	control	treated with 0.6 pM IFNg	1 h	1 replicate, time respective control, part of time series, different cell lines
ARR01815	GSE16253	GSE16253n	GSM409243	GPL8601	linear	raw	NA	JAK-STAT	primary CD8+ T cells	activating	treated with 0.6 pM IFNg	1 h	1 replicate, time respective control, part of time series, different cell lines
ARR01816	GSE19082	GSE19082b	GSM472434	GPL6104	log	raw	NA	JAK-STAT	HMEC (human microvascular endothelial cells)	control	treated with IL-6 50 U/ml  (respective time control)	1 h	4 replicates each, two different treatments
ARR01817	GSE19082	GSE19082b	GSM472438	GPL6104	log	raw	NA	JAK-STAT	HMEC (human microvascular endothelial cells)	control	treated with IL-6 50 U/ml  (respective time control)	1 h	4 replicates each, two different treatments
ARR01818	GSE19082	GSE19082b	GSM472442	GPL6104	log	raw	NA	JAK-STAT	HMEC (human microvascular endothelial cells)	control	treated with IL-6 50 U/ml  (respective time control)	1 h	4 replicates each, two different treatments
ARR01819	GSE19082	GSE19082b	GSM472446	GPL6104	log	raw	NA	JAK-STAT	HMEC (human microvascular endothelial cells)	control	treated with IL-6 50 U/ml  (respective time control)	1 h	4 replicates each, two different treatments
ARR01820	GSE19082	GSE19082b	GSM472435	GPL6104	log	raw	NA	JAK-STAT	HMEC (human microvascular endothelial cells)	activating	treated with IL-6 50 U/ml  (respective time control)	1 h	4 replicates each, two different treatments
ARR01821	GSE19082	GSE19082b	GSM472439	GPL6104	log	raw	NA	JAK-STAT	HMEC (human microvascular endothelial cells)	activating	treated with IL-6 50 U/ml  (respective time control)	1 h	4 replicates each, two different treatments
ARR01822	GSE19082	GSE19082b	GSM472443	GPL6104	log	raw	NA	JAK-STAT	HMEC (human microvascular endothelial cells)	activating	treated with IL-6 50 U/ml  (respective time control)	1 h	4 replicates each, two different treatments
ARR01823	GSE19082	GSE19082b	GSM472447	GPL6104	log	raw	NA	JAK-STAT	HMEC (human microvascular endothelial cells)	activating	treated with IL-6 50 U/ml  (respective time control)	1 h	4 replicates each, two different treatments
ARR01824	GSE23591	GSE23591d	GSM578581	GPL6244	linear	raw	CELS/GSE23591/GSM578581.CEL	JAK-STAT	L1236 lymphoma derived cell line	control	treated with 40 ng/ml IL-13	2 h	1 replicate, time resolved controls, part of time series
ARR01825	GSE23591	GSE23591d	GSM578582	GPL6244	linear	raw	CELS/GSE23591/GSM578582.CEL	JAK-STAT	L1236 lymphoma derived cell line	activating	treated with 40 ng/ml IL-13	2 h	1 replicate, time resolved controls, part of time series
ARR01826	GSE19082	GSE19082a	GSM472434	GPL6104	log	raw	NA	JAK-STAT	HMEC (human microvascular endothelial cells)	control	treated with IFN-gamma 1 ng/ml (respective time control)	3 h	4 replicates each two different treatments
ARR01827	GSE19082	GSE19082a	GSM472438	GPL6104	log	raw	NA	JAK-STAT	HMEC (human microvascular endothelial cells)	control	treated with IFN-gamma 1 ng/ml (respective time control)	3 h	4 replicates each two different treatments
ARR01828	GSE19082	GSE19082a	GSM472442	GPL6104	log	raw	NA	JAK-STAT	HMEC (human microvascular endothelial cells)	control	treated with IFN-gamma 1 ng/ml (respective time control)	3 h	4 replicates each two different treatments
ARR01829	GSE19082	GSE19082a	GSM472446	GPL6104	log	raw	NA	JAK-STAT	HMEC (human microvascular endothelial cells)	control	treated with IFN-gamma 1 ng/ml (respective time control)	3 h	4 replicates each two different treatments
ARR01830	GSE19082	GSE19082a	GSM472436	GPL6104	log	raw	NA	JAK-STAT	HMEC (human microvascular endothelial cells)	activating	treated with IFN-gamma 1 ng/ml (respective time control)	3 h	4 replicates each two different treatments
ARR01831	GSE19082	GSE19082a	GSM472440	GPL6104	log	raw	NA	JAK-STAT	HMEC (human microvascular endothelial cells)	activating	treated with IFN-gamma 1 ng/ml (respective time control)	3 h	4 replicates each two different treatments
ARR01832	GSE19082	GSE19082a	GSM472444	GPL6104	log	raw	NA	JAK-STAT	HMEC (human microvascular endothelial cells)	activating	treated with IFN-gamma 1 ng/ml (respective time control)	3 h	4 replicates each two different treatments
ARR01833	GSE19082	GSE19082a	GSM472448	GPL6104	log	raw	NA	JAK-STAT	HMEC (human microvascular endothelial cells)	activating	treated with IFN-gamma 1 ng/ml (respective time control)	3 h	4 replicates each two different treatments
ARR01834	GSE24409	GSE24409b	GSM601484	GPL6480	linear	raw	NA	JAK-STAT	dermal fibroblasts	control	treated with 50 nM IL-4	4 h	3 replicates control, 1 replicate treatment, part of time series
ARR01835	GSE24409	GSE24409b	GSM601485	GPL6480	linear	raw	NA	JAK-STAT	dermal fibroblasts	control	treated with 50 nM IL-4	4 h	3 replicates control, 1 replicate treatment, part of time series
ARR01836	GSE24409	GSE24409b	GSM601486	GPL6480	linear	raw	NA	JAK-STAT	dermal fibroblasts	control	treated with 50 nM IL-4	4 h	3 replicates control, 1 replicate treatment, part of time series
ARR01837	GSE24409	GSE24409b	GSM601488	GPL6480	linear	raw	NA	JAK-STAT	dermal fibroblasts	activating	treated with 50 nM IL-4	4 h	3 replicates control, 1 replicate treatment, part of time series
ARR01838	GSE24403	GSE24403a	GSM601439	GPL6480	linear	raw	NA	JAK-STAT	dermal fibroblasts	control	treated with 50 nM IL-13	2 h	3 replicates control, 1 replicate treatment, part of time series
ARR01839	GSE24403	GSE24403a	GSM601440	GPL6480	linear	raw	NA	JAK-STAT	dermal fibroblasts	control	treated with 50 nM IL-13	2 h	3 replicates control, 1 replicate treatment, part of time series
ARR01840	GSE24403	GSE24403a	GSM601441	GPL6480	linear	raw	NA	JAK-STAT	dermal fibroblasts	control	treated with 50 nM IL-13	2 h	3 replicates control, 1 replicate treatment, part of time series
ARR01841	GSE24403	GSE24403a	GSM601442	GPL6480	linear	raw	NA	JAK-STAT	dermal fibroblasts	activating	treated with 50 nM IL-13	2 h	3 replicates control, 1 replicate treatment, part of time series
ARR01842	GSE16253	GSE16253m	GSM409241	GPL8601	linear	raw	NA	JAK-STAT	primary CD8+ T cells	control	treated with 0.6 pM IFNg	0.5 h	1 replicate, time respective control, part of time series, different cell lines
ARR01843	GSE16253	GSE16253m	GSM409281	GPL8601	linear	raw	NA	JAK-STAT	primary CD8+ T cells	activating	treated with 0.6 pM IFNg	0.5 h	1 replicate, time respective control, part of time series, different cell lines
ARR01844	GSE16253	GSE16253e	GSM409251	GPL8601	linear	raw	NA	JAK-STAT	primary B cells	control	treated with 0.6 pM IFNg	1 h	1 replicate, time respective control, part of time series, different cell lines
ARR01845	GSE16253	GSE16253e	GSM409290	GPL8601	linear	raw	NA	JAK-STAT	primary B cells	activating	treated with 0.6 pM IFNg	1 h	1 replicate, time respective control, part of time series, different cell lines
ARR01846	GSE8059	GSE8059	GSM198942	GPL570	linear	raw	CELS/GSE8059/GSM198942.CEL	JAK-STAT	NK (Primary Natural Killer cells)	control	treated with IL-2	2 h	comment
ARR01847	GSE8059	GSE8059	GSM198943	GPL570	linear	raw	CELS/GSE8059/GSM198943.CEL	JAK-STAT	NK (Primary Natural Killer cells)	activating	treated with IL-2	2 h	comment
ARR01848	GSE16385	GSE16385	GSM411184	GPL570	log	normalized	CELS/GSE16385/GSM411184.CEL	JAK-STAT	primary macrophage	control	treated with IL-4	4 h	1 replicate, respective time control
ARR01849	GSE16385	GSE16385	GSM411186	GPL570	log	normalized	CELS/GSE16385/GSM411186.CEL	JAK-STAT	primary macrophage	activating	treated with IL-4	4 h	1 replicate, respective time control
ARR01850	GSE9481	GSE9481	GSM240637	GPL570	log	raw	NA	JAK-STAT	side population of ovarian cancer	control	treated with 1000 U/ml IFNa	5 h	2 replicates
ARR01851	GSE9481	GSE9481	GSM240638	GPL570	log	raw	NA	JAK-STAT	side population of ovarian cancer	control	treated with 1000 U/ml IFNa	5 h	2 replicates
ARR01852	GSE9481	GSE9481	GSM240639	GPL570	log	raw	NA	JAK-STAT	side population of ovarian cancer	activating	treated with 1000 U/ml IFNa	5 h	2 replicates
ARR01853	GSE9481	GSE9481	GSM240640	GPL570	log	raw	NA	JAK-STAT	side population of ovarian cancer	activating	treated with 1000 U/ml IFNa	5 h	2 replicates
ARR01854	GSE16251	GSE16251b	GSM409180	GPL8601	linear	raw	NA	JAK-STAT	primary PBMCs	control	treated with IFNa	0.5 h	1 replicate, time respective control, part of time
ARR01855	GSE16251	GSE16251b	GSM409181	GPL8601	linear	raw	NA	JAK-STAT	primary PBMCs	activating	treated with IFNa	0.5 h	1 replicate, time respective control, part of time
ARR01856	GSE16252	GSE16252l	GSM409197	GPL8601	linear	raw	NA	JAK-STAT	primary PBMCs	control	treated with 0.006 pM IFNg	4 h	1 replicate, time respective control, part of time and concentration series
ARR01857	GSE16252	GSE16252l	GSM409214	GPL8601	linear	raw	NA	JAK-STAT	primary PBMCs	activating	treated with 0.006 pM IFNg	4 h	1 replicate, time respective control, part of time and concentration series
ARR01858	GSE4885	GSE4885b	GSM109801	GPL96	log	raw	CELS/GSE4885/GSM109801.CEL	JAK-STAT	HepG2 hepatocellular carcinoma cells	control	treated with IL-6	4 h	2 replicates, part of time series
ARR01859	GSE4885	GSE4885b	GSM109802	GPL96	log	raw	CELS/GSE4885/GSM109802.CEL	JAK-STAT	HepG2 hepatocellular carcinoma cells	control	treated with IL-6	4 h	2 replicates, part of time series
ARR01860	GSE4885	GSE4885b	GSM109805	GPL96	log	raw	CELS/GSE4885/GSM109805.CEL	JAK-STAT	HepG2 hepatocellular carcinoma cells	activating	treated with IL-6	4 h	2 replicates, part of time series
ARR01861	GSE4885	GSE4885b	GSM109806	GPL96	log	raw	CELS/GSE4885/GSM109806.CEL	JAK-STAT	HepG2 hepatocellular carcinoma cells	activating	treated with IL-6	4 h	2 replicates, part of time series
ARR01862	GSE16252	GSE16252e	GSM409200	GPL8601	linear	raw	NA	JAK-STAT	primary PBMCs	control	treated with 60 pM IFNg	0.5 h	1 replicate, time respective control, part of time and concentration series
ARR01863	GSE16252	GSE16252e	GSM409211	GPL8601	linear	raw	NA	JAK-STAT	primary PBMCs	activating	treated with 60 pM IFNg	0.5 h	1 replicate, time respective control, part of time and concentration series
ARR01864	GSE16253	GSE16253d	GSM409250	GPL8601	linear	raw	NA	JAK-STAT	primary B cells	control	treated with 0.6 pM IFNg	0.5 h	1 replicate, time respective control, part of time series, different cell lines
ARR01865	GSE16253	GSE16253d	GSM409219	GPL8601	linear	raw	NA	JAK-STAT	primary B cells	activating	treated with 0.6 pM IFNg	0.5 h	1 replicate, time respective control, part of time series, different cell lines
ARR01866	GSE33264	GSE33264a	GSM823062	GPL4133	log	normalized	NA	JAK-STAT	Calu-3 cells	control	treated with 1000 U/ml IFNa	3 h	3 replicates each, part of time series with 2 treatment conditions
ARR01867	GSE33264	GSE33264a	GSM823063	GPL4133	log	normalized	NA	JAK-STAT	Calu-3 cells	control	treated with 1000 U/ml IFNa	3 h	3 replicates each, part of time series with 2 treatment conditions
ARR01868	GSE33264	GSE33264a	GSM823064	GPL4133	log	normalized	NA	JAK-STAT	Calu-3 cells	control	treated with 1000 U/ml IFNa	3 h	3 replicates each, part of time series with 2 treatment conditions
ARR01869	GSE33264	GSE33264a	GSM823038	GPL4133	log	normalized	NA	JAK-STAT	Calu-3 cells	activating	treated with 1000 U/ml IFNa	3 h	3 replicates each, part of time series with 2 treatment conditions
ARR01870	GSE33264	GSE33264a	GSM823039	GPL4133	log	normalized	NA	JAK-STAT	Calu-3 cells	activating	treated with 1000 U/ml IFNa	3 h	3 replicates each, part of time series with 2 treatment conditions
ARR01871	GSE33264	GSE33264a	GSM823040	GPL4133	log	normalized	NA	JAK-STAT	Calu-3 cells	activating	treated with 1000 U/ml IFNa	3 h	3 replicates each, part of time series with 2 treatment conditions
ARR01872	GSE1925	GSE1925c	GSM34607	GPL8300	linear	raw	NA	JAK-STAT	primary human CD14+ macrophages Pool3	control	treated with IFN-gamma	3 h	comment
ARR01873	GSE1925	GSE1925c	GSM34608	GPL8300	linear	raw	NA	JAK-STAT	primary human CD14+ macrophages Pool3	activating	treated with IFN-gamma	3 h	comment
ARR01874	GSE12664	GSE12664	GSM317891	GPL6480	linear	raw	NA	JAK-STAT	A549 cells	control	treated with IFNb	6 h	3 replicates
ARR01875	GSE12664	GSE12664	GSM317903	GPL6480	linear	raw	NA	JAK-STAT	A549 cells	control	treated with IFNb	6 h	3 replicates
ARR01876	GSE12664	GSE12664	GSM317915	GPL6480	linear	raw	NA	JAK-STAT	A549 cells	control	treated with IFNb	6 h	3 replicates
ARR01877	GSE12664	GSE12664	GSM317927	GPL6480	linear	raw	NA	JAK-STAT	A549 cells	activating	treated with IFNb	6 h	3 replicates
ARR01878	GSE12664	GSE12664	GSM317928	GPL6480	linear	raw	NA	JAK-STAT	A549 cells	activating	treated with IFNb	6 h	3 replicates
ARR01879	GSE12664	GSE12664	GSM317929	GPL6480	linear	raw	NA	JAK-STAT	A549 cells	activating	treated with IFNb	6 h	3 replicates
ARR01880	GSE16252	GSE16252a	GSM409200	GPL8601	linear	raw	NA	JAK-STAT	primary PBMCs	control	treated with 0.6 pM IFNg	0.5 h	1 replicate, time respective control, part of time and concentration series
ARR01881	GSE16252	GSE16252a	GSM409188	GPL8601	linear	raw	NA	JAK-STAT	primary PBMCs	activating	treated with 0.6 pM IFNg	0.5 h	1 replicate, time respective control, part of time and concentration series
ARR01882	GSE1432	GSE1432a	GSM26928	GPL96	linear	raw	NA	JAK-STAT	primary human microglial cells Y20	control	treated with IFN-gamma (respective time control)	1 h	comment
ARR01883	GSE1432	GSE1432a	GSM23899	GPL96	linear	raw	NA	JAK-STAT	primary human microglial cells Y20	activating	treated with IFN-gamma (respective time control)	1 h	comment
ARR01884	GSE3834	GSE3834c	GSM87446	GPL96	linear	raw	NA	Estrogen	MCF-7 cells	control	treated with 10 nM estradiol	4 h	2 replicates each, different cell lines, part of time series
ARR01885	GSE3834	GSE3834c	GSM87447	GPL96	linear	raw	NA	Estrogen	MCF-7 cells	control	treated with 10 nM estradiol	4 h	2 replicates each, different cell lines, part of time series
ARR01886	GSE3834	GSE3834c	GSM87451	GPL96	linear	raw	NA	Estrogen	MCF-7 cells	activating	treated with 10 nM estradiol	4 h	2 replicates each, different cell lines, part of time series
ARR01887	GSE3834	GSE3834c	GSM87452	GPL96	linear	raw	NA	Estrogen	MCF-7 cells	activating	treated with 10 nM estradiol	4 h	2 replicates each, different cell lines, part of time series
ARR01888	GSE9936	GSE9936a	GSM251354	GPL96	linear	raw	CELS/GSE9936/GSM251354.CEL	Estrogen	MCF-7 cells	control	treated with 6 nM estradiol	4 h	3 replicates each, different treatments, contain control vectors
ARR01889	GSE9936	GSE9936a	GSM251355	GPL96	linear	raw	CELS/GSE9936/GSM251355.CEL	Estrogen	MCF-7 cells	control	treated with 6 nM estradiol	4 h	3 replicates each, different treatments, contain control vectors
ARR01890	GSE9936	GSE9936a	GSM251356	GPL96	linear	raw	CELS/GSE9936/GSM251356.CEL	Estrogen	MCF-7 cells	control	treated with 6 nM estradiol	4 h	3 replicates each, different treatments, contain control vectors
ARR01891	GSE9936	GSE9936a	GSM251357	GPL96	linear	raw	CELS/GSE9936/GSM251357.CEL	Estrogen	MCF-7 cells	activating	treated with 6 nM estradiol	4 h	3 replicates each, different treatments, contain control vectors
ARR01892	GSE9936	GSE9936a	GSM251358	GPL96	linear	raw	CELS/GSE9936/GSM251358.CEL	Estrogen	MCF-7 cells	activating	treated with 6 nM estradiol	4 h	3 replicates each, different treatments, contain control vectors
ARR01893	GSE9936	GSE9936a	GSM251359	GPL96	linear	raw	CELS/GSE9936/GSM251359.CEL	Estrogen	MCF-7 cells	activating	treated with 6 nM estradiol	4 h	3 replicates each, different treatments, contain control vectors
ARR01894	GSE18592	GSE18592	GSM462338	GPL6244	log	raw	CELS/GSE18592/GSM462338.CEL	Estrogen	MCF-7 ER+ breast cancer cells	control	treated with estrogen	1 h	3 replicates each
ARR01895	GSE18592	GSE18592	GSM462339	GPL6244	log	raw	CELS/GSE18592/GSM462339.CEL	Estrogen	MCF-7 ER+ breast cancer cells	control	treated with estrogen	1 h	3 replicates each
ARR01896	GSE18592	GSE18592	GSM462340	GPL6244	log	raw	CELS/GSE18592/GSM462340.CEL	Estrogen	MCF-7 ER+ breast cancer cells	control	treated with estrogen	1 h	3 replicates each
ARR01897	GSE18592	GSE18592	GSM462332	GPL6244	log	raw	CELS/GSE18592/GSM462332.CEL	Estrogen	MCF-7 ER+ breast cancer cells	activating	treated with estrogen	1 h	3 replicates each
ARR01898	GSE18592	GSE18592	GSM462333	GPL6244	log	raw	CELS/GSE18592/GSM462333.CEL	Estrogen	MCF-7 ER+ breast cancer cells	activating	treated with estrogen	1 h	3 replicates each
ARR01899	GSE18592	GSE18592	GSM462334	GPL6244	log	raw	CELS/GSE18592/GSM462334.CEL	Estrogen	MCF-7 ER+ breast cancer cells	activating	treated with estrogen	1 h	3 replicates each
ARR01900	GSE13458	GSE13458	GSM339381	GPL571	linear	raw	CELS/GSE13458/GSM339381.CEL	Estrogen	MCF-7 cells	control	treated with estradiol	3 h	3 replicates each, contain luciferase knockdown
ARR01901	GSE13458	GSE13458	GSM339382	GPL571	linear	raw	CELS/GSE13458/GSM339382.CEL	Estrogen	MCF-7 cells	control	treated with estradiol	3 h	3 replicates each, contain luciferase knockdown
ARR01902	GSE13458	GSE13458	GSM339383	GPL571	linear	raw	CELS/GSE13458/GSM339383.CEL	Estrogen	MCF-7 cells	activating	treated with estradiol	3 h	3 replicates each, contain luciferase knockdown
ARR01903	GSE13458	GSE13458	GSM339411	GPL571	linear	raw	CELS/GSE13458/GSM339411.CEL	Estrogen	MCF-7 cells	activating	treated with estradiol	3 h	3 replicates each, contain luciferase knockdown
ARR01904	GSE3834	GSE3834f	GSM87495	GPL570	linear	raw	NA	Estrogen	T47-D cells	control	treated with 10 nM estradiol	4 h	2 replicates each, different cell lines, part of time series
ARR01905	GSE3834	GSE3834f	GSM87496	GPL570	linear	raw	NA	Estrogen	T47-D cells	control	treated with 10 nM estradiol	4 h	2 replicates each, different cell lines, part of time series
ARR01906	GSE3834	GSE3834f	GSM87501	GPL570	linear	raw	NA	Estrogen	T47-D cells	activating	treated with 10 nM estradiol	4 h	2 replicates each, different cell lines, part of time series
ARR01907	GSE3834	GSE3834f	GSM87502	GPL570	linear	raw	NA	Estrogen	T47-D cells	activating	treated with 10 nM estradiol	4 h	2 replicates each, different cell lines, part of time series
ARR01908	GSE3834	GSE3834e	GSM87495	GPL570	linear	raw	NA	Estrogen	T47-D cells	control	treated with 10 nM estradiol	2 h	2 replicates each, different cell lines, part of time series
ARR01909	GSE3834	GSE3834e	GSM87496	GPL570	linear	raw	NA	Estrogen	T47-D cells	control	treated with 10 nM estradiol	2 h	2 replicates each, different cell lines, part of time series
ARR01910	GSE3834	GSE3834e	GSM87499	GPL570	linear	raw	NA	Estrogen	T47-D cells	activating	treated with 10 nM estradiol	2 h	2 replicates each, different cell lines, part of time series
ARR01911	GSE3834	GSE3834e	GSM87500	GPL570	linear	raw	NA	Estrogen	T47-D cells	activating	treated with 10 nM estradiol	2 h	2 replicates each, different cell lines, part of time series
ARR01912	GSE23445	GSE23445	GSM575323	GPL6244	linear	raw	CELS/GSE23445/GSM575323.CEL	Estrogen	MCF-7 breast cancer cells	control	treated with estradiol	4 h	3 replicates each
ARR01913	GSE23445	GSE23445	GSM575324	GPL6244	linear	raw	CELS/GSE23445/GSM575324.CEL	Estrogen	MCF-7 breast cancer cells	control	treated with estradiol	4 h	3 replicates each
ARR01914	GSE23445	GSE23445	GSM575325	GPL6244	linear	raw	CELS/GSE23445/GSM575325.CEL	Estrogen	MCF-7 breast cancer cells	control	treated with estradiol	4 h	3 replicates each
ARR01915	GSE23445	GSE23445	GSM575326	GPL6244	linear	raw	CELS/GSE23445/GSM575326.CEL	Estrogen	MCF-7 breast cancer cells	activating	treated with estradiol	4 h	3 replicates each
ARR01916	GSE23445	GSE23445	GSM575327	GPL6244	linear	raw	CELS/GSE23445/GSM575327.CEL	Estrogen	MCF-7 breast cancer cells	activating	treated with estradiol	4 h	3 replicates each
ARR01917	GSE23445	GSE23445	GSM575328	GPL6244	linear	raw	CELS/GSE23445/GSM575328.CEL	Estrogen	MCF-7 breast cancer cells	activating	treated with estradiol	4 h	3 replicates each
ARR01918	GSE3013	GSE3013h	GSM65282	GPL91	log	raw	NA	Estrogen	endometrial epithelial cells	control	treated with tamoxifen	3 h	2 replicates each on different platforms, different treatments, different tumor stages
ARR01919	GSE3013	GSE3013h	GSM65286	GPL91	log	raw	NA	Estrogen	endometrial epithelial cells	unknown	treated with tamoxifen	3 h	2 replicates each on different platforms, different treatments, different tumor stages
ARR01920	GSE28645	GSE28645	GSM709770	GPL570	linear	raw	CELS/GSE28645/GSM709770.CEL	Estrogen	LY2 breast cancer cell line	control	treated with tamoxifen	2 h	4 replicates each, contain control siRNA, tamoxifen acts as antagonist in breast cell lines
ARR01921	GSE28645	GSE28645	GSM709773	GPL570	linear	raw	CELS/GSE28645/GSM709773.CEL	Estrogen	LY2 breast cancer cell line	control	treated with tamoxifen	2 h	4 replicates each, contain control siRNA, tamoxifen acts as antagonist in breast cell lines
ARR01922	GSE28645	GSE28645	GSM709774	GPL570	linear	raw	CELS/GSE28645/GSM709774.CEL	Estrogen	LY2 breast cancer cell line	control	treated with tamoxifen	2 h	4 replicates each, contain control siRNA, tamoxifen acts as antagonist in breast cell lines
ARR01923	GSE28645	GSE28645	GSM709776	GPL570	linear	raw	CELS/GSE28645/GSM709776.CEL	Estrogen	LY2 breast cancer cell line	control	treated with tamoxifen	2 h	4 replicates each, contain control siRNA, tamoxifen acts as antagonist in breast cell lines
ARR01924	GSE28645	GSE28645	GSM709764	GPL570	linear	raw	CELS/GSE28645/GSM709764.CEL	Estrogen	LY2 breast cancer cell line	inhibiting	treated with tamoxifen	2 h	4 replicates each, contain control siRNA, tamoxifen acts as antagonist in breast cell lines
ARR01925	GSE28645	GSE28645	GSM709766	GPL570	linear	raw	CELS/GSE28645/GSM709766.CEL	Estrogen	LY2 breast cancer cell line	inhibiting	treated with tamoxifen	2 h	4 replicates each, contain control siRNA, tamoxifen acts as antagonist in breast cell lines
ARR01926	GSE28645	GSE28645	GSM709768	GPL570	linear	raw	CELS/GSE28645/GSM709768.CEL	Estrogen	LY2 breast cancer cell line	inhibiting	treated with tamoxifen	2 h	4 replicates each, contain control siRNA, tamoxifen acts as antagonist in breast cell lines
ARR01927	GSE28645	GSE28645	GSM709777	GPL570	linear	raw	CELS/GSE28645/GSM709777.CEL	Estrogen	LY2 breast cancer cell line	inhibiting	treated with tamoxifen	2 h	4 replicates each, contain control siRNA, tamoxifen acts as antagonist in breast cell lines
ARR01928	GSE11567	GSE11567a	GSM291218	GPL6102	log	normalized	NA	Estrogen	SKBR3 cells	control	treated with 1µM estradiol	1 h	3 replicates each, control transfection
ARR01929	GSE11567	GSE11567a	GSM291219	GPL6102	log	normalized	NA	Estrogen	SKBR3 cells	control	treated with 1µM estradiol	1 h	3 replicates each, control transfection
ARR01930	GSE11567	GSE11567a	GSM291220	GPL6102	log	normalized	NA	Estrogen	SKBR3 cells	control	treated with 1µM estradiol	1 h	3 replicates each, control transfection
ARR01931	GSE11567	GSE11567a	GSM291224	GPL6102	log	normalized	NA	Estrogen	SKBR3 cells	activating	treated with 1µM estradiol	1 h	3 replicates each, control transfection
ARR01932	GSE11567	GSE11567a	GSM291225	GPL6102	log	normalized	NA	Estrogen	SKBR3 cells	activating	treated with 1µM estradiol	1 h	3 replicates each, control transfection
ARR01933	GSE11567	GSE11567a	GSM291226	GPL6102	log	normalized	NA	Estrogen	SKBR3 cells	activating	treated with 1µM estradiol	1 h	3 replicates each, control transfection
ARR01934	GSE26834	GSE26834Est	GSM659805	GPL571	linear	raw	CELS/GSE26834/GSM659805.CEL	Estrogen	MCF-7 breast cancer cells	control	treated with estradiol	3 h	2-3 replicates each
ARR01935	GSE26834	GSE26834Est	GSM659806	GPL571	linear	raw	CELS/GSE26834/GSM659806.CEL	Estrogen	MCF-7 breast cancer cells	control	treated with estradiol	3 h	2-3 replicates each
ARR01936	GSE26834	GSE26834Est	GSM659807	GPL571	linear	raw	CELS/GSE26834/GSM659807.CEL	Estrogen	MCF-7 breast cancer cells	activating	treated with estradiol	3 h	2-3 replicates each
ARR01937	GSE26834	GSE26834Est	GSM659808	GPL571	linear	raw	CELS/GSE26834/GSM659808.CEL	Estrogen	MCF-7 breast cancer cells	activating	treated with estradiol	3 h	2-3 replicates each
ARR01938	GSE26834	GSE26834Est	GSM659809	GPL571	linear	raw	CELS/GSE26834/GSM659809.CEL	Estrogen	MCF-7 breast cancer cells	activating	treated with estradiol	3 h	2-3 replicates each
ARR01939	GSE25315	GSE25315	GSM622773	GPL10558	linear	raw	NA	Estrogen	MCF-7 breast cancer cells	control	treated with 100nM estrogen	6 h	3 replicates each, contain control siRNA
ARR01940	GSE25315	GSE25315	GSM622777	GPL10558	linear	raw	NA	Estrogen	MCF-7 breast cancer cells	control	treated with 100nM estrogen	6 h	3 replicates each, contain control siRNA
ARR01941	GSE25315	GSE25315	GSM622781	GPL10558	linear	raw	NA	Estrogen	MCF-7 breast cancer cells	control	treated with 100nM estrogen	6 h	3 replicates each, contain control siRNA
ARR01942	GSE25315	GSE25315	GSM622775	GPL10558	linear	raw	NA	Estrogen	MCF-7 breast cancer cells	activating	treated with 100nM estrogen	6 h	3 replicates each, contain control siRNA
ARR01943	GSE25315	GSE25315	GSM622779	GPL10558	linear	raw	NA	Estrogen	MCF-7 breast cancer cells	activating	treated with 100nM estrogen	6 h	3 replicates each, contain control siRNA
ARR01944	GSE25315	GSE25315	GSM622783	GPL10558	linear	raw	NA	Estrogen	MCF-7 breast cancer cells	activating	treated with 100nM estrogen	6 h	3 replicates each, contain control siRNA
ARR01945	GSE11467	GSE11467	GSM288961	GPL96	log	raw	CELS/GSE11467/GSM288961.CEL	Estrogen	MCF-7 cells	control	treated with 10 nM estradiol	2 h	3 replicates each
ARR01946	GSE11467	GSE11467	GSM288962	GPL96	log	raw	CELS/GSE11467/GSM288962.CEL	Estrogen	MCF-7 cells	control	treated with 10 nM estradiol	2 h	3 replicates each
ARR01947	GSE11467	GSE11467	GSM288963	GPL96	log	raw	CELS/GSE11467/GSM288963.CEL	Estrogen	MCF-7 cells	control	treated with 10 nM estradiol	2 h	3 replicates each
ARR01948	GSE11467	GSE11467	GSM288964	GPL96	log	raw	CELS/GSE11467/GSM288964.CEL	Estrogen	MCF-7 cells	activating	treated with 10 nM estradiol	2 h	3 replicates each
ARR01949	GSE11467	GSE11467	GSM288965	GPL96	log	raw	CELS/GSE11467/GSM288965.CEL	Estrogen	MCF-7 cells	activating	treated with 10 nM estradiol	2 h	3 replicates each
ARR01950	GSE11467	GSE11467	GSM288966	GPL96	log	raw	CELS/GSE11467/GSM288966.CEL	Estrogen	MCF-7 cells	activating	treated with 10 nM estradiol	2 h	3 replicates each
ARR01951	GSE11791	GSE11791	GSM298353	GPL570	log	raw	CELS/GSE11791/GSM298353.CEL	Estrogen	MCF-7 cells	control	treated with 100 nM estradiol	6 h	3 replicates each
ARR01952	GSE11791	GSE11791	GSM298354	GPL570	log	raw	CELS/GSE11791/GSM298354.CEL	Estrogen	MCF-7 cells	control	treated with 100 nM estradiol	6 h	3 replicates each
ARR01953	GSE11791	GSE11791	GSM298355	GPL570	log	raw	CELS/GSE11791/GSM298355.CEL	Estrogen	MCF-7 cells	control	treated with 100 nM estradiol	6 h	3 replicates each
ARR01954	GSE11791	GSE11791	GSM298356	GPL570	log	raw	CELS/GSE11791/GSM298356.CEL	Estrogen	MCF-7 cells	activating	treated with 100 nM estradiol	6 h	3 replicates each
ARR01955	GSE11791	GSE11791	GSM298357	GPL570	log	raw	CELS/GSE11791/GSM298357.CEL	Estrogen	MCF-7 cells	activating	treated with 100 nM estradiol	6 h	3 replicates each
ARR01956	GSE11791	GSE11791	GSM298358	GPL570	log	raw	CELS/GSE11791/GSM298358.CEL	Estrogen	MCF-7 cells	activating	treated with 100 nM estradiol	6 h	3 replicates each
ARR01957	GSE1045	GSE1045b	GSM16943	GPL96	log	raw	NA	Estrogen	MDA-MB-231 breast cancer cells	control	treated with estradiol	2 h	2 replicates each, part of time series
ARR01958	GSE1045	GSE1045b	GSM18491	GPL96	log	raw	NA	Estrogen	MDA-MB-231 breast cancer cells	control	treated with estradiol	2 h	2 replicates each, part of time series
ARR01959	GSE1045	GSE1045b	GSM18494	GPL96	log	raw	NA	Estrogen	MDA-MB-231 breast cancer cells	activating	treated with estradiol	2 h	2 replicates each, part of time series
ARR01960	GSE1045	GSE1045b	GSM18495	GPL96	log	raw	NA	Estrogen	MDA-MB-231 breast cancer cells	activating	treated with estradiol	2 h	2 replicates each, part of time series
ARR01961	GSE3013	GSE3013f	GSM65283	GPL8300	log	raw	NA	Estrogen	endometrial epithelial cells	control	treated with estradiol	3 h	2 replicates each on different platforms, different treatments, different tumor stages
ARR01962	GSE3013	GSE3013f	GSM65285	GPL8300	log	raw	NA	Estrogen	endometrial epithelial cells	activating	treated with estradiol	3 h	2 replicates each on different platforms, different treatments, different tumor stages
ARR01963	GSE21618	GSE21618b	GSM539669	GPL10371	log	raw	NA	Estrogen	MCF-7 breast cancer cells	control	treated with estradiol	2 h	3 replicates each, different treatments, part of time series
ARR01964	GSE21618	GSE21618b	GSM539670	GPL10371	log	raw	NA	Estrogen	MCF-7 breast cancer cells	control	treated with estradiol	2 h	3 replicates each, different treatments, part of time series
ARR01965	GSE21618	GSE21618b	GSM539729	GPL10371	log	raw	NA	Estrogen	MCF-7 breast cancer cells	control	treated with estradiol	2 h	3 replicates each, different treatments, part of time series
ARR01966	GSE21618	GSE21618b	GSM539673	GPL10371	log	raw	NA	Estrogen	MCF-7 breast cancer cells	activating	treated with estradiol	2 h	3 replicates each, different treatments, part of time series
ARR01967	GSE21618	GSE21618b	GSM539674	GPL10371	log	raw	NA	Estrogen	MCF-7 breast cancer cells	activating	treated with estradiol	2 h	3 replicates each, different treatments, part of time series
ARR01968	GSE21618	GSE21618b	GSM539731	GPL10371	log	raw	NA	Estrogen	MCF-7 breast cancer cells	activating	treated with estradiol	2 h	3 replicates each, different treatments, part of time series
ARR01969	GSE23610	GSE23610	GSM578941	GPL570	log	raw	CELS/GSE23610/GSM578941.CEL	Estrogen	MCF-7 breast cancer cells	control	treated with 0.1µM estradiol	6 h	3 replicates each
ARR01970	GSE23610	GSE23610	GSM578942	GPL570	log	raw	CELS/GSE23610/GSM578942.CEL	Estrogen	MCF-7 breast cancer cells	control	treated with 0.1µM estradiol	6 h	3 replicates each
ARR01971	GSE23610	GSE23610	GSM578943	GPL570	log	raw	CELS/GSE23610/GSM578943.CEL	Estrogen	MCF-7 breast cancer cells	control	treated with 0.1µM estradiol	6 h	3 replicates each
ARR01972	GSE23610	GSE23610	GSM578944	GPL570	log	raw	CELS/GSE23610/GSM578944.CEL	Estrogen	MCF-7 breast cancer cells	activating	treated with 0.1µM estradiol	6 h	3 replicates each
ARR01973	GSE23610	GSE23610	GSM578945	GPL570	log	raw	CELS/GSE23610/GSM578945.CEL	Estrogen	MCF-7 breast cancer cells	activating	treated with 0.1µM estradiol	6 h	3 replicates each
ARR01974	GSE23610	GSE23610	GSM578946	GPL570	log	raw	CELS/GSE23610/GSM578946.CEL	Estrogen	MCF-7 breast cancer cells	activating	treated with 0.1µM estradiol	6 h	3 replicates each
ARR01975	GSE28006	GSE28006	GSM692735	GPL10558	log	normalized	NA	Estrogen	MCF-7 breast cancer cell line	control	treated with estradiol	3 h	2 replicates each, contain siControl RNA
ARR01976	GSE28006	GSE28006	GSM692739	GPL10558	log	normalized	NA	Estrogen	MCF-7 breast cancer cell line	control	treated with estradiol	3 h	2 replicates each, contain siControl RNA
ARR01977	GSE28006	GSE28006	GSM692736	GPL10558	log	normalized	NA	Estrogen	MCF-7 breast cancer cell line	activating	treated with estradiol	3 h	2 replicates each, contain siControl RNA
ARR01978	GSE28006	GSE28006	GSM692740	GPL10558	log	normalized	NA	Estrogen	MCF-7 breast cancer cell line	activating	treated with estradiol	3 h	2 replicates each, contain siControl RNA
ARR01979	GSE1045	GSE1045a	GSM16943	GPL96	log	raw	NA	Estrogen	MDA-MB-231 breast cancer cells	control	treated with estradiol	1 h	2 replicates each, part of time series
ARR01980	GSE1045	GSE1045a	GSM18491	GPL96	log	raw	NA	Estrogen	MDA-MB-231 breast cancer cells	control	treated with estradiol	1 h	2 replicates each, part of time series
ARR01981	GSE1045	GSE1045a	GSM18492	GPL96	log	raw	NA	Estrogen	MDA-MB-231 breast cancer cells	activating	treated with estradiol	1 h	2 replicates each, part of time series
ARR01982	GSE1045	GSE1045a	GSM18493	GPL96	log	raw	NA	Estrogen	MDA-MB-231 breast cancer cells	activating	treated with estradiol	1 h	2 replicates each, part of time series
ARR01983	GSE26459	GSE26459b	GSM649496	GPL570	log	raw	CELS/GSE26459/GSM649496.CEL	Estrogen	MCF-7 estrogen resistant breast cancer cells	control	treated with estrogen	4 h	3 replicates each
ARR01984	GSE26459	GSE26459b	GSM649497	GPL570	log	raw	CELS/GSE26459/GSM649497.CEL	Estrogen	MCF-7 estrogen resistant breast cancer cells	control	treated with estrogen	4 h	3 replicates each
ARR01985	GSE26459	GSE26459b	GSM649498	GPL570	log	raw	CELS/GSE26459/GSM649498.CEL	Estrogen	MCF-7 estrogen resistant breast cancer cells	control	treated with estrogen	4 h	3 replicates each
ARR01986	GSE26459	GSE26459b	GSM649499	GPL570	log	raw	CELS/GSE26459/GSM649499.CEL	Estrogen	MCF-7 estrogen resistant breast cancer cells	activating	treated with estrogen	4 h	3 replicates each
ARR01987	GSE26459	GSE26459b	GSM649500	GPL570	log	raw	CELS/GSE26459/GSM649500.CEL	Estrogen	MCF-7 estrogen resistant breast cancer cells	activating	treated with estrogen	4 h	3 replicates each
ARR01988	GSE26459	GSE26459b	GSM649501	GPL570	log	raw	CELS/GSE26459/GSM649501.CEL	Estrogen	MCF-7 estrogen resistant breast cancer cells	activating	treated with estrogen	4 h	3 replicates each
ARR01989	GSE26459	GSE26459a	GSM649484	GPL570	log	raw	CELS/GSE26459/GSM649484.CEL	Estrogen	MCF-7 estrogen sensitive breast cancer cells	control	treated with estrogen	4 h	3 replicates each
ARR01990	GSE26459	GSE26459a	GSM649485	GPL570	log	raw	CELS/GSE26459/GSM649485.CEL	Estrogen	MCF-7 estrogen sensitive breast cancer cells	control	treated with estrogen	4 h	3 replicates each
ARR01991	GSE26459	GSE26459a	GSM649486	GPL570	log	raw	CELS/GSE26459/GSM649486.CEL	Estrogen	MCF-7 estrogen sensitive breast cancer cells	control	treated with estrogen	4 h	3 replicates each
ARR01992	GSE26459	GSE26459a	GSM649487	GPL570	log	raw	CELS/GSE26459/GSM649487.CEL	Estrogen	MCF-7 estrogen sensitive breast cancer cells	activating	treated with estrogen	4 h	3 replicates each
ARR01993	GSE26459	GSE26459a	GSM649488	GPL570	log	raw	CELS/GSE26459/GSM649488.CEL	Estrogen	MCF-7 estrogen sensitive breast cancer cells	activating	treated with estrogen	4 h	3 replicates each
ARR01994	GSE26459	GSE26459a	GSM649489	GPL570	log	raw	CELS/GSE26459/GSM649489.CEL	Estrogen	MCF-7 estrogen sensitive breast cancer cells	activating	treated with estrogen	4 h	3 replicates each
ARR01995	GSE3013	GSE3013i	GSM65288	GPL8300	log	raw	NA	Estrogen	endometrial epithelial cells	control	treated with estradiol	3 h	2 replicates each on different platforms, different treatments, different tumor stages
ARR01996	GSE3013	GSE3013i	GSM65290	GPL8300	log	raw	NA	Estrogen	endometrial epithelial cells	activating	treated with estradiol	3 h	2 replicates each on different platforms, different treatments, different tumor stages
ARR01997	GSE12261	GSE12261	GSM307999	GPL570	log	raw	CELS/GSE12261/GSM307999.CEL	Estrogen	human smooth muscle cells	control	treated with 3 µM 2-methoxyestradiol	4 h	3 replicates each
ARR01998	GSE12261	GSE12261	GSM308000	GPL570	log	raw	CELS/GSE12261/GSM308000.CEL	Estrogen	human smooth muscle cells	control	treated with 3 µM 2-methoxyestradiol	4 h	3 replicates each
ARR01999	GSE12261	GSE12261	GSM308001	GPL570	log	raw	CELS/GSE12261/GSM308001.CEL	Estrogen	human smooth muscle cells	control	treated with 3 µM 2-methoxyestradiol	4 h	3 replicates each
ARR02000	GSE12261	GSE12261	GSM308002	GPL570	log	raw	CELS/GSE12261/GSM308002.CEL	Estrogen	human smooth muscle cells	activating	treated with 3 µM 2-methoxyestradiol	4 h	3 replicates each
ARR02001	GSE12261	GSE12261	GSM308003	GPL570	log	raw	CELS/GSE12261/GSM308003.CEL	Estrogen	human smooth muscle cells	activating	treated with 3 µM 2-methoxyestradiol	4 h	3 replicates each
ARR02002	GSE12261	GSE12261	GSM308004	GPL570	log	raw	CELS/GSE12261/GSM308004.CEL	Estrogen	human smooth muscle cells	activating	treated with 3 µM 2-methoxyestradiol	4 h	3 replicates each
ARR02003	GSE11567	GSE11567b	GSM291218	GPL6102	log	normalized	NA	Estrogen	SKBR3 cells	control	treated with 1o µM hydoxytamoxifen	1 h	3 replicates each, control transfection
ARR02004	GSE11567	GSE11567b	GSM291219	GPL6102	log	normalized	NA	Estrogen	SKBR3 cells	control	treated with 1o µM hydoxytamoxifen	1 h	3 replicates each, control transfection
ARR02005	GSE11567	GSE11567b	GSM291220	GPL6102	log	normalized	NA	Estrogen	SKBR3 cells	control	treated with 1o µM hydoxytamoxifen	1 h	3 replicates each, control transfection
ARR02006	GSE11567	GSE11567b	GSM291221	GPL6102	log	normalized	NA	Estrogen	SKBR3 cells	unknown	treated with 1o µM hydoxytamoxifen	1 h	3 replicates each, control transfection
ARR02007	GSE11567	GSE11567b	GSM291222	GPL6102	log	normalized	NA	Estrogen	SKBR3 cells	unknown	treated with 1o µM hydoxytamoxifen	1 h	3 replicates each, control transfection
ARR02008	GSE11567	GSE11567b	GSM291223	GPL6102	log	normalized	NA	Estrogen	SKBR3 cells	unknown	treated with 1o µM hydoxytamoxifen	1 h	3 replicates each, control transfection
ARR02009	GSE30931	GSE30931	GSM766676	GPL10558	linear	raw	NA	Estrogen	MCF-7 breast cancer cell line	control	treated with estrogen	6 h	3 replicates each
ARR02010	GSE30931	GSE30931	GSM766677	GPL10558	linear	raw	NA	Estrogen	MCF-7 breast cancer cell line	control	treated with estrogen	6 h	3 replicates each
ARR02011	GSE30931	GSE30931	GSM766678	GPL10558	linear	raw	NA	Estrogen	MCF-7 breast cancer cell line	control	treated with estrogen	6 h	3 replicates each
ARR02012	GSE30931	GSE30931	GSM766679	GPL10558	linear	raw	NA	Estrogen	MCF-7 breast cancer cell line	activating	treated with estrogen	6 h	3 replicates each
ARR02013	GSE30931	GSE30931	GSM766680	GPL10558	linear	raw	NA	Estrogen	MCF-7 breast cancer cell line	activating	treated with estrogen	6 h	3 replicates each
ARR02014	GSE30931	GSE30931	GSM766681	GPL10558	linear	raw	NA	Estrogen	MCF-7 breast cancer cell line	activating	treated with estrogen	6 h	3 replicates each
ARR02015	GSE13458	GSE13458a	GSM339421	GPL570	linear	raw	CELS/GSE13458/GSM339421.CEL	Estrogen	MCF-7 cells	control	treated with estradiol	3 h	3 replicates each, contain luciferase knockdown
ARR02016	GSE13458	GSE13458a	GSM339422	GPL570	linear	raw	CELS/GSE13458/GSM339422.CEL	Estrogen	MCF-7 cells	activating	treated with estradiol	3 h	3 replicates each, contain luciferase knockdown
ARR02017	GSE25314	GSE25314b	GSM622757	GPL6947	linear	raw	NA	Estrogen	MCF-7 breast cancer cells	control	treated with 1 µM tamoxifen	6 h	4 replicates each, different treatments
ARR02018	GSE25314	GSE25314b	GSM622761	GPL6947	linear	raw	NA	Estrogen	MCF-7 breast cancer cells	control	treated with 1 µM tamoxifen	6 h	4 replicates each, different treatments
ARR02019	GSE25314	GSE25314b	GSM622765	GPL6947	linear	raw	NA	Estrogen	MCF-7 breast cancer cells	control	treated with 1 µM tamoxifen	6 h	4 replicates each, different treatments
ARR02020	GSE25314	GSE25314b	GSM622769	GPL6947	linear	raw	NA	Estrogen	MCF-7 breast cancer cells	control	treated with 1 µM tamoxifen	6 h	4 replicates each, different treatments
ARR02021	GSE25314	GSE25314b	GSM622760	GPL6947	linear	raw	NA	Estrogen	MCF-7 breast cancer cells	unknown	treated with 1 µM tamoxifen	6 h	4 replicates each, different treatments
ARR02022	GSE25314	GSE25314b	GSM622764	GPL6947	linear	raw	NA	Estrogen	MCF-7 breast cancer cells	unknown	treated with 1 µM tamoxifen	6 h	4 replicates each, different treatments
ARR02023	GSE25314	GSE25314b	GSM622768	GPL6947	linear	raw	NA	Estrogen	MCF-7 breast cancer cells	unknown	treated with 1 µM tamoxifen	6 h	4 replicates each, different treatments
ARR02024	GSE25314	GSE25314b	GSM622772	GPL6947	linear	raw	NA	Estrogen	MCF-7 breast cancer cells	unknown	treated with 1 µM tamoxifen	6 h	4 replicates each, different treatments
ARR02025	GSE3013	GSE3013j	GSM65289	GPL8300	log	raw	NA	Estrogen	endometrial epithelial cells	control	treated with estradiol	3 h	2 replicates each on different platforms, different treatments, different tumor stages
ARR02026	GSE3013	GSE3013j	GSM65291	GPL8300	log	raw	NA	Estrogen	endometrial epithelial cells	activating	treated with estradiol	3 h	2 replicates each on different platforms, different treatments, different tumor stages
ARR02027	GSE3013	GSE3013b	GSM65277	GPL8300	log	raw	NA	Estrogen	endometrial epithelial cells	control	treated with estradiol	3 h	2 replicates each on different platforms, different treatments, different tumor stages
ARR02028	GSE3013	GSE3013b	GSM65279	GPL8300	log	raw	NA	Estrogen	endometrial epithelial cells	activating	treated with estradiol	3 h	2 replicates each on different platforms, different treatments, different tumor stages
ARR02029	GSE35287	GSE35287c	GSM865145	GPL6244	log	normalized	CELS/GSE35287/GSM865145.CEL	Estrogen	endometrial fibroblasts	control	treated with E2	6 h	1 replicate each, 4 donors
ARR02030	GSE35287	GSE35287c	GSM865146	GPL6244	log	normalized	CELS/GSE35287/GSM865146.CEL	Estrogen	endometrial fibroblasts	activating	treated with E2	6 h	1 replicate each, 4 donors
ARR02031	GSE23500	GSE23500	GSM575623	GPL6947	log	normalized	NA	Estrogen	human normal breast cells	control	treated with estradiol	6 h	3 replicates each
ARR02032	GSE23500	GSE23500	GSM575624	GPL6947	log	normalized	NA	Estrogen	human normal breast cells	control	treated with estradiol	6 h	3 replicates each
ARR02033	GSE23500	GSE23500	GSM575625	GPL6947	log	normalized	NA	Estrogen	human normal breast cells	control	treated with estradiol	6 h	3 replicates each
ARR02034	GSE23500	GSE23500	GSM575626	GPL6947	log	normalized	NA	Estrogen	human normal breast cells	activating	treated with estradiol	6 h	3 replicates each
ARR02035	GSE23500	GSE23500	GSM575627	GPL6947	log	normalized	NA	Estrogen	human normal breast cells	activating	treated with estradiol	6 h	3 replicates each
ARR02036	GSE23500	GSE23500	GSM575628	GPL6947	log	normalized	NA	Estrogen	human normal breast cells	activating	treated with estradiol	6 h	3 replicates each
ARR02037	GSE9936	GSE9936c	GSM251354	GPL96	linear	raw	CELS/GSE9936/GSM251354.CEL	Estrogen	MCF-7 cells	control	treated with 300 nM genistein	4 h	3 replicates each, different treatments, contain control vector
ARR02038	GSE9936	GSE9936c	GSM251355	GPL96	linear	raw	CELS/GSE9936/GSM251355.CEL	Estrogen	MCF-7 cells	control	treated with 300 nM genistein	4 h	3 replicates each, different treatments, contain control vector
ARR02039	GSE9936	GSE9936c	GSM251356	GPL96	linear	raw	CELS/GSE9936/GSM251356.CEL	Estrogen	MCF-7 cells	control	treated with 300 nM genistein	4 h	3 replicates each, different treatments, contain control vector
ARR02040	GSE9936	GSE9936c	GSM251363	GPL96	linear	raw	CELS/GSE9936/GSM251363.CEL	Estrogen	MCF-7 cells	activating	treated with 300 nM genistein	4 h	3 replicates each, different treatments, contain control vector
ARR02041	GSE9936	GSE9936c	GSM251364	GPL96	linear	raw	CELS/GSE9936/GSM251364.CEL	Estrogen	MCF-7 cells	activating	treated with 300 nM genistein	4 h	3 replicates each, different treatments, contain control vector
ARR02042	GSE21618	GSE21618e	GSM539717	GPL10371	log	raw	NA	Estrogen	MCF-7 breast cancer cells	control	treated with tamoxifen	1 h	1 replicate each, different treatments, part of time series
ARR02043	GSE21618	GSE21618e	GSM539718	GPL10371	log	raw	NA	Estrogen	MCF-7 breast cancer cells	unknown	treated with tamoxifen	1 h	1 replicate each, different treatments, part of time series
ARR02044	GSE3834	GSE3834h	GSM87509	GPL570	linear	raw	NA	Estrogen	BT-474 cells	control	treated with 10 nM estradiol	4 h	2 replicates each, different cell lines, part of time series
ARR02045	GSE3834	GSE3834h	GSM87510	GPL570	linear	raw	NA	Estrogen	BT-474 cells	control	treated with 10 nM estradiol	4 h	2 replicates each, different cell lines, part of time series
ARR02046	GSE3834	GSE3834h	GSM87513	GPL570	linear	raw	NA	Estrogen	BT-474 cells	activating	treated with 10 nM estradiol	4 h	2 replicates each, different cell lines, part of time series
ARR02047	GSE3834	GSE3834h	GSM87514	GPL570	linear	raw	NA	Estrogen	BT-474 cells	activating	treated with 10 nM estradiol	4 h	2 replicates each, different cell lines, part of time series
ARR02048	GSE21618	GSE21618h	GSM539717	GPL10371	log	raw	NA	Estrogen	MCF-7 breast cancer cells	control	treated with tamoxifen	6 h	1 replicate each, different treatments, part of time series
ARR02049	GSE21618	GSE21618h	GSM539721	GPL10371	log	raw	NA	Estrogen	MCF-7 breast cancer cells	unknown	treated with tamoxifen	6 h	1 replicate each, different treatments, part of time series
ARR02050	GSE22593	GSE22593c	GSM560575	GPL96	linear	raw	CELS/GSE22593/GSM560575.CEL	Estrogen	MDA-MB-231ER+ breast cancer cells	control	treated with estradiol	4 h	2 replicates each, part of time series
ARR02051	GSE22593	GSE22593c	GSM560576	GPL96	linear	raw	CELS/GSE22593/GSM560576.CEL	Estrogen	MDA-MB-231ER+ breast cancer cells	control	treated with estradiol	4 h	2 replicates each, part of time series
ARR02052	GSE22593	GSE22593c	GSM560581	GPL96	linear	raw	CELS/GSE22593/GSM560581.CEL	Estrogen	MDA-MB-231ER+ breast cancer cells	activating	treated with estradiol	4 h	2 replicates each, part of time series
ARR02053	GSE22593	GSE22593c	GSM560582	GPL96	linear	raw	CELS/GSE22593/GSM560582.CEL	Estrogen	MDA-MB-231ER+ breast cancer cells	activating	treated with estradiol	4 h	2 replicates each, part of time series
ARR02054	GSE9936	GSE9936b	GSM251354	GPL96	linear	raw	CELS/GSE9936/GSM251354.CEL	Estrogen	MCF-7 cells	control	treated with 6 nM genistein	4 h	3 replicates each, different treatments, contain control vector
ARR02055	GSE9936	GSE9936b	GSM251355	GPL96	linear	raw	CELS/GSE9936/GSM251355.CEL	Estrogen	MCF-7 cells	control	treated with 6 nM genistein	4 h	3 replicates each, different treatments, contain control vector
ARR02056	GSE9936	GSE9936b	GSM251356	GPL96	linear	raw	CELS/GSE9936/GSM251356.CEL	Estrogen	MCF-7 cells	control	treated with 6 nM genistein	4 h	3 replicates each, different treatments, contain control vector
ARR02057	GSE9936	GSE9936b	GSM251360	GPL96	linear	raw	CELS/GSE9936/GSM251360.CEL	Estrogen	MCF-7 cells	activating	treated with 6 nM genistein	4 h	3 replicates each, different treatments, contain control vector
ARR02058	GSE9936	GSE9936b	GSM251361	GPL96	linear	raw	CELS/GSE9936/GSM251361.CEL	Estrogen	MCF-7 cells	activating	treated with 6 nM genistein	4 h	3 replicates each, different treatments, contain control vector
ARR02059	GSE9936	GSE9936b	GSM251362	GPL96	linear	raw	CELS/GSE9936/GSM251362.CEL	Estrogen	MCF-7 cells	activating	treated with 6 nM genistein	4 h	3 replicates each, different treatments, contain control vector
ARR02060	GSE3013	GSE3013l	GSM65288	GPL8300	log	raw	NA	Estrogen	endometrial epithelial cells	control	treated with tamoxifen	3 h	2 replicates each on different platforms, different treatments, different tumor stages
ARR02061	GSE3013	GSE3013l	GSM65292	GPL8300	log	raw	NA	Estrogen	endometrial epithelial cells	unknown	treated with tamoxifen	3 h	2 replicates each on different platforms, different treatments, different tumor stages
ARR02062	GSE35287	GSE35287d	GSM865173	GPL6244	log	normalized	CELS/GSE35287/GSM865173.CEL	Estrogen	endometrial fibroblasts	control	treated with E2	6 h	1 replicate each, 4 donors
ARR02063	GSE35287	GSE35287d	GSM865204	GPL6244	log	normalized	CELS/GSE35287/GSM865204.CEL	Estrogen	endometrial fibroblasts	activating	treated with E2	6 h	1 replicate each, 4 donors
ARR02064	GSE3834	GSE3834b	GSM87446	GPL96	linear	raw	NA	Estrogen	MCF-7 cells	control	treated with 10 nM estradiol	2 h	2 replicates each, different cell lines, part of time series
ARR02065	GSE3834	GSE3834b	GSM87447	GPL96	linear	raw	NA	Estrogen	MCF-7 cells	control	treated with 10 nM estradiol	2 h	2 replicates each, different cell lines, part of time series
ARR02066	GSE3834	GSE3834b	GSM87449	GPL96	linear	raw	NA	Estrogen	MCF-7 cells	activating	treated with 10 nM estradiol	2 h	2 replicates each, different cell lines, part of time series
ARR02067	GSE3834	GSE3834b	GSM87450	GPL96	linear	raw	NA	Estrogen	MCF-7 cells	activating	treated with 10 nM estradiol	2 h	2 replicates each, different cell lines, part of time series
ARR02068	GSE21618	GSE21618c	GSM539669	GPL10371	log	raw	NA	Estrogen	MCF-7 breast cancer cells	control	treated with estradiol	3 h	3 replicates each, different treatments, part of time series
ARR02069	GSE21618	GSE21618c	GSM539670	GPL10371	log	raw	NA	Estrogen	MCF-7 breast cancer cells	control	treated with estradiol	3 h	3 replicates each, different treatments, part of time series
ARR02070	GSE21618	GSE21618c	GSM539729	GPL10371	log	raw	NA	Estrogen	MCF-7 breast cancer cells	control	treated with estradiol	3 h	3 replicates each, different treatments, part of time series
ARR02071	GSE21618	GSE21618c	GSM539675	GPL10371	log	raw	NA	Estrogen	MCF-7 breast cancer cells	activating	treated with estradiol	3 h	3 replicates each, different treatments, part of time series
ARR02072	GSE21618	GSE21618c	GSM539676	GPL10371	log	raw	NA	Estrogen	MCF-7 breast cancer cells	activating	treated with estradiol	3 h	3 replicates each, different treatments, part of time series
ARR02073	GSE21618	GSE21618c	GSM539732	GPL10371	log	raw	NA	Estrogen	MCF-7 breast cancer cells	activating	treated with estradiol	3 h	3 replicates each, different treatments, part of time series
ARR02074	GSE20081	GSE20081	GSM503884	GPL570	log	raw	CELS/GSE20081/GSM503884.CEL	Estrogen	MCF-7 breast cancer cells	control	treated with estradiol	6 h	3 replicates each, contain control siRNA
ARR02075	GSE20081	GSE20081	GSM503885	GPL570	log	raw	CELS/GSE20081/GSM503885.CEL	Estrogen	MCF-7 breast cancer cells	control	treated with estradiol	6 h	3 replicates each, contain control siRNA
ARR02076	GSE20081	GSE20081	GSM503886	GPL570	log	raw	CELS/GSE20081/GSM503886.CEL	Estrogen	MCF-7 breast cancer cells	control	treated with estradiol	6 h	3 replicates each, contain control siRNA
ARR02077	GSE20081	GSE20081	GSM503887	GPL570	log	raw	CELS/GSE20081/GSM503887.CEL	Estrogen	MCF-7 breast cancer cells	activating	treated with estradiol	6 h	3 replicates each, contain control siRNA
ARR02078	GSE20081	GSE20081	GSM503888	GPL570	log	raw	CELS/GSE20081/GSM503888.CEL	Estrogen	MCF-7 breast cancer cells	activating	treated with estradiol	6 h	3 replicates each, contain control siRNA
ARR02079	GSE20081	GSE20081	GSM503889	GPL570	log	raw	CELS/GSE20081/GSM503889.CEL	Estrogen	MCF-7 breast cancer cells	activating	treated with estradiol	6 h	3 replicates each, contain control siRNA
ARR02080	GSE21618	GSE21618g	GSM539717	GPL10371	log	raw	NA	Estrogen	MCF-7 breast cancer cells	control	treated with tamoxifen	3 h	1 replicate each, different treatments, part of time series
ARR02081	GSE21618	GSE21618g	GSM539720	GPL10371	log	raw	NA	Estrogen	MCF-7 breast cancer cells	unknown	treated with tamoxifen	3 h	1 replicate each, different treatments, part of time series
ARR02082	GSE21618	GSE21618d	GSM539669	GPL10371	log	raw	NA	Estrogen	MCF-7 breast cancer cells	control	treated with estradiol	6 h	3 replicates each, different treatments, part of time series
ARR02083	GSE21618	GSE21618d	GSM539670	GPL10371	log	raw	NA	Estrogen	MCF-7 breast cancer cells	control	treated with estradiol	6 h	3 replicates each, different treatments, part of time series
ARR02084	GSE21618	GSE21618d	GSM539729	GPL10371	log	raw	NA	Estrogen	MCF-7 breast cancer cells	control	treated with estradiol	6 h	3 replicates each, different treatments, part of time series
ARR02085	GSE21618	GSE21618d	GSM539677	GPL10371	log	raw	NA	Estrogen	MCF-7 breast cancer cells	activating	treated with estradiol	6 h	3 replicates each, different treatments, part of time series
ARR02086	GSE21618	GSE21618d	GSM539678	GPL10371	log	raw	NA	Estrogen	MCF-7 breast cancer cells	activating	treated with estradiol	6 h	3 replicates each, different treatments, part of time series
ARR02087	GSE21618	GSE21618d	GSM539733	GPL10371	log	raw	NA	Estrogen	MCF-7 breast cancer cells	activating	treated with estradiol	6 h	3 replicates each, different treatments, part of time series
ARR02088	GSE15717	GSE15717	GSM393484	GPL96	log	raw	CELS/GSE15717/GSM393484.CEL	Estrogen	MCF-7 cells	control	treated with estradiol	4 h	3 replicates each
ARR02089	GSE15717	GSE15717	GSM393485	GPL96	log	raw	CELS/GSE15717/GSM393485.CEL	Estrogen	MCF-7 cells	control	treated with estradiol	4 h	3 replicates each
ARR02090	GSE15717	GSE15717	GSM393486	GPL96	log	raw	CELS/GSE15717/GSM393486.CEL	Estrogen	MCF-7 cells	control	treated with estradiol	4 h	3 replicates each
ARR02091	GSE15717	GSE15717	GSM393487	GPL96	log	raw	CELS/GSE15717/GSM393487.CEL	Estrogen	MCF-7 cells	activating	treated with estradiol	4 h	3 replicates each
ARR02092	GSE15717	GSE15717	GSM393488	GPL96	log	raw	CELS/GSE15717/GSM393488.CEL	Estrogen	MCF-7 cells	activating	treated with estradiol	4 h	3 replicates each
ARR02093	GSE15717	GSE15717	GSM393489	GPL96	log	raw	CELS/GSE15717/GSM393489.CEL	Estrogen	MCF-7 cells	activating	treated with estradiol	4 h	3 replicates each
ARR02094	GSE35287	GSE35287b	GSM865143	GPL6244	log	normalized	CELS/GSE35287/GSM865143.CEL	Estrogen	endometrial fibroblasts	control	treated with E2	6 h	1 replicate each, 4 donors
ARR02095	GSE35287	GSE35287b	GSM865154	GPL6244	log	normalized	CELS/GSE35287/GSM865154.CEL	Estrogen	endometrial fibroblasts	activating	treated with E2	6 h	1 replicate each, 4 donors
ARR02096	GSE3013	GSE3013a	GSM64885	GPL91	log	raw	NA	Estrogen	endometrial epithelial cells	control	treated with estradiol	3 h	2 replicates each on different platforms, different treatments, different tumor stages
ARR02097	GSE3013	GSE3013a	GSM65278	GPL91	log	raw	NA	Estrogen	endometrial epithelial cells	activating	treated with estradiol	3 h	2 replicates each on different platforms, different treatments, different tumor stages
ARR02098	GSE3834	GSE3834a	GSM87446	GPL96	linear	raw	NA	Estrogen	MCF-7 cells	control	treated with 10 nM estradiol	1 h	2 replicates each, different cell lines, part of time series
ARR02099	GSE3834	GSE3834a	GSM87447	GPL96	linear	raw	NA	Estrogen	MCF-7 cells	control	treated with 10 nM estradiol	1 h	2 replicates each, different cell lines, part of time series
ARR02100	GSE3834	GSE3834a	GSM87448	GPL96	linear	raw	NA	Estrogen	MCF-7 cells	activating	treated with 10 nM estradiol	1 h	2 replicates each, different cell lines, part of time series
ARR02101	GSE21618	GSE21618a	GSM539669	GPL10371	log	raw	NA	Estrogen	MCF-7 breast cancer cells	control	treated with estradiol	1 h	3 replicates each, different treatments, part of time series
ARR02102	GSE21618	GSE21618a	GSM539670	GPL10371	log	raw	NA	Estrogen	MCF-7 breast cancer cells	control	treated with estradiol	1 h	3 replicates each, different treatments, part of time series
ARR02103	GSE21618	GSE21618a	GSM539729	GPL10371	log	raw	NA	Estrogen	MCF-7 breast cancer cells	control	treated with estradiol	1 h	3 replicates each, different treatments, part of time series
ARR02104	GSE21618	GSE21618a	GSM539671	GPL10371	log	raw	NA	Estrogen	MCF-7 breast cancer cells	activating	treated with estradiol	1 h	3 replicates each, different treatments, part of time series
ARR02105	GSE21618	GSE21618a	GSM539672	GPL10371	log	raw	NA	Estrogen	MCF-7 breast cancer cells	activating	treated with estradiol	1 h	3 replicates each, different treatments, part of time series
ARR02106	GSE21618	GSE21618a	GSM539730	GPL10371	log	raw	NA	Estrogen	MCF-7 breast cancer cells	activating	treated with estradiol	1 h	3 replicates each, different treatments, part of time series
ARR02107	GSE5258	GSE5258Est	GSM119000	GPL96	log	raw	CELS/GSE5258/GSM119000.CEL	Estrogen	MCF-7 cells	control	treated with 10 nM estradiol	6 h	1-2 replicates each
ARR02108	GSE5258	GSE5258Est	GSM118794	GPL96	log	raw	CELS/GSE5258/GSM118794.CEL	Estrogen	MCF-7 cells	control	treated with 10 nM estradiol	6 h	1-2 replicates each
ARR02109	GSE5258	GSE5258Est	GSM118730	GPL96	log	raw	CELS/GSE5258/GSM118730.CEL	Estrogen	MCF-7 cells	activating	treated with 10 nM estradiol	6 h	1-2 replicates each
ARR02110	GSE3013	GSE3013c	GSM65277	GPL8300	log	raw	NA	Estrogen	endometrial epithelial cells	control	treated with tamoxifen	3 h	2 replicates each on different platforms, different treatments, different tumor stages
ARR02111	GSE3013	GSE3013c	GSM65281	GPL8300	log	raw	NA	Estrogen	endometrial epithelial cells	unknown	treated with tamoxifen	3 h	2 replicates each on different platforms, different treatments, different tumor stages
ARR02112	GSE25314	GSE25314a	GSM622757	GPL6947	linear	raw	NA	Estrogen	MCF-7 breast cancer cells	control	treated with 100nM estrogen	6 h	4 replicates each, different treatments
ARR02113	GSE25314	GSE25314a	GSM622761	GPL6947	linear	raw	NA	Estrogen	MCF-7 breast cancer cells	control	treated with 100nM estrogen	6 h	4 replicates each, different treatments
ARR02114	GSE25314	GSE25314a	GSM622765	GPL6947	linear	raw	NA	Estrogen	MCF-7 breast cancer cells	control	treated with 100nM estrogen	6 h	4 replicates each, different treatments
ARR02115	GSE25314	GSE25314a	GSM622769	GPL6947	linear	raw	NA	Estrogen	MCF-7 breast cancer cells	control	treated with 100nM estrogen	6 h	4 replicates each, different treatments
ARR02116	GSE25314	GSE25314a	GSM622758	GPL6947	linear	raw	NA	Estrogen	MCF-7 breast cancer cells	activating	treated with 100nM estrogen	6 h	4 replicates each, different treatments
ARR02117	GSE25314	GSE25314a	GSM622762	GPL6947	linear	raw	NA	Estrogen	MCF-7 breast cancer cells	activating	treated with 100nM estrogen	6 h	4 replicates each, different treatments
ARR02118	GSE25314	GSE25314a	GSM622766	GPL6947	linear	raw	NA	Estrogen	MCF-7 breast cancer cells	activating	treated with 100nM estrogen	6 h	4 replicates each, different treatments
ARR02119	GSE25314	GSE25314a	GSM622770	GPL6947	linear	raw	NA	Estrogen	MCF-7 breast cancer cells	activating	treated with 100nM estrogen	6 h	4 replicates each, different treatments
ARR02120	GSE24592	GSE24592	GSM606107	GPL571	log	raw	CELS/GSE24592/GSM606107.CEL	Estrogen	MCF-7 breast cancer cells	control	treated with 10nM estradiol	4 h	2-3 replicates each, contain control siRNA
ARR02121	GSE24592	GSE24592	GSM606108	GPL571	log	raw	CELS/GSE24592/GSM606108.CEL	Estrogen	MCF-7 breast cancer cells	control	treated with 10nM estradiol	4 h	2-3 replicates each, contain control siRNA
ARR02122	GSE24592	GSE24592	GSM606109	GPL571	log	raw	CELS/GSE24592/GSM606109.CEL	Estrogen	MCF-7 breast cancer cells	control	treated with 10nM estradiol	4 h	2-3 replicates each, contain control siRNA
ARR02123	GSE24592	GSE24592	GSM606110	GPL571	log	raw	CELS/GSE24592/GSM606110.CEL	Estrogen	MCF-7 breast cancer cells	activating	treated with 10nM estradiol	4 h	2-3 replicates each, contain control siRNA
ARR02124	GSE24592	GSE24592	GSM606111	GPL571	log	raw	CELS/GSE24592/GSM606111.CEL	Estrogen	MCF-7 breast cancer cells	activating	treated with 10nM estradiol	4 h	2-3 replicates each, contain control siRNA
ARR02125	GSE24592	GSE24592	GSM606112	GPL571	log	raw	CELS/GSE24592/GSM606112.CEL	Estrogen	MCF-7 breast cancer cells	activating	treated with 10nM estradiol	4 h	2-3 replicates each, contain control siRNA
ARR02126	GSE3013	GSE3013k	GSM65289	GPL8300	log	raw	NA	Estrogen	endometrial epithelial cells	control	treated with tamoxifen	3 h	2 replicates each on different platforms, different treatments, different tumor stages
ARR02127	GSE3013	GSE3013k	GSM65293	GPL8300	log	raw	NA	Estrogen	endometrial epithelial cells	unknown	treated with tamoxifen	3 h	2 replicates each on different platforms, different treatments, different tumor stages
ARR02128	GSE3834	GSE3834d	GSM87495	GPL570	linear	raw	NA	Estrogen	T47-D cells	control	treated with 10 nM estradiol	1 h	2 replicates each, different cell lines, part of time series
ARR02129	GSE3834	GSE3834d	GSM87496	GPL570	linear	raw	NA	Estrogen	T47-D cells	control	treated with 10 nM estradiol	1 h	2 replicates each, different cell lines, part of time series
ARR02130	GSE3834	GSE3834d	GSM87497	GPL570	linear	raw	NA	Estrogen	T47-D cells	activating	treated with 10 nM estradiol	1 h	2 replicates each, different cell lines, part of time series
ARR02131	GSE3834	GSE3834d	GSM87498	GPL570	linear	raw	NA	Estrogen	T47-D cells	activating	treated with 10 nM estradiol	1 h	2 replicates each, different cell lines, part of time series
ARR02132	GSE22593	GSE22593b	GSM560575	GPL96	linear	raw	CELS/GSE22593/GSM560575.CEL	Estrogen	MDA-MB-231ER+ breast cancer cells	control	treated with estradiol	2 h	2 replicates each, part of time series
ARR02133	GSE22593	GSE22593b	GSM560576	GPL96	linear	raw	CELS/GSE22593/GSM560576.CEL	Estrogen	MDA-MB-231ER+ breast cancer cells	control	treated with estradiol	2 h	2 replicates each, part of time series
ARR02134	GSE22593	GSE22593b	GSM560579	GPL96	linear	raw	CELS/GSE22593/GSM560579.CEL	Estrogen	MDA-MB-231ER+ breast cancer cells	activating	treated with estradiol	2 h	2 replicates each, part of time series
ARR02135	GSE22593	GSE22593b	GSM560580	GPL96	linear	raw	CELS/GSE22593/GSM560580.CEL	Estrogen	MDA-MB-231ER+ breast cancer cells	activating	treated with estradiol	2 h	2 replicates each, part of time series
ARR02136	GSE3013	GSE3013d	GSM64885	GPL91	log	raw	NA	Estrogen	endometrial epithelial cells	control	treated with tamoxifen	3 h	2 replicates each on different platforms, different treatments, different tumor stages
ARR02137	GSE3013	GSE3013d	GSM65280	GPL91	log	raw	NA	Estrogen	endometrial epithelial cells	unknown	treated with tamoxifen	3 h	2 replicates each on different platforms, different treatments, different tumor stages
ARR02138	GSE22012	GSE22012	GSM547196	GPL6480	linear	raw	NA	Estrogen	MCF-7 breast cancer cells	control	treated with estradiol	1 h	4 replicates each
ARR02139	GSE22012	GSE22012	GSM547197	GPL6480	linear	raw	NA	Estrogen	MCF-7 breast cancer cells	control	treated with estradiol	1 h	4 replicates each
ARR02140	GSE22012	GSE22012	GSM547198	GPL6480	linear	raw	NA	Estrogen	MCF-7 breast cancer cells	control	treated with estradiol	1 h	4 replicates each
ARR02141	GSE22012	GSE22012	GSM547199	GPL6480	linear	raw	NA	Estrogen	MCF-7 breast cancer cells	control	treated with estradiol	1 h	4 replicates each
ARR02142	GSE22012	GSE22012	GSM547161	GPL6480	linear	raw	NA	Estrogen	MCF-7 breast cancer cells	activating	treated with estradiol	1 h	4 replicates each
ARR02143	GSE22012	GSE22012	GSM547162	GPL6480	linear	raw	NA	Estrogen	MCF-7 breast cancer cells	activating	treated with estradiol	1 h	4 replicates each
ARR02144	GSE22012	GSE22012	GSM547163	GPL6480	linear	raw	NA	Estrogen	MCF-7 breast cancer cells	activating	treated with estradiol	1 h	4 replicates each
ARR02145	GSE22012	GSE22012	GSM547176	GPL6480	linear	raw	NA	Estrogen	MCF-7 breast cancer cells	activating	treated with estradiol	1 h	4 replicates each
ARR02146	GSE21618	GSE21618f	GSM539717	GPL10371	log	raw	NA	Estrogen	MCF-7 breast cancer cells	control	treated with tamoxifen	2 h	1 replicate each, different treatments, part of time series
ARR02147	GSE21618	GSE21618f	GSM539719	GPL10371	log	raw	NA	Estrogen	MCF-7 breast cancer cells	unknown	treated with tamoxifen	2 h	1 replicate each, different treatments, part of time series
ARR02148	GSE35287	GSE35287a	GSM865133	GPL6244	log	normalized	CELS/GSE35287/GSM865133.CEL	Estrogen	endometrial fibroblasts	control	treated with E2	6 h	1 replicate each, 4 donors
ARR02149	GSE35287	GSE35287a	GSM865134	GPL6244	log	normalized	CELS/GSE35287/GSM865134.CEL	Estrogen	endometrial fibroblasts	activating	treated with E2	6 h	1 replicate each, 4 donors
ARR02150	GSE22593	GSE22593a	GSM560575	GPL96	linear	raw	CELS/GSE22593/GSM560575.CEL	Estrogen	MDA-MB-231ER+ breast cancer cells	control	treated with estradiol	1 h	2 replicates each, part of time series
ARR02151	GSE22593	GSE22593a	GSM560576	GPL96	linear	raw	CELS/GSE22593/GSM560576.CEL	Estrogen	MDA-MB-231ER+ breast cancer cells	control	treated with estradiol	1 h	2 replicates each, part of time series
ARR02152	GSE22593	GSE22593a	GSM560577	GPL96	linear	raw	CELS/GSE22593/GSM560577.CEL	Estrogen	MDA-MB-231ER+ breast cancer cells	activating	treated with estradiol	1 h	2 replicates each, part of time series
ARR02153	GSE22593	GSE22593a	GSM560578	GPL96	linear	raw	CELS/GSE22593/GSM560578.CEL	Estrogen	MDA-MB-231ER+ breast cancer cells	activating	treated with estradiol	1 h	2 replicates each, part of time series
ARR02154	GSE3834	GSE3834g	GSM87509	GPL570	linear	raw	NA	Estrogen	BT-474 cells	control	treated with 10 nM estradiol	2 h	2 replicates each, different cell lines, part of time series
ARR02155	GSE3834	GSE3834g	GSM87510	GPL570	linear	raw	NA	Estrogen	BT-474 cells	control	treated with 10 nM estradiol	2 h	2 replicates each, different cell lines, part of time series
ARR02156	GSE3834	GSE3834g	GSM87511	GPL570	linear	raw	NA	Estrogen	BT-474 cells	activating	treated with 10 nM estradiol	2 h	2 replicates each, different cell lines, part of time series
ARR02157	GSE3834	GSE3834g	GSM87512	GPL570	linear	raw	NA	Estrogen	BT-474 cells	activating	treated with 10 nM estradiol	2 h	2 replicates each, different cell lines, part of time series
ARR02158	GSE9120	GSE9120a	GSM230880	GPL571	linear	raw	CELS/GSE9120/GSM230880.CEL	IL1	Cultured epidermal keratinocytes	control	treated with 25 ng/ml human recombinant IL-1	1 h	none
ARR02159	GSE9120	GSE9120a	GSM230879	GPL571	linear	raw	CELS/GSE9120/GSM230879.CEL	IL1	Cultured epidermal keratinocytes	activating	treated with 25 ng/ml human recombinant IL-1	1 h	none
ARR02160	GSE9120	GSE9120b	GSM230881	GPL571	linear	raw	CELS/GSE9120/GSM230881.CEL	IL1	Cultured epidermal keratinocytes	control	treated with 25 ng/ml human recombinant IL-1	4 h	comment
ARR02161	GSE9120	GSE9120b	GSM230882	GPL571	linear	raw	CELS/GSE9120/GSM230882.CEL	IL1	Cultured epidermal keratinocytes	activating	treated with 25 ng/ml human recombinant IL-1	4 h	comment
ARR02162	GSE32390	GSE32390b	GSM801680	GPL10558	log	normalized	NA	IL1	skin fibroblasts	control	treated with 20 ng/ml IL-1b	4 h	1 replicate each, 3 donors
ARR02163	GSE32390	GSE32390b	GSM801678	GPL10558	log	normalized	NA	IL1	skin fibroblasts	activating	treated with 20 ng/ml IL-1b	4 h	1 replicate each, 3 donors
ARR02164	GSE973	GSE973a	GSM15389	GPL96	linear	raw	CELS/GSE973/GSM15389.CEL	IL1	HUVEC	control	treated with 100 U/ml human IL-1	0.5 h	time series 3 time points
ARR02165	GSE973	GSE973a	GSM15390	GPL96	linear	raw	CELS/GSE973/GSM15390.CEL	IL1	HUVEC	activating	treated with 100 U/ml human IL-1	0.5 h	time series 3 time points
ARR02166	GSE32390	GSE32390a	GSM801681	GPL10558	log	normalized	NA	IL1	skin fibroblasts	control	treated with 20 ng/ml IL-1b	4 h	1 replicate each, 3 donors
ARR02167	GSE32390	GSE32390a	GSM801669	GPL10558	log	normalized	NA	IL1	skin fibroblasts	activating	treated with 20 ng/ml IL-1b	4 h	1 replicate each, 3 donors
ARR02168	GSE32390	GSE32390c	GSM801677	GPL10558	log	normalized	NA	IL1	skin fibroblasts	control	treated with 20 ng/ml IL-1b	4 h	1 replicate each, 3 donors
ARR02169	GSE32390	GSE32390c	GSM801670	GPL10558	log	normalized	NA	IL1	skin fibroblasts	activating	treated with 20 ng/ml IL-1b	4 h	1 replicate each, 3 donors
ARR02170	GSE8515	GSE8515IL1	GSM211500	GPL96	linear	raw	CELS/GSE8515/GSM211500.CEL	IL1	Human monocyte-derived macrophages	control	with IL-1 (15 ng/ml)	4 h	5 replicates each
ARR02171	GSE8515	GSE8515IL1	GSM211501	GPL96	linear	raw	CELS/GSE8515/GSM211501.CEL	IL1	Human monocyte-derived macrophages	control	with IL-1 (15 ng/ml)	4 h	5 replicates each
ARR02172	GSE8515	GSE8515IL1	GSM211502	GPL96	linear	raw	CELS/GSE8515/GSM211502.CEL	IL1	Human monocyte-derived macrophages	control	with IL-1 (15 ng/ml)	4 h	5 replicates each
ARR02173	GSE8515	GSE8515IL1	GSM211503	GPL96	linear	raw	CELS/GSE8515/GSM211503.CEL	IL1	Human monocyte-derived macrophages	control	with IL-1 (15 ng/ml)	4 h	5 replicates each
ARR02174	GSE8515	GSE8515IL1	GSM211504	GPL96	linear	raw	CELS/GSE8515/GSM211504.CEL	IL1	Human monocyte-derived macrophages	control	with IL-1 (15 ng/ml)	4 h	5 replicates each
ARR02175	GSE8515	GSE8515IL1	GSM211505	GPL96	linear	raw	CELS/GSE8515/GSM211505.CEL	IL1	Human monocyte-derived macrophages	activating	with IL-1 (15 ng/ml)	4 h	5 replicates each
ARR02176	GSE8515	GSE8515IL1	GSM211506	GPL96	linear	raw	CELS/GSE8515/GSM211506.CEL	IL1	Human monocyte-derived macrophages	activating	with IL-1 (15 ng/ml)	4 h	5 replicates each
ARR02177	GSE8515	GSE8515IL1	GSM211507	GPL96	linear	raw	CELS/GSE8515/GSM211507.CEL	IL1	Human monocyte-derived macrophages	activating	with IL-1 (15 ng/ml)	4 h	5 replicates each
ARR02178	GSE8515	GSE8515IL1	GSM211508	GPL96	linear	raw	CELS/GSE8515/GSM211508.CEL	IL1	Human monocyte-derived macrophages	activating	with IL-1 (15 ng/ml)	4 h	5 replicates each
ARR02179	GSE8515	GSE8515IL1	GSM211509	GPL96	linear	raw	CELS/GSE8515/GSM211509.CEL	IL1	Human monocyte-derived macrophages	activating	with IL-1 (15 ng/ml)	4 h	5 replicates each
ARR02180	GSE973	GSE973b	GSM15389	GPL96	linear	raw	CELS/GSE973/GSM15389.CEL	IL1	HUVEC	control	treated with 100 U/ml human IL-1	1 h	time series 3 time points
ARR02181	GSE973	GSE973b	GSM15391	GPL96	linear	raw	CELS/GSE973/GSM15391.CEL	IL1	HUVEC	activating	treated with 100 U/ml human IL-1	1 h	time series 3 time points
ARR02182	GSE973	GSE973c	GSM15389	GPL96	linear	raw	CELS/GSE973/GSM15389.CEL	IL1	HUVEC	control	treated with 100 U/ml human IL-1	2.5 h	time series 3 time points
ARR02183	GSE973	GSE973c	GSM15392	GPL96	linear	raw	CELS/GSE973/GSM15392.CEL	IL1	HUVEC	activating	treated with 100 U/ml human IL-1	2.5 h	time series 3 time points
ARR02184	GSE22325	GSE22325	GSM555847	GPL570	linear	raw	CELS/GSE22325/GSM555847.CEL	IL1	HUVECs	control	treated with 100U IL-1b	4 h	1 replicate each
ARR02185	GSE22325	GSE22325	GSM555851	GPL570	linear	raw	CELS/GSE22325/GSM555851.CEL	IL1	HUVECs	activating	treated with 100U IL-1b	4 h	1 replicate each
ARR02186	GSE8658	GSE8658e	GSM214764	GPL570	log	raw	CELS/GSE8658/GSM214764.CEL	PPAR	monocyte derived dendritic cells	control	treated with 1µM rosiglitazone, a PPARg agonist	6 h	1 replicate each, 6 donors
ARR02187	GSE8658	GSE8658e	GSM214766	GPL570	log	raw	CELS/GSE8658/GSM214766.CEL	PPAR	monocyte derived dendritic cells	activating	treated with 1µM rosiglitazone, a PPARg agonist	6 h	1 replicate each, 6 donors
ARR02188	GSE16385	GSE16385a	GSM411184	GPL570	log	normalized	CELS/GSE16385/GSM411184.CEL	PPAR	primary monocytes	control	treated with 1mM rosiglitazone, a PPARg agonist	4 h	1 replicate each, differently activated macrophages
ARR02189	GSE16385	GSE16385a	GSM411185	GPL570	log	normalized	CELS/GSE16385/GSM411185.CEL	PPAR	primary monocytes	activating	treated with 1mM rosiglitazone, a PPARg agonist	4 h	1 replicate each, differently activated macrophages
ARR02190	GSE5258	GSE5258PPAR	GSM119067	GPL3921	log	raw	CELS/GSE5258/GSM119067.CEL	PPAR	MCF7 cells	control	treated with 10µM rosiglitazone, a PPARg agonist	6 h	2 replicates each
ARR02191	GSE5258	GSE5258PPAR	GSM119103	GPL3921	log	raw	CELS/GSE5258/GSM119103.CEL	PPAR	MCF7 cells	control	treated with 10µM rosiglitazone, a PPARg agonist	6 h	2 replicates each
ARR02192	GSE5258	GSE5258PPAR	GSM119249	GPL3921	log	raw	CELS/GSE5258/GSM119249.CEL	PPAR	MCF7 cells	activating	treated with 10µM rosiglitazone, a PPARg agonist	6 h	2 replicates each
ARR02193	GSE5258	GSE5258PPAR	GSM119206	GPL3921	log	raw	CELS/GSE5258/GSM119206.CEL	PPAR	MCF7 cells	activating	treated with 10µM rosiglitazone, a PPARg agonist	6 h	2 replicates each
ARR02194	GSE8658	GSE8658d	GSM214756	GPL570	log	raw	CELS/GSE8658/GSM214756.CEL	PPAR	monocyte derived dendritic cells	control	treated with 1µM rosiglitazone, a PPARg agonist	6 h	1 replicate each, 6 donors
ARR02195	GSE8658	GSE8658d	GSM214763	GPL570	log	raw	CELS/GSE8658/GSM214763.CEL	PPAR	monocyte derived dendritic cells	activating	treated with 1µM rosiglitazone, a PPARg agonist	6 h	1 replicate each, 6 donors
ARR02196	GSE8658	GSE8658a	GSM214750	GPL570	log	raw	CELS/GSE8658/GSM214750.CEL	PPAR	monocyte derived dendritic cells	control	treated with 1µM rosiglitazone, a PPARg agonist	6 h	1 replicate each, 6 donors
ARR02197	GSE8658	GSE8658a	GSM214751	GPL570	log	raw	CELS/GSE8658/GSM214751.CEL	PPAR	monocyte derived dendritic cells	activating	treated with 1µM rosiglitazone, a PPARg agonist	6 h	1 replicate each, 6 donors
ARR02198	GSE17251	GSE17251f	GSM432160	GPL570	linear	raw	CELS/GSE17251/GSM432160.CEL	PPAR	primary hepatocytes	control	treated with 50µM Wy14643, a PPARa agonist	6 h	1 replicate each, 6 donors
ARR02199	GSE17251	GSE17251f	GSM432159	GPL570	linear	raw	CELS/GSE17251/GSM432159.CEL	PPAR	primary hepatocytes	activating	treated with 50µM Wy14643, a PPARa agonist	6 h	1 replicate each, 6 donors
ARR02200	GSE8658	GSE8658c	GSM214754	GPL570	log	raw	CELS/GSE8658/GSM214754.CEL	PPAR	monocyte derived dendritic cells	control	treated with 1µM rosiglitazone, a PPARg agonist	6 h	1 replicate each, 6 donors
ARR02201	GSE8658	GSE8658c	GSM214755	GPL570	log	raw	CELS/GSE8658/GSM214755.CEL	PPAR	monocyte derived dendritic cells	activating	treated with 1µM rosiglitazone, a PPARg agonist	6 h	1 replicate each, 6 donors
ARR02202	GSE17251	GSE17251e	GSM432156	GPL570	linear	raw	CELS/GSE17251/GSM432156.CEL	PPAR	primary hepatocytes	control	treated with 50µM Wy14643, a PPARa agonist	6 h	1 replicate each, 6 donors
ARR02203	GSE17251	GSE17251e	GSM432155	GPL570	linear	raw	CELS/GSE17251/GSM432155.CEL	PPAR	primary hepatocytes	activating	treated with 50µM Wy14643, a PPARa agonist	6 h	1 replicate each, 6 donors
ARR02204	GSE16385	GSE16385c	GSM411188	GPL570	log	normalized	CELS/GSE16385/GSM411188.CEL	PPAR	primary IFNg/TNFa activated monocytes	control	treated with 1mM rosiglitazone, a PPARg agonist	4 h	1 replicate each, differently activated macrophages
ARR02205	GSE16385	GSE16385c	GSM411189	GPL570	log	normalized	CELS/GSE16385/GSM411189.CEL	PPAR	primary IFNg/TNFa activated monocytes	activating	treated with 1mM rosiglitazone, a PPARg agonist	4 h	1 replicate each, differently activated macrophages
ARR02206	GSE16386	GSE16386a	GSM411223	GPL570	log	normalized	CELS/GSE16386/GSM411223.CEL	PPAR	primary IL4 activated monocytes	control	treated with 100 ng/ml rosiglitazone, a PPARg agonist	6 h	2 replicates each, 2 donors
ARR02207	GSE16386	GSE16386a	GSM411224	GPL570	log	normalized	CELS/GSE16386/GSM411224.CEL	PPAR	primary IL4 activated monocytes	control	treated with 100 ng/ml rosiglitazone, a PPARg agonist	6 h	2 replicates each, 2 donors
ARR02208	GSE16386	GSE16386a	GSM411225	GPL570	log	normalized	CELS/GSE16386/GSM411225.CEL	PPAR	primary IL4 activated monocytes	activating	treated with 100 ng/ml rosiglitazone, a PPARg agonist	6 h	2 replicates each, 2 donors
ARR02209	GSE16386	GSE16386a	GSM411226	GPL570	log	normalized	CELS/GSE16386/GSM411226.CEL	PPAR	primary IL4 activated monocytes	activating	treated with 100 ng/ml rosiglitazone, a PPARg agonist	6 h	2 replicates each, 2 donors
ARR02210	GSE17251	GSE17251b	GSM432144	GPL570	linear	raw	CELS/GSE17251/GSM432144.CEL	PPAR	primary hepatocytes	control	treated with 50µM Wy14643, a PPARa agonist	6 h	1 replicate each, 6 donors
ARR02211	GSE17251	GSE17251b	GSM432143	GPL570	linear	raw	CELS/GSE17251/GSM432143.CEL	PPAR	primary hepatocytes	activating	treated with 50µM Wy14643, a PPARa agonist	6 h	1 replicate each, 6 donors
ARR02212	GSE8658	GSE8658f	GSM214767	GPL570	log	raw	CELS/GSE8658/GSM214767.CEL	PPAR	monocyte derived dendritic cells	control	treated with 1µM rosiglitazone, a PPARg agonist	6 h	1 replicate each, 6 donors
ARR02213	GSE8658	GSE8658f	GSM214769	GPL570	log	raw	CELS/GSE8658/GSM214769.CEL	PPAR	monocyte derived dendritic cells	activating	treated with 1µM rosiglitazone, a PPARg agonist	6 h	1 replicate each, 6 donors
ARR02214	GSE17251	GSE17251d	GSM432152	GPL570	linear	raw	CELS/GSE17251/GSM432152.CEL	PPAR	primary hepatocytes	control	treated with 50µM Wy14643, a PPARa agonist	6 h	1 replicate each, 6 donors
ARR02215	GSE17251	GSE17251d	GSM432151	GPL570	linear	raw	CELS/GSE17251/GSM432151.CEL	PPAR	primary hepatocytes	activating	treated with 50µM Wy14643, a PPARa agonist	6 h	1 replicate each, 6 donors
ARR02216	GSE15483	GSE15483c	GSM388448	GPL4044	log	normalized	NA	PPAR	HUVECs	control	treated with 25 µmol fenofibrate, a PPARa ligand	6 h	3 replicates each, time series
ARR02217	GSE15483	GSE15483c	GSM388449	GPL4044	log	normalized	NA	PPAR	HUVECs	control	treated with 25 µmol fenofibrate, a PPARa ligand	6 h	3 replicates each, time series
ARR02218	GSE15483	GSE15483c	GSM388450	GPL4044	log	normalized	NA	PPAR	HUVECs	control	treated with 25 µmol fenofibrate, a PPARa ligand	6 h	3 replicates each, time series
ARR02219	GSE15483	GSE15483c	GSM388451	GPL4044	log	normalized	NA	PPAR	HUVECs	control	treated with 25 µmol fenofibrate, a PPARa ligand	6 h	3 replicates each, time series
ARR02220	GSE15483	GSE15483c	GSM388458	GPL4044	log	normalized	NA	PPAR	HUVECs	activating	treated with 25 µmol fenofibrate, a PPARa ligand	6 h	3 replicates each, time series
ARR02221	GSE15483	GSE15483c	GSM388459	GPL4044	log	normalized	NA	PPAR	HUVECs	activating	treated with 25 µmol fenofibrate, a PPARa ligand	6 h	3 replicates each, time series
ARR02222	GSE15483	GSE15483c	GSM388460	GPL4044	log	normalized	NA	PPAR	HUVECs	activating	treated with 25 µmol fenofibrate, a PPARa ligand	6 h	3 replicates each, time series
ARR02223	GSE16386	GSE16386b	GSM411227	GPL570	log	normalized	CELS/GSE16386/GSM411227.CEL	PPAR	primary IL4 activated monocytes	control	treated with 100 ng/ml rosiglitazone, a PPARg agonist	6 h	2 replicates each, 2 donors
ARR02224	GSE16386	GSE16386b	GSM411228	GPL570	log	normalized	CELS/GSE16386/GSM411228.CEL	PPAR	primary IL4 activated monocytes	control	treated with 100 ng/ml rosiglitazone, a PPARg agonist	6 h	2 replicates each, 2 donors
ARR02225	GSE16386	GSE16386b	GSM411229	GPL570	log	normalized	CELS/GSE16386/GSM411229.CEL	PPAR	primary IL4 activated monocytes	activating	treated with 100 ng/ml rosiglitazone, a PPARg agonist	6 h	2 replicates each, 2 donors
ARR02226	GSE16386	GSE16386b	GSM411230	GPL570	log	normalized	CELS/GSE16386/GSM411230.CEL	PPAR	primary IL4 activated monocytes	activating	treated with 100 ng/ml rosiglitazone, a PPARg agonist	6 h	2 replicates each, 2 donors
ARR02227	GSE15483	GSE15483a	GSM388448	GPL4044	log	normalized	NA	PPAR	HUVECs	control	treated with 25 µmol fenofibrate, a PPARa ligand	2 h	3 replicates each, time series
ARR02228	GSE15483	GSE15483a	GSM388449	GPL4044	log	normalized	NA	PPAR	HUVECs	control	treated with 25 µmol fenofibrate, a PPARa ligand	2 h	3 replicates each, time series
ARR02229	GSE15483	GSE15483a	GSM388450	GPL4044	log	normalized	NA	PPAR	HUVECs	control	treated with 25 µmol fenofibrate, a PPARa ligand	2 h	3 replicates each, time series
ARR02230	GSE15483	GSE15483a	GSM388451	GPL4044	log	normalized	NA	PPAR	HUVECs	control	treated with 25 µmol fenofibrate, a PPARa ligand	2 h	3 replicates each, time series
ARR02231	GSE15483	GSE15483a	GSM388452	GPL4044	log	normalized	NA	PPAR	HUVECs	activating	treated with 25 µmol fenofibrate, a PPARa ligand	2 h	3 replicates each, time series
ARR02232	GSE15483	GSE15483a	GSM388453	GPL4044	log	normalized	NA	PPAR	HUVECs	activating	treated with 25 µmol fenofibrate, a PPARa ligand	2 h	3 replicates each, time series
ARR02233	GSE15483	GSE15483a	GSM388454	GPL4044	log	normalized	NA	PPAR	HUVECs	activating	treated with 25 µmol fenofibrate, a PPARa ligand	2 h	3 replicates each, time series
ARR02234	GSE15483	GSE15483b	GSM388448	GPL4044	log	normalized	NA	PPAR	HUVECs	control	treated with 25 µmol fenofibrate, a PPARa ligand	4 h	3 replicates each, time series
ARR02235	GSE15483	GSE15483b	GSM388449	GPL4044	log	normalized	NA	PPAR	HUVECs	control	treated with 25 µmol fenofibrate, a PPARa ligand	4 h	3 replicates each, time series
ARR02236	GSE15483	GSE15483b	GSM388450	GPL4044	log	normalized	NA	PPAR	HUVECs	control	treated with 25 µmol fenofibrate, a PPARa ligand	4 h	3 replicates each, time series
ARR02237	GSE15483	GSE15483b	GSM388451	GPL4044	log	normalized	NA	PPAR	HUVECs	control	treated with 25 µmol fenofibrate, a PPARa ligand	4 h	3 replicates each, time series
ARR02238	GSE15483	GSE15483b	GSM388455	GPL4044	log	normalized	NA	PPAR	HUVECs	activating	treated with 25 µmol fenofibrate, a PPARa ligand	4 h	3 replicates each, time series
ARR02239	GSE15483	GSE15483b	GSM388456	GPL4044	log	normalized	NA	PPAR	HUVECs	activating	treated with 25 µmol fenofibrate, a PPARa ligand	4 h	3 replicates each, time series
ARR02240	GSE15483	GSE15483b	GSM388457	GPL4044	log	normalized	NA	PPAR	HUVECs	activating	treated with 25 µmol fenofibrate, a PPARa ligand	4 h	3 replicates each, time series
ARR02241	GSE17251	GSE17251c	GSM432148	GPL570	linear	raw	CELS/GSE17251/GSM432148.CEL	PPAR	primary hepatocytes	control	treated with 50µM Wy14643, a PPARa agonist	6 h	1 replicate each, 6 donors
ARR02242	GSE17251	GSE17251c	GSM432147	GPL570	linear	raw	CELS/GSE17251/GSM432147.CEL	PPAR	primary hepatocytes	activating	treated with 50µM Wy14643, a PPARa agonist	6 h	1 replicate each, 6 donors
ARR02243	GSE25547	GSE25547	GSM627985	GPL570	linear	raw	CELS/GSE25547/GSM627985.CEL	PPAR	HepG2 cells	control	treated with 100nM GW7647, a PPARa agonist	6 h	3 replicates each
ARR02244	GSE25547	GSE25547	GSM627986	GPL570	linear	raw	CELS/GSE25547/GSM627986.CEL	PPAR	HepG2 cells	control	treated with 100nM GW7647, a PPARa agonist	6 h	3 replicates each
ARR02245	GSE25547	GSE25547	GSM627987	GPL570	linear	raw	CELS/GSE25547/GSM627987.CEL	PPAR	HepG2 cells	control	treated with 100nM GW7647, a PPARa agonist	6 h	3 replicates each
ARR02246	GSE25547	GSE25547	GSM627988	GPL570	linear	raw	CELS/GSE25547/GSM627988.CEL	PPAR	HepG2 cells	activating	treated with 100nM GW7647, a PPARa agonist	6 h	3 replicates each
ARR02247	GSE25547	GSE25547	GSM627989	GPL570	linear	raw	CELS/GSE25547/GSM627989.CEL	PPAR	HepG2 cells	activating	treated with 100nM GW7647, a PPARa agonist	6 h	3 replicates each
ARR02248	GSE25547	GSE25547	GSM627990	GPL570	linear	raw	CELS/GSE25547/GSM627990.CEL	PPAR	HepG2 cells	activating	treated with 100nM GW7647, a PPARa agonist	6 h	3 replicates each
ARR02249	GSE17251	GSE17251a	GSM432140	GPL570	linear	raw	CELS/GSE17251/GSM432140.CEL	PPAR	primary hepatocytes	control	treated with 50µM Wy14643, a PPARa agonist	6 h	1 replicate each, 6 donors
ARR02250	GSE17251	GSE17251a	GSM432139	GPL570	linear	raw	CELS/GSE17251/GSM432139.CEL	PPAR	primary hepatocytes	activating	treated with 50µM Wy14643, a PPARa agonist	6 h	1 replicate each, 6 donors
ARR02251	GSE8658	GSE8658b	GSM214752	GPL570	log	raw	CELS/GSE8658/GSM214752.CEL	PPAR	monocyte derived dendritic cells	control	treated with 1µM rosiglitazone, a PPARg agonist	6 h	1 replicate each, 6 donors
ARR02252	GSE8658	GSE8658b	GSM214753	GPL570	log	raw	CELS/GSE8658/GSM214753.CEL	PPAR	monocyte derived dendritic cells	activating	treated with 1µM rosiglitazone, a PPARg agonist	6 h	1 replicate each, 6 donors
ARR02253	GSE16385	GSE16385b	GSM411186	GPL570	log	normalized	CELS/GSE16385/GSM411186.CEL	PPAR	primary IL4 activated monocytes	control	treated with 1mM rosiglitazone, a PPARg agonist	4 h	1 replicate each, differently activated macrophages
ARR02254	GSE16385	GSE16385b	GSM411187	GPL570	log	normalized	CELS/GSE16385/GSM411187.CEL	PPAR	primary IL4 activated monocytes	activating	treated with 1mM rosiglitazone, a PPARg agonist	4 h	1 replicate each, differently activated macrophages
ARR02255	GSE14934	GSE14934b	GSM373089	GPL571	linear	raw	CELS/GSE14934/GSM373089.CEL	MAPK	HEK-HT (kidney)	control	Ras (G12V,T35S) activation mutants	not specified	mutants said to be mostly activating Raf
ARR02256	GSE14934	GSE14934b	GSM373094	GPL571	linear	raw	CELS/GSE14934/GSM373094.CEL	MAPK	HEK-HT (kidney)	control	Ras (G12V,T35S) activation mutants	not specified	mutants said to be mostly activating Raf
ARR02257	GSE14934	GSE14934b	GSM373099	GPL571	linear	raw	CELS/GSE14934/GSM373099.CEL	MAPK	HEK-HT (kidney)	control	Ras (G12V,T35S) activation mutants	not specified	mutants said to be mostly activating Raf
ARR02258	GSE14934	GSE14934b	GSM373104	GPL571	linear	raw	CELS/GSE14934/GSM373104.CEL	MAPK	HEK-HT (kidney)	control	Ras (G12V,T35S) activation mutants	not specified	mutants said to be mostly activating Raf
ARR02259	GSE14934	GSE14934b	GSM373109	GPL571	linear	raw	CELS/GSE14934/GSM373109.CEL	MAPK	HEK-HT (kidney)	control	Ras (G12V,T35S) activation mutants	not specified	mutants said to be mostly activating Raf
ARR02260	GSE14934	GSE14934b	GSM373091	GPL571	linear	raw	CELS/GSE14934/GSM373091.CEL	MAPK	HEK-HT (kidney)	activating	Ras (G12V,T35S) activation mutants	not specified	mutants said to be mostly activating Raf
ARR02261	GSE14934	GSE14934b	GSM373096	GPL571	linear	raw	CELS/GSE14934/GSM373096.CEL	MAPK	HEK-HT (kidney)	activating	Ras (G12V,T35S) activation mutants	not specified	mutants said to be mostly activating Raf
ARR02262	GSE14934	GSE14934b	GSM373101	GPL571	linear	raw	CELS/GSE14934/GSM373101.CEL	MAPK	HEK-HT (kidney)	activating	Ras (G12V,T35S) activation mutants	not specified	mutants said to be mostly activating Raf
ARR02263	GSE14934	GSE14934b	GSM373106	GPL571	linear	raw	CELS/GSE14934/GSM373106.CEL	MAPK	HEK-HT (kidney)	activating	Ras (G12V,T35S) activation mutants	not specified	mutants said to be mostly activating Raf
ARR02264	GSE14934	GSE14934b	GSM373111	GPL571	linear	raw	CELS/GSE14934/GSM373111.CEL	MAPK	HEK-HT (kidney)	activating	Ras (G12V,T35S) activation mutants	not specified	mutants said to be mostly activating Raf
ARR02265	GSE10088	GSE10088a	GSM254963	GPL571	log	raw	CELS/GSE10088/GSM254963.CEL	MAPK	SkMel-28 cells	control	treated with PD0325901, MEK inhibitor	2 h	1 replicate each, mainly influencing MAPKs
ARR02266	GSE10088	GSE10088a	GSM254964	GPL571	log	raw	CELS/GSE10088/GSM254964.CEL	MAPK	SkMel-28 cells	inhibiting	treated with PD0325901, MEK inhibitor	2 h	1 replicate each, mainly influencing MAPKs
ARR02267	GSE17939	GSE17939	GSM448023	GPL570	log	raw	CELS/GSE17939/GSM448023.CEL	MAPK	HUVECs	control	transfected with constitutive active MEK5D	40 h	3 replicates each, mainly activating MAPKs
ARR02268	GSE17939	GSE17939	GSM448025	GPL570	log	raw	CELS/GSE17939/GSM448025.CEL	MAPK	HUVECs	control	transfected with constitutive active MEK5D	40 h	3 replicates each, mainly activating MAPKs
ARR02269	GSE17939	GSE17939	GSM448043	GPL570	log	raw	CELS/GSE17939/GSM448043.CEL	MAPK	HUVECs	control	transfected with constitutive active MEK5D	40 h	3 replicates each, mainly activating MAPKs
ARR02270	GSE17939	GSE17939	GSM448029	GPL570	log	raw	CELS/GSE17939/GSM448029.CEL	MAPK	HUVECs	activating	transfected with constitutive active MEK5D	40 h	3 replicates each, mainly activating MAPKs
ARR02271	GSE17939	GSE17939	GSM448041	GPL570	log	raw	CELS/GSE17939/GSM448041.CEL	MAPK	HUVECs	activating	transfected with constitutive active MEK5D	40 h	3 replicates each, mainly activating MAPKs
ARR02272	GSE17939	GSE17939	GSM448047	GPL570	log	raw	CELS/GSE17939/GSM448047.CEL	MAPK	HUVECs	activating	transfected with constitutive active MEK5D	40 h	3 replicates each, mainly activating MAPKs
ARR02273	GSE12764	GSE12764	GSM320243	GPL570	log	raw	CELS/GSE12764/GSM320243.CEL	MAPK	MCF10A cells	control	transfected with MEK1	24 h	6 replicates each, mostly activates MAPKs
ARR02274	GSE12764	GSE12764	GSM320244	GPL570	log	raw	CELS/GSE12764/GSM320244.CEL	MAPK	MCF10A cells	control	transfected with MEK1	24 h	6 replicates each, mostly activates MAPKs
ARR02275	GSE12764	GSE12764	GSM320245	GPL570	log	raw	CELS/GSE12764/GSM320245.CEL	MAPK	MCF10A cells	control	transfected with MEK1	24 h	6 replicates each, mostly activates MAPKs
ARR02276	GSE12764	GSE12764	GSM320246	GPL570	log	raw	CELS/GSE12764/GSM320246.CEL	MAPK	MCF10A cells	control	transfected with MEK1	24 h	6 replicates each, mostly activates MAPKs
ARR02277	GSE12764	GSE12764	GSM320247	GPL570	log	raw	CELS/GSE12764/GSM320247.CEL	MAPK	MCF10A cells	control	transfected with MEK1	24 h	6 replicates each, mostly activates MAPKs
ARR02278	GSE12764	GSE12764	GSM320248	GPL570	log	raw	CELS/GSE12764/GSM320248.CEL	MAPK	MCF10A cells	control	transfected with MEK1	24 h	6 replicates each, mostly activates MAPKs
ARR02279	GSE12764	GSE12764	GSM320254	GPL570	log	raw	CELS/GSE12764/GSM320254.CEL	MAPK	MCF10A cells	activating	transfected with MEK1	24 h	6 replicates each, mostly activates MAPKs
ARR02280	GSE12764	GSE12764	GSM320255	GPL570	log	raw	CELS/GSE12764/GSM320255.CEL	MAPK	MCF10A cells	activating	transfected with MEK1	24 h	6 replicates each, mostly activates MAPKs
ARR02281	GSE12764	GSE12764	GSM320256	GPL570	log	raw	CELS/GSE12764/GSM320256.CEL	MAPK	MCF10A cells	activating	transfected with MEK1	24 h	6 replicates each, mostly activates MAPKs
ARR02282	GSE12764	GSE12764	GSM320257	GPL570	log	raw	CELS/GSE12764/GSM320257.CEL	MAPK	MCF10A cells	activating	transfected with MEK1	24 h	6 replicates each, mostly activates MAPKs
ARR02283	GSE12764	GSE12764	GSM320258	GPL570	log	raw	CELS/GSE12764/GSM320258.CEL	MAPK	MCF10A cells	activating	transfected with MEK1	24 h	6 replicates each, mostly activates MAPKs
ARR02284	GSE12764	GSE12764	GSM320259	GPL570	log	raw	CELS/GSE12764/GSM320259.CEL	MAPK	MCF10A cells	activating	transfected with MEK1	24 h	6 replicates each, mostly activates MAPKs
ARR02285	GSE10088	GSE10088b	GSM254963	GPL571	log	raw	CELS/GSE10088/GSM254963.CEL	MAPK	SkMel-28 cells	control	treated with PD0325901, MEK inhibitor	8 h	1 replicate each, mainly influencing MAPKs
ARR02286	GSE10088	GSE10088b	GSM254965	GPL571	log	raw	CELS/GSE10088/GSM254965.CEL	MAPK	SkMel-28 cells	inhibiting	treated with PD0325901, MEK inhibitor	8 h	1 replicate each, mainly influencing MAPKs
ARR02287	GSE6521	GSE6521a	GSM149913	GPL570	linear	raw	CELS/GSE6521/GSM149913.CEL	MAPK	MCF-7 breast cancer cells	control	Treatment with U0126 (MEK inhibitor)	1.5 h	no stimulation
ARR02288	GSE6521	GSE6521a	GSM149928	GPL570	linear	raw	CELS/GSE6521/GSM149928.CEL	MAPK	MCF-7 breast cancer cells	inhibiting	Treatment with U0126 (MEK inhibitor)	1.5 h	no stimulation
ARR02289	GSE3542	GSE3542c	GSM81189	GPL96	log	raw	CELS/GSE3542/GSM81189.CEL	MAPK	MCF-7 (breast cancer cells)	control	co-transfected with constituitively active Raf	not specified	none
ARR02290	GSE3542	GSE3542c	GSM81190	GPL96	log	raw	CELS/GSE3542/GSM81190.CEL	MAPK	MCF-7 (breast cancer cells)	control	co-transfected with constituitively active Raf	not specified	none
ARR02291	GSE3542	GSE3542c	GSM81191	GPL96	log	raw	CELS/GSE3542/GSM81191.CEL	MAPK	MCF-7 (breast cancer cells)	control	co-transfected with constituitively active Raf	not specified	none
ARR02292	GSE3542	GSE3542c	GSM81204	GPL96	log	raw	NA	MAPK	MCF-7 (breast cancer cells)	activating	co-transfected with constituitively active Raf	not specified	none
ARR02293	GSE3542	GSE3542c	GSM81205	GPL96	log	raw	NA	MAPK	MCF-7 (breast cancer cells)	activating	co-transfected with constituitively active Raf	not specified	none
ARR02294	GSE3542	GSE3542c	GSM81206	GPL96	log	raw	NA	MAPK	MCF-7 (breast cancer cells)	activating	co-transfected with constituitively active Raf	not specified	none
ARR02295	GSE3542	GSE3542b	GSM81189	GPL96	log	raw	CELS/GSE3542/GSM81189.CEL	MAPK	MCF-7 (breast cancer cells)	control	co-transfected with constituitively active MEK	not specified	none
ARR02296	GSE3542	GSE3542b	GSM81190	GPL96	log	raw	CELS/GSE3542/GSM81190.CEL	MAPK	MCF-7 (breast cancer cells)	control	co-transfected with constituitively active MEK	not specified	none
ARR02297	GSE3542	GSE3542b	GSM81191	GPL96	log	raw	CELS/GSE3542/GSM81191.CEL	MAPK	MCF-7 (breast cancer cells)	control	co-transfected with constituitively active MEK	not specified	none
ARR02298	GSE3542	GSE3542b	GSM81198	GPL96	log	raw	NA	MAPK	MCF-7 (breast cancer cells)	activating	co-transfected with constituitively active MEK	not specified	none
ARR02299	GSE3542	GSE3542b	GSM81199	GPL96	log	raw	NA	MAPK	MCF-7 (breast cancer cells)	activating	co-transfected with constituitively active MEK	not specified	none
ARR02300	GSE3542	GSE3542b	GSM81200	GPL96	log	raw	NA	MAPK	MCF-7 (breast cancer cells)	activating	co-transfected with constituitively active MEK	not specified	none
